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The phylum Basidiomycota constitutes the second-largest higher taxonomic group of the 
Kingdom Fungi after the Ascomycota and comprises ca 35,000 species (Halling et al., 1997). 
They have been proved to be a considerable resource for novel natural products. However, only 
a small number (~ 2%) of these fungi have been cultured and studied for their potential of 
producing useful secondary metabolites. The combination of extensive fieldwork, morphology 
study, phylogeny analysis, biotechnology process, and analytical chemistry resulted in a high 
discovery rate of novel metabolites. The research in this thesis focuses on the characterization 
of bioactive secondary metabolites from basidiomycetes originated from Kenyan Kakamega 
tropical forest and Mount Elgon national reserve. Twenty-seven strains were cultivated in three 
standard media. Extractions from both mycelia and supernatant were screened by antimicrobial 
assays and LCMS analysis (Appendix). Five strains were selected for scale-up fermentation, 
which led to the identification of forty-three previously undescribed bioactive compounds 
together with several known compounds. Among these, four compounds were identified with 
new carbon skeletons. In addition, the extraction and isolation of fruiting bodies from one 
fungus also resulted in the discovery of five unknown secondary metabolites. 
Thirteen previously undescribed metabolites, (6R,7S,10R)-7,10-epoxy-7,11-dimethyldodec-1-
ene-6,11-diol and twelve sesquiterpenes elgonenes A-L together with the known compound p-
coumaric were isolated from Sanghuangporus sp. (MUCL56354). Most of these exhibited 
weak antimicrobial effects and cytotoxicity (publication 1). A new phelligridin L together with 
the other six nematicidal and antimicrobial secondary metabolites 3,14-bihispidinyl, hispidin, 
ionylideneacetic acid, phellidine E, phellidine D, and 1S-(2E)-5-[(1R)-2,2-dimethyl-6-
methylidenecyclohexyl]-3-methylpent-2-enoic acid were isolated and characterized from 
another Sanghuangporus sp. (MUCL55592, publication 4). Tyromycin A and twelve previous 
undescribed derivatives, skeletocutins A-L, were identified from Skeletocutis sp. 
(MUCL56074). These showed selective activities against Gram-positive bacteria, while 
skeletocutin J weakly inhibited the formation of biofilm of Staphylococcus aureus. The 
antiviral activity against HCV of tyromycin A is also reported in publication 2. Five further 
tyromycin A derivatives skeletocutins M-Q were isolated from Skeletocutis sp. fruiting bodies 
(publication 3). Five new pregnenolone type steroids aethiopinolones A–E were isolated from 
the mycelial culture of Fomitiporia aethiopica (MUCL56047). These compounds exhibited 
moderate cytotoxic effects against various human cancer cell lines (publication 5). From 
Heimiomyces sp. (MUCL56078), seven novel compounds were isolated and four of them with 
new carbon skeletons. The determination of their stereochemistry is ongoing. The compounds 
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isolated from MUCL56078 exhibited activity against Gram-positive bacteria and moderate 
cytotoxicity.  
Even though a fraction of basidiomycetes obtained from the fieldwork have been studied 
extensively in the past three years, a large number of novel chemical molecules with 
bioactivities could already be identified. This indicating Basidiomycota have the potential to be 
a promising source for novel secondary metabolites, which may lead to the discovery of new 
antibiotics and other useful compounds. 
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cDNA complementary DNA 
ESI                        electrospray ionization  
EtOAc ethyl acetate 
EtOH ethanol 
HCV hepatitis C virus 
HIV                        human immunodeficiency virus  
HPLC                     high performance liquid chromatography  
HR-ESIMS high-resolution electrospray ionization mass spectrometry 
ITS                         internal transcribed spacer region of the ribosomal DNA  
LCMS liquid chromatography-mass spectrometry 
LSU                      large subunit of the ribosomal DNA  
M molar 
MeOH methanol 
MIC minimal inhibitory concentration  
mRNA messenger RNA 
MRSA  methicillin-resistant Staphylococcus aureus  
MS mass spectrometer/spectrometry  
MW molecular weight 
NMR  nuclear magnetic resonance  
NRPS  nonribosomal peptide synthetase  
PCR  polymerase chain reaction  
RAxML randomized accelerated maximum likelihood  
RP  reversed phase  
TFA trifluoroacetic acid  
UV ultraviolet  
w/v weight per volume 




Declaration of Contribution to the Publications 
The contribution of Tian Cheng (TC) and the co-workers to the publications listed above were 
as follows: 
Publication 1 
The first author TC identified the specimen to genus by sequencing the ITS and blasting the 
ITS to the database in NCBI. The fermentation of the fungus, downstream processing, 
extraction, chromatographic isolation of compounds, and the following biological activity 
evaluation were done by the first author TC. CC elucidated the structure of compounds and 
wrote the structure elucidation part in the manuscript. The biological characterization and 
isolation part of the manuscript were written by TC. CD and JCM collected the specimen and 
helped to check the manuscript.  
Publication 2 
The shared first author TC identified the specimen to genus by sequencing the ITS and blasting 
the ITS to the database in NCBI. The fermentation of the fungus, downstream processing, 
extraction, and chromatographic isolation of compounds were done by the TC with assistance 
from WCM. All the biological activity assays were done by TC, except “Inhibitory Effects on 
HCV Infectivity” which was done by DFP. The shared first author CC elucidated the structures 
of the compounds and wrote the manuscript except for the biological characterization and 
isolation part, which were written by TC. CD and JCM collected the specimen and helped to 
check the manuscript. KW and ES helped to check the manuscript.  
Publication 3 
The first author TC identified the specimen to genus by sequencing the ITS and blasting the 
ITS to the database in NCBI. The extraction, chromatographic isolation of compounds, and the 
following biological activity evaluation were done by the first author TC. CC elucidated the 
structures of the compounds. The biological characterization and chemical isolation part of the 
manuscript were written by TC, the structure elucidation part was written by CC. CD and JCM 
collected the specimen and helped to check the manuscript.  
Publication 4 
The first author CC carried out small-scale fermentation of the fungus and screened the extracts 
for bioactivities.  Furthermore, LC-MS analysis of the extracts and database search to identify 
the new metabolites were carried out by CC. Scale-up of fermentation, downstream processing, 
xii 
 
extraction, and chromatographic isolation of the compounds were done by CC. Structure 
elucidation and manuscript writing were also done by CC. TC helped with the bioassay tests.  
JCM facilitated the collection of the specimen and helped with proofreading of the manuscript. 
DC collected, isolated, and identified the producing organism and helped with proofreading of 
the manuscript.  
Publication 5 
The shared first author CC carried out the LC-MS analysis of the extracts and the database 
search to identify the new metabolites. Chromatographic isolation of the compounds was done 
by CC. Structure elucidation and manuscript writing were done by CC. WCS helped with the 
fermentation and isolation of compounds. JCM facilitated the collection of the specimen, 
experiment guidance, and helped with proofreading of the manuscript. TC helped with the 
biological characterization. DC collected, isolated, and identified the producing organism and 
helped with proofreading of the manuscript.  
Publication 6 
The shared first author CP collected the specimen and carried out the LC-MS analysis of the 
extracts and the database search to identify the new metabolites. Chromatographic isolation of 
the compounds, as well as their biological characterization, were done by CP. Structure 
elucidation and related manuscript writing were done by APGM. KDH helped with 
proofreading of the manuscript. VH and TC helped with the biological characterization.  
Publication 7 
TC wrote the “Genomics and molecular biology of secondary metabolite biosynthesis in 
Basidiomycota” part, “Biotechnology of products from Basidiomycota” was written by LCM, 
and “Brief overview about the taxonomy of the Basidiomycota” was written by BT. The shared 
first author BS and CC wrote the major part of the manuscript. MS and SH supervised the 
progress of the project and helped to finalize the manuscript draft. 




1.1 History of Antibiotics and Antimicrobial Resistance 
The first natural antibiotic, mycophenolic acid (Figure 1), was discovered by the Italian 
physician and microbiologist Bartolomeo Gosio from “Penicillium glaucum” (currently valid 
name P. brevicompactum) in 1893 (Gosio, 1896). Mycophenolic acid is a member of the class 
of 2-benzofurans and possesses weak and non-selective antibacterial activity. Mycophenolic 
acid is a potent, reversible, non-competitive inhibitor of inosine-5′-monophosphate 
dehydrogenase (IMPDH), an enzyme essential to the de novo synthesis of guanosine-5'-
monophosphate (GMP) from inosine-5'-monophosphate (IMP). The use of mycophenolic acid 
leads to a relatively selective inhibition of DNA replication in T cells and B cells (Harvey et al., 
2011; Nijkamp and Parnham, 2011). Until 1994, the 2-(morpholin-4-yl)ethyl ester of 
mycophenolic acid was approved by the US Food and Drug Administration (FDA) as an 
immunosuppressant to prevent transplant rejection (Wu, 1994). At the beginning of the 1910s, 
chemist Alfred Bertheim synthesized the first man-made antibacterial agent arsphenamine 
(Salvarsan) in Paul Ehrlich’s lab. Salvarsan (Figure 1) was the first chemotherapeutic 

















Figure 1. Chemical structures of mycophenolic acid and salvarsan. 
 
The well-known antibiotic penicillin was first discovered by Alexander Fleming from 
“Penicillium rubens” (Houbraken et al., 2011). After early trials in treating sepsis and human 
wounds, the collaborations with pharmaceutical companies were motivated by the outbreak of 
the Second World War, which ensured the mass production of penicillin. In 1945, penicillin 
(nicknamed “the wonder drug”) was no longer an exclusive medication for the military (Cully, 
2014). Cephalosporin C (Figure 2), discovered by Giuseppe Brotsu from “Cephalosporium 
acremonium” (currently valid name Sarocladium strictum) as the first member of the 
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cephalosporins (a sub-class of β-lactams) in 1945. Its structure inspired numerous synthetic 
efforts on the designation of analogues from antibacterial drugs, arose with cefalotin (Figure 2) 
being the first clinically approved cephalosporin antibacterial agent (Bo, 2000; Newton and 
Abraham, 1955). Penicillin G  (Figure 2) and cephalosporin C are representatives of the 
important class of β-lactams, they primarily act against Gram-positive bacteria by inhibiting the 


































Figure 2. Chemical structures of ß-lactams. 
 
Prontosil (Figure 3), an antibacterial drug of sulfonamide group, was synthesized by Bayer 
chemists Josef Klarer and Fritz Mietzsch and marketed in 1935 (Domagk, 1935). Antibacterial 
sulfonamides (Figure 3) act as competitive inhibitors of the enzyme dihydropteroate synthase 
(DHPS), an enzyme involved in the synthesis of folate. They are therefore bacteriostatic and 
















Figure 3. Chemical structures of sulfonamide drugs. 
 
Another milestone in the history of antibiotics was the discovery of streptomycin (Figure 4) 
from Streptomyces griseus as the first aminoglycoside antibiotic, with antimicrobial activities 
against Gram-positive and Gram-negative bacteria (Jones et al., 1944; Schatz et al., 1944). 
Gentamicin (Figure 4), was discovered from the fermentation products of Micromonospora 
purpurea in 1963, it was used as a topical treatment for burns initially and introduced into 
intravenous (IV) usage in 1971 (Dean, 2012; Weinstein et al., 1963). Aminoglycosides act as 
inhibitors of protein synthesis in bacteria by binding bacterial 30S or 50S ribosomal subunit, 
3 
 
inhibiting the translocation of the peptidyl-tRNA from the A-site to the P-site, and also causing 
































Figure 4. Chemical structures of aminoglycoside antibiotics. 
 
Tetracyclines are one of the most important classes of antibiotics. The first member in this class 
aureomycin (today known as chlortetracycline, Figure 5, Duggar, 1948) was isolated from 
Streptomyces aureofaciens and approved for clinical use in 1948 (Chopra and Roberts, 2001). 
Soon thereafter, several other members of the tetracycline family were isolated, including 
oxytetracycline (Figure 5) from Streptomyces Rimosus and tetracycline (Figure 5) from 
Streptomyces aureofaciens (Clardy et al., 2009).  Tetracycline antibiotics are protein synthesis 





































Figure 5. Chemical structures of teracyclines. 
 
The 1950s was the start of the golden age for novel antibiotics, and among the most prominent 
were the erythromycins. Erythromycins A (Figure 6) and B (Figure 6) were isolated from 
Saccharopolyspora erythraea in 1952 and marketed with the name llotycin in the same year as 
a mixture (Mcguire et al., 1952). Erythromycins can bind to the 23S ribosomal RNA molecule 
in the 50S subunit of the bacterial ribosome. This causes a blockage in the protein synthesis and 
subsequent structure and function processes that are critical for life or replication (Farzam and 
Quick, 2020). Later on, the ketolide family of antibacterial agents arose from the erythromycin 
class through semisynthetic studies. Telithromycin (Figure 6) was derived from erythromycin 
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A and marketed in Europe (2001) as an antibacterial drug (Johnson, 2001; Jones and 
Biedenbach, 1997). Ketolides have a mechanism of action very similar to erythromycin A from 
















































Figure 6. Chemical structures of erythromycins and telithromycin. 
 
Soon after the discovery of the erythromycins, another family of powerful antibiotics, the 
glycopeptides, were discovered. Vancomycin (Figure 7) was isolated from Strep. orientalis 
(currently valid name Amycolatopsis orientalis) in 1953 (Griffith, 1981; Moellering, 2006) as 
the first member of this class. Telavancin (Figure 7) was derived semisynthetically from 
vancomycin. It is an antibacterial drug belonging to the class of lipoglycopeptides. The 
bactericidal properties of vancomycin and telavancin are derived from the inhibition of bacterial 
cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan in the growing cell 

















































































Figure 7. Chemical structures of vancomycin and telavancin. 
 
Ansamycins are a group of macrolactam cytotoxic antibiotics, among which the early members 
named rifamycins were isolated from Strep. mediterranei (now Amycolatopsis rifamycinica) in 
1959 (Sensi et al., 1959). Rifampicin (Figure 8) was approved by the Food and Drug 
Administration (FDA) in 1971 for the treatment of tuberculosis (Sensi, 1983). The activity of 
rifamycins relies on the inhibition of bacterial DNA-dependent RNA biosynthesis, which in 




































Figure 8. Chemical structures of rifamycins. 
 
The 1940s-1960s were the golden era for antibiotics. Most of the antibiotics we use as 
medicines in present-day were discovered and marketed in that age. However, antibiotic-
resistant bacteria that can survive antibiotic treatment are becoming more and more common 
(Newman and Cragg, 2020). Even before the extensive use of penicillin, some observations 
suggested that penicillin antibiotics could be destroyed by an enzyme from bacteria (Abraham 
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and Chain, 1940). Shortly thereafter, penicillin resistance became a serious clinical problem 
during the 1950s. But new beta-lactam antibiotics were discovered and developed in response 
to restrain the resistance problem (Sengupta et al., 2013; Spellberg and Gilbert, 2014).  
The first cases of methicillin-resistant Staphylococcus aureus (MRSA) were identified in the 
UK in 1961 and in the US in 1968 (Johnson, 2011).  It is prevalent all over the world now and 
in resistant to the entire class of β-lactams (Kumarasamy et al., 2010). Unfortunately, resistance 
has eventually occurred to nearly all antibiotics that have been developed. Even for antibiotics 
like vancomycin, which was introduced for the treatment of methicillin resistance in both S. 
aureus and coagulase-negative staphylococci got ineffective in some cases (Cooper and Shlaes, 
2011; Srinivasan et al., 2002). What makes the situation even worse is the number of new 
antibiotics approved has been steadily declining. 
Studies have indicated the direct relationship between the overuse of antibiotics and the 
emergence of resistant bacterial strains (Read and Woods, 2014). Inappropriately prescribed 
antibiotics have exposed patients to potential complications of antibiotic therapy and also 
contribute to the promotion of resistant bacteria (Lushniak, 2014). Additionally, antibiotics 
used for the purpose of promoting growth and preventing infection of livestock affect the 
environmental microbiome. Resistant bacteria from animals could potentially be transferred to 
humans and result in resistance against antibiotics (Bartlett et al., 2013). To face the growing 
antibiotic resistance crisis, policymakers have been pushing for the careful use of antibiotics, 
while researchers have been searching for treatments that could effectively fight antibiotic-
resistant bacteria (Bush et al., 2011).  
According to the National Institute of Health, up to 80% of human microbial infections are 
associated with biofilms (Jamal et al., 2018), e.g. endocarditis, cystic fibrosis, periodontitis, 
rhinosinusitis, osteomyelitis, non-healing chronic wounds, meningitis, and kidney infections. 
Human pathogens commonly known to be involved in biofilm-associated infections include 
Staphylococcus epidermidis, Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia 
coli and Candida albicans (Gupta et al., 2016; Paharik and Horswill, 2016; Rimondini et al., 
2016).  Compounds with the ability to inhibit the formation of biofilms are thought to avoid the 
rapid evolution of resistance since unlike antibiotics they do not pose a fatal threat to 
microorganisms. Such compounds could operate as adjunctive agents in combination therapy 




1.2 Natural Products from Fungi 
The fungal kingdom represents an invaluable source of bioactive natural products, which have 
long been exploited in various contexts, ranging from crop protection to human disease (Bills 
and Gloer, 2016; Sandargo et al., 2019a). Fungal natural products have been used as 
pharmaceuticals against various diseases and contain the potential for innovative drugs (Stadler 
and Hoffmeister, 2015). The most well-known natural products are penicillins originally 
derived from Penicillium molds (Fleming, 1929), which were among the first medications to 
be effective against many bacterial infections. Fusidic acid (Figure 9), derived from the mold 
Ramularia coccinea, is a steroid-like antibiotic inhibited protein synthesis by preventing the 
turnover of elongation factor G (EF-G), which resulted in the inhibition of both peptide 
translocation and ribosome disassembly (Fernandes, 2016).  
Griseofulvin (Figure 9) was one of the first antifungal agents, isolated from Penicilllium 
griseofulvum and marketed for the treatment of dermatophytosis (Grove et al., 1952). 
Echinocandins and pneumocandins (Figure 9) are important fungicidal agents derived from 
Aspergillus rugulovalvus, Coleophoma empedri, and Zalerion arboricola, both of them belong 
to the family of cyclic lipopeptides. The echinocandin lipopeptide, acrophiarin (antibiotic 
S31794/F-1), circumscribed in a patent in 1979 (Dreyfuss and Tscherter, 1979) and confirmed 
by Lan et al., (2020) that derived from Penicillium arenicola NRRL 8095. Both echinocandins 
and pneumocandins inhibit β-1,3-glucan synthase and prevent the formation of this class of 
glucan, an essential component of the fungal cell wall in many fungi (Baguley et al., 1979; 









































































Figure 9. Chemical structures of fusidic acid and three fungicidal agents. 
 
Apart from the antimicrobial properties of fungal natural products, alternative activities are 
known. For instance, the nonribosomal peptide cyclosporin A (Figure 10)  is a notable 
immunosuppressant clinically adopted for organ transplantation (Borel, 1990; Thomson et al., 
1984), initially derived from Tolypocladium inflatum (Borel and Kis, 1991).  
The nematicidal PF1022A (Figure 10), an N-methylated was first reported by Sasaki et al., 
(1992). A research of  Wittstein et al., (2020) proved that PF1022 derivatives and other 
cyclodepsipeptides are wide-spread in Rosellinia. PF1022A has strong anthelmintic properties 
against gastrointestinal nematodes of different host animals and fully effective against 
benzimidazole-, levamisole- or ivermectin-resistant nematodes in sheep and cattle (Harder et 
al., 2003).   
Another clinically important medication, statins (Figure 10), are the most important class of 
HMG-CoA reductase inhibitor. They are derived from fungal natural products and contain two 
types of structures moieties, a hexahydro-naphthalene system, and a β-hydroxylactone system 
(Hyde et al., 2019). Compactin (mevastatin, ML-236B) was isolated from Penicillium 
brevicompactum and has hypocholesterolemic activity (Brown et al., 1978; Endo et al., 1976).  
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Later mevinolin was isolated from Aspergillus terreus (Alberts et al., 1980). Lovastatin, 
commercialized derived from Aspergillus terreus, was the first statin drug marketed for treating 


























































Figure 10. Chemical structures of cyclosporin A, PF1022A and stains. 
 
1.3 Agrochemicals and Drug Candidates from Basidiomycota 
A number of very important lead compounds have already been obtained from Basidiomycota, 
even though they have been less studied for biologically active metabolites than the 
Ascomycota, which has led to marketed drugs, agrochemicals, and clinical candidates. 
Strobilurins are a group of naturally occurring antibiotics from the mycelial cultures of various 
Basidiomycota including Strobilurus, Favolaschia, Mycena, Oudemansiella, and Xerula 
(Stadler and Hoffmeister, 2015). These compounds have represented a major development in 
fungus-based fungicides and served as lead compounds for the agricultural β-methoxyacrylate 
fungicides (Sauter et al., 1999). Interestingly, new 9-oxo strobilurin derivatives have been 
identified from Favolaschia calocera originating from Kenya (Chepkirui et al., 2016) even after 
50 years of intensive studies. By binding to the ubiquinol-oxidation centre (responsible for the 
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generation of the proton gradient used for ATP synthesis and the transfer of electrons to 
nitrogenase) in the mitochondrial cytochromes, strobilurins prevent the growth of mycelia and 
germination of spores (Sauter et al., 1999). Some strobilurins exhibit strong antifungal activity 
and together with their low cytotoxicity towards mammals and plants, and their relatively easy 
access by total synthesis has made them promising lead compounds for the development of 
agricultural fungicides (Anke, 1995). However, since they are “single-target” compounds, it is 
easy for the pathogens to acquire resistance through single point mutation in the target proteins 
(Ishii et al., 2001; Vaghefi et al., 2016). Nevertheless, azoxystrobin (Figure 11) and kresoxim 
methyl (Figure 11) are still being applied at a large scale in combination with other antifungal 



















Figure 11. Chemical structures of strobilurins. 
 
Pleuromutilin (Figure 12)  is another important antibiotic from Basidiomycota, which was first 
isolated from Clitopilus passeckerianus (formerly named Pleurotus passeckerianus, Kavanagh 
et al., 1951), Drosophila subatrata (currently valid name: Parasola conopilus), Clitopilus 
scyphoides, and some other Clitopilus species (Hartley et al., 2009; Kavanagh et al., 1952). 
Regarding the metabolic stability, gastrointestinal side effects, cardiac safety, and intravenous 
tolerability, the application of this class of compounds were limited even though their ability 
against most Gram-positive and some Gram-negative pathogens is quite promising (Novak, 
2011; Paukner and Riedl, 2017). 
Later on, the semisynthetic pleuromutilin derivatives tiamulin (Figure 12)  and valnemulin 
(Figure 12)  were introduced as veterinary medicine treatment of swine dysentery and enzootic 
pneumonia in animals (Egger and Reinshagen, 1976a, 1976b). However, due to the unique 
highly specific mode of action of this class of compounds, the resistance development has been 
uncommon. Another semisynthetic derivative retapamulin (Figure 12) was later marketed as 
the first approved antibiotic from Basidiomycota for treating skin infections of humans. The 
recent advances in lead optimization by combing potent antibacterial activity with favorable 
pharmaceutical properties have led to the synthesis of three further new semisynthetic 
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pleuromutilin derivatives, BC-3205 (Figure 12), and BC-7013 (Figure 12)  that are currently 
in clinical trials (Paukner and Riedl, 2017; Prince et al., 2013). 
Lefamulin (Figure 12), formerly known as BC-3781, is the first systemic pleuromutilin 
derivative developed for intravenous and oral administration in humans. It is marketed for the 
treatment of community-acquired bacterial pneumonia since 2019 in the U.S. Lefamulin is 
highly effective against Chlamydia trachomatis, Mycoplasma genitalium, and Neisseria 
gonorrhoeae even for multidrug-resistant isolates in antimicrobial activity tests (Bradshaw et 
al., 2017; Jacobsson et al., 2017). Moreover, lefamulin has demonstrated full activity against 
methicillin-susceptible and –resistant Staphylococcus aureus and β-hemolytic streptococci 
(Paukner et al., 2013; Sader et al., 2012). Lefamulin prevents the correct positioning of the 
ribosomal RNA for peptide transfer interfering with bacterial protein synthesis and is unaffected 
by resistance to other antibiotic classes, such as fluoroquinolones, macrolides, tetracyclines or 
β-lactams (Long et al., 2006; Yi et al., 2017), which confers a low tendency for the development 
of bacterial resistance. The marketing authorization application in Europe is under review by 
Europe marketing authorization (EMA), which will take approximately 12 to 15 months from 
June of 2019. Once approved by EMA, Lefamulin will receive marketing authorization in all 



























































Figure 12.  Chemical structures of pleuromutilin and its derivatives. 
 
Further important basidiomycete natural products are the illudins, which are consistently 
produced by the genera Omphalotus (Schobert et al., 2011; Tanasova and Sturla, 2012). These 
sesquiterpenes possess an unusual cyclopropane ring and exhibit antitumor properties. However, 
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their high toxicity has restricted potential use as anticancer agents in their natural form 
(Tanasova and Sturla, 2012). The semisynthetic analogue of illudin S (Figure 13), Irofulven 
(Figure 13), is currently under development as an anticancer drug in clinical phase II (Schilder 
et al., 2010). Interestingly, omphalotin type cyclopeptides were only reported from Omphalotus 
species and co-occur in the cultures with illudins. These compounds exhibited activity against 
root knot nematodes (Büchel et al., 1998; Mayer et al., 1999). Omphalotin A (Figure 13) was 
first reported from Omphalotus olearius. Later on, several derivatives were isolated from the 








Illudin M, R= CH3 





























Figure 13. Chemical structures of natural products derived from Omphalotus spp. and related 
analogue. 
 
“Lingzhi”, species of genus Ganoderma, are fungus in Asian countries and regarded as 
“panacea” for hundreds of years. The fruiting bodies of “Lingzhi” were supposed to treat 
various diseases such as nephritis, hepatopathy, chronic hepatitis, hypertension and so on (Jong 
and Birmingham, 1992). The well-known compounds from Ganoderma belong to the classes 
of lanostane-type triterpenoids, ergostane-type steroids, and pentacyclic triterpenes (Richter et 
al., 2015). These include the cytotoxic triterpenoids such as ganoderic acids, lucidimols, 
ganodermanondiols, ganoderiols, lucidenic acids, and ganodermanontriols. Ganoderic acids, in 
particular, ganoderic acids T (Figure 14)  and DM (Figure 14) have been studied for their 
anticancer activity in detail (De Silva et al., 2013; Liu et al., 2012; Tang et al., 2006).  
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Figure 14. Chemical structures of ganoderic acids. 
 
Blazeispirols (Figure 15) are a unique class of spiro-triterpenoids that were isolated from 
mycelia cultures of Agaricus mushrooms (Hirotani et al., 1999, 2000, 2002a, 2002b). The 
blazeispirol derivatives were comprised of two major structural types, represented by 
blazeispirol A (blazeispirane type) and blazeispirol U (protoblazeispirane type, Hirotani et al., 
2002b). Prior research on blazeispirols revealed their potential as anti-hypercholesterolemic 
agents and indicated that they may contain toxic effects on liver function by inhibiting P450 
enzymes, especially in case of ovarian cancer (Grothe et al., 2011; Sweet et al., 2013). 
Moreover, blazeispirol A was proved as a chemotaxonomic marker from the mycelia of the 








































































Figure 15. Chemical structure of blazeispirols. 
 
Another two genera, Inonotus and Phellinus, in the Hymenochaetaceae constitute important 
medicinal mushrooms. The boundaries between these genera remained unclear until a 
phylogenetic study and rearrangement of the taxa, which are now being accommodated in the 
new genera Sanghuangporus and Tropicoporus (Zhou et al., 2016). The respective fungi have 
been widely used in Asia as traditional medicine for the treatment of cardiovascular disease, 
tuberculosis, gastrointestinal, as well as diabetes (De Silva et al., 2013; Wasser and Weis, 1999). 
The metabolites from these mushrooms are mainly hispidin derivatives (Figure 16) such as 
3,14’-bihispidinyl, phelligridins, and inoscavin that exhibit antioxidant, antimicrobial and 
cytotoxic effects (De Silva et al., 2013). Another predominant class of metabolites that occurs 
in these fungi are the sesquiterpenoids such as phellidenes and phellelanes (Figure 16) from 
Phellinus linteus (Kobayashi et al., 2010), inonoalliacanes and inonotins from Inonotus sp. 


























Hispindic acid A, R1=H, R2=CHO
Hispindic acid B, R1=OH, R2=CHCH3
 
Figure 16. Chemical structures of natural products derived from genus Inonotus and Phellinus. 
 
The medicinal mushrooms from genus Hericium and in particular Hericium erinaceus have 
been used as food supplements and alternative medicine in traditional Chinese medicine for a 
long time (Thongbai et al., 2015). Metabolites from both fruiting bodies and cultures of H. 
erinaceus exhibit antimicrobial, cytotoxicity, and neuritogenic effects (Kawagishi et al., 1994; 
Wittstein et al., 2016). Erinacines and hericenones (Figure 17) isolated from H. erinaceus were 
investigated for their effects on nerve growth factor (NGF) and brain-derived neurotrophic 
factor (BDNF), which demonstrated their therapeutic potential for the treatment of Alzheimer’s 
disease. Erinacines are cyathane diterpenoids are produced exclusively in the cultures, while 
hericenones and isoindolinones are benzofuranone that are produced only in the fruiting bodies 










































Erinacerin C, R= H
Erinacerin D, R= -CH2CH2OH
Erinacerin E, R= CH2CH3










Figure 17. Chemical structures of erinacines and hericenones. 
 
In addition to the aforementioned compounds from valuable basidiomycetes complex, plenty 
of new metabolites have been isolated from random screening programs in recent years 
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(Sandargo et al., 2019a). For instance, the cyathane diterpenoids pyristriatin A and B from 
Cyathus pyristriatus with moderate antimicrobial and weak cytotoxic activity (Richter et al., 
2016). Striatoids A-F from Cyathus striatus exhibited dose-dependently enhanced nerve growth 
factor (NGF)-mediated neurite outgrowth in PC-12 cells (Bai et al., 2015). Laetiporins A and 
B from Laetiporus sp. showed cytotoxicity against various human cancer human cell lines 
(Chepkirui et al., 2017). Ostalactones A-C from Stereum ostrea while ostalactones A and B 
exhibited moderate activity against human pancreatic lipase (Kang and Kim, 2016). Lentinoids 
A-D from Lentinus strigellus (Vásquez et al., 2018). Pseudohygrophorones A and B from the 
fruiting bodies of Hygrophorus abieticola (Otto et al., 2016). Rosellins A and B from Mycena 
rosella fruiting bodies (Lohmann et al., 2018). The antiviral meroterpenoid rhodatin and 
sesquiterpenoids rhodocoranes A-E from Rhodotus palmatus (Sandargo et al., 2019b). In recent 
years, the importance of natural products from Basidiomycota has been highlighted (Sandargo 
et al., 2019a; Schüffler, 2018). This thesis is focused on the chemical diversity and the potential 
activity of secondary metabolites from tropical fungi. 
 
1.4 Biosynthesis of Secondary Metabolites in Basidiomycota 
With the purpose to sequence the genomes of fungi throughout the kingdom, a series of 
databases have been launched to accelerate the pace of fungal genomics. Examples include the 
fungal genome initiative (FGI, https://www.broadinstitute.org/fungal-genome-initiative, Haas 
et al., 2011), Mycocosm portal from joint genome institute (JGI, 
https://mycocosm.jgi.doe.gov/mycocosm/home, Grigoriev et al., 2014) and FungiDB 
(https://fungidb.org/fungidb/, Stajich et al., 2012). Taking advantage of the increasing 
availability of genome sequences, several computational tools like antiSMASH (Blin et al., 
2017), SMURF (Khaldi et al., 2010), and NRPS predictor (Röttig et al., 2011) have been 
developed to identify secondary metabolic gene clusters. However, it is not clear whether they 
work well in all Basidiomycota genomes because there are too few examples of elucidated 
pathways for known compounds. Basidiomycetes are much more difficult to work with than 
ascomycetes because of the very high prevalence of introns which makes gene finding and 
annotation much more difficult.  As discussed by Sandargo et al (2019a), the process of 
identifying gene clusters currently requires a combination of the use of algorithm platforms 
with manual annotation. 
The first biosynthesis gene cluster (BGC) study on Basidiomycota was dealing with the 
discovery of six sesquiterpene synthases (cop1-cop6) and two cytochrome P450 
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monooxygenases (cox1-cox2) from Coprinopsis cinerea. All genes except for cop5 were cloned 
and functionally expressed in Escherichia coli and/or Saccharomyces cerevisiae (Agger et al., 
2009; Engels et al., 2008; Jennewein et al., 2013). The BGC of the diterpene pleuromutilin 
(Table 1) from Clitopilus pseudopinsitus and Clitopilus passeckerianus was recently found to 
contain seven genes. It was meanwhile expressed heterologously in Aspergillis oryzae, giving 
a significant increase (over 2000%) in the production of pleuromutilin (Alberti et al., 2017; 
Bailey et al., 2016; Yamane et al., 2017). The erinacine BGC was identified containing three 
cytochrome P450s (eriA, eriC, and eril), one GGPPS (eriE), two prenyltransferases (eriF and 
eriG) and a UDP-glycosyltransferase (eriJ) (Liu et al., 2019). 
In addition to terpenoids, the biosynthesis of metabolites from other compound classes has also 
been elucidated. The alkaloid psilocybin isolated from the genus Psilocybe has long been used 
for medicinal and religious purposes by native people of Mexico and British teenagers 
(Andersson et al., 2009). The psilocybin BGC has been identified from Psilocybe cubensis and 
Psilocybe cyanescens, including an L-tryptophan decarboxylase (psiD), a kinase (psiK), an S-
adenosyl-L-methionine (SAM)-dependent N-methyltransferase (psiM) and a P450 
monooxygenase (psiH) (Fricke et al., 2017).  
Ramm et al. and Van Der Velden et al. identified the biosynthetic genes ophMA and ophP by 
mining the genome of Omphalotus olearius for the BCG of omphalotin A (Table 1) and 
provided the first example of the incorporation of α-N-methylation in a peptide backbone via 
the RiPP pathway (Ramm et al., 2017; Van Der Velden et al., 2017). RiPP pathway is much 
different from NRPS biosynthesis of other fungal cyclopeptides and is so far unparalleled in 
fungi.  
The strobilurin BGC was identified from Strobilurus spp. (Nofiani et al., 2018), and was shown 
to encode a highly reducing polyketide synthase with very unusual C-terminal hydrolase and 
methyltransferase domains. The expression in Aspergillus oryzae NSAR1 leads to the 
formation of prestrobilurin A. The FAD-dependent oxygenase str9 is responsible for the 
oxidative rearrangement of prestrobilurin A to form the key β-methoxyacrylate toxophore of 
the strobilurin fungicides. Two SAM-dependent methyltransferases str2 and str3 are required 
and give the product strobilurin A (Nofiani et al., 2018). 
Much of the structural diversity of natural products from Basidiomycota could already be 
accessed by improving chemical methods and synthetic biology, while the mechanism of the 
biosynthesis of many molecules from Basidiomycota remains unexplored. For the natural 
products with notable biological activities and medicinal properties, the elucidation of the 
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biosynthesis pathways could accelerate the development of these molecules for agricultural and 
pharmacological applications (Lin et al., 2019). 
 
Table 1. Some published biosynthesis gene clusters 
Biosythesis gene cluster (BGC) Gene Putative function Reference 
Pleuromutilin BGC 
 
P450-3 Cytochrome P450 
 (Bailey et 
al., 2016) 
ATF Acetyltransferase 





P450-1 P450 monooxygenase 





Omphalotin A BGC 
 
ophB1 Monooxygenase 











1.5 Aim of the Thesis 
The main purpose of this thesis is to screen and identify the active components from the largely 
neglected basidiomycetes originated from African tropics. In order to clarify the diversity of 
Basidiomycota and its prosperous chemistry structures, the extensive study of natural products 
in several basidiomycetes collected from Kenyan tropical rainforest Kakamega and Mount 
Elgon national reserve was carried on in the past years. Twenty-eight basidiomycetes will be 
screened for antimicrobial activities and yield in three standard media. Afterward, some strains 
will be selected for large scale fermentation. The crude extracts from large fermentation will be 
purified by preparative HPLC, the molecular weight of fractions will be analysed by LC-MS 
and HR-ESIMS, structures of pure fractions will be elucidated by NMR data. Biological 
activities of compounds will be tested by a series of tests: antimicrobial, nematicidal, biofilm 
inhibition, and cytotoxicity assays. 
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Basidiomycetes that can produce novel compounds with prominent biological activities will be 
selected for genome sequencing. The illudins are sesquiterpenes with antitumor properties, 
which have been reported 70 years ago. However, the illudin biosynthetic pathway remains 
unknown. The side project of this thesis is about elucidation of illudin biosynthesis of 
Omphalotus olearius. The identification of gene clusters will be annotated by software and 
manual methods. Plasmids will be constructed by homologous recombination in 





















2. Experimental Section 
2.1 Chemicals 
Chemical       Supplier 
Acetic acid       Carl Roth  
Acetonitrile, HPLC gradient    J.T. Baker  
Adenine      Carl Roth 
Ammonium sulfate      Carl Roth  
Agar       Carl Roth  
Calcium carbonate     AppliChem  
Calcium chloride     Carl Roth 
Casein peptone     Becton dickinson 
Complete supplement mixture minus Uracil  Sigma-Aldrich 
Cottonseed flour     Sigma-Aldrich 
Czapek Dox broth     Duchefa Biochemie 
Dichloromethane      J.T. Baker  
Dipotassium hydrogen phosphate   AppliChem 
Edamin      Oxoid Limited 
Ethylenediaminetetraacetic acid   Sigma-Aldrich 
Formic acid      Carl Roth  
D (+)-Glucose      Cargill Incorporated 
D (+)-Glucose Monohydrate    Carl Roth 
Glycerol      Carl Roth  
Glycine      Sigma-Aldrich 
n-Heptane      Carl Roth  
Magnesium sulfate heptahydrate    Carl Roth  
Molasses      Nordzucker AG 
Malt extract      Organotechnie SAS 
L-methionine      Carl Roth 
MHB medium      AppliChem  
D (+)-Maltose      Carl Roth  
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D-Mannitol       AppliChem  
D (+)-Mannose     AppliChem  
Methanol      J.T. Baker  
Nutrient broth Nr. 2 from Oxoid   Fisher Scientific 
Oatmeal      Herrnmühle Reichelsheim, Germany 
Polypeptone      Carl Roth 
Potassium chloride     J.T. Baker  
Potassium dihydrogen phosphate   Carl Roth  
Potassium hydroxide     Carl Roth  
Sodium nitrate      Carl Roth  
Sodium chloride     Sigma-Aldrich 
D-sorbitol      Carl Roth 
Soy peptone      Oxoid Limited 
Sucorse      Carl Roth  
Trifluoroacetic     Carl Roth 
Trizma base       Carl Roth 
Tryptone      Duchefa Biochemie 
Milli-Q Water, deionised, ultrapure  Merck KGaA, Darmstadt, Germany                    
Yeast extract             Becton dickinson  
Yeast nitrogen base     Sigma-Aldrich 
 
 
2.2 Media, Buffers and Solutions 
All media, buffers, and solutions were sterilised by autoclaving for 20 min at 120 oC or by a 
disposable sterile filter (0.45 μm pore size, Roth) and are summarised in Table 2-5. Before 
autoclaving, the pH was measured (inoLab pH 730 pH-meter, WTW/Xylem Analytics 
Germany Sales GmbH & Co. KG, Weilheim, Germany) and adjusted to the desired pH by slow 




Table 2. Media and agar used for fermentation and bioactivity test in this study. 
Meida  Ingredients Composition (g/L) 
Casein-peptone soymeal-peptone (CASO) Casein peptone 17 
 Soy peptone  3 
 Sodium chloride (NaCl) 5 
 Dipotassium hydrogen phosphate 2.5 
 D (+)-Glucose 2.5 
 PH 7.3 ± 0.2 
MHB agar MHB medium 
 Agar 15 
Nematode agar  Soy peptone  2 
 NaCl  1 
 Agar  20 
Q6 1/2 Glycerol 10 
 D (+)-Glucose 2.5 
 Cottonseed flour 5 
 PH 7.2  
YMG Malt extract 10 
 D (+)-Glucose 4 
 Yeast extract  4 
 PH 6.3  
YMG agar  YMG medium 
 Agar 15 
ZM 1/2  Molasses 5 
 Oatmeal 5 
 Sucrose 4 
 Mannitol 4 
 D (+)-Glucose 1.5 
 Calcium carbonate 1.5 
 Edamin 0.5 
 Ammonium sulfate 0.5 









Table 3. Media and agar used for E. coli and S. cerevisiae in this study. 
Media  Ingredients Composition [% (v/w)] 
LB NaCl 0.5 
 Tryptone 1 
 Yeast extract 0.5 
LB Agar LB medium  
 Agar 1.5 
YPAD Yeast extract 1 
 Tryptone 2 
 D(+)-Glucose Monohydrate 2 
 Adenine 0.03 
YPAD Agar YPAD medium  
 Agar 1.5 
SM-URA Agar Yeast nitrogen base 0.17 
 (NH4)2SO4 0.5 
 D(+)-Glucose Monohydrate 2 
 Complete supplement mixture minus Uracil 0.077 






















Table 4. Media and agar used for A. oryzae in this study. 
Media  Ingredients Composition [% (v/w)] 
CZD/S agar Czapek Dox broth 3.5 
 D-sorbitol 18.22 
 (NH4)2SO4 0.1 
 L-methionine 0.15 
 Adenine 0.05 
 Agar 1.5 
CZD/S soft agar Czapek Dox broth 3.5 
 D-sorbitol 18.22 
 (NH4)2SO4 0.1 
 L-methionine 0.15 
 Adenine 0.05 
 Agar 0.8 
CZD/S1 agar (-met) Czapek Dox broth 3.5 
 D-sorbitol 18.22 
 (NH4)2SO4 0.1 
 L-methionine (optional) 0.15 
 Agar 1.5 
CZD/S1 soft gar (-met) Czapek Dox broth 3.5 
 D-sorbitol 18.22 
 (NH4)2SO4 0.1 
 L-methionine (optional) 0.15 
 Agar 0.8 
DPY Dextrin from potato starch 2 
 Polypeptone 1 
 Yeast extract 0.5 
 KH2PO4 0.5 
 MgSO4 * H2O 0.05 
DPY Agar DPY medium  
 Agar 2.5 
GNB D(+)-Glucose Monohydrate 2 










Table 5. Buffers and solutions used in this study. 
Buffers Ingredients Composition (g/L) 
Glycine-HCl (0,1 M) Glycine  7.5 
 Hydrochloric acid (HCl) 0.832 
 PH 3  
Hank’s  NaCl 8 
 KCl 0.4 
 KH2PO4   0.06 
 D (+)-Glucose 1 
 Na2HPO4   0.048 
 MgSO4 0.098 
 CaCl 0.14 
 NaHCO3 0.35 
Loading-dye (6 x) Na2HPO4 7.098 
 pH 8  
M9 KH2PO4 3.0 
 Na2HPO4 6.0 
 NaCl 5.0 
 1 mL 1 M MgSO4 was added after autoclaving 
PBS NaCl   8.0 
 KCl   0.2 
 Na2HPO4   1.44 
  KH2PO4   0.24 
10  SDS running buffer Tris 3.029 
 Glycine 14.413 
 SDS 0.1 % (w/v) 
  pH 8.3   
TAE buffer Tris 4.846 
 Acetate 1.181 
 EDTA 0.292 
Solutions Ingredients Composition (g/L) 
Solution 1 NaCl 46.752 
 CaCl2 1.110 
 Tris-HCl 2.423 
 pH 7.5  
Solution 2 PEG 3350 60 % (w/v) 
 Tris–HCl 6.057 
 NaCl 46.752 




2.3 Enzyme and Antibiotics 
Antibiotics stock solutions were prepared in distilled water, ethanol or methanol, and filter 
sterilized through 0. 45 μm syringe filters and stored at – 20 oC. Stock and working 
concentrations are listed in Table 6. 






Carbenicillin  H2O 50 50 
Chloramphenicol EtOH 30 30 
Ciprofloxacin MeOH 50 150 
Hygromycin B H2O 50 150 
Kanamycin H2O 50 50 
Nystatin MeOH 50 250 
Oxytetracycline MeOH 50 100 
Penicillin G MeOH 50 250 
Streptomycin MeOH 50 250 
Tetracyclin H2O 50 10 
Vancomycin MeOH 50 100 
 
2.4 Specimen Collection and Isolation 
The strains of Basidiomycota used in the current thesis and the related publications were 
collected either from the Kakamega rainforest or Mount Elgon National Reserve in the western 
part of Kenya. The strains were isolated on YMG agar plates either from spore prints or by 
incubation of sterile mycelial plugs from the context of the basidiome. Bacteria were prevented 
to grow by adding the antibiotics, penicillin G, and streptomycin (250 µg/ml) to the YMG 
medium. The pure cultures have been deposited at MUCL, Louvain-la-Neuve, Belgium and 
Helmholtz Centre for Infection Research (HZI) in Germany. 
 
2.5 Fungal Identification 
The fungal strains were identified by morphological studies and molecular analysis of rDNA 
(5.8S gene region, the internal transcribed spacers ITS1 and ITS2) and in some cases the D1/D2 
domains of the large subunit (LSU). For isolation of DNA from pure cultures, a small amount 
of mycelium was disrupted with a Precellys 24 homogenizer (Bertin Technologies, France) at 
a speed of 6000 rpm for 2 × 40 s.  The extraction of DNA was performed according to EZ-10 
Spin Column Genomic DNA Miniprep kit (Bio Basic Canada Inc., Markham, Ontario, Canada). 
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Primes ITS1F (Gardes and Bruns, 1993) and ITS4 (White et al., 1990) were used for 
amplification of the ITS region, LR7 (Vilgalys and Hester, 1990) and NL4 (Reynolds and 
Taylor, 1993) were used for the LSU amplification. Electrophoresis in 2% agarose gel with a 
small amount PCR product was used to check the quality. EZ-10 Spin Column PCR Purification 
Kit (Bio Basic Canada Inc., Markham, Ontario, Canada) was used for purification of the PCR 
products. The purified amplicons were sent to the department Genome Analytics at the 
Helmholtz Centre for Infection Research (Braunschweig, Germany) for sequencing. The 
generated raw data were assembled by the software Geneious 7.1.4 (Biomatters Ltd, Auckland, 
New Zealand). Afterward, a BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi) search based on 
the GenBank database was conducted to obtain the 20 closest hits of the ITS sequence, the 
phylogenetic relationships were then analyzed by RAxML method (Stamatakis, 2014). 
 
2.6 Agar Diffusion Assay for Preliminary Screening  
In the purpose of screening bioactive specimen, small pieces pure fungal cultures cut out by 
using a cork borer (7 mm) and tested for their antimicrobial activity in an agar diffusion assay, 
using the following culture media and conditions: YMG and MHB agar plates were used to 
incubate Mucor plumbeus MUCL 49355 and Bacillus subtilis DSM 10, respectively. 5 × 104 
cells per litre of tested organisms were added in the media before pouring the plates. Five agar 
plugs from mature cultures were placed on the agar plate in a circle. Ciprofloxacin dissolved in 
methanol (1.5 mg/ml) was used as positive control and 200 µL was added on a filter disc for 
Bacillus subtilis DSM10, nystatin used for the positive control of Mucor plumbeus 
MUCL49355 with the same concentration and volume. The filter discs contain antibiotics were 
placed in the middle of agar plates. The antibacterial and antifungal activities were observed by 
checking the inhibition around the cultures after 24h and 48h, respectively. 
 
2.7 Cultivation and Extraction of Small Scale Fermentation 
Fungal strains exhibited activity in the agar diffusion assay were selected for further screening. 
For this purpose, the strains were cultivated in three different media: YMG, ZM 1/2, and Q6 1/2. 
200 mL of the three media were prepared in 500 mL Erlenmeyer flasks and autoclaved, five 
pieces cultures (cut by 7 mm cork borer) were inoculated in the media. The cultures were 
incubated on a rotary shaker (140 rpm) at 23 °C. The growth of cultures was monitored by 
checking the amount of free glucose with Medi-test glucose/100 (Macherey-Nagel) constantly. 
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The fermentation process was terminated three days after glucose depletion. Biomass and the 
culture fluid were separated by filtration with gauze. The mycelium was extracted with 200 mL 
acetone in an ultrasonic bath for 30 min. The filtrate was evaporated in vacuum at 40 °C, the 
remaining aqueous residue was diluted with distilled water and extracted with the same amount 
ethyl acetate and filtered through anhydrous sodium sulphate, the resulting organic phase was 
evaporated to dryness in vacuum at 40° using a rotary evaporator. The supernatant was 
extracted by directly adding the same amount of ethyl acetate and subjected to the same 
procedure as biomass. 
 
2.8 Antimicrobial Assay for Small Scale Crude Extracts 
Serial dilution assay was used for evaluation of the antimicrobial activity of the crude extracts 
from small-scale fermentation. The minimum inhibition concentrations (MIC) against Bacillus 
subtilis DSM 10, Escherichia coli DSM 498, Candida tenuis MUCL 29892, and Mucor 
plumbeus MUCL 49355 were determined. The starting concentration of the extracts was 300 
µg/mL, the assays were conducted with 96-well microtiter plates in MHB medium for bacteria 
and YMG medium for fungi. 
 
2.9 Analytical LC-MS 
The extracts were analysed by HPLC (Ultimate 3000 system, Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) equipped with a DAD and an ESI-TOF mass spectrometer 
(Amazon speed, Bruker, Billerica, Massachusetts, USA). An Acquity UPLC BEH C18 column 
(50 × 2.1 mm, 1.7 µm; Waters, Milford, Connecticut, USA) was used as stationary phase and 
the temperature was 40 °C, the mobile phase (solvent A: water + 0.1 % formic acid; solvent B: 
acetonitrile + 0.1 % formic acid) started with isocratic conditions at 5 % solvent B and increased 
in 20 min to 100% solvent B followed by 10 min isocratic condition with solvent B, the flow 
rate was 0.6 mL/min and compounds were detected by DAD in the range of 200 - 600 nm. The 
concentration of the extracts was adjusted to 4.5 mg/mL and 2 µL were injected. The novelty 
of the compounds in the extracts was determined by comparing the molecular formula and 




2.10 Analytical GC-MS 
GC-MS analyses were performed on a Thermo ITQ 900 system (Thermo Fisher Scientific Inc., 
Hudson, NH, USA) equipped with a ZB-5MS column (Phenomenex; dimensions 30m x 
0,25mm, film thickness 0,25µm). The samples were collected through a solid phase micro 
extraction fibre (SPME-fibre; stationary phase Divinylbenzene/Carboxen/PDMS) from the 
headspace of the samples within 45 min at room temperature. The desorption of samples from 
SPME-fibre was performed in the PTV injector of the gas chromatograph for 1 min at 230 oC. 
The temperature gradient was 50 °C for 1 min, 10 °C/min increase rate up to 320 °C, followed 
by 320 °C for 2 min. The carrier gas was helium, with a column head pressure of 10 psi. The 
transfer line temperature was set at 250 °C and the ion source at 220 °C. Mass spectra were 
recorded from m/z 50 to 700. Raw data were converted to cdf-files by Xcalibur 2.1 software 
(Thermo Scientific), the initial identification of unknown compounds was made by library 
comparison using the build in NIST-database (version 11). 
 
2.11 Scale-up Fermentation and Extraction 
Promising strains were scaled up for fermentation in 25 to 50 flasks with 200 mL medium, the 
medium was selected depends on both the bioactivities and HPLC-MS results. The mycelia and 
supernatant were separated via vacuum filtration. The mycelia were extracted with 500 mL of 
acetone in an ultrasonic bath for 30 min for four times. The extracts were combined and the 
solvent was evaporated by rotary. The remaining water phase was suspended in 200 mL of 
distilled water, extracted with the same amount of ethyl acetate three times, and filtered through 
anhydrous sodium sulphate. The resulting ethyl acetate extract was evaporated to dryness. The 
supernatant was extracted by adding 5% Amberlite XAD-16N absorbent (Rohm & Haas GmbH, 
Frankfurt am Main, Germany) and incubated for three hours on a shaker or stirred by a blender. 
The XAD resin was then filtered and eluted with 500 mL of acetone four times. The resulting 
acetone extracts were evaporated, and the remaining water phase was extracted with an equal 
amount of ethyl acetate. The organic phase was dried over anhydrous sodium sulphate and 
evaporated to dryness. 
 
2.12 Purification of Compounds by Preparative LC-MS 
The extracts were filtered using an SPME Strata-X 33 u Polymeric RP cartridge (Phenomenex, 
Inc., Aschaffenburg, Germany) to get rid of undesired highly hydrophobic compounds, such as 
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fatty acids. A preparative reverse-phase liquid chromatography system (PLC 2020, Gilson, 
Middleton, USA) was used for fractionation of the crude extracts, VP Nucleodur 100−5C 18 ec 
column (250 mm × 40 mm, 7 μm, Macherey-Nagel) was used as a stationary phase. Deionized 
water (Milli-Q, Millipore, Schwalbach, Germany) with 0.05% trifluoroacetic acid (TFA) 
(solvent A) and acetonitrile with 0.05% TFA (solvent B) were used as the mobile phase. UV 
monitoring was carried out at 210, 254, and 350 nm, the flow rate was 40 mL/min. The applied 
gradients were estimated according to the results of the analytical HPLC data and have been 
reported in related publications. The purity of the isolated compounds was evaluated by HPLC-
DAD-MS and NMR. 
Another equipment Waters mass-directed auto purification system was also used for 
purification of compounds, comprising of a Waters 2767 autosampler, Waters 2545 pump 
system, a Phenomenex Kinetex Axia column (5 μm, C18, 100 Å, 21.2 × 250 mm) equipped with 
a Phenomenex Security Guard precolumn (Luna, C5, 300 Å). Gradient was run over 10 min 
starting at 10 % acetonitrile/ 90 % HPLC grade water (0.05 % formic acid) and ramping to 90 % 
acetonitrile. The flow was set to 20 mL/min and the post-column flow was split (100:1) and the 
minority flow was made up with HPLC grade MeOH + 0.045 % formic acid to 1 ml/min for 
simultaneous analysis by diode array detector (Waters 2998) in the range 210 to 600 nm and an 
ELSD detector (Waters 2424) together with mass spectrometry, Waters SQD-2 mass detector, 
operating simultaneously in ES+ and ES- modes between 150 and 1000 m/z. Detected peaks 
were collected into glass test tubes. Combined tubes were evaporated (vacuum centrifuge). 
 
2.13 Structure Elucidation 
The exact mass of compounds were determined by high-resolution electrospray ionization mass 
spectrometry (HR-ESIMS), equipped with an Agilent 1200 series HPLC-UV system (Agilent, 
Santa Clara, California, USA) combined with an ESI-TOF-MS (Maxis, Bruker, Billerica, 
Massahusetts, USA), an Acquity UPLC BEH C18 column 2.1 × 50 mm, 1.7 µm, (Waters, 
Milford, Connecticut, USA) was used. Solvent A: H2O + 0.1% formic acid; solvent B: 
acetonitrile + 0.1% formic acid, gradient: 5% solvent B for 0.5 min increasing to 100% solvent 
B in 19.5 min and then maintaining 100% solvent B for 5 min, flow rate 0.6 mL/min, uv/vis 
detection 200 – 600 nm.  For NMR spectroscopy, a maximum of 10 mg of a pure substance 
was dissolved in 600 µl deuterated solvent in NMR tube, the smaller amounts (< 1 mg) 
compounds were dissolved in 300 µl deuterated solvent in a high precision NMR tube (Shigemi 
Inc, Allison Park, Pennsylvania, USA). NMR spectra were recorded with a Bruker 500 MHz 
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Avance III spectrometer with a BBFO (plus) SmartProbe (1H 500 MHz, 13C 126 MHz) and a 
Bruker 700 MHz Avance III spectrometer with a 5 mm TCI cryoprobe (1H 700 MHz, 13C 175 
MHz).  Chemical shifts δ were referenced to the solvents: acetone-d6 (
1H, δ = 2.05 ppm; 13C, δ 
= 29.3 ppm), acetonitrile-d3 (
1H, δ = 1.94 ppm; 13C, δ = 1.9 ppm), chloroform-d (1H, δ = 7.27 
ppm; 13C, δ = 77.0 ppm), pyridine-d5 (
1H, δ = 7.22 ppm; 13C, δ = 123.9 ppm). Moshers method 
(Hoye et al., 2007) was used to determine the absolute stereochemistry. Optical rotations were 
obtained from a PerkinElmer 241 (Überlingen, Germany) polarimeter. UV spectra were 
recorded by using a Shimadzu UV-vis spectrophotometer UV-2450. CD spectra were 
determined with a JASCO spectropolarimeter, model J-815 (JASCO, Pfungstadt, Germany). 
The structures in this thesis were elucidated by Dr. Clara Chepkirui. 
 
2.14 Bioactivity Tests for Pure Compounds 
2.14.1 Serial Dilution Assay 
The pure compounds were studied for their antimicrobial activities by serial dilution assay as 
described in section 2.8. Additional microorganisms Micrococcus luteus DSM1790, 
Mycobacterium smegmatis DSM43524, MRSA Staphylococcus aureus DSM11822, 
Staphylococcus aureus DSM346, Mucor hiemalis DSM2656 were included in the test panel. 
2.14.2 Biofilm Inhibition Assay 
According to the data from the Centre for Disease Control and Prevention Report in 2007, 
infections from biofilm are a serious threat in hospitals, about 1.7 million infections occur are 
caused by infections related to biofilms per year. Human pathogens commonly known to be 
involved in biofilm associated infections include Staphylococcus epidermidis, Staphylococcus 
aureus, Pseudomonas aeruginosa, Escherichia coli and Candida albicans (Adam et al., 2002; 
Khatoon et al., 2018). 
In this study, Staphylococcus aureus DSM1104 was used in the biofilm inhibition assay and 
grown in casein-peptone soymeal-peptone (CASO) medium containing 4% glucose with PH 
7.0. The concentration of S. aureus cell was adjusted to match the turbidity of 0.5 McFarland 
standard. The assay was performed in 96-well flat bottom plates (Falcon Microplates, USA) by 
serially diluted compounds from a start concentration of 256 µg/mL and incubated for 24 h at 
37 °C. The supernatant medium was discarded after incubation, the biofilm stained with crystal 
violet for 15 min and washed with PBS buffer for three times, the dye was solubilized with 30% 
32 
 
acetic acid and incubated at room temperature for 10 - 15 min, the absorbance of the solution 
was quantified in a plate reader at 550 nm. Methanol was used as negative control; all 
experiments were carried out in triplicates with two repetitions and cytochalasin B was used as 
a positive standard (de Carvalho et al., 2016; Yuyama et al., 2018). 
2.14.3 Nematicidal Assay 
The nematicidal activity against Caenorhabditis elegans of all isolated compounds were 
determined by a slightly modified method according to Stadler et al. (1994). Caenorhabditis 
elegans was inoculated on an autoclaved nematode agar plate, the following ingredients were 
added as sterile filtered solutions: cholesterol (1 mg/mL dissolved in EtOH 0.5 mL), 1M CaCl2 
1 mL, 1M MgSO4 1 mL, 40 mM potassium phosphate buffer 12.5 mL PH 6.8 with living 
Escherichia coli DSM498 (1 mL of a suspension containing approximately 10 cells/mL, pre-
inoculated in MHB medium for 12 h at 37 °C) and the plates were incubated at 21 °C for 4 - 5 
days. Thereafter, nematodes were washed down from the plates with M9 buffer. Finally, a 
nematode suspension of approximately 500 nematodes/mL in M9 buffer was prepared and used 
in the microtiter plate assay. The assay was performed in 24-well microtiter plates at four 
concentrations (100, 50, 25, and 12.5 µg/ml) for each compound. Ivermectin (Sigma Aldrich) 
with related concentrations was used as a positive control, while methanol was used as a 
negative control. The plates were incubated at 20 °C in the dark and nematicidal activity was 
recorded after 18 h of incubation and expressed as LD90 (i.e. concentration causing over 90 % 
immobility of the nematodes) (Rupcic et al., 2018). 
2.14.4 Cytotoxicity Assay 
In vitro cytotoxicity (IC50) of the isolated compounds was determined against a panel of 
mammalian cell lines, including mouse fibroblast L929, HeLa cells KB 3.1, squamous cell 
carcinoma A431, human breast adenocarcinoma MCF-7, human prostate cancer PC-3 and 
human lung carcinoma A549. The cell lines L929, KB 3.1 and A549 were cultured in DMEM 
(Gibco, ThermoFisher Scientific, Hilden, Germany), PC-3 in F12-K (Gibco), MCF-7 and A431 
in RPMI (Lonza, Cologne, Germany), all media were supplemented with 10% of fetal bovine 
serum (Gibco) under 10% CO2 at 37 °C. The cytotoxicity assay was performed according to 
using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method in 96-
well microplates. 60 μL aliquots of serial dilutions from an initial stock with 1 mg/mL in 
methanol of the test compounds were added to 120 μL aliquots of a cell suspension (5.0 × 104 
cells/mL) in 96-well microplates. After 5 days of incubation, MTT assay was performed, and 
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the absorbance was measured at 590 nm using an ELISA plate reader (Victor, PerkinElmer, 
Überlingen, Germany). The concentration at the growth of cells was inhibited to 50% of the 
control (IC50) was obtained from the dose-response curves. Experiments were repeated three 
times. Epothilone B was used as a positive control, and negative control was methanol 
(Kuephadungphan et al., 2019). This assay was performed by our technician Wera Collisi. 
2.14.5 Leucine Aminopeptidases Inhibition Assays 
Hydrolysis of L-Leucine-7-amido-4-methylcoumarin (L-Leu-AMC) by the surface bound 
aminopeptidases of HeLa (KB3.1) cell lines was evaluated according to the method described 
by  Weber et al., (1992) with slight modifications. KB3.1 cell was grown as monolayer cultures 
in Dulbecco’s Modified Eagle (DMEM) medium containing 10% of fetal calf serum at 37 °C 
in 24-well multidishes. After three days the confluent monolayers were washed twice with 
phosphate buffered saline (PBS) and the reaction mixture (450 μL Hank’s buffer PH 7.2 
containing 50 μM and 100 μM substrate L-Leu-AMC, and compounds dissolved in 50 μL 
DMSO) was added. After 30 min of incubation at 23 °C, 1 mL of cold 0.2 M glycine-buffer PH 
10.5 was added. The amount of hydrolyzed 7-amino-4-methylcoumarin (AMC) was determined 
in a fluorescence spectrophotometer (excitation/emission: 365/440 nm; Tecan Infinite M200 
PRO). Bestatin (Mathé, 1991) and DMSO were used as positive control and negative control, 
respectively. 
2.14.6 Inhibitory Effects on HCV Infectivity 
Huh-7.5 cells were inoculated with RLuc Jc1 reporter viruses in the presence of different 
compounds. Monolayers were washed three times with PBS 4 h later and overlaid with fresh 
medium without inhibitors. Infected cells were lysed three days later, and reporter virus 
infection was determined by Renilla luciferase activity. The cell viability was measured by the 
determination of Firefly luciferase. Huh-7.5 cells stably expressing Firefly luciferase (Huh-7.5 
Fluc) were cultured in Dulbecco's modified minimum essential medium (DMEM, Life 
Technologies Manchester UK) (containing 2 mM/L glutamine, 1× minimum essential medium 
nonessential amino acids (MEM NEAA, Life Technologies)), 100 μg/mL streptomycin, 100 
IU/mL penicillin (Life Technologies), 5 μg/mL blasticidin and 10 % fetal bovine serum). Cells 
were incubated at 37 °C with 5 % CO2 supply. Infected cells were lysed and then frozen at 
−80 °C for 1 h following measurements of Renilla and Firefly luciferase activities on a Berthold 
Technologies Centro XS3 Microplate Luminometer as indicators of viral genome replication 
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and cell viability, respectively (Ciesek et al., 2011; Sandargo et al., 2019b). This assay was 
done by our collaborator from Twincore. 
 
2.15 Microbial Strains Used for Biosynthesis  
 
Table 7.  Microbial strains used in this work for heterologous expression. 
Strain Genotype Reference 
BL21 (DE3) 





F-mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 araΔ139 Δ(ara-leu)7697 galU galK 
rpsL (StrR) endA1 nupG fhuA::IS2 
Thermo Fisher 
Scientific 




3_112/leu2-3_112 his3 D1/his3 D1MAL2 8C/MAL2-
8C SUC2/SUC2 Euroscarf 
 
2.16 Molecular Biology Methods for Biosynthesis 
2.16.1 Oligonucleotides 
All oligonucleotides used in this work were purchased from Sigma Aldrich and listed in Table 
8. 
Table 8. Oligonucleotides used in this study. 
Oligonucleotide  5’-3’ sequence 
TCF TTTCTTTCAACACAAGATCCCAAAGTCAAAATGCCGGAAACTTTCTACCT 
TCR (teno) GGTTGGCTGGTAGACGTCATATAATCATACCTAGAGCTCAGAAATATCAA 
TCR (tadh) TTCATTCTATGCGTTATGAACATGTTCCCTCTAGAGCTCAGAAATATCAA 
P450F (pgpd) AACAGCTACCCCGCTTGAGCAGACATCACCATGGGTACCAGCATCGCTTC 
P450R (teno) GGTTGGCTGGTAGACGTCATATAATCATACTTACACGACCAGACCGTGGT 










2.16.2 Polymerase Chain Reaction (PCR) 
PCR was used to amplify DNA fragments. OneTaq® 2  Master Mix (NEB) with standard 
buffer was used for screening purposes. For cloning the proofreading Q5® High–Fidelity 2  
Master Mix (NEB) was used. Manufacturers’ instructions were followed for both enzymes. 
2.16.3 RNA Extraction and cDNA Preparation 
The Omphalotus olearius strain was inoculated in 100 mL YMG medium in 500 mL flask and 
incubated in 28 oC at 120 rpm for 5 days. Grown mycelia were harvested by filtration through 
sterile miracloth, about 100 mg fresh mycelia were processed according to instructions of 
RNAeasy Plant Mini Kit (Qiagen). A digestion step was carried out by the DNase (Qiagen) 
according to manufacturer instructions to remove genomic DNA. Fresh purified total RNA was 
used in further steps. 
The RevertAid Premium Transcriptase kit (Thermo Fisher Scientific) was used for preparing 
cDNA from total RNA (Beate Bonsch) using oligo (dT) nucleotides. Manufacturers’ 
instructions were followed. 
2.16.4 Construction of Vectors In this Thesis 
Construction of fungal and bacterial expression vectors was performed in vitro cloning and in 
vivo homologous recombination in S. cerevisiae. The expression vectors constructed in this 
study are listed in Table 9. 
Table 9. Constructed expression vectors (A. oryzae) in this study. 
Name  Vector backbone  Oligonucleotides for construction in S. cerevisae 
argTC pTYGSargB TCF, TCR (teno) 
argTC-P450 pTYGSargB TCF, TCR (tadh), P450F (pgpd), P450R (teno) 
argTC-P450-oxi1 pTYGSargB 
TCF, TCR (tadh), P450F (peno), P450R (teno), oxi1F, 
oxi1R 
ade-oxi2-oxi3 pTYGSade oxi2F, oxi2R, oxi3F, oxi3R 
 
2.16.5 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to analyse double stranded DNA fragments or RNA 
samples and was performed using horizontal gel tanks (BioRad) with 1 × TAE buffer. DNA 
samples were mixed with 6 × loading buffer and loaded on 1% (w/v) agarose gels which 
contained Roti® -Safe GelStain (1 µl in 40 ml). 1 kb DNA Ladder (New England Biolabs) was 
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used as a size marker. Electrophoresis was carried out at 80 -120 V for 20 min to 45 min in a 
Bio-Rad gel chamber containing 1 x TAE running buffer. DNA was visualised under a by the 
Molecular Imager Gel doc XR+ (Bio-Rad) system under UV light (312 nm). 
2.16.6 DNA Purification from Gel or PCR 
Amplified DNA was purified for sequencing or cloning using NucleoSpin® Gel and PCR 
Clean–up kit (Macherey-Nagel) according to the protocols.  
2.16.7 Isolation of Plasmid DNA from E. coli   
The NucleoSpin® Plasmid kit (Machery-Nagel) was used to isolate plasmid DNA from an 
overnight culture of E. coli.  
2.16.8 Isolation of Plasmid DNA from S. cerevisae  
The Zymoprep Yeast Plasmid Miniprep II kit (Zymo Research) was used to isolate plasmid 
DNA from transformed S. cerevisae cells grown on SM-URA plates. The whole amount of cells 
was collected and added directly to the lysis buffer provided by the kit. 10 µL ddH2O was used 
for the final elution. 
2.16.9 Cloning Procedure 
Restriction Enzyme Digestion 
Restriction enzyme digestions (single or double) were performed according to the 
manufacturer’s protocols (New England Biolabs). Reaction mixtures were incubated at 37 oC 
in an incubator for 0.5 to 5 h and afterward enzymes were inactivated at 65 oC or 80 oC for 20 
min. The resulting fragments were then analysed by agarose gel electrophoresis and purified by 
the NucleoSpin® Gel and PCR Clean up kit (Macherey-Nagel) as described previously. 
Dephosphorylation of Linear DNA and Ligation 
In order to prevent self-ligation of linearized plasmids, they were treated with shrimp alkaline 
phosphatase (SAP). 1 μL of enzyme was added after digestion to the reaction mixture for 1 h at 
37 oC. Ligation reactions were performed using T4 DNA ligase. The reaction typically 
contained 5 × molar excess of DNA inserts. Reaction mixtures were incubated in the fridge (4 




2.17 Transformation of Chemically Competent Escherichia coli Cells 
2.17.1 Growth of E. coli Strain 
E. coli strains were inoculated in liquid LB medium/agar with carbenicillin solution (1 μL/mL) 
and incubated at 37 oC for 12 – 18 h with 200 rpm. For long term storage glycerol stocks (25 % 
glycerol) were stored at -80 °C. 
2.17.2 Transformation 
An aliquot of 50 μL chemically competent E. coli cells was defrosted on ice. After the addition 
of either 1 μL of purified plasmid or 10 μL for a ligation mixture, the mixture was left on ice 
for 20 min. The heat shock was carried out at 42 oC for 60 s. Afterward, the cells were 
immediately placed on ice for 3 min, following by the addition of 500 μL of LB medium and 1 
h incubation at 37 C, 300 rpm. The cells were spun down for 15 s, most of the supernatant was 
discard and around 200 μl were spread on LB agar plates with an appropriate antibiotic(s). The 
plates were incubated overnight in a 37 oC incubator. 
 
2.18 Transformation of Competent Saccharomyces cerevisiae Cells 
2.18.1 Growth of S. cerevisiae Strain 
A stock of S. cerevisiae CEN.PK2 was spread on a YPAD agar plate and incubated at 30 oC for 
72 h. A single colony was used to inoculate in 10 ml liquid YPAD, grown overnight at 30 oC 
and 200 rpm. S. cerevisiae CEN.PK2 transformed with ura3 containing plasmids was grown 
on solid or liquid SM–URA agar plate, incubated at 30 oC for 2 - 4 days. 
2.18.2 Transformation 
Preparation of S. cerevisiae competent cells was done using the LiOAc/SS carrier DNA/PEG 
protocol developed by Giezt and Woods (Gietz and Woods, 2002). A single colony was 
inoculated into 10 mL of YPAD medium and grown overnight at 30 oC, 200 rpm. The seed 
culture was added to 40 mL of YPAD in a 250 mL flask and incubated at 30 oC, 200 rpm, for 
4 - 5 h. Cells were then harvested by centrifugation for 5 min at 3000 rpm and washed with 25 
mL water, the cell pellet was resuspended in 1 mL water and transferred to a 1.5 mL tube. The 
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cells were pelleted at 20, 000  g for 15 s, the supernatant was discarded. Afterward the 
suspension was aliquoted (50 μL into 1.5 mL tubes each). A solution of ssDNA (Single-Strand 
Carrier DNA or salmon sperm DNA, 2 mg/mL) was boiled at 95 °C for 5 min and stored on ice 
until usage. For each transformation the following components were added to the 50 μL yeast 
suspension aliquot:  240 μL PEG solution (50% w/v polyethylene-glycol [PEG] 3350), 36 μL 
1 M LiOAc, 50 μL ssDNA and up to 34 μL of DNA (the master mix containing the linearized 
plasmid and desired inserts in equimolar concentration). Cells were resuspended in the 
transformation mixture by careful pipetting. The mixture was incubated at 42 °C for 40 min and 
afterward cells were pelleted at 21, 000  g for 60 s and supernatant was discarded. The cell 
pellet was gently resuspended in 0.5 mL water, 250 μL of the mixture was spread over SM–
URA plates and incubated at 30 °C for 3 to 4 days. 
 
2.19 PEG-mediated Transformation of Aspergillus oryzae NSAR1 
2.19.1 Growth of A. oryzae Strain 
Aspergillus oryzae NSAR1 was grown on DPY agar plates or in DPY medium at 28 °C for 3-
7 days (120 rpm). For long term storage, A. oryzae spores were collected from plates by adding 
3 mL distilled water, mixed with glycerol (final concentration 50 %) and stored at −80 °C. 
2.19.2 Transformation 
1 mL of A. oryzaea spore suspension from a sporulating plate were inoculated into 100 mL GN 
medium in a 500 mL flask, which was incubated overnight for 28 oC, 110 rpm. The grown 
mycelia were collected by filtration through sterile miracloth and was incubated in 10 mL 
protoplasts solution (0.8 M NaCl) containing 10 mg/mL Lysing Enzyme, which was sterilized 
through a 0.45 μm syringe filter. After gentle shaking at 30 °C for 2-3 h, protoplasts were 
released from hyphae strands by gentle pipetting with wide-bore pipette. Afterward the mycelia 
were collected by filtration through sterile miracloth and centrifugation for 5 min at 3000  g. 
The resulting supernatant was discarded and collected protoplasts were resuspended in solution 
1 (100 μL per transformation) and 10 μL of purified plasmid DNA was added. The 
transformation mixture was incubated on ice for 5 min before adding 1 mL solution 2 and 
incubated again for 20 min at room temperature. Afterward pre-warmed 5 mL CZD/S (or 
CZD/S1) soft agar (50 oC) was added to the mixture and overlaid onto prepared CZD/S (or 
CZD/S1) plates. Plates were incubated at 28 oC for 2-4 days until colonies visible. 
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Transformants were then further selected twice on CZD/S (or CZD/S1) plates (-methionine) 
(2nd and 3rd selection plate) to reduce the number of false-positive transformants. From the 3rd 
selection plates a single colony was picked with a toothpick and grown alone on DPY agar for 
one week before they were used for fermentation and long-term storage. For fermentation, A. 
oryzae transformants were grown on DPY plates for 5-7 days before spores were collected and 
used to inoculate in 100 mL DPY medium (500 mL flasks). The inoculated flasks were 




















3. Results and Discussion 
3.1 Secondary Metabolites from Sanghuangporus species 
3.1.1 Sesquiterpenes from Sanghuangporus sp. (MUCL 56354) 
Strain MUCL 56354 was obtained from a specimen that had been collected from Mount Elgon 
National Reserve in western Kenya, identified as Sanghuangporus sp. by morphological study 
and 5.8S/ITS nrDNA sequence. An initial BLAST search of ITS nucleotide sequence from 
NCBI database gave KP030787.1 (Sanghuangporus microcystideus, Zhou et al., 2016), the 
closest hit with identity 96%, the next closest hit (JF895464.2 with 93%) belonged to an 
Inonotus species (Zhou et al., 2016). The comparison of the 20 closest ITS BLAST results 
showed the relationship of MUCL56354, Sanghuangporus species, Inonotus species and 
Phellinus species (Figure 18, Wu et al., 2012; Zhou et al., 2016). Most of the sequences used 
for phylogenetic analysis are either from the publication of Wu et al., 2012 or Zhou et al., 2016. 
Based on molecular data we have addressed the strain as Sanghuangporus sp. Further 
taxonomic studies including comparisons with type specimens of related species are ongoing 
to characterize this strain to the species level. More information about Sanghuangporus spp. 
are stated in the “introduction (Section 1.3)”.  
 
Figure 18. RAxML phylogenetic tree of the MUCL56354 ITS and the 20 closest BLAST results. 
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A well-grown YMG agar plate of the Sanghuangporus sp. culture was cut into small pieces 
using a 7 mm cork borer, five pieces were inoculated into a 500 mL Erlenmeyer flask containing 
200 mL of three media: YM 6.3, Q6 ½, and ZM ½. The cultures were incubated at 23 °C on a 
rotary shaker (140 rpm). The fermentation was terminated 3 days after glucose depletion.  
Supernatant and biomass from this fermentation were separated by filtration. The supernatant 
was extracted by an equal amount of ethyl acetate and evaporated to dryness by means of a 
rotary evaporator. The mycelia were extracted with 200 mL of acetone in an ultrasonic bath for 
30 min and filtered, and the filtrate was evaporated. The remaining water phase was suspended 
in an equal amount of distilled water, extracted with an equal amount of ethyl acetate, filtered 
through anhydrous sodium sulphate, and the resulting ethyl acetate extract was evaporated to 
dryness. 
Analysis of the HPLC-MS data of crude extracts from three media and subsequent search in the 
Dictionary of Natural Products (DNP, https://www.crcpress.com/go/the_dictionary_of_ 
natural_products) revealed the presence of potentially new bioactive metabolites of the 
production from YMG 6.3 medium and the crude extract exhibited activity against Bacillus 
subtilis with an MIC of 37.5 µg/mL (compared to the positive control ciprofloxacin with 3.1 
µg/mL). The strains were inoculated into YMG media in a sterile flask (50 × 200 mL). 
Extraction from mycelium and supernatant leading to a yield of 151 mg and 369 mg crude 
extracts, respectively.  
The crude extracts from supernatant and mycelia were fractionated by preparative reverse-
phase liquid chromatography. Twenty-four fractions were collected according to the observed 
peaks (F1−F24) from supernatant extracts, and 14 fractions (F1−F14) were collected from the 
mycelial extracts.  
The compounds were then purified by reversed-phase HPLC (solvent A, H2O + 0.05% TFA; 
solvent B, ACN + 0.05% TFA) with a preparative HPLC column (Kromasil, MZ 
Analysentechnik, Mainz, Germany; 250 × 20 mm, 7 μm C18) as stationary phase and a flow rate 
of 15 mL/min. The related gradients for each compound are listed in (Table 10).  
Thirteen previously undescribed metabolites, 6R,7S,10R-7,10-epoxy-7,11-dimethyldodec-1-
ene-6,11-diol 1 and twelve sesquiterpenes named elgonenes A−L 2−13, and the known 
compound P-coumaric acid 14 (Figure 20) were purified. The structure elucidation of 
compounds was based on 2D NMR spectroscopy, high- resolution mass spectrometry. By 
searching the structures of identified compounds in SciFinder (https://scifinder-n.cas.org), 
some compounds are closely related compounds named phelilanes: compound 2 and 3 are 
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structurally related to phelilane D (Figure 19) from Inonotus vaninii (Yang et al., 2013), a 
species that is closely related to Sanghuangporus; compound 5, 6, and 7 have similar structure 
to phelilane H (Figure 19), previously reported from Phellinus linteus (currently valid name 
Tropicoporus linteus, Zhou et al., 2016); Compound 8 and 9 are closely related to phelilane E 
(Figure 19)  from Tropicoporus linteus (Kobayashi et al., 2010).  Phelilanes have previously 
been patented (Kobayashi et al., 2010) as part of the composition of an antibacterial agent that 
is being marketed for the treatment of ailments as diverse as gastroenteric dysfunction, diarrhea, 
hemorrhage, cancers, and prevention of periodontal disease and in the form of toothpaste and 
mouthwash agents in Asia.  
Table 10. Details for purification of compounds from Sanghuangporus sp. (MUCL56354). 
Details for purification of compounds from MUCL56354 
Compound 
No. Amount (mg) 
Fractions used for 
purifications Gradient (solvent B) 







2, 3, 8/9, 
and 11 
0.28, 0.49, 
3.31, and 2.55  
Mycelia fraction F12 and 
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100% 
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100% 
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 100%  
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100% 
(5 min) 






(2 min)  
100% 
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Supernatant fraction F21 






(2 min)  
100% 
(5 min) 





 100%  
(5 min)  
 
Compounds 8/9 (tested as an inseparable mixture), 10, 11, and 13 showed weak antimicrobial 
activity against Bacillus subtilis; compounds 8/9 and 13 demonstrated weak activities against 
Micrococcus luteus; compounds 4, 8/9, and 13 exhibited weak activities against Staphylococcus 
aureus. Further, most of the tested compounds demonstrated moderate activity against Mucor 
hiemalis, except for compound 7, which was inactive. In the cytotoxicity assay compounds 4, 
8−11, and 13 exhibited weak effects against KB 3.1 cells, while compounds 10 and 13 showed 




























































R = CH3, Elgonene D 5







R = CH2OH, Elgonene I 10
R = COOH, Elgonene J 11
R = CH2OH, Elgonene K 12












Figure 20. Chemical structures of the secondary metabolites isolated from Sanghuangporus sp. 
(MUCL56354) publication 1. 
 
3.1.2 Unprecedented Metabolite from Sanghuangporus sp. (MUCL 55592) 
Specimen MUCL 55592 collected from Kakamega equatorial rainforest was also identified as 
Sanghuangporus sp. by morphological examination and ITS sequence analysis. ZM ½ medium 
was selected for the scale-up fermentation with 30 flasks containing 200 mL media in each. 
Bioassay guided fractionation of supernatant extracts led to the isolation of a new highly 
oxygenated spiro [furan-2,1′-indine]-3-one derivative named phelligridin L 15, together with 
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six known compounds: 3,14′-bihispidinyl 16, hispidin 17, ionylideneacetic acid 18, 1S-2E-5-
[1R-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enoic acid 19, phellidene E 20 
and phellidene D 21 (Publication 4, Figure 21). Compounds 15-19 exhibited moderate 
antimicrobial activity against various test organisms. Furthermore, compounds 15-17 showed 
moderate nematicidal activities against Caenorhabditis elegans with LD50 < = 25 µg/mL, which 
is the first report about the nematicidal activity of 3,14′-bihispidinyl and hispidin even after 



















































3.2 Antibacterial Agents from Skeletocutis sp. (MUCL 56074) 
3.2.1 Antibacterial Agents from Liquid Cultures of Skeletocutis sp. 
Skeletocutis is a genus of about 40 species in family Polyporaceae (Cui and Dai, 2008).  Even 
though this genus has a worldwide distribution, most of its known species are distributed in the 
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Northern hemisphere (Cui and Dai, 2008). Like other polypores, species in this genus are 
known to be sapriorophs that attack dead wood or grow on other fungi. Interestingly, some 
species have been reported to grow on the dead fruiting bodies of other polypores, giving 
indications to their mycophilic lifestyle.  
YMG medium was used in the scale-up because fermentation in this medium produced the 
highest volume of metabolites and HPLC-MS results indicated the extracts from 3 standard 
media are similar. The extraction of supernatant and mycelia led to 610.2 mg and 5.2 g crude 
extracts, respectively. The extracts were combined since they showed the same metabolite 
profile by HPLC-MS analysis. The combined extracts were fractionated by preparative HPLC 
with VP Nucleodur 100-5 C-18 ec column (25 × 40 mm, 7 μm: Macherey- Nagel). 22 fractions 
(F1-F22) were collected according to the observed peaks. A detailed description of the gradients 
used for purification of each compound can be found in Table 11.  
Extensive chromatographic studies of the extract were conducted and led to the isolation of 
twelve new compounds (Publication 2) named skeletocutins A-L 22-26 and 28-34 (Figure 22). 
All of them are derivatives of tyromycin A 27 (Weber et al., 1992), which was originally 
reported from mycelial cultures of Tyromyces lacteus in 1992. Tyromycin A was the first 
naturally occurring citraconic anhydride derivate with two 3-methyl-maleic anhydride units. 
The total synthesis of tyromycin A and analogues has been conducted in one step from readily 












Table 11. Details for purification of compounds from liquid cultures of Skeletocutis sp. 
(MUCL56074) 





Fractions used for 
purification Gradient (solvent B) 
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Among the enzymes bound to the outer surface of mammalian cells, aminopeptidases have been 
reported as potential targets for immunomodulation of drugs (Drinkwater et al., 2017). Bestatin, 
the first clinically approved aminopeptidase inhibitor (Figure 23), was designed as an immune-
modulating agent and is still used for the treatment of lung cancer (Singh et al., 2017). HeLa 
S3 cells were detected containing aminopeptidases bound to their outer surface which could be 
easily assayed with L-leucine-7-amido-4-methylcoumarin (Leu-AMC) as substrates (Weber et 
al., 1992). Tyromycin A was found inhibit both the hydrolyzing activities of Leu-AMC and 
Bzl-Cys-AMC in HeLa S3 cells with IC50 31 and 7 μg/mL at 50 μM substrate concentration, 
respectively (Weber et al., 1992), hence the new analogues were also tested for inhibition of L-
Leu-AMC hydrolysis in HeLa (KB 3.1) cells.  Bestatin was used as a positive control. Only 
compounds 26, 28, 32, and 34 were weakly active in this assay with IC50 values in the range 
72.3−92.5 and 78.3−118.4 μg/mL when 100 and 50 μM of the substrate were used, respectively, 
while the positive control bestatin had IC50 10.8 and 40.9 μg/mL at 100 μM and 50 μM substrate 
concentration. Even though tyromycin A was previously reported to be active in a similar assay 
against HeLa S3 cells with IC50 values of 31 μg/mL at 50 μM substrate concentration, an IC50 
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Figure 22. Chemical structures of tyromycin A derivatives isolated from liquid cultures of 




Figure 23. Mechanism of action of aminopeptidase inhibitors bestatin and tosedostat. 
Aminopeptidase inhibitors elicit two main effects: (1) amino acid deprivation response (AADR) and 
(2) inhibition of mTOR (Hitzerd et al., 2014). 
 
All compounds except for 28−31 showed moderate activity against Bacillus subtilis, 
Staphylococcus aureus, and Micrococcus luteus with compounds 22−24, 26−27, and 33−34 
exhibiting the highest activity in the range of 9.38−37.5 μg/mL. Further, the compounds 
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demonstrated weak activities against MRSA (methicillin-resistant Staphylococcus aureus). 
None of the compounds showed any activity against the tested Gram-negative bacteria nor fungi.  
All compounds were also tested for nematicidal activities against Caenorhabditis elegans and 
cytotoxicity against mouse fibroblast (L929) and HeLa (KB 3.1) cell lines but they did not show 
any significant activities in these assays at concentrations of ≤100 μg/mL. Compounds that did 
not show any significant activity (i.e with MIC ≥ 150 μg/mL) against S. aureus were subjected 
to the biofilm inhibition assay against S. aureus biofilm. Only compound 31 inhibited the 
formation of the biofilm up to 86% at 256 μg/mL and 28% at 150 μg/mL. 
Hepatitis C virus (HCV), is one of the major causes of chronic liver disease, with 71 million 
people infected worldwide. Although curative medications are available for HCV, the majority 
of infected individuals do not have access to treatment due to the high cost of the treatment. 
Hence, all of the compounds were tested for their antiviral activity against HCV in a cellular 
replication assay in human liver cells. Compound 27 strongly inhibited HCV infectivity at the 
initial concentration of 40 μM while compounds 25 and 26 inhibited HCV with moderate 
activity. Compounds 22, 24, and 34 showed weak activity and the rest of the compounds were 
not active. All tested compounds except for 27 were found devoid of cytotoxicity on the liver 
cells. We therefore next evaluated the antiviral activity of 27 against HCV in a dose dependent 
manner. Compound 27 incubated for 3 days resulted in a dose-dependent inhibition of HCV 
infectivity with an IC50 6.6 μM. The green tea molecule epigallocatechin gallate (EGCG, see 
Ciesek et al., 2011) was used as a positive control. 
 
3.2.2 Undescribed Metabolites from Fruiting Bodies of Skeletocutis sp.  
A quantity of 9.8 g fruiting bodies was extracted using 500 mL of acetone overnight. Then, the 
extract was filtered and another 500 mL of acetone was added, this was extracted in an 
ultrasonic bath for 30 min. The acetone extracts were combined and the solvent evaporated to 
afford 226 mg of crude extract. The purification via preparative HPLC with a VarioPrep (VP) 
column system packed with NUCLEODUR® 100-5 C18 ec (Machery-Nagel, column size: 25 
mm⋅40 mm, packing: 7 µm), elution gradient: 50% solvent B, increasing solvent B to 100% 
within 60 min, 100% solvent B for 5 min, flow rate: 40 mL/min, resulted in eight fractions (F1-
F8). The further purification (details can be found in Table 12) of the fractions with a 
Kromasil® C18 HPLC column (Nouryon, column size: 250 mm⋅20 mm, packing: 7 μm, flow 
rate: 15 mL/min), elution gradient: 45% solvent B for 3 min, increasing solvent B to 100% 
49 
 
within 18 min, 100% solvent B for 4 min, led to the isolation of 5 previously undescribed 
tyromycin A derivatives, skeletocutins M-Q (35-39) and one known compound tyromycin A 
27 (Publication 3, Weber et al., 1992, Figure 24).  
Table 12. Details for purification of compounds from fruiting bodies of Skeletocutis sp. 
Details for purification of compounds from fruiting bodies of Skeletocutis 
sp. 
Compound No. amount (mg) Fractions used for purification 
35 4.84 Fraction F6 
36 2.26 Fraction F7 
37 4.26 Fraction F4 
38 2.50 Fraction F1 
39 2.87 Fraction F2 
27 2.15 Fraction F8 
 
Skeletocutins M-Q 35-39 were devoid of significant activity in antimicrobial, cytotoxic, and 
nematicidal assays. In the antimicrobial assay, compounds 37 and 39 were observed to interfere 
with the formation of biofilms commonly produced by S. aureus. They were then evaluated for 
biofilm inhibition activity against S. aureus, with a concentration of 256 µg/mL. However, only 
weak activity with 20 and 56% inhibition of the biofilm, respectively was observed. According 
to a previous report on the activity of tyromycin A 27 (Weber et al., 1992) to inhibit leucine 
aminopeptidase in HeLa S3 cells, the isolated compounds were checked in the same assays. 
Compound 38 exhibited moderate activity, with an IC50 value of 71.1 μg/mL when 50 μM of 
the substrate was used. Compounds 37 and 39 exhibited weak activities, with IC50 values of >80 
μg/mL at 50 and 100 μM substrate concentration, while the positive control bestatin showed 


































Skeletocutin P 38 Skeletocutin Q 39 Tyromycin A 27
 
Figure 24. Chemical structures of compounds isolated from fruiting bodies of Skeletocutis sp. 




The metabolites isolated from fruiting bodies of Skeletocutis sp. are closely related to the 
skelotocutins that were isolated from liquid cultures. There have been relatively few studies on 
the production of secondary metabolites in mycelial cultures vs fruiting bodies in higher fungi, 
but so far, there are only a few examples where the same compounds were predominant in both. 
For instance, in most species hitherto studied of the ascomycete order Xylariales, the fruiting 
bodies and cultures mostly showed a complementary secondary metabolite production (Helaly 
et al., 2018). From the current case, it appears that the basidiomes of Skeletocutis can be used 
for chemotaxonomic studies. Investigations of herbarium specimens may not even be helpful 
for the taxonomic revision of the genus but may lead to the discovery of further, previously 
undescribed members of the tyromycin/skeletocutin type. 
 
3.3 Pregnenolone Type steroids from Fomitiporia aethiopica (MUCL 56047) 
Strain MUCL 56047 was identified as Fomitiporia aethiopica by morphological studies and 
ITS sequence analysis. The mycelial culture was fermented in 21 flasks rice media (prepare 90 
g rice in 500 mL Erlenmeyer flasks containing 90 mL distilled water and autoclaved twice) at 
23 °C for 28 days. The cultures were diced into small pieces and extracted with methanol to 
afford 800 mg crude extract. The subsequent chromatographic purification of the crude extract 
led to the identification of 5 previously undescribed pregnenolone type triterpenes 
aethiopinolones A–E 40-44 (Publication 5, Figure 25). They were found devoid of significant 
nematicidal and antimicrobial activities, however, they exhibited moderate cytotoxic effects 




































Aethiopinolone A 40 Aethiopinolone B 41 Aethiopinolone C 42
Aethiopinolone D 43 Aethiopinolone E 44  
Figure 25. Chemical structures of compounds isolated from Fomitiporia aethiopica (MUCL56047) 
publication 5. 
 
3.4 Novel Metabolites from Heimiomyces sp. (MUCL 56078) 
By comparing the 5.8S/ITS nrDNA sequence and morphological studies, the strain 
MUCL56078 was assigned tentatively to the genus Heimiomyces with a closest hit of 98% 
query cover to MF100953.1 (Heimiomyces tenuipes, Desjardin and Perry, 2018). The next 
closest hit is KM975407.1 (Heimiomyces neovelutipes) with 97% query cover (Cooper and Park, 
2014). The comparison of the 20 closest ITS BLAST results showed the relationship of 
MUCL56078, Heimiomyces and Xeromphalina (Figure 26). Heimiomyces, which was 
described as an independent genus related to Xeromphalina (a genus of Agaricales; cf. (Singer, 
1959). Singer (1962), later considered Heimiomyces as a subgenus of Xeromphalina but Horak 
(1978) studied the macromorphology, micromorphology, and ecology of Heimiomyces and 
Xeromphalina, and resurrected Heimiomyces again. Xeromphalina and Heimiomyces are 
related genera and there are several intermediate species linking the two generic units (Esteve-
Raventós et al., 2010). Six sesquiterpenoids and one fungal pigment, xerocomic acid (Figure 
27), have been isolated and reported from Xeromphalina sp. (Liermann et al., 2010).  
MUCL56078 was selected for large-scale fermentation in YMG medium since its extracts from 
the small-scale presented activity against Bacillus subtilis at 18.8 μg/mL, 376.2 and 331.3 mg 
crude extracts were obtained from mycelia and supernatant, respectively. The crude extracts 
purified by preparative HPLC with elution gradient: 5-100% solvent B in 63 min and thereafter 
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isocratic condition at 100% solvent B for 5 min. UV detection was carried out at 210, 254, and 
350 nm and the flow rate was 40 mL/min. This led to the collection of 14 (F1-F14) and 13 (F1-
F13) fractions from supernatant and mycelia, respectively. The further purification of fractions 
(Table 13) resulted in seven novel compounds heimiomycins A-C 45-47, calamenene 
derivatives 48-49, phenanthridine derivative 50, sesquiterpene 51 and one known compound 
(17R)-4-hydroxy-17-methylincisterol 52 (Kawagishi et al., 2006a, Figure 28). VP Nucleodur 
100-10 C18 ec column (Macherey-Nagel, Düren, Germany; 250×10 mm) with flow rate 5 
mL/min was used for purification to get compounds 45 , 46 and 51; preparative HPLC column 
(Kromasil, MZ Analysentechnik, Mainz, Germany; 250 x 20 mm, 7 μm C18) with flow rate 12 
mL/min was used for purification to get compounds 47,  49, 50 and 52; compound 48 was 
obtained from the fraction purified by preparative Nucleodur Phenyl hexyl column (Macherey-
Nagel, Düren, Germany; 250×21 mm, 5 μm) with flow rate 12 mL/min. 
 
 














































Figure 27. Secondary metabolites isolated from Xeromphalina sp. (Liermann et al., 2010). 
 
Table 13. Details for purification of compounds from MUCL56078. 
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purification 
gradient (solvent B) 
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Figure 28. Chemical structures of compounds isolated from Heimiomyces sp. (MUCL56078). 
 
The antimicrobial activities of compounds 45-52 were assessed by serial dilution assay against 
bacteria, fungi, and yeast (Table 14). Conspicuous is their activity against Gram-positive 
bacteria Bacillus subtilis and Micrococcus luteus; filamentous fungi Mucor hiemalis. 
Compound 47 exhibited the most outstanding activity against M. luteus with concentration of 
3.1 μg/mL, while it also inhibits the growth of B. subtilis and M. hiemalis at 12.5 and 25 μg/mL, 
respectively. Furthermore, the metabolites showed moderate cytotoxicity against the human 
HeLa cell line and KB 3.1 mouse fibroblast cell line L929 except for compound 48 and 51 
(Table 14). Compound 52 exhibited the strongest cytotoxicity against KB 3.1 cells at 5.4 μM, 
while compound 47 inhibited L929 robustly with concentration 5.5 μM. Four compounds 45, 
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46, 50 and 51 contain novel carbon skeletons, among them 45 and 46 are two polyketides, 51 
is a sesquiterpene. The left part of 50 is a monoterpene, while the right part is polyketide. The 
structure of 50 is quite unusual, the further plan for this compound is to elucidate the 
biosynthesis pathway of it. For this, gene clusters that contain both terpene cyclase and PKS 
are highly interested. 
 
Table 14. Minimum inhibitory concentration (MIC for bacteria and fungi) and half-inhibitory 
concentrations (IC50 for cell lines) in μg/mL.
[a] 
  MIC (μg/mL) 
Organisms 45 46 47 48 49 50 51 52    Reference 
Bacillus subtilis 
DSM10 




- - 100 - - - - 100 0.6[d] 
Micrococcus luteus 
DSM1790 
25 12.5 3.1 100 50 6.3 50 6.3 0.3[c] 
Staphylococcus 
aureus DSM346 
100 100 50 100 100 50 50 50 9.2[e] 
Mucor hiemalis 
DSM2656 
100 100 25 50 25 50 25 6.3 9.2[f] 
Candida albicans 
DSM1665 
- - 100 - - 100 - - 9.2[f] 
Pichia anomala 
DSM6766 
100 100 100 - 100 100 - 50 4.6[f] 
  Cytotoxicity (μM) 














[a] For MIC, 20 μL of 1.5 mg/mL stock solution (start concentration 100μg/mL) of 33-40 were 
tested. Cell density was adjusted to 6.7 × 105 cells/mL; 20 μL of methanol was tested as 
negative control and no activity against tested organisms. For cytotoxicity assay, 6 × 103 
cells/well were selected in 96-well microtiter plates and treated with compounds for 5 days; [b] 
-, no activity; [c] oxytetracyclin; [d] kanamycin; [e] gentamycin; [f] nystatin; [g] epothilon B. 
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4. Additional Project - Illudin Biosynthesis in Omphalotus olearius 
4.1 Introduction 
4.1.1 Biological Activity  
As stated in the National Cancer Institute (NCI) statistics, about 10 million people die of cancer 
annually worldwide (Ritchie, 2018). The treatment of cancer is a great challenge for both 
oncologists and medicinal chemists. Alkylating agents that exert their biological activity by 
modifying DNA and proteins eventually leading to the death of tumour cells have been a 
mainstay of cancer therapy ever since the very early days (Singh et al., 2018). Historically, the 
first examples of such agents were accidentally found among compounds intended for use as 
poison gas. Derivatives of these are still in clinical use, e.g., the N-mustards (chlorambucil, 
cyclophosphamide), N-heterocyclic triazenes (dacarbazine, temozolomide) and N-nitrosoureas 
(BCNU, Carvalho et al., 1998; Eisenbrand et al., 1988; Năstasă et al., 1983). Nature also 
provided us alkylants with great antitumoral potency: the mitomycins, duocarmycins, and 
illudins. 
The first illudins, illudin M and S, were isolated from culture broths of the bioluminescent jack 
o’ lantern mushroom Omphalotus olearius that grows on rotting wood in the east of North 
America and in mild areas of South and Western Europe (Anchel et al., 1950). Related species 
producing illudins M and S are Lampteromyces japonicus and the Australian ghost fungus 
(Schobert et al., 2011). The name of illudins M and S derived from their antibacterial activity, 
illudin M got its name from the activity against Mycobacterium smegmatis, while illudin S 
exhibited activity against Staphylococcus aureus (McMorris and Anchel, 1963). Preclinical 
research revealed that illudins M and S show selective cytotoxicity in leukemia cells and can 
overcome drug resistance (McMorris et al., 1992). Yet, they turned out to be too toxic in their 
natural form and with little therapeutic value. Fortunately, they are accessible in gram quantities, 
which made chemical modification possible aiming at broadening their therapeutic index and 
at increasing their cancer selectivity. For instance, the oxidation of illudin M with pyridinium 
dichromate (PDC) afforded dehydroilludin M which showed an improved therapeutic index in 
animal studies (McMorris et al., 1992, Figure 29). HMAF, prepared from illudin S via a reverse 
Prins reaction, displayed a significantly improved therapeutic index and was admitted to clinical 
























Figure 29. Semi-synthetic analogs of illudin M and S (McMorris et al., 1996). 
 
A number of other illudin-related natural products (Figure 30) have been isolated from various 
basidiomycetes since the discovery of illudin M and S. Illudins A, B, I and J2 exhibit moderate 
antimicrobial activity against S. aureus but are devoid of significant cytotoxicity, except for 
illudin I, which is highly cytotoxic against HepG2 hepatoma cells (Dufresne et al., 1997; 
Gonzalez Del Val et al., 2003; Lee et al., 1996). Illudinic acid showed strong antibacterial 
activity and exhibited moderate cytotoxicity in mammalian cell cultures (Dufresne et al., 1997; 
Taetle et al., 1987; Twentyman and Luscombe, 1987). A possible biological precursor of illudin 
M, dihydroilludin M, also isolated from Omphalotus olearius, is devoid of significant biological 
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Figure 30. Naturally occurring illudin analogs. 
 
4.1.2 Biosynthesis of Illudins – status quo 
Since the early 1970s, the investigation of the biosynthesis of illudins has been an area of intense 
interest and research. Sesquiterpenoids may be classified in terms of the mode of initial 
cyclisation of farnesyl diphosphate (Hanson et al., 1976). It has been suggested that humulene 
(α-caryophyllene) may form the first cyclic intermediate in the synthesis of illudin series of 
metabolites (McMorris and Anchel, 1965). 
Feeding studies with labelled mevalonates and acetates and proposed biosynthesis 
Terpenoids retain hydrogen atoms derived from mevalonic and acetic acids until the late stages 
of their biosynthesis (Popják and Cornforth, 1966). The chirality of mevalonate hydrogen atoms 
in all-trans-farnesyl pyrophosphate has been established (Figure 31). Accordingly, feeding 
studies using labelled mevalonates and acetates could provide some information into the 








































































































Figure 31. Mevalonate pathway to terpene precursor, from acetate to IPP and DMAPP.  denotes 
acetate C-1 position, D denotes deuterium. 
It has been postulated that illudins are formed biogenetically from farnesyl pyrophosphate (FPP) 
via a primary cyclisation forming a humulene-type intermediate (McMorris and Anchel, 1963). 
However, it has subsequently been suggested that cyclisation may proceed via a protoilludane 
intermediate after the formation of a humulene ion intermediate (Bradshaw et al., 1982).  
Feeding studies with sodium [1,2-13C]- and [1-13C]-acetate determined that C-3 and C-11 of 
illudin M (Figure 32) derived from carbons of an intact acetate unit, defining the 
stereochemistry of the folding of FPP in the cyclopropane portion of the molecule during 
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Figure 32. Possible biosynthesis of illudins from FPP. Illudin M and S isolated from the labelling 
experiment.   ̶  denotes pairs of intact acetates coupled atoms in the [1,2-13C2]-acetate experiment, 
 denotes acetate C-1 position,  denotes acetate C-2 position. 
 
[1-13C], [2-13C], [1,2-13C2] and [1-
13C, 2-2H3]-acetates were employed in labelling experiments 
in Omphalotus nidiformis shake cultures. Incorporation of 13C and 2H labels into illudosin and 
illudin M were observed (Burgess and Barrow, 1999). In the [1-13C, 2-2H3]-acetate feeding 
experiment, fewer deuterium atoms were incorporated into illudin due to illudin M is less 




































































































Figure 33. Biosynthetic incorporation of [1-13C]-, [2-13C]-, [1,2-13C2]- and [1-13C, 2-2H3]-acetate into 




13C]- and [2-2H2]-mevalonate were fed to Clitocybe illudens for studies in the 
biosynthesis of illudins by applications of 2H and 13C NMR spectroscopy. One mevalonate 
proton was lost from C-12 in the cyclopropane region of illudin M. The retention of a 2H-13C 
coupling at H-6 in illudin M indicated that this hydrogen atom is not involved in a hydride 
rearrangement. This observation can be accommodated by the suggested mechanism of 








































Figure 34. Biosynthetic incorporation of [5-2H2, 5-13C]-, and [2-2H2]-mevalonate into illudins M and 
S.  denotes mevalonate C-5 position, D denotes deuterium. 
 
The biosynthesis of illudin M has been examined by feeding [3H, 14C]-mevalonates to Clitocybe 
illudens, followed by degradation experiments (Hanson and Marten, 1973). Incorporation of 
14C label of [2-3H2, 2-
14C]-mevalonate illustrated that three molecules of mevalonate are 
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incorporated into illudin M. One labelled mevalonoid hydrogen atom from [4(R)-4-3H]-
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Figure 35. Biosynthetic incorporation of [3H, 14C]-mevalonate into illudins M and followed 
degradation experiments.  denotes mevalonate C-2 position, D denotes deuterium.  
 
In order to prove the intermediary role of 6-protoilludene in the biosynthesis of illudins. 
Morisaki et al. (1985) synthesized [13-2H3]-6-protoilludene and fed it to the growing mycelium 
of Omphalotus olearius (ATCC 11719). The feeding substrate [13-2H3]-6-protoilludene has 
been converted to illudins M and S, which indicated 6-protoilludene is the biosynthetic 























The results of these feeding experiments support a pathway in which cyclisation of farnesyl 
pyrophosphate generates a humulyl cation. Subsequent ring contraction reactions would give 
rise to the 6-protoilludene intermediate. Later hydroxylation and oxidation would then generate 
illudin M and S (Figure 37). However, the precise nature and order of the tailoring steps after 











R = H, illudin M
R = OH, illudin S
?
 
Figure 37. Proposed overall route of illudin biosynthesis. 
 
Gene cluster and proposed biosynthesis of illudin 
The investigation of the illudin gene clusters started by Wawrzyn et al. (2012). The illudin 
producing strain Omphalotus olearius was sequenced and bioinformatic analyses revealed three 





putative BGC for sesquiterpenoid production.  Among them, two BGC (omp6 and omp7, 
Figure 38) could be involved in the production of illudins since the direct chemical product of 
omp6 and omp7 was shown to be the precursor of illudins, 6-protoilludene (Wawrzyn et al., 
2012). These two clusters contain genes (omp6 and omp7) which encode terpene cyclases, and 
further numerous genes encoding tailoring proteins involved in oxidation and redox reactions 
(Wawrzyn et al., 2012). The omp6 BGC is well defined in roughly 25 kb and includes four 
P450 monooxygenases and fourteen additional putative genes that include eight putative 
oxidoreductases, two presumptive transferases, a presumed multiple drug transporter, a 
GATase1 anthranilate synthase, a polygalactonurase, and two seemingly unrelated enzymes. 
Contrarily, the omp7 BGC is much smaller and was reported to contain only a P450 
monooxygenase and an FAD binding protein. 
 
Figure 38. I, organization of genes in omp6 and omp7 BGCs; II, overview of predicted protein 
functions of encoded genes in the two BGC (Wawrzyn et al., 2012). 
 
The genes omp6, omp7 and some of their neighboring putative biosynthetic genes were cloned 
and expressed in E. coli (Wawrzyn et al., 2012). The results suggested that both gene clusters 
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are functional and expressed in O. olearius (Wawrzyn et al., 2012). Synthesis of illudins M and 
S should involve at least five oxidation steps, which may be catalyzed by P450s and 
oxidoreductases surrounding omp6 and omp7 (Kinder and Bair, 1994). Interestingly, omp7 
showed a 10-fold higher catalytic efficiency than Omp6 in a kinetic experiment, suggesting that 
maybe both BGC are important for the biosynthesis of illudins (Wawrzyn et al., 2012).  
 
 
4.2 Project Aims 
Omphalotus olearius is not a genetically amenable fungus that allows examination of 
biosynthetic functions by gene knockouts (Wawrzyn et al., 2012). Step-wise reconstruction of 
the biosynthesis reaction sequences in another fungal host such as Aspergillus oryzae for 
functional expression could elucidate the illudin pathways. Later manipulation of the illudin 
BGC pathway could enable the production of new illudin derivatives with improved 
bioactivities. But until now there is no molecular evidence for the biosynthetic step of illudins. 
Earlier acetate feeding studies showed that 6-protoilludene is a probable biosynthetic precursor 
of illudins M and S (Morisaki et al., 1985). The aim of this project is elucidation of biosynthesis 
pathway of illudins from O. olearius in a step-wise way, particularly the unusual oxidative and 
reductive transformations of 6-protoilludene. Therefore, all putative genes involved in illudin 
biosynthesis should be coexpressed with core terpene cyclase genes (especially P450s and 
oxidoreductase encoding genes) in the heterologous host A. oryzae NSAR1 in order to re-
establish illudin production in this ascomycete host. 
In vivo characterization of P450 encoding genes by heterologous expression of the illudin BGC 
in A. oryzae NSAR1 should reveal the order of oxidation steps. Using the same methodology 
should reveal the role of short chain reductases (SDR) and remaining functional genes during 
the biosynthesis of illudins. 
 
4.3 Results 
4.3.1 Analysis of Potential Illudin Biosynthetic Gene Clusters 
Based on the available genome sequence of Omphalotus olearius from JGI 
(https://mycocosm.jgi.doe.gov/Ompol1/Ompol1.home.html, Wawrzyn et al., 2012), eleven 
putative sesquiterpene synthases (STS) were identified by both BLAST homology searches 
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with six STS (cop1-6, Wawrzyn et al., 2012) and HMMER (http://hmmer.org/) searches with 
Pfam database (https://pfam.xfam.org/). Three STS genes (omp1, omp6, and omp7) are located 
in biosynthetic gene clusters based on fungiSMASH (https://fungismash.secondarymetabolites. 
org/#!/start) analysis and manual annotation. Omp6 and Omp7 (Figure 38) were previously 
proved to be 6-protoilludene synthases by functional characterization after heterologous 
expression in E. coli. 
The Omp7 STS was verified to have a 10-fold higher catalytic efficiency than the Omp6 STS 
(Section 5.1.2), which indicates that the small omp7 gene cluster is a possible gene duplication 
to boost rate-limiting steps in the biosynthesis of illudins (Wawrzyn et al., 2012). Two scaffolds 
(Sca034 and Sca146) from a new O. olearius genome sequence were provided by a collaborator 
at the University of Bristol. The BGC derived from these two scaffolds were compared with 
the omp6 and omp7 BGC by ARTEMIS comparison (https://www.sanger.ac.uk/science/tools/ 
artemis-comparison-tool-act). The Sca034 and sca146 sequences were shown to overlap with 
the small omp7 gene cluster (Figure 39).  
 
Figure 39. Artemis comparison of the omp7, Sca034 + sca146 and omp6 gene clusters. 
 
The omp7 gene cluster and the gene cluster derived from Sca034 + sca146 overlap and therefore 
create a longer gene cluster potentially related to the biosynthesis of illudins, here named as 




Another illudin BGC named omp6 BGC (Figure 39) is identical to the one reported by 
Wawrzyn et al., (2012), which contains one terpene cyclase, four P450s, and five 
oxidoreductase genes. The assumed functions of the genes in these gene clusters were annotated 
as stated in the UniProtKB database (https://www.uniprot.org, Table 15 & 16). 
 
 
Figure 40. The proposed biosynthesis gene clusters of illudins. 
 
Table 15. The annotation of genes in omp7 BGC. 
Gene Putative function InterPro homolog 
(identity %) 
Genbank homolog 
(identity %)  
Reference 
ootc Terpene cyclase IPR008949 (63) - Olson et al., 2012 
ool1 P450  IPR001128 (59) - Sipos et al., 2017 
ool2 - - - - 
ool3 FAD binding 
protein 
IPR016166 (63) - Hess et al., 2014 
ool4 - - - - 
ool5 - - - - 
ool6 HMG box protein IPR009071 (73) XM_008042079.1 (89) Varga et al., 2019 
ool7 - - - - 
oor1 - - - - 
oor2 FAD binding 
protein 
IPR016166 (70) - Choi et al., 2018 
oor3 FAD binding 
protein 
IPR016166 (66) CP017346.1 (92) Riley et al., 2014 
oor4 Na+ solute 
symporter 
IPR038377 (74) - Sakamoto et al., 2016 
oor5 AP complex 
subunit beta 





Table 16. The annotation of genes in omp6 BGC. 






oo2tc Terpene cyclase IPR008949 (84) - Mondo et al., 2018 
oo2l1 P450 IPR001128 (55) - Floudas et al., 2012 
oo2l2 P450 IPR001128 (65) - Olson et al., 2012 
oo2l3 GH131_N protein - - - 
oo2l4 Chorismate_bind 
protein 
IPR005801 (74) - Mondego et al., 2008 
oo2l5 N-acetyltransferase IPR001447 (56) CP036208.1 (90) Semeiks et al., 2014 
oo2l6 - - - - 
oo2l7 Aldo/keto reductase IPR023210 (83) - Semeiks et al., 2014 
oo2l8 P450 IPR001128 (80) - Olson et al., 2012 
oo2r1 P450  IPR001128 (84) - Nagy et al., 2016 
oo2r2 Aldo/keto reductase  IPR036188 (74) - Nagy et al., 2016 
oo2r3 NADP-binding 
protein 
IPR001509 (82) - Nagy et al., 2016 
oo2r4 O-
methyltransferase 
IPR016461 (73) - Suzuki et al., 2012 
oo2r5 Glycoside hydrolase 
protein 
IPR002575 (77) - Sakamoto et al., 2016 
oo2r6 - - - - 
oo2r7 MFS transporter IPR011701 (70) - Varga et al., 2019 
oo2r8 FAD binding 
protein 
IPR016166 (66) - Nagy et al., 2016 
oo2r9 GMC 
oxidoreductase 
IPR012132 (75) - Olson et al., 2012 
 
4.3.2 Heterologous Expression of the Illudin BGC in A. oryzae 
Microbial natural products are a tremendous source of new bioactive chemical entities for drug 
discovery (Karwehl and Stadler, 2016). Basidiomycota have been playing a secondary role in 
discovering natural products because they can hardly be isolated from soil samples and their 
fermentation often requires special protocols (Karwehl and Stadler, 2016). However, numerous 
natural products with distinct structures have been characterized from both cultures and fruiting 
bodies of Basidiomycota since the mid-1970s (Chen and Liu, 2017; De Silva et al., 2013). 
Compared to other microbial producers such as bacteria and filamentous fungi (especially 
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Ascomycota), Basidiomycota remains greatly undescribed for the discovery and applications 
of enzymatic machinery in biosynthesis (Sandargo et al., 2019a).  
The number of genome sequence data available for Basidiomycota has increased in recent years 
(Grigoriev et al., 2014). Genome mining has further led to the discovery of numerous 
uncharacterized metabolic pathways in Basidiomycota. Since many BGC are silent under 
laboratory conditions or their expression levels are very low, heterologous expression of natural 
products has gained more interest in the last decades (Zhang et al., 2019). These BGC may 
encode metabolites with improved biological activities, heterologous expression of them also 
allow the elucidation of biosynthetic pathways of microorganisms. 
For the reconstitution of the desired biosynthetic pathway, the genes from the gene clusters can 
be amplified from genomic DNA (gDNA) or, if intron splicing might be a problem between 
distantly related species, from complementary DNA (cDNA). In this project, the genes were 
amplified from cDNA since the genes from O. olearius contain numerous introns.  
Vector construction and gene combination for A. oryzae transformation 
The quadruple auxotrophic host A. oryzae NSAR1 is often used as a model host organism for 
the expression of large BGC (Lazarus et al., 2014). A. oryzae NSAR1 is deficient in arginine 
(∆argB), adenine (adeA−), methionine (sC−) and ammonium (niaD−) metabolism. Genes 
involved in BGCs assembled in one or a few multiple gene expression plasmids is performed 
using homologous recombination in yeast. Using designed pTYGS expression vectors featuring 
different selection markers (argB, adeA, sC, niaD, bleR, barR) enables the reconstruction of 
larger biosynthetic pathways by simultaneous expression of multiple genes. Each plasmid 
possesses four fungal promotor/terminator pairs for gene cloning (P/Tadh, P/TgpdA, P/Teno, and 
P/TamyB, Figure 41). The first three can be used to add up to three tailoring genes in vivo by 
yeast homologous recombination, which include at least 30 bp homologous overlap sequence 




Figure 41. pTYGS vector family used in this thesis. 
 
For selection in S. cerevisiae, the vector contains the URA3 marker to allow growth in the 
absence of uracil. Transformant colonies contain vector DNA which can be isolated for 
bacterial transformation and screening. The fungal expression vectors contain a colE1 origin 
for replication in E. coli, selection of the vector facilitates resistance to chloramphenicol (camR) 
and ampicillin (ampR). 
In this project, the biosynthesis of illudins starts from omp7 BGC since the core gene omp7 has 
a 10-fold higher catalytic efficiency than omp6. The omp7 BGC encoding a terpene cyclase, a 
cytochrome P450 monooxygenase, and three FAD-binding oxidoreductases. Plasmids were 
constructed in different stages (Figure 42): (1) pTYGS-Arg-ootc; (2) pTYGS-Arg-ootc-ool1; 
(3) pTYGS-Arg-ootc + ool1 + ool3, pTYGS-Ade- oor2 + oor3. The plasmids were recombined 




Figure 42. Vectors constructed in this study and PCR results. 
        
Heterologous expression of vectors in A. oryzae 
Heterologous expression of constructed vectors in A. oryzae NSAR1 led to the acquisition of 
14 transformants from the expression of terpene cyclase (ootc), 11 transformants from the 
expression of terpene cyclase (ootc) and P450 (ool1), and 12 transformants from the expression 
of terpene cyclase (ootc), P450 (ool1) and three oxidoreductases (ool3, oor2, oor3). As stated 
in the introduction (Section 5.1.2), heterologous expression of the core gene ootc from illudin 
omp7 BGC in A. oryzae NSAR1 should lead mainly to the formation of 6-protoilludene, the 
precursor of illudins (stage 1).  
Fourteen transformants from the expression of terpene cyclase (ootc) alone were inoculated in 
20 mL screw top GC headspace vials that contain 6 mL DPY agar slope. The vials were sent 
for GCMS (Thermo Scientific ITQ 900 GC/MS) measurements every two days after an initial 
incubation for four days. The samples were collected through a solid phase microextraction 
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SPME-fibre from the headspace of the samples within 45 min at room temperature. The 
desorption of samples from SPME-fibre was performed in the PTV injector of the gas 
chromatograph for 1 min at 230 oC. The temperature gradient was 50 °C for 1 min, 10 °C/min 
increase rate up to 320 °C, followed by 320 °C for 2 min.  
Obtained raw data were converted to cdf-files by Xcalibur 2.1 software (Thermo Scientific), 
cdf-files were analysed Openchrom (https://lablicate.com/platform/openchrom). Products from 
the transformants were compared to those from A. oryzae NSAR1 controls and blank vials 
(DPY agar only). Seven out of fourteen transformants showed a new peak in comparison to 
controls (Figure 43). This peak has a mass of 206, which would correspond to a reduced 
protoilludene or caryophyllene (Figure 43). However, these results are consistent with the 
release of one of many possible C15H24 isomers, followed by reduction (e.g. addition of H2). 
The purification of this mixture and NMR elucidation will be done in the future since I run out 
of time for this PhD project. 
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Figure 43. A. Production of transformants from expression of ootc detected by GC-MS; B. The 









5. Conclusion and Discussion 
Antibiotic resistance is an increasing threat to human health, to overcome the resistance of 
pathogenic bacteria and fungi, the discovery of compounds with new structures and modes of 
action is needed urgently. Fungi have been proven as a rich source of new and biologically 
active secondary metabolites, which broadened from saprophytic terrestrial strains to living 
plants with their endophytes and marine habitats. However, only ~ 5% fungal species have been 
characterised and most of the collected strains are waiting for identification (Hawksworth, 
2011). Tropical rainforests are widely known as the most biologically diverse terrestrial 
ecosystems on earth (Armstrong, 2018), offering high opportunities for discovering new fungal 
species. Those give rise to a high probability that tropical rainforests are a promising source for 
novel structures and active compounds (Reddell and Gordon, 2000). 
Most of the metabolites currently in developmental pipelines are derived from ascomycetes, 
e.g. Penicillium and Aspergillus species. Basidiomycetes cultures are difficult to handle with 
respect to large scale production of secondary metabolites since they grow slowly and have low 
yields. They were therefore neglected for a long time in natural product research and studied 
less (Hyde et al., 2019). However, interest in basidiomycetes, and the number of new natural 
products derived from them, has grown considerably due to the unique structures and promising 
biologically activities of metabolites produced by them (Stadler and Hoffmeister, 2015). The 
main purpose of this project is to screen and identify the active components from the largely 
neglected basidiomycetes originated from African tropics. In order to clarify the diversity of 
Basidiomycota and its prosperous chemistry structures, the extensive study of natural products 
in several basidiomycetes collected from Kenyan tropical rainforest Kakamega and Mount 
Elgon national reserve was carried on in the past years. 
About 200 cultures of basidiomycetes were isolated from the collected species in Kakamega 
and Mount Elgon national reserve (Chepkirui, 2018), and 27 (see Appendix) among them were 
screened for antimicrobial activities in three standard media in this project. Five strains and one 
corresponding fruitbody collection were selected and studied extensively for secondary 
metabolites, which led to the characterization of over forty undescribed metabolites together 
with several known secondary metabolites. The undescribed compounds contain various 
structures and bioactivities. Promisingly, five of them with four novel carbon skeletons.  
The previous unprecedented tyromycin A derivatives skeletocutins A-Q isolated from both the 
liquid cultures and fruiting bodies of Skeletocutis sp. and their activities tested in this project 
enriched the published knowledge of tyromycins. These compounds were evaluated in 
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antimicrobial, cytotoxicity, biofilm inhibition, nematicidal, leucine aminopeptidases inhibition, 
and antiviral assays. Notably, the activity inhibits HCV by tyromycin A was reported firstly 
after 27 years of the discovery of this compound.  
Several sesquiterpenes (elgonenes A-L) were obtained from the important traditional Asian 
medicinal mushroom Sanghuangporus sp.. Some of these elgonenes are structurally related to 
the phelilanes, which were patented as part of an antibacterial agent that is being marketed for 
the treatment of ailments (Kobayashi et al., 2010). Additionally, elgonenes devoid of the 
activity or weakly active against tested Gram-positive bacteria and M. hiemalis, some of 
cytotoxic against human cell lines as well. The metabolites derived from Heimiomyces sp. are 
even interesting since five of them contain four novel carbon skeletons, the stereochemistry 
analysis is ongoing. They exhibited moderate antimicrobial and cytotoxic activities against 
Gram-positive bacteria and human cell lines, respectively. Further bioactivities evaluation of 
these compounds could give help for searching the specific and selective targets for them, and 
the chemical modification may also improve the activities of the reported compounds.  
Apart from the natural products mining by fermentation and preparative HPLC approaches from 
basidiomycetes, the attention at the genetic modification is increasing with the development of 
genomics technology. Basidiomycetes producing notable biological activities yields could be 
selected for genome sequencing, gene clusters identifying and heterologous expression. The 
elucidation of biosynthesis pathway could accelerate the development of natural products for 
medicinal applications.  
With the purpose of identifying agents like alkylants with antitumor activity, the modification 
of illudins M and S have awakened a lot of interest among academic research since the early 
1990s. The dehydroilludin M and HMAF (irofulven), which were modified from illudins M 
and S, respectively, have shown an improved therapeutic index. However, the biosynthesis of 
illudins still remains undiscovered.  
Three plasmids were constructed based on the sesquiterpene gene cluster omp7 BGC in this 
thesis. They were expressed in A. oryzae NSAR1. The plasmid contains only one terpene 
cyclase gene, was expected to produce the proposed precursor of illudins 6-protoilludene. The 
production of transformants from the expression of ootc was detected by GCMS system since 
the structure of 6-protoilludene make it a volatile compound. Here we obtained a violate with 
m/z 206, which we proposed as the intermediate of illudins. Based on our results and report of 









































Figure 44. Proposed biosynthesis pathway of illudin. The known steps are in black, proposed steps 
are in grey. 
 
In future work, the screening of rest transformants from stage 2 and stage 3 would be further 
investigated in order to understand the oxidation of the precursor in the biosynthesis of illudins. 
In addition, the research of the second sesquiterpene gene cluster BGC2 annotated from O. 
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7.  Appendices 
Spirodioxynaphthalene derivatives from Sparticola junci (MFLUCC 15-
0030) 
The ascomycete Sparticola junci Phukhamsakda, Camporesi & K.D. Hyde represents the ex-
type strain of this species, was collected and isolated from a dead branch of Spartium junci 
(Phukhamsakda et al., 2016). Five plugs mycelium from a 20-day old Sparticola junci in YMG 
agar plate were used for preparing seed cultures (500 mL flask containing 200mL YMG media 
and incubated on a shaker at 23 °C and 140 rpm). After 30 days, the seed cultures were 
homogenized by using an Ultra Turrax and 10 mL of them were inoculated in each of the 30 × 
500 mL flasks with 200mL Q6 ½ medium, all of them incubated in same condition as seed 
cultures for 21 day. The extraction of supernatant and mycelia yielded 3g of a brown syrup. 
The purification by preparative HPLC led to the characterization of 7 highly oxygenated and 
functionalized spirodioxynaphthalene natural products sparticolins A-G 53-59 (Publication 6, 
Figure 45). Among them, Sparticolin B and sparticolin G exhibited inhibitory activity against 
various Gram-positive bacteria and fungi. All other sparticolins were only weakly active against 
Staphylococcus aureus and also showed weak activities against the nematode Caenorhabditis 
elegans. Sparticolin B and sparticolin G also showed moderate cytotoxic activities against 


























Sparticolin A (53) Sparticolin B (54) Sparticolin C (55) Sparticolin D (56)
Sparticolin E (57) Sparticolin F (58) Sparticolin G (59)  




Table 17. Basidiomycetes screened in this project 
Strain code  Name 
bioactivity screening results of extracts from small 
scale fermentation 
MUCL56056 Abortiporus sp. Nov weak antibacterial and moderate antifungal activity 
MUCL56348 Antrodia sp. Nov 
weak antifungal activity and potential to inhibit the 
formation of B. subtilis 
MUCL56349 Antrodia sp. Nov potential to inhibit the formation of B. subtilis 
MUCL56350 Antrodia sp. Nov potential to inhibit the formation of B. subtilis 
MUCL56165 Asterostroma sp. moderate antifungal activity 
MUCL56166 Asterostroma sp. moderate antifungal activity 
MUCL55600 Fuscoporia sp. moderate antifungal activity 
MUCL55606 Fuscoporia sp. weak antibacterial and moderate antifungal activity 
MUCL56038 Fuscoporia sp. moderate antifungal activity 
MUCL56351 Gloeophyllum sp. 
weak antifungal activity and potential to inhibit the 
formation of B. subtilis   
MUCL56368 Haploporus sp. no activity 
MUCL56369 Haploporus sp. no activity 
MUCL56078 Heimiomyces sp. strong antibacterial activity 
MUCL55557 Lentinus sp. moderate antifungal activity 
MUCL55560 Lentinus sp. moderate antifungal activity 
MUCL55566 Lentinus sp. moderate antifungal activity 
MUCL55578 Lentinus sp. moderate antifungal activity 
MUCL56028 Perenniporia sp. no activity 
MUCL56044 Perenniporia sp. no activity 
MUCL56346 Rigidoporus ulmarius weak antibacterial and moderate antifungal activity 
MUCL56354 Sanghuangporus sp. moderate antibacterial activity 
MUCL56345 Sanghuangporus sp. weak antibacterial activity 
MUCL56347 Sanghuangporus sp. weak antibacterial activity 
MUCL56352 Sanghuangporus sp. weak antibacterial activity 
MUCL55598 Schizoporia sp. weak antifungal activity 
MUCL56036 Schizoporia sp. weak antifungal activity 
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ABSTRACT: During the course of searching for new anti-
infective and other biologically active secondary metabolites from
Kenyan basidiomycetes, 13 previously undescribed metabolites,
(6R,7S,10R)-7,10-epoxy-7,11-dimethyldodec-1-ene-6,11-diol (1)
and 12 sesquiterpenes named elgonenes A−L (2−13), and the
known compound P-coumaric acid (14) were isolated from a
basidiomycete collected in Mount Elgon Natural Reserve. The
producing organism represents a new species of the genus
Sanghuangporus, which is one of the segregates of the important
traditional Asian medicinal mushrooms that were formerly known
as the “Inonotus linteus” complex. The structure elucidation of
compounds 1−13, based on 2D NMR spectroscopy, high-
resolution mass spectrometry, and other spectral methods, and
their antibacterial, antifungal, and cytotoxic activities are reported.
The phylum Basidiomycota comprises the mushroom-forming fungi and various other organisms that represent
a considerable part of the global biodiversity. Recent molecular
ecology studies have revealed huge diversity of fungi in
different habitats, including soil, plants, and invertebrates.1
Unfortunately, most of these fungi and especially the majority
of the species from tropical areas have neither been cultured
nor studied for potential beneficial traits such as the
production of antibiotics or other useful secondary metabo-
lites.2 For the last four years, we have embarked on an
extensive study of the secondary metabolites of basidiomycetes
collected from Kenya’s tropical rain forests, Kakamega and
Mount Elgon National Reserves. This study has resulted in the
discovery of novel structurally diverse metabolites.3−8 The
genus Sanghuangporus in the family Hymenochaetaceae and
the order Hymenochaetales belongs to the group of medicinal
mushrooms commonly known as the Inonotus linteus complex
(also referred to as the Phellinus linteus complex). This
complex consists of species originally described in the genera
Phellinus and Inonotus, which were eventually transferred to
Inonotus based on molecular studies.9 Although the species of
the I. linteus complex were placed in the genus Inonotus, their
perennial basidiomes with a dimitic hyphal system distinguish
the complex from other species in the genus. This has led to
the segregation of this group to accommodate the I. linteus
complex in the new genera Sanghuangporus and Tropicoporus.10
These medicinal mushrooms have been used as folk medicines
in Asian countries for thousands of years, in particular for the
treatment of hemorrhage, hemostasis, and diseases related to
menstruation. The species Phellinus linteus (Tropicoporus
linteus) in particular has been used in traditional Chinese
medicine because of its therapeutic effects on various ailments
including tumor, diabetes, inflammation, and obesity.9,11
The novel phelligridin L together with the four known
sesquiterpenes ionylideneacetic acid, 1S-(2E)-5-[(1R)-2,2-
dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enoic acid,
and phellidines D and E were reported previously from a study
of Sanghuangporus sp. (MUCL55592).5 In the study reported
here a fungal strain identified as Sanghuangporus sp.
(MUCL56354) was examined for the production of bioactive
metabolites. Herein, we describe the isolation, structure
elucidation, and biological evaluation of 13 previously
undescribed secondary metabolites (1−13) and P-coumaric
acid (14).
■ RESULTS AND DISCUSSION
The strain MUCL 56354 was identified by comparison of
morphological characteristics and sequencing of the 5.8S/ITS
nrDNA,12 as described in the Experimental Section. A BLAST
search in GenBank confirmed the generic affinities of the strain
to the genus Sanghuangporus in the Hymenochaetaceae by a
closest hit to KP030787.1 (Sanghuangporus microcystideus)
with 96% identity (cf. Figure 109 in the Supporting
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Table 1. NMR Spectroscopic Data for Compound 1 (1H 700 MHz, 13C 175 MHz in Acetone-d6), Compounds 2 and 3 (
1H 700
MHz, 13C 175 MHz, in CDCl3), and Compound 4 (
1H 500 MHz, 13C 125 MHz, in CDCl3)
1 2 3 4
no. 13C 1H/HSQC 13C 1H/HSQC 13C 1H/HSQC 13C/DEPT 1H/HSQC
1 113.8, CH2 5.05, dd (17.64, 1.08) 29.4, CH2 1.55, m 31.5, CH2 2.02, m 170.6, C
5.30, dd (17.64, 1.08) 1.88, m 2.06, m
2 139.9, CH 6.39, dd (17.64, 10.76) 30.6, CH2 1.99, m 30.6, CH2 1.98, m 130.3, C
2.07, m 2.05, m
3 147.8, C 133.9, C 133.9, C 140.1, CH 6.87, br d (8.82)
4 29.2, CH2 a: 2.23, m 120.2, CH 5.41, m 120.2, CH 5.40, m 69.9, CH 4.53, dd (8.82, 4.52)
b: 2.55, m
5 31.9, CH2 a: 1.42, m 31.6, CH2 2.05, m 29.4, CH2 1.49, m 76.4, CH 4.34, d (4.52)
b: 1.69, m 2.12, m 1.86, m
6 77.2, CH 3.50 dd (17.64) 36.9, CH 2.14, m 36.9, CH 2.05, m 152.7, C
7 86.9, C 152.1, C 151.1, C 36.8, CH 2.12, ma
8 32.7, CH2 a: 1.50, m 73.3, CH 4.41, d (4.30) 71.9, CH 4.54, br s 29.6, CH2 1.49, m
b: 2.12, m 1.84, m
9 27.3, CH2 1.87, m 82.3, CH 4.95, m 78.9, CH 4.49, ddd (3.44, 6.29, 9.84) 30.6, CH2 1.98, m
a
1.97, m 2.04, ma
10 85.5, CH 3.79, t (7.42) 145.3, CH 7.07, m 29.4, CH2 1.95, m 133.7, C
2.20, m
11 71.7, C 131.7, C 35.5, CH 2.68, m 120.5, CH 5.41, m
12 26.6, CH3 1.07, s 173.9, C 179.4, C 31.6, CH2
a1.99, m
a2.08, m
13 27.8, CH3 1.20, s 23.4, CH3 1.67, s 23.4, CH3 1.66, s 23.4, CH3 1.66, s
14 23.7, CH3 1.11, s 111.4, CH2 5.15, br s 110.8, CH2 5.07, s 111.3, CH2 5.07, s
5.27, br s 5.28, s 5.22, s
15 116.2, CH2 a: 5.04, s 10.9, CH3 1.96, t (1.94) 15.1, CH3 1.30, s 13.0, CH3 1.92, s
b: 5.05, s
aPeaks overlapping with other peaks.
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Information). Further taxonomic studies including compar-
isons with type specimens of related species are ongoing to
characterize this strain to the species level, but it constitutes an
undescribed taxon according to the data presently available.
The extracts of the strain (MUCL56354) exhibited activity
against Bacillus subtilis with an MIC 37.5 μg/mL (compared to
the positive control ciprofloxacin at MIC 3.1 μg/mL).
Extensive chromatography of the extracts led to the
bioactivity-guided isolation of 13 previously undescribed
compounds and the known P-coumaric acid, the latter of
which was identified by comparing its NMR data with those
reported in the literature.13
Compound 1 was obtained from the supernatant as a yellow
oil with the molecular formula C15H26O3 deduced from the
HR-ESIMS data. The 13C NMR spectroscopic data of 1
revealed the presence of 15 carbon signals, which were further
identified as three methyl, six methylene, three methine, and
three nonprotonated carbons (one sp2 carbon and two sp3
oxygenated carbons) from the DEPT NMR data. The 1H
NMR spectrum revealed three methyl singlets resonating at δ
1.07 (H3-12), 1.11 (H3-14), and 1.20 (H3-13). A doublet and
triplet resonating at δ 3.50 and 3.79 attributed to oxygenated
methines were also recorded. HMBC correlations of H2-1 to
C-2/C-3, H2-15 to C-2/C-4, and H2-5 to C-3/C-4/C-6/C-7
along with the COSY correlations of H2-1 to H-2 and H2-5 to
H2-4/H-6 confirmed the first side chain in the molecule
attached at C-7. The methyl protons H3-14 showed HMBC
correlations to C-6/C-7/C-8, while methylene protons H2-9
correlated with C-7/C-8/C-10/C-11. Cross-peaks were
recorded between H2‑8 and H2-9 in the COSY spectra. The
chemical shifts of C-7 (δ 86.9) and C-10 (δ 85.5) and the
HMBC correlation of H-10 to C-7 indicated that these carbons
were connected via an oxygen bridge forming the oxolane. The
methyl group protons H3-12 showed HMBC correlations to C-
11/C-10/C-13. Based on the molecular formula of 1 and the
chemical shift of C-11 (δ 71.7), it was determined that a
hydroxy group was attached to this carbon. Cross-peaks were
also observed in the ROESY spectra between H3-14 and H-6/
Hb-5/Ha‑8, H-6 and Hb-5/Ha-4/Ha-8, and Ha-9 and Ha-8/H-
10. The closely related compounds neroplofurol and 7,10-
epoxy-3,7,11-trimethyldodec-2-ene-1,6,11-triol have been re-
ported from the plant Oplopanax horridus and the actino-
bacterium Streptomyces scopuliridis, respectively.14,15 The
relative stereochemistry at C-10 for this class of compounds
was reported to be significantly impacted by the orientation of
14-Me and the 2-hydroxysopropyl moiety. According to Inui et
al.,14 a chemical shift of C-10 (about δ 85 ppm) indicates the
anti-orientation of these two substituents because of the γ-
gauche effect caused by an alkyl substituent at C-6. For the
case where the two substituents are in the syn-orientation, the
C-10 is shifted downfield by around 3.3 ppm. Based on these
literature data and the ROESY correlations observed by us, the
relative stereochemistry of 1 was assigned as 6R*, 7S*, 10R*.
The absolute stereochemistry of 1 was consequently assigned
by derivatization with both R- and S-MTPA chloride to their
corresponding S- and R-MTPA esters.16 The C-5/C-4
methylene protons gave positive values, while the H3-14/H2-
8/H2-9 gave negative values for the ΔδSR = δ(S-MTPA ester)
− δ(R-MTPA ester) (see Table 1 in the Supporting
Information). Therefore, the absolute stereochemistry at C-6
was assigned as R and the absolute configurations of the other
stereocenters were assigned as 7S and 10R. The structure of 1
was concluded to be (6R,7S,10R)-7,10-epoxy-7,11-dimethyl-
dodec-1-ene-6,11-diol (1).
Table 2. NMR Spectroscopic Data for Compound 5 (1H 500 MHz, 13C 125 MHz in Acetone-d6), Compound 6, (
1H 500 MHz,
13C 125 MHz in Methanol-d4), and Compounds 7−9 (1H 700 MHz, 13C 175 MHz in CDCl3)









DEPT 1H/HSQC 13C 1H/HSQC 13C 1H/HSQC
1 169.2, C 171.8, C 171.0, C 24.6, CH2 1.48, m 24.5, CH2 1.48, m
1.88, m 1.86, m
2 128.9, C 129.9, C 130.3, C 29.8, CH2 1.98, m 29.9, CH2 1.98, m
3 142.4, CH 6.99, m 142.7, CH 6.98, m 141.5, CH 6.89, dd (8.93,
1.18)
134.1, C 134.1, C
4 31.8, CH2 2.32, m 32.0, CH2 2.31, m 69.9, CH 4.73, dd (8.82,
6.45)
119.5, CH 5.35, m 119.6, CH 5.35, m
2.59, m 2.58, m
5 75.2, CH 3.68, dd (2.59,
9.92)
75.6, CH 3.64, m 74.9, CH 3.72, d (6.45) 27.0, CH2 1.86, m 27.1, CH2 1.86, m
2.00, m 2.05, m
6 75.6, C 76.7, C 77.4, C 41.4, CH 1.40, m 41.6, CH 1.40, m
7 41.3, CH 1.77, m 42.3, CH 1.79, m 40.7, CH 1.74, m 64.2, C 64.1, C
8 24.6, CH2 1.34, m 27.7, CH2 1.36, m
a 23.5, CH2 1.35, m 61.1, CH 2.57, d (8.39) 63.1, CH 2.80, d (7.96)
1.81, m 1.84, ma 1.81, m
9 31.7, CH2 1.93, m 27.7, CH2 2.04, m
a 30.6, CH2 1.98, m
a 78.1, CH 4.63, dt (1.77,
8.50)
75.2, CH 4.17, ddd (5.83, 7.96,
13.55)2.13, ma 2.04, ma
10 133.9, C 138.5, C 133.8, C 147.1, CH 7.22, m 35.5, CH2 1.88, m
2.64, tt (5.81, 8.60)
11 122.3, CH 5.38, m 123.8, CH 5.67, m 120.5, CH 5.40, m 130.9, C 35.0, CH 2.69, m
12 26.7, CH2 2.01, m
a 26.7, CH2 2.04, m
a 25.6, CH2 2.05, m
a 173.6, C 179.1, C
2.16, ma 2.20, ma 2.09, ma
13 23.6, CH3 1.61, br s 67.4, CH2 3.91, s 23.3, CH3 1.66, s 23.4, CH3 1.64, br s 23.4, CH3 1.64, br s
14 19.8, CH3 1.16, s 19.2, CH3 1.17, s 19.8, CH3 1.31, s 13.9, CH3 1.38, s 13.9, CH3 1.31, s
15 12.8, CH3 1.81, d (1.22) 12.9, CH3 1.84, s 13.0, CH3 1.96, s 10.8, CH3 1.97, d (1.72) 15.2, CH3 1.33, d (6.88)
aPeaks overlapping with other peaks.
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Compound 2 was isolated as a yellow oil from both the
supernatant and the mycelia. The HR-ESIMS data revealed the
molecular formula to be C15H20O3 with six degrees of
unsaturation. Two methyl peaks at δ 1.67 (H3-13) and 1.96
(H3-15) and two olefinic singlets at δ 5.15 and 5.27 were
recorded in the 1H NMR spectrum. A total of 15 carbons, two
methyl groups, four methylene groups, five methine groups,
and four nonprotonated carbons could be identified from the
13C and DEPT NMR data. In the HMBC spectrum
correlations of H-9 to C-10/C-11/C-12/C revealed the
dihydrofuran part of the molecule. Correlations of H3-15 to
C-10/C-11/C-12 were also observed in the HMBC spectra.
Further, HMBC correlations of H-8 to C-6/C-7/C-9/C-10/C-
14 were observed. Cross-peaks in the COSY spectrum were
also recorded between H-9 and H-8/H-10. The position of the
vinyl group was confirmed from the HMBC correlations of H2-
14 to C- 6/C-7/C-8. The COSY correlations of H2-1 to H-6/
H2-2 and H2-5 to H-6/H-4 along with the HMBC correlations
of H3-13 to C-2/C/3/C-4 confirmed the cyclohexyl part of the
molecule connected through C-6. ROESY correlations were
observed between H-8 and H-6/H-9. The absolute stereo-
chemistry of 2 was assigned by derivatization with R and S
MTPA chloride. The ΔδSR = δ(S-MTPA ester) − δ(R-MTPA
ester) for protons neighboring C-8 (see Table 2 in the
Supporting Information) led to the S-configuration assignment
at C-8 and consequently the assignment of 6R and 9R for the
other respective stereocenters.
Compound 3, with the molecular formula C15H22O3 and five
degrees of unsaturation deduced from HR-ESIMS data, was
isolated from both the supernatant and the mycelial extracts.
Analysis of the 1D and 2D NMR data for 3 revealed a similar
structure to 2 with the double bond at C-10 missing in
compound 3. Analysis of the 13C NMR data for 3 indicated the
absence of the olefinic C-10 occurring at δ 145.3 and the C-11
(131.7) in compound 2 and a methylene and methine signals
at δ 29.4 and 35.5, respectively, were observed. The H3-15 (δ
1.30) showed HMBC correlation to C-10 (δ 29.4)/C- 11 (δ
35.5)/C-12 (δ 179.4). Additional ROESY correlations
between H-9 and H-11 were also observed. Since compounds
2 and 3 were obtained as congeners, the absolute stereo-
chemistry of 3 was assigned as 6R, 8S, 9R, and 11R.
Compounds 2 and 3 are structurally related to phelilane D
from Inonotus vaninii,17 i.e., a species that is closely related to
Sanghuangporus.
Compound 4 was isolated as a yellow oil only from the
supernatant. The HR-ESIMS data revealed the molecular
formula to be C15H22O4 with five degrees of unsaturation.
Analysis of the 1D and 2 D NMR data suggested a structure
closely related to compound 2. Similar COSY, HMBC, and
ROESY correlations were observed except for the HMBC
correlations of H-4 to C-1, which was missing in 4, indicating
that this compound had an open end chain instead of the
dihydrofuran in 2. This was in agreement with the HR-ESIMS
data, which showed the presence of four oxygen atoms for this
molecule. The olefenic double bond between C-2 and C-3 was
Table 3. NMR Spectroscopic Data for Compound 10 (1H 500 MHz, 13C 125 MHz in Acetone-d6), Compound 11 (
1H 700
MHz, 13C 175 MHz in Acetone-d6), Compound 12 (
1H 500 MHz, 13C 125 MHz in CDCl3), and Compound 13 (
1H 700 MHz,
13C 175 MHz in CDCl3)
10 11 12 13
no. 13C/DEPT 1H/HSQC 13C/DEPT 1H/HSQC 13C/DEPT 1H/HSQC 13C/DEPT 1H/HSQC
1 150.1, C 148.8, C 150.1, C 149.1, C
2 33.0, CH2 2.03, m
a 34.5, CH2 2.03, m 33.0, CH2 2.03, m 32.3, CH2 2.03, m
2.16, m 2.25, ma 2.16, ma 2.06, m
3 24.2, CH2 1.53, m
a 25.2, CH2 1.59, m
a 23.6, CH2 1.56, m
a 23.6, CH2 1.53, m
a
1.66, m
4 31.7, CH2 1.34, m
a 34.8, CH2 1.56
a 33.1, CH2 1.29, m
a 36.1, CH2 1.23, m
a
1.59, m 1.95, td (4.62, 8.44) a1.63, m 1.47, ma
5 40.1, C 49.3, C 40.0, C 34.9, C
6 49.3, CH 2.06, ma 49.1, CH 2.66, dd (2.37, 11.4) 45.5, CH 2.12, dd (2.90, 11.75) 53.8, CH 1.73, dd (3.01, 11.19)
7 27.2, CH2 1.68, m 28.4, CH2 1.58, m
a 22.9, CH2 1.63, m
a 24.8, CH2 1.50, m
a
1.75, m 1.75, m 1.63, m
8 23.9, CH2 2.21, m
a 23.9, CH2 2.27, m
a 34.4, CH2 2.03, m 34.4, CH2 1.90, m
2.40, m 2.47, m 2.16, ma 2.13, m
9 126.4, C 126.1, C 143.6, C 144.5, C
10 111.9, CH 6.35, br s 111.9, CH 6.34, br s 127.9, CH 5.62, t (6.87) 126.1, CH 5.64, t (6.88)
11 143.7, CH 7.44, br s 143.7, CH 7.43, br s 58.5, CH2 4.14, dd (12.36, 6.87) 58.7, CH2 4.24, br d (6.88)
4.22, ma 4.28, dd (3.44, 6.88)a
12 139.8, CH 7.34, br s 139.8, CH 7.34, br s 108.8, CH2 4.59, s 109.2, CH2 4.56, s
4.86, s 4.78, s
13 109.8, CH2 4.60, s 109.8, CH2 4.69, s 19.1, CH3 0.74, s 26.4, CH3 0.85, s
4.81, s 4.87, s
14 21.6, CH3 0.82, s 19.8, CH3 1.06, s 69.5, CH2 3.29, d (11.29) 28.4, CH3 0.92, s
3.56, d (11.29)
15 68.6, CH2 3.23, d (10.76) 178.5, C 60.7, CH2 4.05, s 61.2, CH2 4.18, s
3.50, d (10.76) 4.23, s 4.19, s
aPeaks overlapping with other peaks.
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assigned an E-configuration because of the upfield shifts of C-
15 (δ 13.0). ROESY correlations of H-7 suggested that this
compound shared the same R-configuration with 2 at C-7;
hence the stereochemistry of this molecule was assigned as 4S,
5S, and 7R. This compound is closely related to 2-methyl-6-(4-
methyl-3-cyclohexen-1-yl)-2,6-heptadienoic acid, (E)-(9CI),
previously reported in the patent by Kobayashi et al.
Tropicoporus linteus.18
Compound 5 was isolated as a yellow oil from the
supernatant extract. It had the molecular formula C15H24O4
and showed four degrees of unsaturation as established from
the HR-ESIMS data. Three methyl singlets at δ 1.16 (H3-14),
1.61 (H3-13), and 1.81 (H3-15) were observed in the
1H NMR
spectrum. Further, three methyl, four methylene, four
methane, and four nonprotonated carbons (three sp2 carbons
and one oxygenated sp3 carbon) were identified from the 13C
and DEPT NMR data. HMBC correlations of H3-15 to C-1/C-
2/C-3, H-5 to C-3/C-4/C-6/C-14, and H3-14 to C-5/C-6/C7
established the structure of the side chain. COSY correlations
were also observed between H-4 and H-3/H-5. Similar COSY
and HMBC correlations making up the cyclohexyl moiety
connected to the side chain through C-7 in compounds 1, 2,
and 3 were also established for this compound. The double
bond at C-2 was assign as E based on the upfield shift of C-15
(δ 12.8). ROESY correlations H-14 to H-7/H2-4 (δ 2.32)/H2-
12 (δ 2.01) indicated that these protons were on the same side
of the plane. On the other hand cross-peaks were observed
between H-5 and H2-4 (δ 2.59)/H2-12 (δ 2.16) in the ROESY
spectra. To assign the absolute stereochemistry, both S- and R-
MTPA ester derivatives of 5 were prepared from R- and S-
MTPA chloride, respectively. The ΔδSR = δ(S-MTPA ester) −
δ(R-MTPA ester) for protons neighboring C-5 gave negative
values for the C-4 methylene protons (−0.005 and −0.008)
and positive values for H3-14 and H-7, i.e, + 0.003 and +0.012,
respectively (Table 3 in the SI). Therefore, the absolute
stereochemistry at C-5 was assigned as S, and consequently the
other centers were assigned as 6R, 7R. Phellilane H, previously
reported from Phellinus linteus (current valid name Tropicopo-
rus linteus10), has a similar structure to 5 but a different
stereochemistry.18
Compound 6, with the molecular formula C15H24O5 and
four degrees of unsaturation deduced from HR-ESIMS data,
was isolated from supernatant extracts. Analysis of the 1D and
2D NMR data for 6 indicated a similar structure to 5 with the
C-13 methyl group missing in compound 6, but an
oxymethylene peak at δ 67.4 (C-13) was recorded instead.
The H2-13 (δ 3.91) showed HMBC correlations to C-9/C-10/
C-11.
Compound 7, which was isolated as a yellow oil only from
the supernatant extract, had a molecular formula of C15H24O5
and four degrees of unsaturation established from the HR-
ESIMS data. Analysis of the 1D and 2D NMR data for 7
indicated a similar structure to that of 5 with the C-4
methylene group replaced by an oxymethine signal resonating
at δ 69.9. COSY correlations between the oxymethine proton
(δ 4.73) and H-3/H-5 were observed. Furthermore, a
correlation of this proton (H-4) to C-2/C-3/C-5/C-6 could
be established in the HMBC spectra. In the ROSY spectra of 7,
similar correlations to those observed for 5 were recorded. In
addition, cross-peaks in the ROESY spectra of 7 were recorded
between H-4 and H3-14/H-7. Thus, the 4S, 5S, 6R, and 7R
configurations were concluded for this molecule. The
comparison of the circular dichroism (CD) spectra of 5 and
7 supported this conclusion, as the electronic circular
dichroism (ECD) curves of these compounds were comparable
in the range of 204−240 nm (positive Cotton effect registered)
(Figure 1). Compounds 6 and 7 are also closely related to
phelilane H.18
Compounds 8 and 9 were isolated as yellow oils from both
the supernatant and mycelial extracts. The mixture of the two
compounds (ratio 2:1) could not be separated, but their NMR
data were clearly resolved and, thus, their structures could be
determined independently. HR-ESIMS data revealed their
molecular weights as C15H20O3 and C15H22O3 for compounds
8 and 9, respectively.
For compound 8 HMBC correlations of H3-15 to C-10/C-
11/C-12, H-9 to C7/C-8/C10/C-11/C-12, and H3-14 to C-6/
C-7/C-8 together with the COSY correlations of H-9 to H-8/
H-10 confirmed one part of the structure. The chemical shift of
C-9 (δ 78.1) and the HMBC correlations of H-9 to C-12
suggested that C-9 and C-12 were linked via an oxygen bridge,
forming a dihydrofuran. Similar HMBC and COSY correla-
tions making up the cyclohexyl part of the molecules already
described above for the congeners were also recorded for this
molecule. Based on the chemical shifts of the C-7 (δ 64.2) and
C-8 (δ 61.1) an epoxide was concluded to be in the molecule.
The 1D and 2 D NMR data of 9 were similar to those of 8,
with the difference being the absence of the olefinic bond
between C-10 and C-11. For both compounds ROESY
correlations of H3-14 to H-6/H-8/H-9 and H-8 to H-6/H-9
were observed and cross-peaks were recorded between H-9
and H-11 in the ROSY spectra of 9. These correlations
revealed that these compounds had the same stereochemistry
as 5 at C-5 and C-6. The stereochemistry of this molecule was
thus assigned as 6R, 7R, 8R, and 9R. Comparison of the CD
spectra of the mixture of compounds 8/9 with that of 5
supported this assignment, as only a positive Cotton effect in
the range of 194−240 nm was observed for the mixture
(Figure 1). Therefore, the structures of 8 and 9 were




respectively. These two compounds are closely related to
phelilane E from Tropicoporus linteus.18
Compound 10, with the molecular formula C15H22O2 and
five degrees of unsaturation determined from the HR-ESIMS
Figure 1. ECD spectra of compounds 5, 7, and 8/9 in ethanol.
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data, was obtained as a yellow oil only from the supernatant
extract. One methyl, seven methylene, four methane, and three
nonprotonated carbons (two sp2 carbons and one sp3 carbon)
were identified in the 13C and DEPT NMR spectra. COSY
correlations of H2-3 to H2-2/H2-4, as well as the HMBC
correlations of H2-13 to C-1/C-2/C-6 and H3-14/H2-15 to C-
4/C-5/C-6, confirmed the cyclohexane ring part in the
molecule. Further cross-peaks in the COSY spectra between
H2-7 and H-6/H2-8 were established. In the HMBC spectra
H2-8 showed correlations to C-6/C-7/C-9/C-10/C-12, H-10
to C-9/C-11/C-12, and H-12 to C/9/C-10/C-11. Based on
the chemical shift of C-11 (δ 143.7) and C-12 (δ 139.8) the
two carbons were linked via an oxygen bridge forming the
furan. Hence the structure was elucidated as {5-[9-(furan-9-
yl)ethyl]-5-methyl-1-methylidenecyclohexyl}methanol.
Compound 11 was isolated as a yellow oil from both the
supernatant and mycelia extracts. The HR-ESIMS data
revealed the molecular formula to be C15H20O3 with 6 degrees
of unsaturation. The 1D and 2D NMR data for 11 revealed a
similar structure to 10 except that the oxymethylene group at δ
68.6 (C-15) in 10 was missing and a carboxylic acid peak at δ
178.5 (H-15) was observed instead. The H3-14 correlated to
this carbon in the HMBC spectra. Interestingly, compounds 10
and 11 are somewhat structurally related to dihydropallescen-
sin-2 from the defensive organs of the nudibranch Tyrinna
nobilis.19
Compound 12 was isolated as a yellow oil from the
supernatant with the molecular formula C15H26O3 established
from the HR-ESIMS data. 1D and 2D NMR data for 12
indicated a structure similar to 10 with the open end chains
instead of the furan. Two oxymethylene carbons at δ 58.5 (C-
11) and 60.7 (C-15) were identified in the 13C/DEPT NMR
data. HMBC correlations of the diastereotopic protons H2-11
(δ 4.14, 4.22) to C-9/C-10 and H2-15 (δ 4.05, 4.23) to C-8/C-
9/C-10 were observed. The olefinic bond between C-9 and C-
10 was assigned the Z-configuration because of the ROESY
correlations of H-10 (δ 5.62) to the diastereotopic protons H2-
8 (δ 2.03, 2.16). Therefore, the structure was unambiguously
determined to be (9Z)-9-{9-[(5-(hydroxymethyl)-5-methyl-1-
methylidenecyclohexyl]ethyl}but-9-ene-11,15-diol.
Compound 13 was obtained as a yellow oil from both
supernatant and mycelia extracts with the molecular formula
C15H26O2 determined from the HR-ESIMS data. The 1D and
2D NMR data indicated a similar structure to that of
compound 12 with the difference being the substituents at
C-5. The C-14 hydroxymethyl group in 12 was replaced with a
methyl group (δ 28.4). The structure of 13 was therefore
c on c l ud ed t o b e (9Z ) - 9 - { 9 - [ ( 5 , 5 - d ime t h y l - 1 -
methylidenecyclohexyl]ethyl}but-9-ene-11,15-diol. The abso-
lute stereochemistry of 13 at C-6 was assigned as S from
comparison of its optical rotation ([α]20D +7.9 in methanol) to
that of the known compound dihydropallescensin-2 ([α]20D
+6.0 in chloroform), which has the same stereocenter.20 To
determine the stereochemistry at C-6 for compounds 10 and
11, CD spectra of these three compounds were measured.
While a negative Cotton effect was observed in the range of
190−220 nm of the ECD curve of compound 13 in EtOH, a
positive Cotton effect was recorded for 10 and 11 (opposite
that of 13) in the same region, suggesting a 6R-configuration
for these two compounds (Figure 2). H3-14 and H-6 did not
correlate in the ROESY spectra, and therefore, a 5R-
configuration was concluded for these compounds. Com-
pounds 12 and 13 are closely related to trans-γ-monocyclo-
farnesol.21
As already mentioned above, some closely related
compounds named phelilanes have previously been patented
from Tropicoporus linteus as part of the composition of an
antibacterial agent that is being marketed for the treatment of
ailments as diverse as gastroenteric dysfunction, diarrhea,
hemorrhage, cancers, and prevention of periodontal disease
and in the form of toothpaste and mouthwash agents in Asia.18
These compounds have to the best of our knowledge never
been published in peer-reviewed papers, but a comparison of
their spectral data proved helpful.
Compounds 4, 5, and 7−14 were evaluated for their
antimicrobial activity (Table 4). Metabolites 1−3 and 6 were
not tested because they were produced in small quantities
(0.42, 0.28, 0.49, and 0.89 mg for each) and they were used in
the pretest bioassay (serial dilution assay tested for Bacillus
subtilis, Escherichia coli, and Candida albicans). Compounds 8/
9 (tested as an inseparable mixture, see above), 10, 11, and 13
showed weak antimicrobial activity against Bacillus subtilis;
compounds 8/9 and 13 demonstrated weak activities against
Micrococcus luteus; compounds 4, 8/9, and 13 exhibited weak
activities against Staphylococcus aureus. Further, most of the
tested compounds demonstrated moderate activity against
Mucor hiemalis, except for compound 7, which was inactive. No
activity against Gram- bacteria or yeast was observed. In the
cytotoxicity assay 4, 8−11, and 13 exhibited weak effects
against KB 3.1 cells, while 10 and 13 showed weak activity
against L929 cells.
Notably, none of the isolated metabolites has reached the
initially observed MIC of the crude extracts. Therefore, we
cannot exclude cumulative effects. However, it might also be
possible that we have lost some potent components due to its
instability during the isolation procedure or that some of the
minor congeners we obtained that were not tested for lack of
material could be more active.
■ EXPERIMENTAL SECTION
General Experimental Procedures. CD spectra were deter-
mined with a JASCO spectropolarimeter, model J-815 (JASCO,
Pfungstadt, Germany). Optical rotations were recorded on a
Figure 2. ECD spectra of compounds 10, 11, and 13 in ethanol.
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PerkinElmer (Überlingen, Germany) 241 MC polarimeter. NMR
spectra were recorded on Bruker 700 spectrometers with a 5 mm TXI
cryoprobe (1H 700 MHz, 13C 175 MHz, 15N 71 MHz) and Bruker
AV III-600 (1H 600 MHz, 13C 150 MHz) spectrometers. HR-ESIMS
mass spectra were measured by using an Agilent 1200 series HPLC-
UV system (column 2.1 × 50 mm, 1.7 μm, C18 Acquity UPLC BEH
(waters), solvent A (H2O + 0.1% formic acid); solvent B (AcCN +
0.1% formic acid), gradient: 5% B for 0.5 min increasing to 100% in
19.5 min and then maintaining 100% B for 5 min, flow rate 0.6 mL/
min, UV/vis detection 200−600 nm combined with ESI-TOF-MS
(Maxis, Bruker)) [scan range 100−2500 m/z, capillary voltage 4500
V, dry temperature 200 °C]. UV spectra were recorded by using a
Shimadzu UV-2450 UV−vis spectrophotometer.
Fungal Material. The fungal specimen was collected by C.
Decock and J. C. Matasyoh from Mount Elgon National Reserve,
located in the western part of Kenya (1°7′6″ N, 34°31′30′′ E) in
April 2016 from wood. A dried specimen and the corresponding
mycelial culture, which was obtained from the contents of the
basidome, were deposited at MUCL, Louvain-la-Neuve, Belgium,
under the accession number MUCL 56354.
DNA was extracted from the culture of MUCL 56354 by using the
EZ-10 spin column genomic DNA miniprep kit (Bio Basic Canada
Inc., Markham, Ontario, Canada) as described previously.12 A
Precellys 24 homogenizer (Bertin Technologies, France) was used
for cell disruption at a speed of 6000 rpm for 2 × 40 s. Standard
primers ITS 1f and NL4 were used for the DNA region amplification
by following the protocol by Otto et al.22
Small-Scale Fermentation. Sanghuangporous sp. MUCL56354
was cultivated in three different liquid media: YM 6.3, Q61/2, and
ZM1/2 (media compositions see Supporting Information). A well-
grown culture from a YM agar plate (YM supplemented with 1.5%
agar, pH = 6.3) was cut into small pieces using a cork borer (7 mm),
and five pieces were inoculated into a 500 mL Erlenmeyer flask
containing 200 mL of the three media. The cultures were incubated at
23 °C on a rotary shaker (140 rpm). The growth of the fungus was
monitored by measuring the amount of free glucose using Diastix
Harnzuckerstreifen (Bayer). The fermentation was terminated 3 days
after glucose depletion.
Scale-up of Fermentation. Analysis of the HPLC-MS data and
subsequent search in the Dictionary of Natural Products database23
revealed the presence of potentially new bioactive metabolites in the
YM 6.3 medium, and this was selected for scale-up. A well-grown YM
agar plate of mycelial culture was cut into small pieces using a 7 mm
cork border and five pieces inoculated into larger batches of sterile
flasks (in total 10 L) by following the original protocol.
Preparation of the Extracts. Supernatant and biomass from
small-scale fermentation were separated by filtration. The supernatant
resulting from an ethyl acetate extract was evaporated to dryness by
means of a rotary evaporator. The mycelia were extracted with 200
mL of acetone in an ultrasonic bath for 30 min and filtered, and the
filtrate was evaporated. The remaining water phase was suspended in
an equal amount of distilled water, extracted with an equal amount of
ethyl acetate, and filtered through anhydrous sodium sulfate, and the
resulting ethyl acetate extract was evaporated to dryness.
The mycelia and supernatant from the large-scale fermentation
were separated via vacuum filtration. The mycelia were extracted with
4 × 500 mL of acetone in an ultrasonic bath for 30 min. The extracts
were combined and the solvent was evaporated by means of a rotary
evaporator. The remaining water phase was suspended in 200 mL of
distilled water, extracted with 3 × 500 mL of ethyl acetate, and filtered
through anhydrous sodium sulfate. The resulting ethyl acetate extract
was evaporated to dryness, leaving a brown solid (151 mg). The
supernatant was extracted by adding 5% Amberlite XAD-16N
absorbent (Rohm & Haas Deutschland GmbH, Frankfurt am Main,
Germany) and incubation of the resin overnight on a shaker. The
Amberlite resin was then filtered and eluted with 4 × 500 mL of
acetone. The resulting acetone extract was evaporated, and the
remaining water phase was extracted with an equal amount of ethyl
acetate. The organic phase was dried by sodium sulfate and
evaporated to dryness, and a brown extract (369 mg) was obtained.
Isolation of Compounds 1−14. The extract was filtered using a
SPME Strata-X 33 u Polymeric RP cartridge (Phenomenex, Inc.,
Aschaffenburg, Germany). The supernatant and mycelia crude
extracts were fractionated by preparative reverse-phase liquid
chromatography (PLC 2020, Gilson, Middleton, WI, USA). The
VP Nucleodur 100−5C 18 ec column (250 mm × 40 mm, 7 μm,
Macherey-Nagel) was used as stationary phase. Deionized water
(Milli-Q, Millipore, Schwalbach, Germany) with 0.05% trifluoroacetic
acid (TFA) (solvent A) and acetonitrile with 0.05% TFA (solvent B)
were used as the mobile phase. The elution gradient used 5−100%
solvent B over 45 min and thereafter isocratic conditions at 100%
solvent B for 10 min. UV monitoring was carried out at 210, 254, and
350 nm, and the flow rate was 40 mL/min. Twenty-four fractions
were collected according to the observed peaks (F1−F24) from
supernatant extracts, and 14 fractions (F1−F14) were collected from
the mycelial extracts.
Fraction F15 of the supernatant was further purified by reversed-
phase HPLC (solvent A (H2O + 0.05% TFA)/solvent B (ACN +
0.05% TFA), elution gradient: 52−100% solvent B for 23 min,
followed by maintaining isocratic conditions at 100% for 5 min with a
preparative HPLC column (Kromasil, MZ Analysentechnik, Mainz,
Germany; 250 × 20 mm, 7 μm C18) as stationary phase and a flow
rate of 15 mL/min, to afford compound 1 (0.42 mg; equivalent to
0.1% of the crude extract). Unless stated otherwise, the same column
was used for the purification of the other fractions. Fraction F12 and
supernatant fraction F23 were combined and purified with a gradient
of 60−85% solvent B for 18 min, followed by a gradient shift from
85% to 100% in 2 min and isocratic conditions at 100% for 5 min to
afford compounds 2 (0.28 mg; 0.05%), 3 (0.49 mg; 0.1%), 8/9 (3.31
mg; 0.65%), and 11 (2.55 mg; 0.5%). Application of the elution
gradient of 40−80% solvent B for 18 min, followed by gradient shift
from 80% to 100% in 2 min and maintaining isocratic conditions
Table 4. Antimicrobial and Cytotoxic Activities of Compounds 4−14a
test organisms 4 5 7 8/9 10 11 12 13 14 reference
MIC (μg/mL)
Gram-Positive Bacteria
Bacillus subtilis DSM 10 − − − 100 75 75 − 100 − ciprofloxacin 3.1
Micrococcus luteus DSM 1790 − − − 100 / − − 100 − oxytetracycline 0.4
Mycobacterium smegmatis DSM 43524 − − − − / − − − − kanamycin 0.4
Staphylococcus aureus DSM 346 100 − − 100 / − − 100 − oxytetracycline 0.4
Filamentous Fungi
Mucor hiemalis DSM 2656 100 50 − 100 / 50 50 25 50 nystatin 16.7
Cytotoxicity IC 50 (μM)
Cell Lines
L929 / / / − 59.8 − − 117.5 − epothilon B 0.00275
KB3.1 172.9 / / 144.5 27.8 141 − 79.8 − epothilon B 6.5 × 10−5
a− no activity; / not tested; starting concentrations for antimicrobial assay and cytotoxicity assay were 300 and 37 μg/mL, respectively.
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100% for 5 min, yielded compound 4 (1.51 mg; 0.4%) and compound
7 (4.08 mg; 1.1%) from fraction F18 of the supernatant. Compound 5
(3.07 mg; 0.8%) was purified from supernatant fraction F17 with the
following elution gradient: 60−100% solvent B for 23 min, followed
by isocratic conditions at 100% B for 5 min. Compound 6 (0.89 mg;
0.25%) was purified from supernatant fraction F11 by application of
the following gradient: 38−62% solvent B for 23 min, followed by
gradient shift from 62% to 100% in 2 min and isocratic gradient 100%
for 5 min. The same gradient was used to isolate compound 10 (1.34
mg; 0.35%) from supernatant fraction F20. Fraction F15 of the
supernatant was purified using the elution gradient 38−75% solvent B
for 23 min, followed by a gradient shift from 75% to 100% in 2 min
and isocratic conditions of 100% solvent B for 2 min to afford
compound 12 (1.2 mg; 0.3%). Compound 13 (2.17 mg; 0.4%) was
obtained from purification of supernatant fraction F21 and mycelia
fraction F10 with the gradient 55−85% solvent B for 18 min, followed
by 2 min gradient shift from 85% to 100% and finally isocratic
conditions at 100% B for 5 min. The known compound 14 (6.79 mg;
2%) was purified from supernatant fraction F7 with the elution
gradient 34−100% solvent B for 23 min, followed by isocratic elution
with 100% B for 5 min.
Antimicrobial Assay.Minimum inhibitory concentrations (MIC)
were determined in serial dilution assays using different test
microorganisms. The assays were conducted in 96-well plates in
Mueller Hinton Broth (comprising beef infusion solids, 2.0 g/L;
casein hydrolysate, 17.5 g/L; starch, 1.5 g/L) for bacteria and YM
medium for filamentous fungi and yeasts, as described earlier.24
Cytotoxicity Assay. In vitro cytotoxicity (IC50) of compounds 3,
4, and 8−14 were evaluated against mouse fibroblast L929 and HeLa
(KB-3.1) cell lines according to the method described earlier.6
(6R,7S,10R)-7,10-Epoxy-7,11-dimethyldodec-1-ene-6,11-diol (1):
[α]20D +40.7 (c 1.075, MeOH); UV (MeOH, c 0.125) λmax (log ε)
222 (3.828); HR-ESIMS m/z 255.1954 [M + H]+, calcd for
C15H27O3 255.1960.
(9R)-9-{(8S)-8-Hydroxy-7-[(6R)-3-methylcyclohex-3-en-6-yl]prop-
7-en-8-yl}-11-methylfuran-12-one (elgonene A (2)): [α]20D +82.3 (c
1.0, MeOH); UV (MeOH, c 0.125) λmax (log ε) 222 (3.879); HR-
ESIMS m/z 249.1486 [M + H]+, calcd for C15H21O3 249.1490.
(9R,11R)-9-{(8S)-8-Hydroxy-7-[(6R)-3-methylcyclohex-3-en-6-yl]-
prop-7-en-8-yl}-11-methyloxolan-12-one (elgonene B (3)): [α]20D
+14.3 (c 1.0, MeOH); UV (MeOH, c 0.125) λmax (log ε) 230 (3.659);
HR-ESIMS m/z 251.1641 [M + H]+, calcd for C15H23O3 251.1647.
(2E,4S,5S)-4,5-Dihydroxy-2-methyl-6-[(7R)-10-methylcyclohex-
10-en-7-yl]hepta-2,6-dienoic acid (elgonene C (4)): [α]20D +25.9 (c
2.0, MeOH); UV (MeOH, c 0.125) λmax (log ε) 281 (2.589), 203
(3.849); HR-ESIMS m/z 267.1588 [M + H]+, calcd for C15H23O3
267.1596.
(2E,5S,6R)-5,6-Dihydroxy-2-methyl-6-[(7R)-10-methylcyclohex-
10-en-7-yl]hept-2-enoic acid (elgonene D (5)): [α]20D −12.2 (c 1.99,
MeOH); UV (MeOH, c 0.1) λmax (log ε) 197 (3.986); HR-ESIMS m/
z 269.1743 [M + H]+, calcd for C15H25O4 269.1752.
(2E,5S,6R)-5,6-Dihydroxy-6-[(7R)-10-(hydroxymethyl)cyclohex-
10-en-7-yl]-2-methylhept-2-enoic acid (elgonene E (6)): [α]20D
+61.1 (c 1.49, MeOH); UV (MeOH, c 0.0) λmax (log ε) 218
(3.890); HR-ESIMS m/z 285.1694 [M + H]+, calcd for C15H25O5
285.1702.
(2E,4S,5S,6R)-4,5,6-Trihydroxy-2-methyl-6-[(7R)-10-methylcyclo-
hex-10-en-7-yl]hept-2-enoic acid (elgonene F (7)): [α]20D −20.5 (c
1.29, MeOH); UV (MeOH, c 0.05) λmax (log ε) 212 (4.103); HR-
ESIMS m/z 285.1695 [M + H]+, calcd for C15H25O5 285.1702.
(9R)-11-Methyl-9-{(7R,8R)-7-methyl-6-[(6R)-3-methylcyclohex-3-
en-6-yl]oxiran-8-yl}furan-12-one (elgonene G (8)): UV (MeOH, c
0.125) λmax (log ε) 216 (3.879); HR-ESIMS m/z 249.1486 [M + H]
+,
calcd for C15H21O3 249.1490.
(9R,11R)-11-Methyl-9-{(7R,8R)-7-methyl-6-[(6R)-3-methylcyclo-
hex-3-en-6-yl]oxiran-8-yl} oxolan-12-one (elgonene H (9)): UV
(MeOH, c 0.125) λmax (log ε) 216 (3.879); HR-ESIMS m/z 251.1639
[M + H]+, calcd for C15H23O3 251.1647.
{ ( 5 R , 6 R ) - 5 - [ 9 - ( F u r a n - 9 - y l ) e t h y l ] - 5 - m e t h y l - 1 -
methylidenecyclohexyl}methanol (elgonene I (10)): [α]20D −11.9 (c
2.0, MeOH); UV (MeOH, c 0.125) λmax (log ε) 228 (3.8453); HR-
ESIMS m/z 235.1689 [M + H]+, calcd for C15H23O2 235.1698.
(5R,6R)-5-[9-(Furan-9-yl)ethyl]-5-methyl-1-methylidenecyclohex-
ane-5-carboxylic acid (elgonene J (11)): [α]20D +11.9 (c 3.6,
MeOH); UV (MeOH, c 0.25) λmax (log ε) 277(2.894), 216 (3.834);
HR-ESIMS m/z 249.1483 [M + H]+, calcd for C15H21O3 249.1490.
( 9Z ) - 9 - { 9 - [ ( 5R , 6R ) - 5 - (Hyd roxyme thy l ) - 5 -me thy l - 1 -
methylidenecyclohexyl]ethyl}but-9-ene-11,15-diol (elgonene K
(12)): [α]20D +10.8 (c 10.41, MeOH); UV (MeOH, c 0.125) λmax
(log ε) 203 (3.849); HR-ESIMS m/z 255.1954 [M + H]+, calcd for
C15H27O3 255.1960.
(9Z)-9-{9-[(6S)-5,5-Dimethyl-1-methylidenecyclohexyl]ethyl}but-
9-ene-11,15-diol (elgonene L (13)): [α]20D +7.9 (c 1.24, MeOH); UV
(MeOH, c 0.25) λmax (log ε) 213 (3.634); HR-ESIMS m/z 239.2002
[M + H]+, calcd for C15H27O2 239.2011.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.jnat-
prod.8b01086.
Experimental procedures, 1D and 2D NMR data, LCMS









The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
We are grateful to W. Collisi for conducting the cytotoxicity
assays, C. Kakoschke for recording NMR data, and C.
Schwager and E. Surges for recording HPLC-MS data.
Financial support by the “ASAFEM” Project (grant no. IC-
070) under the ERAfrica Programme of the European
Commission to J.C.M and M.S. and personal Ph.D. stipends
from the China Scholarship Council (CSC), the German
Academic Exchange Service (DAAD), and the Kenya National
Council for Science and Technology (NACOSTI) to T.C. and
C.C., respectively, are gratefully acknowledged.
■ REFERENCES
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ABSTRACT: Fermentation of the fungal strain Skeletocutis sp. originating from Mount Elgon Natural Reserve in Kenya,
followed by bioassay guided fractionation led to the isolation of 12 previously undescribed metabolites named skeletocutins A-L
(1−5 and 7−13) together with the known tyromycin A (6). Their structures were assigned by NMR spectroscopy
complemented by HR-ESIMS. Compounds 1−6 and 11−13 exhibited selective activities against Gram-positive bacteria, while
compound 10 weakly inhibited the formation of biofilm of Staphylococcus aureus. The isolated metabolites were also evaluated
for inhibition of L-leucine aminopeptidase, since tyromycin A had previously been reported to possess such activities but only
showed weak effects. Furthermore, all compounds were tested for antiviral activity against Hepatitis C virus (HCV), and
compound 6 moderately inhibited HCV infectivity with an IC50 of 6.6 μM.
KEYWORDS: polyporaceae, secondary metabolites, basidiomycota, structure elucidation
■ INTRODUCTION
Tropical rainforest ecosystems represent a treasure trove of
biological heritage, and the vast majority of its biodiversity still
remain unexploited. The constant chemical innovations that
exist in these habitats may be driven by the active evolutionary
race, making tropical species a rich source for new bioactive
molecules.1 Fungi represent a considerable proportion of the
total biodiversity in these ecosystems, but the majority of the
tropical fungi remain unstudied for production of bioactive
secondary metabolites. We have recently started to explore
Basidiomycota from Kenya’s rain forests, Kakamega and
Mount Elgon National Reserve and have already reported
several novel bioactive secondary metabolites from new or rare
species. Those include the calocerins and the new 9-oxo
strobilurins from Favolaschia calocera, the antibiotic laxitextines
from Laxitextum incrustatum, the biofilm inhibitors named
microporenic acids from Microporus sp. and the triterpenes,
laetiporins and aethiopilonones from Laetiporus sp. and
Fomitiporia aethiopica, respectively.2−6 Two strains of
Sanghuangporus were also evaluated, and numerous bioactive
compounds were discovered in their cultures.7,8 The current
study deals with another basidiomycete, Skeletocutis sp.
(MUCL56074) and the identification and characterization of
its bioactive secondary metabolites.
Skeletocutis is a genus of about 40 species in family
Polyporaceae. Even though this genus has a worldwide
distribution, most of its known species are distributed in the
Northern Hemisphere.9 Like other polypores, species in this
genus are known to be forest pathogens causing white rot in a
diverse array of woody plants. Interestingly, some species have
been reported to grow on the dead fruiting bodies of other
polypores, giving indications to their mycophilic lifestyle.
Those include Skeletocutis brevispora and Skeletocutis chrysella,
which were reported from dead basidiomes of Phellinidium
ferrugineofuscum and Phellinus chrysoloma, respectively.10
Phylogenetically, Skeletocutis is closely related to the genus
Tyromyces, and in recent phylogenetic studies, the two genera
clustered together in the “Tyromyces clade” on a branch lying
outside of the core polyporoid clade.11−13
Herein we report the isolation, structure elucidation and
bioactivities of 12 new compounds that are the first secondary
metabolites known from Skeletocutis, and for which we
propose the trivial names skeletocutins A-L accordingly.
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■ MATERIAL AND METHODS
General Experimental Procedures. NMR spectra were
recorded with Bruker 700 spectrometer with 5 mm TXI cryoprobe
(1H 700 MHz, 13C 175 MHz, 15N 71 MHz) and Bruker AV II-500
(1H 500 MHz, 13C 125 MHz) spectrometers. HR-ESIMS mass
spectra were recorded with Agilent 1200 series HPLC-UV system
(column 2.1 × 50 mm, 1.7 μm, C18 Acquity UPLC BEH (waters),
solvent A: H2O + 0.1% formic acid; solvent B: AcCN + 0.1% formic
acid, gradient: 5% B for 0.5 min increasing to 100% in 19.5 min and
then maintaining 100% B for 5 min, flow rate 0.6 mL/min, UV−vis
detection 200−600 nm combined with ESI-TOF-MS (Maxis,
Bruker)) [scan range 100−2500 m/z, capillary voltage 4500 V, dry
temperature 200 °C]. UV spectra were recorded by using a Shimadzu
UV−2450 UV−vis spectrophotometer.
Fungal Material. The fungal specimen was collected by Decock
and Matasyoh from Mount Elgon National Reserve, located in the
western part of Kenya (1°7′6″ N, 34°31′30′′ E). Dried specimen and
corresponding cultures were deposited at MUCL, Louvain-la-Neuve,
Belgium, under the accession number MUCL 56074. The genus was
determined by morphological studies and comparison of the internal
transcribed spacer (ITS)-nrDNA sequences with those of other
Basidiomycota deposited in GenBank.
For molecular phylogenetic studies, DNA was extracted by using
the EZ-10 Spin Column Genomic DNA Miniprep kit (Bio Basic
Canada Inc., Markham, Ontario, Canada) as described previously.14,17
Precellys 24 homogenizer (Bertin Technologies, France) was used for
cell disruption at a speed of 6000 rpm for 2 × 40 s. Standard primers
ITS 1f and NL4 were used for amplification of the 5.8S/ITS nrDNA
regions according to the protocol of Lambert et al.16
Small-Scale Fermentation. Skeletocutis sp. MUCL56074 was
cultivated in 3 different liquid media: YMG 6.3, Q6 1/2 and ZM 1/2
(media compositions see Supporting Information). A well grown
culture from a YMG agar plate (YMG supplemented with 1.5% agar,
pH 6.3) was cut into small pieces using a cork borer (7 mm) and five
pieces were inoculated in a 500 mL Erlenmeyer flask containing 200
mL of the three media. The cultures were incubated on a rotary
shaker (140 rpm) at 24 °C. The growth of the fungus was monitored
by constantly checking the amount of free glucose using Medi-test
Glucose (Macherey-Nagel). The fermentation was terminated 2 days
after glucose depletion.17
Scale-up of Fermentation. LC-MS dereplication was carried out
by comparing the masses of the detected peaks and their molecular
formula obtained from HRMS data with those in the Dictionary of
natural products (http://dnp.chemnetbase.com). Several new com-
pounds in the three media screened were detected in both the extracts
from mycelia and supernatants. Preliminary LC-MS results indicated
that similar metabolites were produced in all the three media but
YMG medium produced the highest amount of metabolites, this
medium was used in the scale-up. A well-grown YMG agar plate of
mycelial culture was cut into small pieces using 7 mm cork border and
five pieces inoculated into 500 mL sterile flasks containing 200 mL
(25 flasks).
Preparation of the Extracts. Supernatant and biomass from
small scale fermentation were separated by filtration. The supernatant
was extracted with equal amount of ethyl acetate and filtered through
anhydrous sodium sulfate. The resulting ethyl acetate extract was
evaporated to dryness by means of rotary evaporator. The mycelia
were extracted with 200 mL of acetone in ultrasonic bath for 30 min,
filtered, and the filtrate evaporated. The remaining water phase was
mixed with equal amount of distilled water, extracted with equal
amount of ethyl acetate, and filtered through anhydrous sodium
sulfate and dried by evaporator.
The mycelia and supernatant from the large scale fermentation
were separated via vacuum filtration. The mycelia were ultrasonicated
for 30 min with 4 × 500 mL of acetone. The extracts were combined
and evaporated and the remaining water phase was suspended in 200
mL distilled water and extracted 3 times with 500 mL ethyl acetate.
The organic layer was filtered and evaporated to dryness, leaving
brown solid extract (610.2 mg). 5% Amberlite XAD-16N absorbent
(Rohm & Haas Deutschland GmbH, Frankfurt am Main, Germany)
was added to the supernatant and shook overnight. The Amberlite
resin was then filtered and eluted with 4 × 500 mL of acetone. The
resulting extract was evaporated and the remaining water phase was
extracted three times with equal amount of ethyl acetate. The organic
phase was dried by to afford 5.2 g of extract.
Isolation of Compounds 1−13. The extracts from mycelia and
supernatant were combined and filtered using an SPME Strata-X 33 u
Polymeric RP cartridge (Phenomenex, Inc., Aschaffenburg, Ger-
many). The extract was then fractionated by preparative reverse phase
liquid chromatography (PLC 2020, Gilson, Middleton, USA), using
VP Nucleodur 100-5 C-18 ec column (25 × 40 mm, 7 μm: Macherey-
Nagel). Deionized water (Milli-Q, Millipore, Schwalbach, Germany)
with 0.05% TFA (solvent A) and acetonitrile with 0.05% TFA
(solvent B) were used as mobile phase. Elution gradient: 50% solvent
B increased to 100% in 60 min and finally isocratic conditions at
100% solvent B for 5 min. The flow rate was 40 mL/min and UV
detection was carried out at 210, 254, and 350 nm. A total of 22
fractions were collected according to the observed peaks (F1−F22).
Detailed description of the methods can be found in the SI.
Antimicrobial Assays. Compounds 1−13 were evaluated for
antimicrobial activity (minimum inhibition concentrations, MIC) in
serial dilution assays against several test microorganisms (Table 5)
according to our previous research.14,15The assays were conducted in
96-well plates in Mueller-Hinton broth (MHB) media for bacteria and
YMG media for filamentous fungi and yeasts.
Cytotoxicity Assays. Compounds 1−13 were evaluated in the
cytotoxicity assay against mouse fibroblasts (L929) and HeLa
(KB3.1) cell lines as described previously.17
Biofilm Inhibition Assay. Staphylococcus aureus DSM1104 was
grown overnight in casein-peptone soymeal-peptone (CASO)
medium containing 4% glucose with PH7.0. The S. aureus cell
concentration was adjusted to match the turbidity of 0.5 McFarland
standard. The assay was performed in 96-well flat bottom plates
(Falcon Microplates, U.S.A.) as previously described.18 Methanol was
used as negative control; all experiments were carried out in triplicates
and cytochalasin B was used as a standard (cf. Yuyama et al.19)
Nematicidal Assay. The nematicidal activity against Caenorhab-
ditis elegans was performed in 24-well microtiter plates as previously
described.20 Ivermectin and methanol were used as positive and
negative control, respectively. The results were expressed as LD90.
Leucine Aminopeptidases Inhibition Assays. Hydrolysis of L-
leucine-7-amido-4-methylcoumarin (L-Leu-AMC) by the surface
bound aminopeptidases of HeLa (KB3.1) cell lines was evaluated
according to the method described by Weber et al.21 with slight
modifications. KB3.1 cells were grown as monolayer cultures in
Dulbecco’s Modified Eagle (DMEM) medium containing 10% of fetal
calf serum at 37 °C in 24-well multidishes. After 3 days the confluent
monolayers were washed twice with phosphate buffered saline (PBS)
and the reaction mixture (450 μL Hank’s buffer PH 7.2 containing 50
μM and 100 μM substrate L-Leu-AMC, and compounds dissolved in
50 μL DMSO) was added. After 30 min of incubation at 23 °C, 1 mL
of cold 0.2 M glycine-buffer PH 10.5 was added. The amount of
hydrolyzed 7-amino-4-methylcoumarin (AMC) was determined in a
fluorescence spectrophotometer (excitation/emission: 365/440 nm;
Tecan Infinite M200 PRO). Bestatin22 and DMSO were used as
positive control and negative control, respectively.
Inhibitory Effects on HCV Infectivity. Compounds 1−13 were
tested for antiviral activity against Hepatitis C virus (HVC) as
previously described.23,24 Detailed information can be found in the SI.
■ RESULTS AND DISCUSSION
As described in the Experimental section, the strain
MUCL56074 was assigned to the genus Skeletocutis by
morphological studies and sequencing of the rDNA (5.8S
gene region and ITS). The BLAST result from GenBank
confirmed the identity of this fungus to genus Skeletocutis in
the Polyporaceae family. The closest hit was the DNA
sequence with GenBank acc no KY953026.1 (Skeletocutis
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nivea) with 96.99% identity (see Figure S106, Supporting
Information), from which no metabolites had hitherto been
reported.
The extracts from small scale fermentation of Skeletocutis sp.
(strain MUCL 56074) exhibited good antibacterial activity
(4.68 μg/mL) against Bacillus subtilis. Moreover, analyses of
the secondary metabolite profiles by HPLC-MS pointed
toward the presence of several hitherto unknown compounds.
Therefore, extensive chromatographic studies of the extract as
described in the Experimental Section were conducted and
finally led to the isolation of 12 new compounds named
skeletocutins A-L. Their characteristics are reported further
below.
Compound 1 ( skeletocutin A) with the molecular formula
C25H34O8 and nine degrees of unsaturation deduced from the
HR-ESIMS spectrum was isolated as a white solid. The 13C
NMR spectroscopic data of 1 (Table 1) revealed the presence
of 25 carbon signals, which could further be classified into one
methyl carbon, 15 methylene carbons and nine nonprotonated
carbons (including five attached to heteroatoms) in the DEPT
NMR spectrum. The HMBC correlations of H3-6′ (∂ 2.08) to
C-3′/C-4′/C-5′ and H2-1 to C-2′/C-3′/-4′ confirmed the
maleic anhydride moiety in the molecule. The presence of the
glutaric anhydride moiety was revealed by HMBC correlations
of H2-14 (∂ 2.50) to C-2″/C-3′′/C-4′′ and H2-5″ (∂ 3.57) to
C-3′′/C-4′′/C-6′′. Further, HMBC correlations of H-5′′ to C-
7′′ confirmed the position of the C-7′′ carboxylic acid
substituent. COSY correlations of H2-1 triplet (∂ 2.46) to
H2-2 (∂ 1.60) and H2-13 (∂1.62) to H2-14 triplet (∂ 2.50)
were also observed. A multiplet resonating between (∂ 1.26−
1.32) was attributed to the remaining ten methylene groups of
the tetradecamethylene chain in the molecule. This was further
confirmed by the integration of the multiplet, which gave an
integral value of 20, confirming the 20 methylene protons or
C-3 to C-12. The connection of the tetradecamethylene chain
to the maleic and glutaric anhydride moieties was confirmed by
Table 1. NMR Data (1H 500 MHz and 13C 125 MHz) in CDCl3 for 1 and 2 and (
1H 500 MHz and 13C 125 MHz) in Acetone-d6
for 3 and 4
1 2 3 4
no. 13C 1H/HSQC 13C 1H/HSQC 13C 1H/HSQC 13C 1H/HSQC
1 24.4, CH2 2.46 (t),
J = 7.78 Hz
24.4, CH2 2.45 (t),
J = 7.78 Hz
24.8, CH2 2.50 (t),
J = 7.63 Hz
24.1, CH2 2.50 (t),
J = 7.48 Hz












13/15 27.5, CH2 1.62 (m) 27.6, CH2 1.59 (m) 28.3, CH2 1.61 (m) 28.3, CH2 1.61 (m)
14/16 24.9, CH2 2.50 (t), J = 7.63
Hz
27.6, CH2 24.9 (t), J = 7.63
Hz
25.2, CH2 2.57 (t), J = 7.63
Hz
25.2, CH2 2.56 (t), J = 7.78
Hz
2’ 165.9,C 165.9,C 167.2,C 167.2,C
3′ 144.8, C 144.8, C 145.0, C 145.0, C
4’ 140.5, C 140.4, C 141.8, C 141.8, C
5′ 166.3, C 166.3, C 167.4, C 167.4, C
6’ 9.5, CH3 2.08 (s) 9.5, CH3 2.07 (s) 9.6, CH3 2.08 (s) 9.6, CH3 2.08 (s)
2’’ 165.1, C 165.9, C 166.7, C 166.7, C
3′’ 148.0, C 148.0, C 148.0, C 148.0, C
4’’ 135.6, C 135.6, C 137.9, C 137.9, C
5′’ 29.0, CH2 3.57 (s) 29.1, CH2 3.57 (s) 39.9, CH2 3.68 (s) 30.1, CH2 3.68 (s)
6’’ 165.1, C 165.9, C 166.4, C 166.4, C
7’’ 171.5, C 171.3, C 169.0, C 169.1, C
52.6, OCH3 3.7 (s) 52.9, OCH3 3.7 (s)
Figure 1. Chemical structures of compounds 1−12.
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HMBC correlations of H2-1/H2-2 to C-3′ and H2-13/H2-14 to
C-3″, respectively. Therefore, the structure of 1 was
unambiguously concluded to be 5″-[14-(4′methyl-2,5-dioxo-
2,5-dihydrofuran-3yl-)tetradecyl]-2′′,6′′-dioxo-2′′,6′′-dihydro-
pyran-4′′-carboxylic acid (Figure 1).
Compound 2, which had the molecular formula C27H38O8
derived from HR-ESIMS data, was isolated as white solid. 1D
and 2 D NMR data of 2 pointed to a similar structure as 1 with
the difference being the size of the carbon chain in the
molecule. The multiplet occurring at ∂ 1.26−1.32 for the
methylene groups (C-3-C-14) in 2 gave an integral value of 24
indicating a hexadecamethylene chain in the molecule instead
of the tetradecamethylene chain elucidated for compound 1.
This was further supported by the fact that the two molecules
mass difference was 28, which is equivalent to the mass of two
methylene groups. The structure of 2 was therefore concluded
to be 5″-[16-(4′methyl-2′,5′-dioxo-2′,5′-dihydrofuran-3′-yl-)-
tetradecyl]-2′′,6′′-dioxo-2′′,6′′-dihydropyran-4′′-carboxylic
acid that we propose the trivial name skeletocutin B.
Compound 3 (skeletocutin C) with the molecular formula
C26H36O8 and 9 degrees of unsaturation and compound 4 with
molecular formula C28H40O8 and 9 degrees of unsaturation
were obtained as yellow solid and white solid, respectively.
Analysis of the 13C NMR spectra of 2 revealed a structure
closely related to that of 1 with the difference being methoxy
group signal occurring at ∂ 52.6. The methoxy group proton (∂
3.70) showed HMBC correlations to C-7″ (∂ 169.0). Similarly,
for compound 4 ( skeletocutin D), the 1D and 2 D NMR data
indicated a similar structure as 2 with the difference being a
methoxy group (∂ 52.9) whose proton (∂ 3.70) showed a
HMBC correlation to C-7″ (∂169.1).
Compound 5 (skeletocutin E), which was obtained as yellow
oil, had the molecular formula C24H34O6 and eight degrees of
unsaturation. The 13C NMR spectrum of 5 showed only 12
signals which indicates that the compound consisted of two
identical halves. A methyl singlet resonance at ∂ 2.07 (H3-6′)
along with methylene groups triplet and quintet occurring at ∂
2.45 (H2-1/H2-14) and ∂ 1.57 (H2-2/H2-13) respectively were
observed in the 1H NMR spectrum (Table 2). HMBC
correlations of the C-6′ methyl group proton (∂ 2.07) to C-
3′/C-4′/C-5′ and H2-1/H2-14 to C-2′/ C-3′/C-4′ confirmed
the maleic anhydride moiety in the molecule. Integration of the
methyl singlet (H3-6′) gave an integral value of 6 confirming
the presence of two maleic anhydride groups. The multiplet
occurring between ∂ 1.26−1.32 was attributed to the
remaining ten methylene groups of carbon chain. The integral
value of 20 obtained for this multiplet confirmed the chain
length. Cross peaks in the HMBC spectrum between the H2-1/
H2-14 and H2-2/H2-13 and C-3′confirmed the connection of
the chain to the two maleic anhydride and therefore
confirming the structure of 5 to be 1,14-bis [4′-methyl-2′,5′-
dioxo-3′-furyl] tetradecane. Compound 5 has been reported
before as a product of chemical synthesis, but to the best of our
knowledge it has never before been isolated from a natural
source. The published MS data and 1H and 13C NMR data
reported for the synthetic product matched our own findings.25
Compound 6 was isolated as white crystalline solid. The HR
mass spectrum revealed the molecular formula to be C26H38O6
with nine degrees of unsaturation. This compound was
identified as tyromycin A by comparing its NMR and HR-
MS data previously reported from Tyromyces lacteus, which
belongs to the same family (Polyporaceae) as Skeletocutis.21 An
efficient one-step synthesized of this compound using double
radical decarboxylation has also been reported.25
Compound 7 (skeletocutin F) with the molecular formula
C25H36O9 and eight degrees of unsaturation was isolated as
yellow solid. Analysis of the 1D and 2D NMR data of 7 (Table
3) indicated the presence of the maleic anhydride like in the
other compounds described above. Further, the HMBC
correlations of H2-18 (∂ 2.39) to C-2′/C-3′-C4′ confirmed
the linkage of this moiety to the 14-carbon chain in the
molecule. The three carboxylic acid moieties for the
tricarboxylic acid part of the molecule had resonance at ∂
171.5 (C-1), 171.4 (C-19), and 170.2. (C-20) in the 13C NMR
spectrum. Cross peaks in the HMBC spectrum were observed
between H2-2 and C-1/C-3/C-4/C-19. HMBC correlations of
H2-5 to C-3/C-4/C-20 confirmed the connection of the
tricarboxylic acid moiety to the chain and the position of C-20.
The COSY correlations of H2-5 to H2-6 and H2-18 to H2-17
were also recorded. The olefinic bond between C-3 and C-4
was assigned the E configuration due to the absence of cross
peaks in the ROESY spectra between the C-2 and C-5
methylene protons. The integration of the multiplet signal at ∂
1.23−1.30 indicated ten additional methylene groups and
hence the compound was identified as 3E-18-(4′-methyl-2′,5′-
dioxo-2′,5′-dihydrofuran-3′-yl) octadecane-1,2,3-tricarboxylic
acid.
Compound 8 (skeletocutin G) with molecular formula
C26H38O9 and 8 degrees of unsaturation was isolated as white
solid. The 13C NMR spectra of 8 revealed a structure closely
related to that of 7 with the difference being methoxy group,
indiacted by a signal occurring at ∂ 52.8. The methoxy group
proton (∂ 3.74) showed HMBC correlations to C-19 (∂
171.8).
Compound 9 ( skeletocutin H), which was designated the
molecular formula C27H40O9 from the HRMS data was
obtained as white solid. The 1 and 2D NMR data indicated
a similar structure as 7 with the difference being the size of the
carbon chain. The multiplet occurring at ∂ 1.28−1.36 for the
methylene groups C-7-C-18 gave an integral value of 24
indicating icosane-1,2,3- tricarboxylic acid in the molecule
instead of the octadecane-1,2,3-tricarboxylic acid elucidated in
compound 7.
Compound 10 ( skeletocutin I) with molecular formula
C28H42O9, 1 and 2 D NMR data indicated a similar structure as
9 with the difference being a methoxy group (∂ 52.5) whose
proton (∂ 3.74) showed HMBC correlation to C-21 (∂170.6).
Table 2. NMR Data (1H 500 MHz and 13C 125 MHz) in
CDCl3 for 5 and (
1H 500 MHz and 13C 125 MHz) in DMSO
for 6
5 6
no. 13C/HSQC 1H 13C/HSQC 1H
1/14/16 24.4, CH2 2.45 (t),
J = 7.78 Hz
23.6, CH2 2.40 (t),
J = 7.53 Hz
2/13/15 3, CH2 1.57 (p),
J = 7.78HZ
26.7, CH2 1.48 (p),









2’ 165.9, C 166.2, C
3′ 144.8, C 143.4, C
4’ 140.4, C 140.8, C
5′ 166.3, C 166.4, C
6’ 9.5, CH3 2.08 (s) 9.2, CH3 1.99 (s)
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Compound 11 (skeletocutin J), which was assigned the
molecular formula C24H36O7 from the HRMS data, was
isolated as white oil. Analysis of the 1D and 2D NMR data
suggested a structure closely related to that of 7, with the
difference being the absence of the tricarboxylic acid moiety
and the presence of a dicarboxylic acid moiety instead. HMBC
correlations of H2-2 to C-1/C-3/C-4/C-19, H-4 to C-2/C-19/
C-5/C-6 and H2-5 to C-3/C-4/C-6 were observed. Further,
COSY correlations of H2-5 to H-4/H2-6 were also recorded.
The olefinic bond between C-4 and C-5 was assigned the cis
configuration because of the small coupling constant of 7.48
Hz recorded. Therefore, the structure of 11 was concluded to
be (3Z)-3-[6-(4′-methyl-2′,5′-dioxo-2′,5′-dihydrofuran-3′-yl)
pentadecene]butanedioic acid.
Compound 12 (skeletocutin K) which was isolated as yellow
oil, had molecular formula C26H40O7 deduced from the HR
mass spectrum. The 1 and 2 D NMR data revealed a similar
structure as 11 but the integration of the methylene groups’
multiplet occurring between ∂ 1.26−1.31 gave an integral value
of 24 suggesting a 16 carbon chain. Also, the mass difference
between these two compounds is 28 i. e two methylene groups.
Hence, the structure of 12 was unambiguously assigned as
(3Z)-3-[6-(4′-methyl-2′,5′-dioxo-2′,5′-dihydrofuran-3′-yl)
heptadecene]butanedioic acid (Table 4).
Compound 13 (skeletocutin L), which was designated the
molecular formula C27H42O7 from the HRMS data was isolated
as yellow oil. The 1D and 2 D NMR data indicated a similar
structure as 12 with the difference being a methoxy group (∂
Table 3. NMR Data (1H 500 MHz and 13C 125 MHz) in DMSO for 7 (1H 500 MHz and 13C 125 MHz) in Acetone-d6 for 9 and
(1H 500 MHz and 13C 125 MHz) in CDCl3 for 8 and 10
7 8 9 10
no. 13C/HSQC 1H 13C/HSQC 1H no. 13C/HSQC 1H 13C/HSQC 1H
1 171.5, C 170.7, C 1 171.9, C 172.3, C
2 36.9, CH2 3.30 (s) 36.5, CH2 3.60 (s) 2 37.4, CH2 3.56 (s) 36.5, CH2 3.61 (s)
3 128.0, C 128.1, C 3 129.5, C 128.2, C
4 143.5, C 145.8, C 4 144.9, C 145.9, C
5 30.4, CH2 2.53 (t), J = 7.9
Hz
31.5, CH2 2.72 (t), J = 7.93
Hz
5 31.9, CH2 2.70 (t), J = 7.93
Hz
31.5, CH2 2.73 (t), J = 7.78
Hz
6 28.1, CH2 1.36 (q), J = 6.71
Hz
28.7, CH2 1.54 (m) 6 29.5, CH2 1.52 (br p),
J = 7.50 Hz










17 26.9, CH2 1.48 (q), J = 7.48
Hz
27.6, CH2 1.57 (m) 19 28.3, CH2 1.59 (br p),
J = 7.48 Hz
27.7, CH2 1.57 (m)
18 23.6, CH2 2.39, (s), J = 7.48
Hz
24.4, CH2 2.45 (s), J = 7.71
Hz
20 24.8, CH2 2.50, (s), J = 7.63
Hz
24.4, CH2 2.46, (t), J = 8.09
Hz
19 171.4, C 171.8, C 21 169.0, C 171.6, C
20 170.2, C 171.6, C 22 170.5, C 171.8, C
2’ 166.2, C 165.9, C 2’ 167.2, C 165.9, C
3′ 143.5, C 144.8, C 3′ 145.0, C 144.8, C
4’ 140.9, C 140.4, C 4’ 141.8, C 140.5, C
5′ 166.4, C 166.3, C 5′ 167.4, C 166.3, C
6’ 9.2, CH3 1.99 (s) 9.5, CH3 2.08 (s) 6’ 9.6, CH3 2.08 (s) 9.5, CH3 2.08 (s)
52.8, OCH3 3.74 (s) 52.5, OCH3 3.74 (s)
Table 4. NMR Data (1H 500 MHz and 13C 125 MHz) in CDCl3 CDCl3 for 11−13
11 12 13
no. 13C/HSQC 1H no. 13C/HSQC 1H 13C/HSQC 1H
1 176.3, C 1 177.2, C 171.2, C
2 32.1, CH2 3.37 (s) 2 32.1, CH2 3.37 (s) 31.8, CH2 3.36 (s)
3 124.4, C 3 124.5, C 124.6, C
4 148.9, CH 7.11 (t), J = 7.48 Hz 4 148.9, CH 7.12 (t), J = 7.48 Hz 148.8, CH 7.10 (t), J = 7.63 Hz
5 29.2, CH2 2.23 (q), J = 7.48 Hz 5 29.1, CH2 2.22 (q), J = 7.48 Hz 28.7, CH2 2.21 (q), J = 7.63 Hz
6 28.3, CH2 1.47 (p), J = 7.48 Hz 6 28.3, CH2 1.47 (p), J = 7.48 Hz 28.3, CH2 1.47 (p), J = 7.63 Hz
7−16 29.2−29.6, CH2 1.26−1.31 (m) 7−18 29.1−29.6, CH2 1.26−1.31 (m) 29.4−2.6, CH2 1.26- 1.32(m)
17 27.5, CH2 1.58 (P), J = 7.63 Hz 19 27.5, CH2 1.58 (p), J = 7.55 Hz 27.6, CH2 1.58 (p), J = 7.32 Hz
18 24.4, CH2 2.46, (t), J = 7.63 Hz 20 24.4, CH2 2.45, (t), J = 7.55 Hz 24.4, CH2 2.45, (t), J = 7.32 Hz
19 171.9, C 21 172.4, C 171.2, C
2’ 165.9, C 2’ 165.9, C 165.9, C
3′ 144.8, C 3′ 144.8, C 144.8, C
4’ 140.4, C 4’ 140.4, C 140.4, C
5′ 166.3, C 5′ 166.3, C 166.3, C
6’ 9.5, CH3 2.07 (s) 6’ 9.5, CH3 2.07 (s) 9.5, CH3 2.07 (s)
52.1, OCH3 3.69 (s)
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52.1). The protons of the methoxy group (∂ 3.69) showed a
HMBC correlation to C-21 (∂171.2).
Biological Activity. Compounds 1−13 were evaluated for
their antimicrobial activity against different organisms (Table
5). All tested compounds except for 7−10 showed moderate
activity against Bacillus subtilis, Staphylococcus aureus, and
Micrococcus luteus with compounds 1−3, 5−6, and 12−13
exhibiting the highest activity in the range of 9.38−37.5 μg/
mL. Further, the compounds demonstrated weak activities
against MRSA (methicillin resistant Staphylococcus aureus).
Neither of the compounds showed any activity against the
tested Gram negative bacteria (Chromobacterium violaceum,
Escherichia coli, Mycobacterium smegmatis, and Pseudomonas
aeruginosa) nor fungi (Candida albicans, Candida tenuis, Mucor
plumbeus, and Pichia anomala).
All compounds were also tested for nematicidal activities
against Caenorhabditis elegans and cytotoxicity against mouse
fibroblast (L929) and HeLa (KB 3.1) cell lines but they did
not show any significant activities in these assays at
concentrations ≤100 μg/mL and 37 μg/mL, respectively.
Compounds that did not show any significant activity (i.e with
MIC ≥ 150 μg/mL) against S. aureus were subjected to the
biofilm inhibition assay against S. aureus biofilm. Only
compound 10 inhibited the formation of the biofilm up to
86% at 256 μg/mL and 28% at 150 μg/mL. Tyromycin A (6)
was reported before as an inhibitor of leucine aminopeptidase
in HeLa S3 cells,21 hence the novel analogues were also tested
for inhibition of L-Leu-AMC hydrolysis in HeLa (KB 3.1) cells.
Only compounds 5, 7, 11, and 13 were weakly active in this
assay with IC 50 values in the range 72.3−92.5 and 78.3−118.4
μg/mL when 100 and 50 μM of the substrate were used,
respectively (Figure 2 and Table 6). Even though tyromycin A
(6) was previously reported to be active in a similar assay
against HeLa S3 cells with IC50 values of 31 μg/mL at 50 μM
substrate concentration, an IC50 value >150 μg/mL for this
compound was recorded on the HeLa (KB3.1) cells when
tested in this study.
Furthermore, all of the compounds were tested for their
antiviral activity against hepatitis C virus (HCV), which is one
of the major causes of chronic liver disease, with 71 million
people infected worldwide. Although curative medications are
available for HCV, the majority of infected individuals do not
having an access to treatment due to high cost of the
treatment. In a cellular replication assay to evaluate antiviral
activity against HCV in human liver cells (Figure 3),
compound 6 strongly inhibited HCV infectivity at the initial
concentration 40 μM while compounds 4 and 5 inhibited
HCV with moderate activity. Compounds 1, 3 and 13 showed
weak activity and the rest of compound were not active. All
tested compounds except for 6 were found devoid of
cytotoxicity on the liver cells. We therefore next evaluated
the antiviral activity of 6 against HCV in a dose dependent
manner. As depicted in Figure 3C, incubation of 6 for 3 days
Table 5. Antimicrobial Activities of Compounds 1−13
MIC (μg/mL)
organism 1 2 3 4 5 6 11 12 13 ref
Bacillus subtilis DSM10 150 18.75 37.5 75 18.75 9.375 300 18.75 3.1a
MRSA Staphylococcus aureus DSM11822 150 150 300 300 150 150 150 75 75 0.4b
Staphylococcus aureus DSM346 37.5 300 150 150 37.5 150 150 37.5 18. 75 6.7c
Micrococcus luteus DSM20030 150 150 150 150 37.5 0.4c
aCiprofloxacin. bVancomycin. cOxytetracycline.
Figure 2. Inhibition of hydrolysis of leu-AMC (A) concentration of L-Leu-AMC: 100 μM and (B) concentration of L-Leu-AMC: 50 μM.
Table 6. Inhibition of L-Leu-AMC by the Metabolites from
Skeletocutis sp
IC50 (μg/mL)
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resulted in a dose-dependent inhibition of HCV infectivity
with a 50% inhibitory concentration (IC50) of 6.6 μM. The
green tea molecule epigallocatechin gallate (EGCG) was used
as positive control.24
Skeletocutin A (1). White solid; UV (MeOH) λmax(log ε)
209 (4.54), 257 (3.02); ESIMS m/z 947 [2 M + Na] +, 485
[M + Na] +, 463 [M + H] +, 445 [M + H − H2O] +; HRMS
m/z 463.2330 [M + H] + (calcd for C25H35O8, 463.2331).
Skeletocutin B (2). White solid; UV (MeOH) λmax(log ε)
206 (4.54), 256 (3.02); ESIMS m/z 1003 [2 M + Na] +, 513
[M + Na] +, 491 [M + H] +, 473 [M + H − H2O] +; HRMS
m/z 491.2646 [M + H] + (calcd for C27H39O8, 491.2645).
Skeletocutin C (3). Yellow solid; UV (MeOH) λmax(log ε)
215 (4.65), 256 (3.17); ESIMS m/z 975 [2 M + Na] +, 499
[M + Na] +, 477 [M + H] +, 459 [M + H − H2O] +; HRMS
m/z 477.2470 [M + H] + (calcd for C26H37O8, 477.2488).
Skeletocutin D (4). White solid; UV (MeOH) λmax(log ε)
222 (4.39), 253 (3.61); ESIMS m/z 1031 [2 M + Na] +, 527
[M + Na] +, 505 [M + H] +, 487 [M + H − H2O] +; HRMS
m/z 505.2798 [M + H] + (calcd for C28H41O8, 505.2801).
Skeletocutin E (5). Yellow oil; UV (MeOH) λmax(log ε) 207
(4.39), 253 (3.65); ESIMS m/z 859 [2 M + Na] +, 441 [M +
Na] +, 419 [M + H] +, 401[M + H − H2O] +; HRMS m/z
419.2429 [M + H] + (calcd for C24H35O6, 419.2433).
Tyromycin A (6). White crystalline solid; UV (MeOH)
λmax(log ε) 214 (3.74), 256 (3.62); ESIMS m/z 915[2 M +
Na] +, 469 [M + Na] +, 447 [M + H] +, 429 [M + H − H2O]
+; HRMS m/z 447.2738 [M + H] + (calcd for C26H39O6,
447.2746).
Skeletocutin F (7). Yellow solid; UV (MeOH) λmax(log ε)
215 (4.48), 252 (3.08); ESIMS m/z 983 [2 M + Na] +, 503
[M + Na] +, 481 [M + H] +, 463 [M + H − H2O] +; HRMS
m/z 481.2422 [M + H] + (calcd for C25H37O9, 481.2437).
Skeletocutin G (8). White solid; UV (MeOH) λmax(log ε)
214 (4.20), 253 (4.33); ESIMS m/z 1011 [2 M + Na] +, 517
[M + Na] +, 495 [M + H] +, 477 [M + H − H2O] +; HRMS
m/z 495.2576 [M + H] + (calcd for C26H39O9, 495.2594).
Skeletocutin H (9). White solid; UV (MeOH) λmax(log ε)
227 (4.09), 256 (3.68); ESIMS m/z 1039 [2 M + Na] +, 531
[M + Na] +, 509 [M + H] +, 491 [M + H − H2O] +; HRMS
m/z 509.2746 [M + H] + (calcd for C27H41O9, 509.2750).
Skeletocutin I (10). White solid; UV (MeOH) λmax(log ε)
218 (4.28), 255 (3.40); ESIMS m/z 1067 [2 M + Na] +, 545
[M + Na] +, 523 [M + H] +, 505 [M + H − H2O] +; HRMS
m/z 523.2904 [M + H] + (calcd for C28H43O9, 523.2907).
Skeletocutin J (11). White oil; UV (MeOH) λmax(log ε)
218 (4.27), 256 (3.87); ESIMS m/z 895 [2 M + Na] +, 459
[M + Na] +, 437 [M + H] +, 419 [M + H − H2O] +; HRMS
m/z 437.2519 [M + H] + (calcd for C24H37O7, 437.2539).
Skeletocutin K (12). Yellow oil; UV (MeOH) λmax(log ε)
216 (4.505), 253 (4.02); ESIMS m/z 951 [2 M + Na] +, 487
[M + Na] +, 465 [M + H] +, 447 [M + H − H2O] +; HRMS
m/z 465.2850 [M + H] + (calcd for C26H41O7, 465.2852).
Skeletocutin L (13). Yellow oil; UV (MeOH) λmax(log ε)
218 (4.21), 259 (3.97); ESIMS m/z 979 [2 M + Na] +, 501
[M + Na] +, 479 [M + H] +, 461 [M + H − H2O] +; HRMS
m/z 479.2993 [M + H] + (calcd for C27H43O7, 479.3008).
Figure 3. Antiviral activity of compound 1-13 against Hepatitis C virus (HCV). Huh-7.5 cells were inoculated with RLuc-Jc1 reporter viruses in the
presence of the compounds. The inoculum was removed 4 h later and monolayers were washed three times with PBS and overlaid with fresh
medium containing no inhibitors. Infected cells were lysed 3 days later, and reporter virus infection was determined by the Renilla luciferase activity
(A). The cell viability was measured by determination of Firef ly luciferase (B), which is stably expressed in the target cells. Dose-dependent
inhibition of HCV infectivity was observed after treatment with compound 6 for 3 days (C).
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Abstract
During the course of screening for new metabolites from basidiomycetes, we isolated and characterized five previously unde-
scribed secondary metabolites, skeletocutins M–Q (1–5), along with the known metabolite tyromycin A (6) from the fruiting bodies
of the polypore Skeletocutis sp. The new compounds did not exhibit any antimicrobial, cytotoxic, or nematicidal activities. Howev-
er, compound 3 moderately inhibited the biofilm formation of Staphylococcus aureus (S. aureus), while compounds 3 and 4 per-
formed moderately in the ʟ-leucine-7-amido-4-methylcoumarin (ʟ-Leu-AMC) inhibition assay. These compounds represent the first
secondary metabolites reported to occur in the fruiting bodies by Skeletocutis. Interestingly, tyromycin A (6) was found to be the
only common metabolite in fruiting bodies and mycelial cultures of the fungus, and none of the recently reported skeletocutins from
the culture of the same strain were detected in the basidiomes.
Introduction
Over the past years, we have been studying the secondary
metabolites of African Basidiomycota that were collected in
rainforests and mountainous areas of Western Kenya. These
species were new to science, and proved to be a prolific source
of unprecedented natural compounds showing a set of promi-
nent biological activities [1-3].
The present study deals with the comparison of the secondary
metabolites located in the basidiomes (fruiting bodies) of
another, putatively new species belonging to the genus Skeleto-
cutis, strain MUCL56074. We have recently reported the
known metabolite tyromycin A (6), together with 12 unprece-
dented congeners for which we proposed the trivial names
Beilstein J. Org. Chem. 2019, 15, 2782–2789.
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Figure 1: HPLC–UV chromatogram of the extract from fruiting bodies of Skeletocutis sp. (detection wavelength λ = 190–600 nm).
skeletocutins A–L, which were obtained from a liquid culture of
the same fungus [4]. A preliminary characterization of the
producer organism suggested that it belongs to a new species
because neither DNA sequence data in the public domain nor
morphological characteristics matched the previously reported
species, as compared to the literature. The genus Skeletocutis
(of the Polyporaceae) consists of approximately 40 species,
which grow as a crust on the surface of collapsing wood [5] and
mostly occur in the temperate climate zones.
In our preceding study, the fungal specimen MUCL56074 has
been assigned to the genus Skeletocutis by comparison of mor-
phological features and 5.8S/ITS rDNA sequences, as reported
previously [4]. Strain MUCL56074 represents a hitherto unde-
scribed species, which will be formally described in a separate
paper in a mycological journal, pending the examination of type
material of related species. In view of a potential application of
chemotaxonomic methodology, the basidiomes of the fungus
were checked for the presence of secondary metabolites for
later comparison with herbarium specimens of other species by
HPLC–diode array detection (HPLC–DAD)–MS. Surprisingly,
we detected further members of the skeletocutin family that
were not present in the cultures. The current paper is dedicated
to the description of their isolation as well as biological and
physicochemical characterization.
Results and Discussion
The fruiting bodies of the fungal specimen MUCL56074 were
extracted with acetone and subsequently purified via prepara-
tive HPLC, which led to the isolation of five previously unde-
scribed secondary metabolites, 1–5 (tR = 17.8, 18.8, 15.7, 14.0,
and 14.3 min, respectively), and one known compound, namely
tyromycin A (6, tR = 16.8 min) [6] (Figure 1).
Compound 1 (Table 1 and Figure 2), named skeletocutin M,
was isolated as a yellow solid. Its molecular formula was deter-
mined to be C28H42O6, with eight degrees of unsaturation, by
HRESIMS. Signals for m/z = 475.3054, 497.2868, and
971.5839, corresponding to the ions [M + H]+, [M + Na]+, and
[2M + Na]+, respectively, were also recorded in the mass spec-
trum. A singlet resonating at δ = 2.08 ppm for the methyl
protons H3-6′ and a triplet and quinted resonating at δ = 2.50
and 1.59 ppm, respectively, for the methylene groups, were re-
corded in the 1H NMR spectrum. Further, the 13C NMR spec-
trum revealed only 14 signals instead of 28, as indicated by the
molecular formula, suggesting that the molecule consisted of
two identical halves.
Determination of HMBC correlations between the C-6′ methyl
protons (δ = 2.08 ppm) and C-3′/4′/5′ as well as between
H2-1/18 and C-2′/3′/4′ confirmed the presence of a maleic an-
hydride moiety in the molecule. Integration of the singlet for the
C-6′ methyl group in the 1H NMR spectrum gave a value of 6,
indicating the presence of two maleic anhydride functions. The
multiplet at δ = 1.28–1.36 ppm was assigned to the remaining
14 methylene units making up the carbon chain. Integration of
this multiplet gave a value of 28, confirming the length of the
chain. The connection of this chain to two maleic anhydride
units was confirmed by HMBC correlations between the
protons H2-1/2/17/18 and C-3′ (δ = 144.9 ppm). Additionally,
long-range correlations between the protons H2-1 and H3-6′
were observed in the COSY spectrum. Therefore, the structure
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Table 1: 1H and 13C NMR data for 1 (in acetone-d6) and 2 (in CDCl3).
1 2
Position 13C/DEPT 1H 13C/DEPT 1H
1/18 (1) or 1/20 (2) 24.8, CH2 2.50 (t), J = 7.6 Hz 24.4, CH2 2.46 (t), J = 7.6 Hz
2/17 (1) or 2/19 (2) 28.2, CH2 1.59 (p), J = 7.6 Hz 27.6, CH2 1.58 (p), J = 7.6 Hz
3–16 (1) or 3–18 (2) 29.4–29.8, CH2 1.28–1.36 (m) 29.2–29.7, CH2 1.26–1.32 (m)
2’ 167.1, C 165.9, C
3’ 144.9, C 144.8, C
4’ 141.7, C 140.4, C
5’ 167.4, C 166.3, C
6’ 9.6, CH3 2.08 (s) 9.5, CH3 2.08 (s)
Figure 2: Chemical structures of compounds 1–6.
of natural product 1 was unambigously concluded to be 1,18-
bis[4′-methyl-2′,5′-dioxo-3′-furyl]octadecane.
Compound 2 (skeletocutin N, Table 1 and Figure 2) was ob-
tained as a white solid, with the molecular formula C30H46O6
and eight degrees of unsaturation determined from HRESIMS
data. The 1D and 2D NMR data for 2 revealed a similar struc-
ture to 1, with the difference being the size of the carbon chain
in the molecule. A value of 32 obtained from the integration of
the C-3–C-18 multiplet (δ = 1.26–1.32 ppm) led to the conclu-
sion that 2 had an icosane chain instead of the octadecane chain
elucidated for skeletocutin M (1).
Compound 3 (skeletocutin O, Table 2 and Figure 2), isolated as
a yellow oil, had the molecular formula C28H44O7 and seven
degrees of unsaturation, deduced from HRESIMS data. Signals
for m/z = 493.3163 ([M + H]+), 515.2980 ([M + Na]+),
475.3058 ([M + H − H2O]+), and 1007.6067 ([2M + Na]+) were
also recorded by HRESIMS. A singlet for a methyl group
(δ = 2.08 ppm, H3-6′), along with another singlet (δ = 3.37 ppm,
H2-2), a quintet (δ = 1.58 ppm, H2-21), a triplet (δ = 2.45 ppm,
H2-22) for three methylene groups, and a triplet for a methine
unit (δ = 7.13 ppm, H-4) were observed in the 1H NMR spec-
trum of 3. Analysis of 1D and 2D NMR data for 3 indicated a
similar structure to 1, with a difference being the absence of one
maleic anhydride moiety, which was replaced by a dicar-
boxylic acid motif and an olefinic bond between position C-3
(δ = 124.5 ppm) and C-4 (δ = 148.9 ppm). Resonances for the
carbon atoms of the carboxylic acid moieties occurred at
δ = 176.8 ppm (C-1) and 172.0 ppm (C-23). The dicarboxylic
acid function could be elucidated through HMBC correlations
between H2-2 and C-1/3/4/23, H-4 and C-23/3, as well as H2-5
and C-3. Further cross peaks between H2-5 and H2-6/H-4 were
observed in COSY spectra, which confirmed the linkage of the
dicarboxylic acid motif to the chain at C-3. The diastereotopic
protons H2-2 (δ = 3.37) showed ROESY correlations to H2-5
(δ = 2.23 ppm), but no correlations between H2-2 and H-4
(δ = 7.13 ppm) were recorded. Therefore, the configuration of
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Table 2: 1H and 13C NMR data for 3 (in CDCl3) and compounds 4 and 5 (in DMSO-d6).
3 4 5
Position 13C/DEPT 1H 13C/DEPT 1H 13C/DEPT 1H
1 176.8, C 174.5, C 174.3, C
2 32.1, CH2 3.37 (s) 35.8, CH2 2.23 (dd),
J = 16.3, 5.8 Hz
2.92 (dd),
J = 16.3, 7.8 Hz
33.6, CH2 2.29 (dd),
J = 16.6, 2.4 Hz
2.53 (m)a
3 124.5, C 39.6, CH 3.86 (dd),
J = 7.8, 5.8 Hz
42.8, CH 2.83 (ddd),
J = 10.5, 6.7,
3.4 Hz
4 148.9, CH 7.13 (t),
J = 7.6 Hz
131.9, C 46.1, CH 2.50 (m)a
5 29.12, CH2 2.23 (m) 144.7, CH 6.74 (t),
J = 7.4 Hz
28.6, CH2 1.56 (m)
6 28.3, CH2 1.48 (m) 28.5, CH2 2.19 (q),
J = 7.4 Hz
28.6, CH2 1.35 (m)
7 28.5, CH2 1.38 (m)
8–20 29.3–29.7, CH2 1.26–1.31 (m) 29.1–29.5, CH2 1.23–1.26 (m) 28.82–29.0, CH2 1.23–1.26 (m)
21 27.6, CH2 1.58 (p),
J = 7.6 Hz
27.3, CH2 1.48 (p),
J = 7.5 Hz
26.9, CH2 1.49 (p),
J = 8.0 Hz
22 24.4, CH2 2.45 (t),
J = 7.6 Hz
24.1, CH2 2.39 (t),
J = 7.5 Hz
23.6, CH2 2.40 (t),
J = 8.0 Hz
23 172.0, C 173.8, C 172.9, C
24 167.8, C 174.7, C
2’ 165.9, C 166.7, C 166.2, C
3’ 144.8, C 143.9, C 143.4, C
4’ 140.4, C 141.3, C 140.8, C
5’ 166.3, C 166.9, C 166.4, C
6’ 9.3, CH3 2.08 (s) 9.7, CH3 1.99 (s) 9.2, CH3 2.00 (s)
aOverlapping signals.
the olefinic bond between C-3 and C-4 was assigned (E)-con-
figuration. As such, the structure of 3 was concluded to be (E)-
2-(19-(4’-methyl-2’,5’-dioxo-2’,5’-dihydrofuran-3’-yl)nonade-
cylidene)butanedioic acid.
Compound 4 (Table 2 and Figure 2), named skeletocutin P, was
isolated as a white solid. Its molecular formula was established
to be C29H44O9, with eight degrees of unsaturation, from
HRESIMS data. Peaks for m/z = 537.3058 ([M + H]+),
559.2877 ([M + Na]+), 519.2953 ([M + H − H2O])+, and
1095.5860 ([2M + Na]+) were observed in the mass spectrum.
The 1D and 2D NMR data of 4 were similar to those of 3, with
the difference being the presence of a tricarboxylic acid moiety
instead of a dicarboxylic acid motif at one end of the chain. The
three carboxylic acid functions of the molecule had resonances
at δ = 174.5 (C-1), 173.8 (C-23), and 167.8 ppm (C-24) in the
13C NMR spectrum. The HMBC correlations between H2-2 and
C-1/3/4/23 as well as H-5 and C-3/24 and the COSY correla-
tions between H2-2 and H-3 confirmed the tricarboxylic acid
moiety in the molecule. COSY correlations between H2-6 and
H2-5/7 confirmed the linkage of this moiety to the rest of the
molecule. The absence of ROESY correlations between H-5
and H-3 but the presence of such between the protons H-3 and
H2-6 indicated (Z)-configuration of the olefinic bond between
C-4 and C-5. Therefore, the structure of 4 was unambiguously
elucidated as (Z)-21-(4’-methyl-2’,5’-dioxo-2’,5’-dihydrofuran-
3’-yl)henicos-3-ene-1,2,3-tricarboxylic acid.
Compound 5 (skeletocutin Q, Table 2 and Figure 2), with the
molecular formula C29H46O9 and seven degrees of unsatura-
tion, as established from HRESIMS data, was obtained as a
yellow solid. Analysis of 1D and 2D NMR data of 5 indicated a
similar structure to 4, with saturation of the olefinic bond be-
tween C-4 and C-5. In the 13C NMR spectrum of 5, the signals
that had occurred at δ = 144.7 and 131.9 ppm for compound 4
were missing, and instead, a methylene signal at δ = 28.5 ppm
(C-5) and a methine signal at δ = 46.1 ppm (C-4) were re-
corded. HMBC correlations were observed between H-4
(δ = 2.50 ppm) and C-2/3/23/24 as well as H2-5 (δ = 1.56 ppm)
and C-4/C6/24. Furthermore, COSY correlations between H-3
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Table 3: Inhibition of ʟ-Leu-AMC hydrolysis by the metabolites 1–5.
IC50 (μg/mL)
Substrate (c) 1 2 3 4 5 6 Bestatin [12]
ʟ-Leu-AMC (50 µM) – – 89.6 71.1 153.2 138.4 10.8
ʟ-Leu-AMC (100 µM) – – 130.4 102.3 225.3 – 40.9
Figure 3: Inhibition Leu-AMC hydrolysis. a) c (ʟ-Leu-AMC) = 100 µM. b) c (ʟ-Leu-AMC) = 50 µM.
and H2-2/H-4 as well as H2-5 and H-4/H2-6 could be recorded.
Hence, 5 was concluded to be 21-(4’-methyl-2’,5’-dioxo-2’,5’-
dihydrofuran-3’-yl)henicosane-1,2,3-tricarboxylic acid.
Tyromycin A (6), a closely related compound to the metabo-
lites 1–5, has been reported before, and was isolated from the
cultures of the same fungus (i.e., the corresponding mycelial
culture of the specimen that was the subject of the present study
[4]) and originally from Tyromyces lacteus [6]. In these two
cases, 6 was reported to be the major component of the culture
extracts. Even though this compound is occurring in fruiting
bodies, in this case, skeletocutin M (1) was the major compo-
nent instead of tyromycin A (6). The two molecules 1 and 6
differ in their chain length, with the former having an 18-car-
bon chain instead of a 16-carbon chain, as in 6.
The isolated compounds 1–6 were evaluated for antimicrobial,
cytotoxic, and nematicidal activities, as described in the Experi-
mental section. However, compounds 1–5 were devoid of activ-
ity in these assays, whereas tyromycin A (6) and skeletocutin
A–L had been reported before to be active against several
Gram-positive bacteria [4], namely Bacillus subtilis
(B. subtilis), S. aureus, methicillin-resistant S. aureus (MRSA),
and Micrococcus luteus (M. luteus). In the antimicrobial assay,
compounds 3 and 5 were observed to interfere with the forma-
tion of biofilms commonly associated with S. aureus. When
compounds 3 and 5 were evaluated for biofilm inhibition activi-
ty against S. aureus, they showed only weak activity with 20
and 56% inhibition of the biofilm, respectively, at a concentra-
tion 256 µg/mL. Tyromycin A (6) was previously reported to be
an inhibitor of leucine aminopeptidase in HeLa S3 cells [6]. Ac-
cordingly, all compounds 1–5 were tested for their inhibition
activity against hydrolysis of ʟ-leucine-7-amido-4-methyl-
coumarin (ʟ-Leu-AMC). Compound 4 exhibited moderate ac-
tivity, with an IC50 value of 71.1 µg/mL (Table 3 and Figure 3)
when 50 µM of the substrate was used. Compounds 3 and 5
exhibited weak activities, with IC50 values of >80 µg/mL at 50
and 110 µM substrate concentration. Although tyromycin A (6)
was previously reported to be active in a similar assay against
HeLa S3 cells, with IC50 values of 31 μg/mL at 50 μM sub-
strate concentration, an IC50 value >150 μg/mL for this com-
pound was recorded on the HeLa (KB3.1) cells during this cyto-
toxicity study [6].
Conclusion
In summary, five previously undescribed tyromycin A deriva-
tives 1–5 could be isolated from Skeletocutis sp. fruiting bodies.
These metabolites are closely related to the skelotocutins that
were previously reported as isolates from liquid cultures. Com-
pounds 3 and 5 were observed to weakly inhibit the biofilm for-
Beilstein J. Org. Chem. 2019, 15, 2782–2789.
2787
mation by S. aureus and constrain inhibitory activity of ʟ-Leu-
AMC hydrolysis in KB 3.1 cells. There have been relatively
few studies on the production of secondary metabolites in
mycelial cultures vs fruiting bodies in higher fungi, but so far,
there are only few examples where the same compounds were
predominant in both. For instance, in most species hitherto
studied of the ascomycete order Xylariales, the fruiting bodies
and cultures mostly showed a complementary secondary
metabolite production [7]. In the current case, it appears that the
basidiomes of Skeletocutis can be used for chemotaxonomic
studies. Investigations of herbarium specimens may not even be
helpful for the taxonomic revision of the genus but may even
lead to the discovery of further, previously undescribed
members of the tyromycin/skeletocutin type.
Experimental
General information
NMR spectra were recorded with a Bruker 500 MHz spectrom-
eter at frequencies of 500.130 (1H NMR) and 125.758 MHz
(13C NMR). HRESIMS spectra were recorded after purification
with an Agilent 1200 series HPLC–UV system (column size:
2.1 mm⋅50 mm, packing: 1.7 µm, Waters ACQUITY UPLC
BEH C18 sorbent, solvent A: H2O + 0.1% formic acid, solvent
B: acetonitrile + 0.1% formic acid, elution gradient: 5% solvent
B for 0.5 min, increasing solvent B to 100% within 19.5 min,
100% solvent B for 5 min, flow rate: 0.6 mL/min, UV–vis
detection at λ = 200–600 nm) and ESI–TOF–MS analysis
(maXis™ system, Bruker, scan range: 100–2500 m/z, capillary
voltage: 4500 V, drying temperature: 200 °C). UV–vis spectra
were recorded with a Shimadzu UV-2450 UV–vis spectropho-
tometer. The chromatogram in Figure 1 was recorded on a
Bruker Agilent 1260 Infinity Series equipped with DAD and an
ESI ion trap mass spectrometer (amaZon speed ion trap,
Bruker).
Fungal material
The fungal specimen was collected by C. Decock and J. C.
Matasyoh in the Mount Elgon National Reserve [4]. The dried
specimen and corresponding cultures were deposited in the
MUCL collection (MUCL accession number: 56074).
Extraction of the crude extract
A quantity of 9.8 g fruiting bodies were extracted using 500 mL
of acetone overnight. Then, the extract was filtered and another
500 mL of acetone were added. This was extracted in an ultra-
sonic bath for 30 min. The extracts were combined and the sol-
vent evaporated to afford 226 mg of crude extract.
Isolation of compounds 1–6
The crude extract (vide supra) was filtered using solid-phase
microextraction (SPME) with a Strata™-X 33 µm Polymeric
Reversed Phase (RP) cartridge (Phenomenex). The extract was
fractionated by preparative RP chromatography (RPC) using a
PLC 2020 purification system (Gilson). A VarioPrep (VP)
column system packed with NUCLEODUR® 100-5 C18 ec was
used as stationary phase (Machery-Nagel, column size:
25 mm⋅40 mm, packing: 7 µm). Deionized water, obtained from
a Milli-Q® water purification system (Millipore), + 0.05% TFA
(solvent A) and acetonitrile + 0.05% TFA (solvent B), respec-
tively, were used as mobile phases (elution gradient: 50% sol-
vent B, increasing solvent B to 100% within 60 min, 100% sol-
vent B for 5 min, flow rate: 40 mL/min, UV–vis detection at
210, 254, and 350 nm). Eight fractions (F1–F8) were collected,
in accordance with the observed signals.
F1 was further purified by RPC using solvent A and solvent B
(elution gradient: 45% solvent B for 3 min, increasing solvent B
to 100% within 18 min, 100% solvent B for 4 min). A
Kromasil® C18 HPLC column (Nouryon, column size:
250 mm⋅20 mm, packing: 7 μm, flow rate: 15 mL/min) was
used as stationary phase. This led to the isolation of compound
4 (2.50 mg). Using the same column and elution gradient, 5
(2.87 mg) was purified from F2, compound 3 (4.26 mg) from
F4, compound 1 (4.84 mg) from F6, compound 2 (2.26 mg)
from F7, and tyromycin A (6, 2.15 mg) was obtained from F8.
Physicochemical data for compounds 1–5
Skeletocutin M (1): yellow solid (4.84 mg). UV (MeOH) λmax,
(log ε): 220 nm (4.26); HRESIMS (m/z): [M + H]+ calcd for
C28H43O6, 475.3054; found, 475.3059.
Skeletocutin N (2): white solid (2.26 mg). UV (MeOH) λmax,
(log ε): 214 (4.84), 254 nm (5.02); HRESIMS (m/z): [M + H]+
calcd for C30H47O6, 503.3374; found, 503.3373.
Skeletocutin O (3): yellow oil (4.26 mg). UV (MeOH) λmax,
(log ε): 220 nm (3.87); HRESIMS (m/z): [M + H]+ calcd for
C28H45O7, 493.3163; found, 493.3165.
Skeletocutin P (4): white solid (2.50 mg). [α]D20 +12 (c 0.0025,
MeOH); UV (MeOH) λmax, (log ε): 222 nm (5.14); HRESIMS
(m/z): [M + H]+ calcd for C29H45O9, 537.3058; found,
537.3064.
Skeletocutin Q (5): yellow solid (2.87 mg). [α]D20 +8.7
(c 0.001, MeOH); UV (MeOH) λmax, (log ε): 206 (4.49),
256 nm (4.65); HRESIMS (m/z): [M + H]+ calcd for C29H47O9,
539.3215; found, 539.3220.
Antimicrobial assay
Minimum inhibitory concentrations (MIC) were determined in
serial dilution assays using several microorganisms, as de-
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scribed previously [8,9]. Herein, Gram-positive bacteria used
were B. subtilis DSM10, MRSA DSM11822, S. aureus
DSM346, M. luteus DSM20030, and Mycobacterium smeg-
matis (M. smegmatis) ATCC700084, Gram-negative bacteria
were Escherichia coli (E. coli) DSM498, Chromobacterium
violaceum (C. violaceum) DSM30191, and Pseudomonas
aeruginosa (P. aeruginosa) PA14. Moreover, the filamentous
fungus Mucor plumbeus (M. plumbeus) MUCL49355 and the
yeasts Candida tenuis (C. tenuis) MUCL29892, Pichia anomala
(P. anomala) DSM6766, and Candida albicans (C. albicans)
DSM1665 were applied. The assays were conducted in 96-well
plates and Mueller–Hinton Broth (MHB) for bacteria, or yeast,
malt, and gluocse (YMG) medium for filamentous fungus and
yeasts.
Cytotoxicity assay
In vitro cytotoxicity, using IC50 values as a measure, was evalu-
ated against mouse fibroblasts cell line L929 and HeLa (KB3.1)
cells and carried out according to our previous reports [8,9].
Inhibition of biofilm formation
The assay was performed in Falcon® 96-well flat bottom plates
as previously described [10]. S. aureus DSM1104 was enriched
overnight to reach 0.5 McFarland standard turbidity in casein-
peptone soymeal-peptone (CASO) medium containing 4%
glucose at pH 7.0 for biofilm formation. Methanol was used as
negative control, while tetracycline was used as positive
control. All experiments were made in triplicates.
Nematicidal activity assay
The nematicidal activity of isolated compounds against
Caenorhabditis elegans (C. elegans) was performed in 24-well
microtiter plates as previously described [11]. Ivermectin was
used as positive control and methanol was used as negative
control. The results are expressed as LD90 values.
Inhibition of leucine aminopeptidases
Hydrolysis of ʟ-Leu-AMC by the surface-bound aminopepti-
dases of KB3.1 cells was assayed based on the method from
Weber and co-workers [6] with slight modifications. KB3.1
cells were grown as monolayer cultures in Dulbecco's modified
Eagle's medium (DMEM) containing 10% fetal calf serum at
37 °C in 24-well multidishes. After three days, the confluent
monolayers were washed twice with phosphate buffered saline
(PBS), and the reaction mixture (450 µL Hanks' buffer at
pH 7.2 containing 50 or 100 µM substrate ʟ-Leu-AMC, com-
pounds dissolved in 50 µL DMSO) was added. After being in-
cubated at 23 °C for 30 min, 1 mL cold 0.2 M glycine buffer at
pH 10.5 was added. The amount of hydrolyzed 7-amino-4-
methylcoumarin (AMC) was measured in a Tecan Infinite
M200 PRO fluorescence spectrophotometer (excitation and
emission at λ = 365 and 440 nm, respectively). Bestatin [12]
and DMSO were used as positive and negative control, respec-
tively.
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A B S T R A C T
Bioassay guided fractionation of extracts derived from submerged cultures of a Sanghuangporus sp. (i.e., the
genus that was until recently referred to as the “Inonotus linteus complex” of medicinal mushrooms) originating
from Kenya led to the isolation of a new spiro [furan-2,1’-indine]-3-one derivative, for which we propose the
trivial name phelligridin L (1) together with the known compounds 3,14′-bihispidinyl (2), hispidin (3), ionyli-
deneacetic acid (4), 1S-(2E)-5-[(1R)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enoic acid (5),
phellidine E (6) and phellidine D (7). Compounds 1–3, showed moderate nematicidal activity against
Caenorhabditis elegans with LD50 of 12.5 μg/m. The nematicidal activity of 3, 14′-bihispidinyl and hispidin (1, 2)
has not been reported before. Furthermore, compounds 1–5 demonstrated moderate antimicrobial activity
against various test organisms.
1. Introduction
Fungi have been recognized as source of structurally unique and
bioactive metabolites (Karwehl and Stadler, 2016). The fungal diversity
in the tropical rainforest ecosystems has been underexplored, since the
majority of the fungal species found in these habitats have not been
described nor has their chemistry been studied. In an effort to document
this diversity and its rich chemistry, we embarked on extensive study of
the secondary metabolite production of several basidiomycetes col-
lected from Kenya’s tropical rain forest Kakamega. Novel structurally
diverse and bioactive metabolites like laetiporins, calocerins, 9-oxos-
trobilurins, laxitextines, microporenic acids and aethiopinolones are
some of the metabolites that we have reported recently (Chepkirui
et al., 2018a, 2018b, 2017, 2016; Mudalungu et al., 2015) from our
ongoing study.
The present paper deals with a species belonging to the genus
Sanghuangporus (Hymenochaetaceae), whose extracts from mycelial
cultures had shown prominent antimicrobial effects during the course
of the aforementioned study. The specimen was collected from the
Kakamega Nature Reserve, a spot of rain forest at medium elevation in
Kenya. The genus Sanghuangporus was erected for the “Inonotus linteus
complex”, and several additional species from the Paleotropics pre-
viously included in Phellinus (Zhou et al., 2015). It originally included S.
alpinus, S. baumii, S. lonicericola, S. lonicerinus, S. microcystideus, S.
sanghuang, S. vaninii, S. weigelae, S. weirianus and S. zonatus (Zhou et al.,
2015). Three more species have been added later, viz. S. ligneus, S. pilatii
and S. quercicola (Ghobad-Nejhad, 2015; Tomsovsky, 2015; Zhu et al.,
2017). The Asian species have been referred to in the literature as
medicinal mushrooms. Only one species in the genus, S. microcystideus,
has been reported from Eastern Africa (Zhou et al., 2015). In this study
we report the isolation, structure elucidation and biological activities of
secondary metabolites from another African Sanghuangporus sp., which
probably represents an undescribed species.
2. Experimental section
2.1. General experimental procedure
Optical rotations were determined with a Perkin-Elmer (Überlingen,
Germany) 241 spectrometer; UV spectra were recorded with a
Shimadzu (Duisburg, Germany) UV–vis spectrophotometer UV-2450.
NMR spectra were recorded with a Bruker (Bremen, Germany) Ascend
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700 spectrometer with 5mm TXI cryoprobe (1H 700MHz, 13C
175MHz) and Bruker AV II-600 (1H 500MHz, 13C 150MHz) spectro-
meters. HR-ESI–MS mass spectra were recorded with a Bruker (Bremen,
Germany) Agilent 1200 series HPLC-UV system (column 2.1×50mm,
1.7 μm, C18 Waters Acquity UPLC BEH, solvent A: H2O+0.1% formic
acid; solvent B: AcCN+0.1% formic acid, gradient: 5% B for 0.5 min
increasing to 100% B in 19.5 min and then maintaining 100% B for
5min, flow rate 0.6mL/min-1, (UV–vis detection 200–600 nm) com-
bined with ESI-TOF-MS (Maxis, Bruker) [scan range 100–2500 m/z,
capillary voltage 4500 V, dry temperature 200 °C]. Chemicals and sol-
vents were obtained from AppliChem GmbH, Avantor Performance
Materials, Carl Roth GmbH & Co. KG and Merck KGaA in analytical and
HPLC grade.
2.2. Fungal material
The specimen MUCL 55592 was collected from Kakamega equa-
torial rainforest, located in the western part of Kenya (0°17′3.19”N
34°45′8.24”E) by C. Decock on Feb. 17, 2015. The dried herbarium
specimen and culture are deposited at MUCL, Louvain-la-Neuve,
Belgium (designation no. MUCL 55592). The fungus was identified as a
species of the genus Sanghuangporus by morphological examination and
sequencing of the rDNA (5.8S gene region, the internal transcribed
spacer (ITS) and part of the nuclear ribosomal large subunit (nLSU).
DNA extraction was performed as reported previously (Wendt et al.,
2018) with the EZ-10 Spin Column Genomic DNA Miniprep kit (Bio
Basic Canada Inc., Markham, Ontario, Canada). A Precellys 24 homo-
genizer (Bertin Technologies, France) was used for cell disruption at a
speed of 6000 rpm for 2× 40 s. The gene regions were amplified with
primers ITS 1f and NL4 for sequencing of the rDNA (5.8S gene region,
the internal transcribed spacer ITS1 and ITS2). Genomic DNA Miniprep
kit (Bio Basic Canada Inc., Markham, Ontario, Canada). The gene re-
gions were amplified with primers ITS 1f and ITS4 for ITS and LROR
and LR7 for nLSU.
2.3. Fermentation
Sanghuangporus sp. was cultivated in 500mL Erlenmeyer flask
containing 200mL of the three different liquid media YMG, Q6 ½ and
ZM ½ (for details on the composition of these media see Supplementary
information). These three media were selected because previous studies
had revealed that they were optimal for attaining complementary sec-
ondary metabolites profiles in filamentous fungi (Bitzer et al., 2008). A
well grown culture grown on an YMG agar plate was cut into small
pieces using a cork borer (7 mm) and five pieces inoculated in each
flask. The cultures were incubated at 23 °C on a rotary shaker
(140 rpm). The growth of the fungus was monitored by constantly
checking the amount of free glucose (using Bayer Diastix Harnzuck-
erstreifen). The fermentation was terminated five days after glucose
depletion.
2.4. Extraction of crude extracts from small scale fermentation
The supernatant and the mycelia from the small scale fermentation
were separated by filtration. The supernatant was extracted with equal
amount of ethyl acetate and filtered through anhydrous sodium sul-
phate. The resulting ethyl acetate extract was evaporated to dryness by
means of rotary evaporator. The mycelia were extracted with 200mL of
acetone in ultrasonic bath for 30min, filtered and the filtrate evapo-
rated. The remaining water phase was suspended in equal amount of
distilled water and subjected to same procedure as the supernatant. The
mycelia and supernatant crude extracts from the three media HRMS
were measured. Analysis of the MS spectra by comparing the masses of
the detected peaks and their molecular formula obtained from HRMS
with those in the data base (Dictionary of natural products) led to the
identification of the new compound on the ZM ½ supernatant crude
extract (Dictionary of Natural Products on DVD, 2017).
2.5. Scale-up fermentation
A well-grown seven days old YMG agar plate of the mycelial culture
was cut into small pieces using a 7mm cork borer and five pieces in-
oculated in 500mL Erlenmeyer flask containing 200mL (30 flasks) of
ZM ½ medium. The culture was incubated at 23 °C on a rotary shaker
(140 rpm). The growth of the fungus was monitored by constantly
checking the amount of free glucose (using Bayer Diastix
Harnzuckerstreifen). The fermentation was terminated five days after
glucose depletion.
2.6. Isolation of compounds 1–7
The supernatant culture crude extracts (700mg) were fractionated
using preparative reverse phase liquid chromatography (PLC 2020,
Gilson, Middleton, USA). VP Nucleodur 100-5C 18 ec column
(250× 40mm, 7 μm: Macherey-Nagel) used. Deionized water (Milli-Q,
Millipore, Schwalbach, Germany) (solvent A) and acetonitrile (solvent
B) were used as the mobile phase. The elution gradient used was
5–100% solvent B in 52min and thereafter isocratic condition at 100%
solvent B for 10min. UV detection was carried out at 210, 254 and
350 nm and flow rate 35mL/min. Five fractions (F1-F5) were collected
according to the observed peaks.
Fraction F1 and F2 were further purified by reversed phase LC
(solvent A/solvent B), elution gradient 20–30% solvent B for 30min
followed by gradient shift from 35 to 100% in 3min and finally iso-
cratic condition at 100% solvent B for 5min with a preparative
Nucleodur Phenyl hexyl column (Macherey-Nagel, Düren, Germany;
250× 21mm, 5 μm) as stationary phase and a flow rate of 15mL/min,
to afford compound 1 (3 mg) and compound 3 (50mg). Using the same
column and a modified elution gradient (25–45% solvent B for 30min
fraction) F3 was purified to afford 45mg of 2. Fractions F4 and F5 were
purified by reversed phase HPLC (solvent A/solvent B), elution gradient
78–100% solvent B for 25min followed by isocratic condition at 100%
solvent B for 5min with a preparative (Kromasil, MZ Analysentechnik,
Mainz, Germany) 250×20mm 7 μm C-18 column as stationary phase
to give compound 4 (125mg) and 5 (10mg). The same separation and
purification conditions were applied to the mycelial culture. Compound
6 (5 mg) and 7 (2mg) were purified from F4 by reverse phase LC
(solvent A/solvent B), elution gradient 65–85% solvent B for 20min
followed by gradient shift from 85 to 100% in 3min and finally iso-
cratic condition at 100% solvent B for 5min with a preparative HPLC
column (Kromasil, 250×20mm, 7 μm C-18) as stationary phase.
2.7. Antimicrobial assay
Minimum Inhibition Concentrations (MIC) against different test
organisms were determined in serial dilution assay as described pre-
viously by Teponno et al. (2017), against Candida tenuis MUCL 29982,
Mucor plumbeus MUCL 49355, Escherichia coli DSM498 and Bacillus
subtilis DSM10 and Micrococcus luteus DSM 1790. The assays were car-
ried out in 96-well microtiter plates in YMG medium for filamentous
fungi and yeasts and MH for bacteria. The stock solution concentration
was 300 μg/mL.
2.8. Nematicidal assay
Compounds 1-5 were assessed for nematicidal activity against
Caenorhabditis elegans according to Rupcic et al. (2018) and
Kuephadungphan et al. (2017) with slight modification. Caenorhabditis
elegans were inoculated monoxenically on nematode agar at room
temperature for 4–5 days. Thereafter, nematodes were washed down
from the plates with M9 buffer. The final nematodes concentration was
adjusted to 500 nematodes/mL of M9 buffer. Assay was performed in
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24-well microtiter plate at four different concentration (100, 50, 25 and
12, 5 μ/mL) of each compound. Ivermectin was used as the positive
control and methanol as a negative control. The plates were incubated
at 20 °C in the shaker in the dark and nematicidal activity was recorded
after 18 h of incubation and expressed as a LD50.
3. Results and discussion
The fungal strain Sanghuangporus sp. (MUCL 55592 was identified to
generic level by sequencing parts of the rDNA (5.8S gene region, in-
cluding the internal transcribed spacers (ITS1 and ITS2) and part of the
large subunit (LSU) as described in the Experimental. A BLAST search in
GenBank confirmed the identity affinities of this strain with members of
Sanghuangporus since the most homologous sequences were derived
from this genus. This was in agreement with the morphological features
of the basidiomata. Currently, further taxonomic studies are ongoing to
assess whether MUCL 55592 constitutes a new species; still a bulk of
Inonotus and Phellinus species need to be re-evaluated in a modern
taxonomic scheme.
Sanghuangporus sp. MUCL 55592 was investigated for active sec-
ondary metabolites as its crude extract exhibited antimicrobial activity
against Bacillus subtilis. Analysis of the HPLC–MS data and subsequent
search in public databases such as the Dictionary of Natural Products
(Dictionary of Natural Products on DVD, 2017), revealed the presence
of a potentially new metabolite. The secondary metabolite profile of the
crude extracts is shown in (Fig. 1). Bioassay guided fractionation led to
the isolation of one new compound of the phelligridrin family named
phelligridin L (1) together with known compounds: 3, 14′-bihispidinyl
(2), hispidin (3), ionylideneacetic acid (4), 1S-(2E)-5-[(1R)-2,2-di-
methyl-6-methylidenecyclohexyl]-3-methylpent-2-enoic acid (5), phel-
lidine E (6) and phellidine D (7) (Fig. 2) (Klaar and Steglich, 1977;
Edwards et al., 1961; Kobayashi et al., 2010). The known compounds
were identified by comparing their NMR and HR-MS data with those
reported in the literature.
Phelligridin L was isolated as a brown powder. The molecular for-
mula C25H16O9 with 18° of unsaturation was deduced from the HRMS
data. Furthermore, the ion peaks [M+H]+ at m/z 461.0871, [M+Na]+
at m/z 483.0690 and [2M+H]+ at m/z 921.1660 were identified in the
HR mass spectrum. The 1H NMR spectrum revealed 6 singlets, 4
doublets and one doublet of doublets attributed to aromatic and/or
olefinic protons. From the 13C and DEPT/HSQC NMR spectra 11 me-
thines and 14 quaternary carbons were identified (Table 1).
The HMBC correlations (Fig. 3) of H-3 to C-2, C-5 and H-5 (δH 5.72)
to C-3, C-4, C-6, C-2′ established the 4,6-disubstituted pyrone moiety in
the molecule. Although C-3 (δC 90.4) and C-5 (δC 100.9) were missing
in the 13C spectra their existence was confirmed from the HSQC and
HMBC correlations of H-5 (Fig. 4). The oxygenated substituents were
attached to C-2 (δC163.0), C-4 (δC 174.8) and C-6 (δC156.3) based on
their chemical shifts. Further HMBC correlations of H-3′ (δH 7.63) to C-
6, C-7′a, C-1′, C-3′a, H-4′ (δH 6.93) to C-7′a, C-3′, C-6′ and H-7′ (δH 6.62)
to C-3′a, C-5′, C-1′ unambiguously established the disubstituted-5′,6′-
dihydroxyindene moiety. The chemical shifts of the quaternary carbons
C-5′ (148.4) and C-6′ (δC148.1) indicated that these carbons were
oxygenated. The long range HMBC correlations of H-5 to C-2′ and H-3′
to C-6 confirmed the linkage of the pyrone moiety to the indene moiety
part of the molecule through C-2′ and C-6 bond.
The HMBC correlations of a doublet occurring at δH7.16 (H-4‴) with
a coupling constant 1.94 Hz to C-2‴, C-5‴, C-6‴, C-8‴, a doublet H-7‴
(δH 6.80, J=8.17 Hz) to C-3‴, C-5‴, C-6‴ and a doublet of doublets H-
8‴ (δH 7.07, J=1.94, 8.17 Hz) to C-4‴, C-2‴, C-6‴ observed pointed to
a 1,2,4-trisubstituted benzene ring. Based on their chemical shifts δC
147.2 and δC 150.5 for C-5‴ and C-6‴ respectively, hydroxyl groups
were attached to these carbons. Further HMBC correlations of H-1‴
(δH7.01) to C-3‴, C-5″, 4‴ and H-2‴ to C-4‴, C-8‴, C-5″ were observed.
Cross peaks between H-1‴ and H-2‴ were also observed in the COSY
spectrum with the olefinic bond between them being trans because of
the large coupling constant of 15.92 Hz recorded. From these HMBC
and COSY correlations a trans-5‴, 6‴-dihydroxystyryl moiety was elu-
cidated.
The singlet at δH 6.08 (H-4″) long range HMBC correlations to C-1′,
C-3″, C-5″, C-1‴ were recorded thus establishing the connection of C-1′
to C-5″ through C-3″ and C-4″. The HMBC correlations of H-4″ to C-5″,
C-1‴ and H-4″ to C-1′ established the connection between this part of
the molecule to the trans-5‴, 6‴-dihydroxystyryl moiety and the dis-
ubstituted-5′, 6′-dihydroxyindene moiety respectively. The molecular
formula of compound 1 had been established from the HRMS data as
C25H16O9 and the 18° of unsaturation, to these 25 carbons, 16 hydro-
gens, 8 oxygens and 17° of unsaturation have been accounted for.
Therefore based on the chemical shifts of C-5″ (δC 188.0) and C-1′ (δC
96.9) and the molecular formula, C-1′ and C-5″ were connected via an
oxygen atom establishing the spiroindene moiety in the molecule.
Therefore the structure of compound 1 was elucidated as 5′,6′-dihy-
droxy-2′-(4-hydroxy-2-oxo-2H-pyran-6-yl)-5-[(E)-2-(4-hydroxy-phenyl)
ethenyl]-3H-spiro[furan-2,1′-inden]-3-one.
Phelligridin L (1) is closely related to other naturally occurring
antioxidant and cytotoxic agents such as phelligridin G, phelligridin E















Fig. 1. “HPLC profile (chromatogram recorded of the total UV/Vis adsorption between 200–600 nm)” of the crude extract from the supernatant of Sanhuangporus sp.
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and inoscavin A (Wang et al., 2005; Mo et al., 2004; Kim et al., 1999).
Like the above mentioned compounds phelligridin L was optically in-
active. The biogenetic formation of the chiral centre at C-1′ of the
spiroindene moiety has been reported before to be nonstereo-selective
(Wang et al., 2005).
The nematicidal effects of compounds 1–7 on Caenorhabditis elegans
are shown in Table 2. Compounds 1 and 3 showed moderate nemati-
cidal activity with LD50 of 12.5 μg/mL. Compound 2 exhibited a weak
effect with LD50 of 50 μg/mL. The other compounds 4–7 did not show
any significant nematicidal effects on C. elegans. Although the biological
activities of hispidin (3), and 3, 14′-Bihispidinyl (2) have already been
studied for decades, to the best of our knowledge their nematicidal
activities have not been reported. Furthermore 1–7 were tested for
antimicrobial activities against various test organisms (Table 2). Com-
pound 1 and 3 were found to be active against Micrococcus luteus with
MIC of 25 μg/mL and 100 μg/mL respectively. Further 4–5 demon-
strated non selective antibacterial and antifungal activities. Anti-
microbial activities of these two compounds have been reported before
(Kobayashi et al., 2010). However, when studied by us, phellidines D
and E exhibited no significant antimicrobial activities at concentrations
up to 100 μg/mL. This observation may relate to the different test or-
ganism and protocols used by us in comparison to the aforementioned
reference.
4. Conclusion
Sanghuangporus sp. belongs to the Inonotus linteus complex of med-
icinal mushrooms. A new highly oxygenated spiro [furan-2,1′-indine]-
3-one derivative (1) together with six known compounds were isolated
Fig. 2. Chemical structures of 1–7.
Table 1
1H and 13C data of phelligridin L (1) recorded in methanol-d4 (1H 700MHz, 13C
150MHz).
No δC DEPT δH
2 163.0 C
3 90.4 CH 5.34
4 174.8 C




3′ 141.4 CH 7.63 (s)
3a’ 134.4 C
4′ 112.1 CH 6.93 (s)
5′ 148.4 C
6′ 148.1 C
7′ 110.5 CH 6.62 (s)
7a’ 136.1 C
3” 201.6 C
4” 104.5 CH 6.08 (s)
5” 188.0 C
1‴ 113.4 CH 7.01 (d), J=15.92 Hz
2‴ 143.9 CH 7.60 (d), J=15.92 Hz
3‴ 128.3 C
4‴ 115.7 CH 7.16 (d), J=1.94 Hz
5‴ 141.4 C
6‴ 150.5 C
7‴ 116.8 CH 6.80 (d), J=8.17 Hz
8‴ 124.0 CH 7.07 (dd), J=1.94, 8.17
Fig. 3. HMBC and COSY correlations of 1.
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from Sanghuangporus sp. Compounds 1–5 showed moderate anti-
microbial activity. Furthermore, compound 1–3 showed moderate ne-
maticidal activities against C. elegans. Even though 3,14′-bihispidinyl
and hispidin have been studied for several decades their nematicidal
activity have not been reported before. Some of the biological activities
of hispidin and other hispidin derivatives include antimicrobial, anti-
oxidants, cytotoxic, anti-inflammatory and β-secretase inhibition ac-
tivities (Chen et al., 2016; De Silva et al., 2013; Hsieh et al., 2013; Lee
et al., 2006; Lee and Yun, 2011).
5. Chemical data
Phelligridin L (1): Brown powder; UV (MeOH, c=0.25) λmax (log ε)
202 (3.663), 256 (3.3950), 385 (3.646); 1H NMR (700MHz, Methanol-
d4 see Table 1, 13C NMR (175MHz, Methanol-d4) see Table 1; HRESIMS
m/z 461.0871 [M+H]+ (calcd for C25H17O6, 461.0872).
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Fig. 4. Extracted part of HMBC spectra of phelligridin L (1) showing H-5 HMBC correlations.
Table 2
Antimicrobial and nematicidal activities of compounds 1-7.
Test strains 1 2 3 4 5 6 7 Reference
Antimicrobial activities MIC (μg/mL)
Bacillus subtilis DSM 10 / / / 6.25 / / / 2.3a
Micrococcus luteus DSM
1790
25 25 100 25 ≤100 / / 8.3a
Escherichia coli DSM 498 / / / / / / / 2.3a
Candida tenuis MUCL 29982 / / / 50 / / / 2.3b
Mucor plumbeus MUCL
49355
100 / / 12.5 100 / / 9.4b
Nematicidal activities LD50 (μg/mL)
Caenorhabditis elegans 12.5 12.5 25 / / / / ≤3.1c
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Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.phytol.2018.04.022.
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Abstract: A mycelial culture of the Kenyan basidiomycete Fomitiporia aethiopica was fermented on
rice and the cultures were extracted with methanol. Subsequent HPLC profiling and preparative
chromatography of its crude extract led to the isolation of five previously undescribed pregnenolone
type triterpenes 1–5, for which we propose the trivial name aethiopinolones A–E. The chemical
structures of the aethiopinolones were determined by extensive 1D- and 2D-NMR, and HRMS data
analysis. The compounds exhibited moderate cytotoxic effects against various human cancer cell
lines, but they were found devoid of significant nematicidal and antimicrobial activities.
Keywords: cytotoxicity; fungi; Hymenochaetaceae; triterpenes
1. Introduction
The fungal kingdom includes many species that produce various classes of structurally unique
and biologically active metabolites [1,2]. Of interest to us are the largely neglected basidiomycetes and
more so, those available from rich untapped sources like the African tropics. During the course of
our studies on Kenya’s tropical basidiomycetes we have encountered various interesting organisms
that yielded new biologically active metabolites such as laetiporins, calocerins, 9-oxostrobilurins
and laxitextines [3–5]. Another specimen collected in Kenya was identified as Fomitiporia aethiopica,
a species that had been first reported from the Ethiopian highlands [6]. The mycelial culture showed
an interesting secondary metabolite profile when studied by HPLC-MS. Although the taxonomy of the
genus Fomitiporia in Africa has been reported, the secondary metabolites of these genus have so far not
been studied extensively, even though one of its species is involved in the esca disease syndrome of
grapevine [6–8]. The present paper is dedicated to the first investigation of the secondary metabolite
production in mycelial cultures of Fomitiporia aethiopica.
2. Results and Discussion
2.1. Structure Elucidation
Solid phase fermentation on rice of the strain Fomitiporia aethiopica was carried out as described
in the Materials and Methods section. In the antimicrobial assay the crude extracts initially showed
Molecules 2018, 23, 369; doi:10.3390/molecules23020369 www.mdpi.com/journal/molecules
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activity against Bacillus subtilis but the activity was later attributed to fatty-acid like components
of the extracts. However, we found some interesting peaks upon analysis of the HPLC-MS data.
A subsequent search in the Dictionary of Natural Products database suggested the presence of hitherto
undescribed metabolites [9]. Scale-up of fermentation and subsequent preparative chromatography
yielded five new triterpenes 1–5, for which we propose the trivial names aethiopinolones A–E.
Aethiopinolone A (1) was isolated as yellow oil with the molecular formula C21H30O5 and
seven degrees of unsaturation deduced from the HRMS data. The 13C-NMR spectroscopic data of 1
revealed the presence of 21 carbon signals (Table 1). From the DEPT NMR data three methyl groups,
six methylene groups, six methane groups and six quaternary carbons were identified. In the 1H-NMR
spectrum, three methyl singlets resonating at δ 0.58 (H3-18), δ 0.93 (H3-19) and δ 2.16 (H3-21) were
recorded. Further, peaks at δ 2.71 (H-17), δ 3.50 (H-3) and 4.74 (H-16) attributed to oxygenated methine
groups were observed in the 1H-NMR.
Table 1. NMR data for compounds 1 (in acetone-d6) and 2 (in DMSO-d6).
1 2
Position ∂C, Type ∂H (J in Hz) ∂C, Type ∂H (J in Hz)
1 30.5, CH2 β:1.31, m b; α:1.48, m b 24.2, CH2 β:1.01, m b; α:2.27, m b
2 31.6, CH2 β:1.32, m b; α:1.77, m b 27.4, CH2 α:1.52, m b, β:1.40, m b
3 70.3, CH 3.50, tt, (4.5, 11.3) 63.1, CH 3.91, m
4 31.5, CH2 β:2.05, m b; α:2.12 m b 27.9, CH2 β:1.35, m b; α:1.80, m b
5 47.2, CH 2.90, dd, (12.2, 3.8) 41.4, CH 3.17 dd, (12.05, 3.9)
6 199.3, C 200.7, C -
7 124.2, CH 5.48, d, (2.3) 122.6, CH 5.39, d(1.9)
8 160.8, C 160.4, C
9 74.2, C 72.6, C
10 42.7, C 41.9, C
11 28.5, CH2 α:1.84, m b; β:2.01, m b 26.8, CH2 α:1.69, dd, (13.6, 3.9); β:1.78, dd, (13.6, 4.43)
12 35.5, CH2 β:1.97, m b, α:2.07, m b 34.0, CH2 β:1.83, m; α:1.94, m
13 46.8, C 45.6, C
14 50.1, CH 3.12, ddd, (12.8, 6.7, 2.3) 48.8, CH 3.01, ddd, (12.4, 6.6, 1.9)
15 35.1, CH2 β:1.61, m b; α:2.02, m b 33.8, CH2 α:1.47, m b; α:1.88, m b
16 71.6, CH 4.74, bt, (3.0) 69.9, CH 4.55, bt, (3.1)
17 74.3, CH 2.71, d, (6.0) 73.0, CH 2.63, d, (6.1)
18 14.8, CH3 0.58, s 14.2, CH2 0.46, s
19 17.2, CH3 0.93, s 15.8, CH3 0.80, s
20 207.6, C 207.7, C
21 31.9, CH3 2.16, s 31.6, CH3 2.15, s
b Signals partially obscured, b- broad.
HMBC correlations of H3-18 to C-12/C-13/C-14/C-17, H3-19 to C-1/C-5/C-9/C-10, H-5 to
C-3/C-4/C-6/C-9/C-10/C-19, H-14 to C-7/C-8/C-9/C-13/C-15/C-18 and H3-21 to C-17/C-20
suggested a pregnenolone type of steroids (Figure 1). COSY correlations of H2-2 to H2-1/H-3, H2-4
to H-3/H-5, H2-11 to H2-12, H-14 to H2-15 and H-16 to H2-15/H-17 further supported these HMBC
correlations. Furthermore, cross peaks observed between H-7 and C-5/C-9/C-14 in the HMBC
spectrum and long range COSY correlation to H-14 with a coupling constant of 1.9 Hz helped to
confirm the position of the double bond.
A network of ROESY correlations were observed between H3-18 to H3-19/H2-12β/H-15β/
H-16/H3-21 and H3-19 to H3-18/ H2-1β/H2-11β, suggesting that these protons are on the same side
of the plane (Figure 2). On the other hand, cross peaks in the ROESY spectra were observed between
H-3 to H2-1α/H2-4α/H2-2α/H-5, H-14 to H2-15α/H2-12α/H-17 and H-17 to H2-15α/H-14. For H-3,
an α orientation was established based on the coupling constant of 4.52 Hz and 11.3 Hz together with
the ROESY correlations of H-3 to H-5/H2-1α/ H2-4α/H2-2α. Conversely, H-16 was β oriented as
indicated by the small coupling constant of 3.0 Hz and the cross peaks observed between H-16 and
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H3-18/H2-15β in the ROESY spectrum. The absolute configuration of 1 was finally determined using
Mosher’s method [10]. The difference in chemical shifts ∆δSR = (∆s − δR) for protons neighboring
C-3 gave positive values +0.079, +0.041 and +0.015 for H2-4α, H2-4β and H-5 respectively. On the
contrary, negative values of ∆δSR i.e., −0.078 (H2-α), −0.110 (H2-2β), −0.016 (H-2-1α), −0.061 (H2-1β)
and −0.011 (H3-19 were obtained. Therefore the absolute configuration of the C-3 stereocenter can
be assigned as S (Supplementary Information, Table S1). Using C-3 as the reference the other stereo
centers were assigned as 5S, 9S, 10S, 13S, 14R, 16R and 17R.
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Figure 2. HMBC, COSY and ROSY correlations of 1.
Aethiopinolone B (2) was obtained as a white solid. The molecular formula C21H30O5 and seven
degrees of unsaturation were deduced from the HR mass spectrum. The 1D and 2D-NMR data of 2
suggested that it possesses the same planar structure as 1, the difference being the stereochemistry
at C-3. The ROESY correlation of H-3 to H3-19 and the OH-3 (δ 4.26) to H-5 pointed to H-3 having β
orientation. In the 1H-NMR spectrum of compound 1 H-3 resonated as a triple triplet while H-3 of
compound 2 resonated as multiplet. Furthermore, C-3 was slightly shielded resonating at δ 63.1 as
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compared to C-3 of 1, which occurred at δ 70.3. Consequently the stereochemistry at C-3 was assigned
as R.
Aethiopinolone C (3) with a molecular formula C21H28O4 and eight degrees of unsaturation
deduced from HR mass spectrum was further isolated as yellow oil. Analysis of the 1H-NMR revealed
the absence of the methine proton at δ 2.71 (H-17) and the oxygenated methine proton δ 4.74 (H-16)
which were observed in the 1H-NMR of 1. Instead an olefinic doublet of doublet resonating at δ 6.91
(H-16) was recorded. In the 13C spectrum new signals at δ 144.3 and δ 155.1 were identified (Table 2).
H-16 showed HMBC correlations to C-13/C-14/C-20 and COSY correlations to H2-15 implying that
3 has similar planar structure as 1 with the difference being the double bond between C-16/C-17.
Further, similar ROESY correlations patterns in compounds 1 and 3 were recorded. Derivatization of
3 with both S and R- MPA chloride gave similar results as 1 for protons neighboring C-3 hence the
absolute stereochemistry was assigned as 3S, 5S, 9S, 10S, 13S and 14R (Table S2, SI).
Aethiopinolone D (4) was isolated as yellow oil with molecular formula C21H28O4 and eight
degrees of unsaturation established from the HRMS data. The 1D and 2D data of 4 indicated that 4
was analogous to 3 with the difference being the stereochemistry at C-3. The same ROESY correlations
of H-3 to H3-19, H-3 multiplicity in the 1NMR spectrum and the shielding effect reported in 13C-NMR
data of compound 2 were also observed in the 13C-NMR of 4, evincing the same stereochemistry at C-3
for the two molecules. Esterification of compound 4 with both S and R- MPA chloride, and subsequent
determination of ∆δSR from the resulting esters gave negative values −0.096, −0.012 and −0.11
for H-5, H2-4β and H2-4α respectively. Positive values +0.005, +0.162, +0.028 for H-19, H2-2β and
H2-2α respectively were obtained (Supplementary Information, Table S3). Therefore the absolute
stereochemistry of compound 4 was assigned as 3R, 5S, 9S, 10S, 13S and 14R.
Aethiopinolone E (5) was obtained as yellow oil. The molecular formula C21H26O4 and nine
degrees of unsaturation were deduced from the HRMS data. Analysis of the 13C and DEPT NMR
data of 5 indicated that it was similar to 3 with the difference being a keto group at position 3.
The oxygenated methine signal of compound 3 resonating at δ 70.3 was missing and instead a keto
carbonyl group was observed at δ 210.1. HMBC correlations of diastereotopic protons H2-2α (δ 2.35),
H2-2β (δ 2.26), H2-4α (δ 2.39), H2-4β (δ 2.51), to this carbon supported the assignment.
2.2. Biological Activities
Compounds 1–5 were tested for their cytotoxic effects against various mammalian cell lines
(Table 3). 3–4 showed moderate activity against all the tested cell lines. All compounds apart from
2 showed significant activities against MCF-7 and A431 with IC50 in the range 16–20 µg/mL and
14–27 µg/mL respectively. Compound 1 generally showed the strongest activity against the tested cell
lines with the highest effects against PC-3 (8 µg/mL). Compound 2 showed moderate activity only
against L929 and KB3.1 cells with IC50 of 45 µg/mL and 39 µg/mL respectively. Aside from these
cytotoxic activities, compounds 1–5 were found devoid of significant antimicrobial and nematicidal
effects at concentrations ≤300 µg/mL and ≤100 µg/mL respectively.
Although steroids are rather common in the Basidiomycota, they have not been reported yet from
the genus Fomitiporia. Studies on Fomitiporia ellipsoidea metabolites indicated that this fungus produced
a large amount of common ergosterol and its derivatives but this species has since been moved to the
genus Phellinus (currently valid name: Phellinus ellipsoidea) [11,12]. The close relationship between
these two genera has seen the transfer of several other species previously assigned to the genus
Phellinus to the genus Fomitiporia, examples being species like F. erecta, F. hartigii, F. robusta, F. punctata,
F. hippophaeicola and F. pseudopunctata [13]. Styrylpyrones like the protein kinase C inhibitor, bihispidinyl
and hypholomin B, which are common metabolites among the Hymenochaetales, have been reported
to occur in some Fomitiporia species [14,15].
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Table 2. NMR data for compounds 3–5 in acetone-d6.
3 4 5
Pos. ∂C, Type ∂H (J in Hz) ∂C, Type ∂H (J in Hz) ∂C, Type ∂H (J in Hz)
1. 30.4, CH2 β:1.29, m b; α:1.49, m b 25.3, CH2 β:1.16, m b; α:2.47, m b 32.2, CH2 β:1.82, m b; α:1.91, m b
2. 30.4, CH2 β:1.33 m b; α:1.77, m b 28.7, CH2 α:1.60, m b; β:1.65, m b 37.5, CH2 β:2.26, m b; α:2.35, m b
3. 70.3, CH 3.47, tt, (4.4, 11.3) 65.0, CH 4.05, m 210.1, CH
4. 31.5, CH2 β:2.10, m b; α:2.13 m b 29.2, CH2 β:1.54, m b; α:1.97, m b 37.6, CH2 α:2.39, m b; β:2.51, m b
5. 47.3, CH 2.91, dd, (12.2, 3.8) 42.7, CH 3.32, dd, (12.3, 4.1) 49.0, CH 3.30, dd, (12.7, 4.9)
6. 199.4, C 201.1, C 198.4, C
7. 123.4, CH 5.60, d, (2.1) 123.5, CH 5.58, d, (2.2) 123.1, CH 5.68, d, (2.2)
8. 160.2, C 160.0, C 160.8, C
9. 74.4, C 74.5, C 74.6, C
10. 42.8, C 43.4, C 43.1, C
11. 31.3, CH2 α:1.77, m b; β:2.15, m b 29.4, CH2 β:1.84, m b; α:2.13, m b 29.6, CH2 α:1.92, m b; β:2.24, m b
12. 32.1, CH2 β:1.81, m b; α:2.30 m b 32.1, CH2 β:1.80, m b; α:2.32, m b 32.1, CH2 β:1.82, m b; α:2.35, m b
13. 46.8, C 49.0, C 49.0, C
14. 52.9, CH 3.11, ddd, (11.6, 6.6, 2.1) 52.7, CH 3.13, ddd, (11.6, 6.5, 2.2) 52.7, CH 3.14, ddd (11.6, 2.2 Hz, 6.2)
15. 31.3, CH2 β:2.39, m; α:2.47, m 31.3, CH2 β:2.41, m; α:2.47, m 31.3, CH2 β:2.42, m; α:2.51, m
16. 144.3, CH 6.91, dd, (1.9, 3.4) 144.3, CH 6.91, dd, (1.9, 3.2) 144.3, CH 6.92, dd, (3.4, 1.9)
17. 155.1, C 155.2, C 155.1, C
18. 16.4, CH3 0.88, s 16.4, CH3 0.88, s 16.4, CH3 0.91, s
19. 17.2, CH3 0.99, s 16.5, CH3 0.99, s 16.5, CH3 1.24, s
196.3, C 196.3, C - 196.3, C
27.14, CH3 2.25, s 27.2, CH3 2.26, s 27.1, CH3 2.26, s
b Signals partially obscured.
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Table 3. Cytotoxic activities of compounds 1–5.
Cell Lines Cytotoxicity IC50 (µg/mL)
1 2 3 4 5 Epothilon B
L929 28 45 40 45 40 0.0014
KB3.1 19 39 35 39 33 0.00022
A431 22 - 27 21 14 0.0006
A549 nt - 70 52 43 0.005
PC-3 8 - 45 40 39 0.0002
SKOV-3 26 - 38 36 34 0.0014
MCF-7 20 - 18 17 16 0.0004
Not active, nt- not tested.
3. Materials and Methods
3.1. General Experimental Procedures
Optical rotations were determined with a Perkin-Elmer (Überlingen, Germany) 241 spectrometer;
UV spectra were recorded with a Shimadzu (Duisburg, Germany) UV-2450 UV-vis spectrophotometer.
NMR spectra were recorded with a Bruker (Bremen, Germany) Ascend 700 spectrometer equipped with
a 5 mm TXI cryoprobe (1H-700 MHz, 13C-175 MHz) and Bruker AV II-600 (1H-500 MHz, 13C-150 MHz)
spectrometers. HR-ESI-MS mass spectra were recorded with a Bruker (Bremen, Germany) Agilent
1260 series HPLC-UV/Vis system (column 2.1 × 50 mm, 1.7 µm, C18 Acquity UPLC BEH (waters),
solvent A: H2O + 0.1% formic acid; solvent B: AcCN + 0.1% formic acid, gradient: 5% B for 0.5 min
increasing to 100% B in 19.5 min and then maintaining 100% B for 5 min, flow rate 0.6 mL/min−1,
uv/vis detection 200–600 nm combined with ESI-TOF-MS (Maxis, Bruker) [scan range 100–2500 m/z,
capillary voltage 4500 V, dry temperature 200 ◦C]. Chemicals and solvents were obtained from
AppliChem GmbH (Darmstadt, Germany), Avantor Performance Materials (Arnhem, Netherlands),
Carl Roth GmbH & Co. KG (Karlsruhe, Germany) and Merck KGaA (Darmstadt, Germany) in
analytical and HPLC grade.
3.2. Fungal Material
The specimen MUCL 56047 was collected from Mount Elgon, located in the western part of
Kenya (1◦7′6′′ N, 34◦31′30′′ E) by C. Decock in April 2016 (collection and isolation number KE/16-163).
The dried herbarium specimen and culture are deposited at MUCL (Louvain-la-Neuve, Belgium)
as MUCL 56047. The fungus was identified as Fomitiporia aethiopica by morphological studies and
sequencing of the rDNA (5.8S gene region, the internal transcribed spacer ITS1 and ITS2). Genomic
DNA Miniprep kit (Bio Basic Canada Inc., Markham, ON, Canada). A Precellys 24 homogenizer (Bertin
Technologies, Saint-Quentin-en-Yvelines, France) was used for cell disruption at a speed of 6000 rpm
for 2 × 40 s. The gene regions were amplified with primers ITS 1f and ITS 4. Details are given in the
Supplementary Material.
3.3. Fermentation
The mycelial culture of MUCL 56047 was subjected to solid state fermentation in rice according
to [16] with slight modifications. The rice medium was prepared by weighing 90 g of rice into 500 mL
Erlenmeyer flasks containing in 90 mL of distilled water and autoclaved twice. A well-grown YMG
agar plate of the mycelial culture was cut into small pieces using a 7 mm cork borer and five plugs
inoculated into each of the 21 flasks containing sterile rice media. The cultures were incubated in a
dark room at 23 ◦C for 28 days.
3.4. Extraction
The cultures were diced into smaller pieces with a spatulum and each of the 21 flasks was soaked
in 150 mL of methanol overnight. Repeated extraction and filtration in an ultrasonic bath at 40◦ C
for 30 min until an exhausted residue was yielded was carried out. The residue was discarded and
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the filtrate evaporated by means of a rotary evaporator. The resulting aqueous phase was suspended
in equal amount of distilled water and extracted with equal amount of ethyl acetate four times.
The aqueous phase was discarded and the organic phase filtered through anhydrous sodium sulphate.
The resulting ethyl acetate extracts were evaporated to dryness by means of rotary evaporator to afford
800 mg of crude product.
3.5. Isolation and Physico-Chemical Characteristics of Compounds 1–5
The crude extract was fractionated using preparative reverse phase liquid chromatography (PLC
2020, Gilson, Middleton, MA, USA). A VP Nucleodur 100-5 C 18 ec column (250 × 40 mm, 7 µm:
Macherey-Nagel, Schkeuditz, Germany) was used. Deionized water (Milli-Q, Millipore, Schwalbach,
Germany) (solvent A) and acetonitrile (solvent B) were used as the mobile phase. The elution gradient
used was 10–100% solvent B in 55 min and thereafter isocratic condition at 100% solvent B for 10 min.
UV detection was carried out at 210, 254 and 350 nm. Seven fractions (F1–F7) were collected according
to the observed peaks. Fraction F4 was purified by reverse phase LC (solvent A/solvent B), elution
gradient 20–35% solvent B for 30 min, followed by a gradient shift from 35% to 100% in 3 min and
finally isocratic condition at 100% solvent B for 5 min with a preparative (Kromasil, Mainz, Germany)
250 × 20 mm, 7 µL C-18 column as stationary phase to give compounds 1 (30 mg) and 3 (16 mg). Using
the same column and elution gradient 25–40% solvent B for 35 min, fraction F6 was purified to afford
60 mg of compound 2, as well as 12 mg of 4 and 8 mg of 5.
Aethiopinolone A (1): Yellow oil; [α]25D −13◦ (c 0.001, MeOH); UV (MeOH) λmax(log ε) 236 (3.73);
HREIMS m/z 363.2166 (calcd. for C21H31O5, 363.2171); 1H-NMR (acetone-d6, 700 MHz) and 13C-NMR
(acetone-d6, 175 MHz) data: see Table 1.
Aethiopinolone B (2): White solid; [α]25D −33◦, (c 0.001, MeOH); UV (MeOH) λmax(log ε) 240 (3.77);
HREIMS m/z 363.2162 (calcd. for C21H31O5, 363.2171); 1H-NMR (DMSO, 500 MHz) and 13C-NMR
(DMSO, 125 MHz) data: see Table 1.
Aethiopinolone C (3): Yellow oil; [α]25D +15
◦, (c 0.001, MeOH); UV (MeOH) λmax(log ε) 234 (3.45);
HREIMS m/z 345.2060 (calcd. for C21H29O4, 345.2065); 1H-NMR (acetone-d6, 500 MHz) and 13C-NMR
(acetone-d6, 125 MHz) data: see Table 2.
Aethiopinolone D (4): Yellow oil; [α]25D +19
◦, (c 0.001, MeOH); UV (MeOH) λmax(log ε) 234 (3.38);
HREIMS m/z 345.2052 (calcd. for C21H29O4, 345.2065); 1H-NMR (acetone-d6, 700 MHz) and 13C-NMR
(acetone-d6, 175 MHz) data: see Table 2.
Aethiopinolone E (5): Yellow oil; [α]25D +10
◦, (c 0.001, MeOH); UV (MeOH) λmax(log ε) 238 (3.61);
HREIMS m/z 343.1901 (calcd. for C21H27O4, 343.1909); 1H-NMR (acetone-d6, 700 MHz) and 13C-NMR
(acetone-d6, 175 MHz) data: see Table 2.
Aethiopinolone A (1) 3-O-(S)-MTPA ester: 1H-NMR (chloroform-d, 700 MHz) δ 7.55 (2H, m, ArH), 7.43
(3H, m, ArH), 5.766 (1H, d, J = 2.2 Hz, H-7), 5.016 (1H, tt, J = 4.5, 11.8 Hz, H-3), 3.994 (1H, m, H-16),
3.590 (3H, s, OCH3), 3.040 (1H, m, H-14), 2.985 (1H, dd, J = 3.9, 12.3, H-5), 2.472 (1H, d, J = 5.8 Hz,
H-17), 2.443 (1H, m, 15α), 2.388 (1H, m, H-4α), 2.309 (3H, s, H-21), 2.011 (1H, m, H-1α), 1.945 (1H, m,
H-2α), 1.631 (1H, m, H-4β), 1.568 (1H, m, H-15α), 1.515 (1H, m, H-2β), 1.303 (1H, m, H-1β), 1.034 (3H,
s, H-19), 0.896 (3H, s, H-18). EIMS m/z 579.27 (calcd. for C31H38F3O7, 579.2569)
Aethiopinolone A (1) 3-O-(R)-MTPA ester: 1H-NMR (chloroform-d, 700 MHz) δ 7.55 (2H, m, ArH), 7.43
(3H, m, ArH), 5.757 (1H, d, J = 1.9 Hz, H-7), 5.012 (1H, tt, J = 4.7, 11.6 Hz, H-3), 3.994 (1H, m, H-16),
3.570 (3H, s, OCH3), 3.038 (1H, m, H-14), 2.970 (1H, dd, J = 3.9, 12.5, H-5), 2.473 (1H, d, J = 5.6 Hz,
H-17), 2.446 (1H, m, 15α), 2.334 (1H, m, H-1α), 2.309 (1H, m, H-4α), 2.310 (3H, s, H-21), 2.024 (1H, m,
H-2α), 1.625 (1H, m, H-2β), 1.569 (1H, m, H-15α), 1.590 (1H, m, H-4β), 1.364 (1H, m, H-1β), 1.045 (3H,
s, H-19), 0.897 (3H, s, H-18). EIMS m/z 579.29 (calcd. for C31H38F3O7, 579.2569)
Aethiopinolone C (3) S-MTPA ester: 1H-NMR (pyridine-d5, 700 MHz) δ 7.40–7.48 (5H, m, ArH), 6.615
(1H, dd, J = 1.9, 3.2, H-16), 5.956 (1H, d, J = 2.2 Hz, H-7), 5.290 (1H, tt, J = 4.7, 11.6, H-3), 3.528 (1H, dd,
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J = 3.7, 12.3 Hz, H-5), 3.695 (3H, s, OCH3), 3.413 (1H, ddd, J = 1.9, 6.5, 11.6 Hz, H-14), 2.711 (1H, m,
H-4α), 2.397 (2H, m, H-1), 2.2351 (1H, m, 15α), 2.238 (1H, m, H-15β), 2.251(3H, s, H-21), 1.983 (1H, m,
H-2α), 1.926(1H, m, H-4β), 1.556 (1H, m, H-2β), 1.019 (3H, s, H-19), 0.948 (3H, s, H-18). EIMS m/z
561.28 (calcd. for C31H36F3O6, 561.2463)
Aethiopinolone C (3) R-MTPA ester: 1H-NMR (pyridine-d5, 700 MHz) δ 7.40–7.47 (5H, m, ArH), 6.612
(1H, dd, J = 1.7, 3.2, H-16), 5.944 (1H, d, J = 2.2 Hz, H-7), 5.287 (1H, tt, J = 4.5, 11.8, H-3), 3.506 (1H, dd,
J = 3.9, 12.5 Hz, H-5), 3.852 (3H, s, OCH3), 3.399 (1H, ddd, J = 2.2, 6.0, 11.6 Hz, H-14), 2.669 (1H, m,
H-4α), 2.418 (2H, m, H-1), 2.2350 (1H, m, 15α), 2.232 (1H, m, H-15β), 2.250(3H, s, H-21), 2.049 (1H, m,
H-2α), 1.846(1H, m, H-4β), 1.685 (1H, m, H-2β), 1.027 (3H, s, H-19), 0.950 (3H, s, H-18). EIMS m/z
561.26 (calcd. for C31H36F3O6, 561.2463)
Aethiopinolone D (4) S-MTPA ester: 1H-NMR (pyridine-d5, 700 MHz) δ 7.40–7.47 (5H, m, ArH), 6.600
(1H, dd, J = 1.9, 3.4, H-16), 5.910 (1H, d, J = 2.2 Hz, H-7), 5.639 (1H, m, H-3), 3.619 (1H, dd, J = 4.1, 12.5
Hz, H-5), 3.850 (3H, s, OCH3), 3.367 (1H, ddd, J = 2.2, 6.0, 11.6 Hz, H-14), 2.657 (1H, 1β, H-1), 2.530
(1H, m, H-4α), 2.296 (1H, m, 15α), 2.222 (1H, m, H-15β), 2.078 (1H, m, H-2α), 2.015(3H, s, H-21), 1.999
(1H, m, H-4β), 1.741 (1H, m, H-2β), 1.361 (1H, m, 1α), 1.067 (3H, s, H-19), 0.971 (3H, s, H-18). EIMS
m/z 561.30 (calcd. for C31H36F3O6, 561.2463)
Aethiopinolone D (4) R-MTPA ester: 1H-NMR (pyridine-d5, 700 MHz) δ 7.40–7.47 (5H, m, ArH), 6.600
(1H, dd, J = 1.7, 3.2, H-16), 5.945 (1H, d, J = 2.2 Hz, H-7), 5.640 (1H, m, H-3), 3.715 (1H, dd, J = 4.1, 12.2
Hz, H-5), 3.698 (3H, s, OCH3), 3.366 (1H, ddd, J = 1.94, 6.2, 11.8 Hz, H-14), 2.640 (1H, m, H-4α), 2.507
(1H, 1β, H-1), 2.300 (1H, m, 15α), 2.229 (1H, m, H-15β), 1.976 (1H, m, H-2α), 2.015(3H, s, H-21), 2.011
(1H, m, H-4β), 1.713 (1H, m, H-2β), 1.298 (1H, m, 1α), 1.062 (3H, s, H-19), 0.959 (3H, s, H-18). EIMS
m/z 561.29 (calcd. for C31H36F3O6, 561.2463)
3.6. Preparation of the (R)- and (S)-MTPA Ester Derivatives
Compound 1 (3 mg) were dissolved in pyridine (6 mL) and transferred into two vials (3 mL
each). (R)-(−)-α-Methoxy-α-(trifluoromethyl)phenylacetyl chloride (5 µL) was added to one of
the vials and (S)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (5 µL) was added into
the other vial, and stirred for 1 h. The products were purified by reverse phase LC (acetonitrile
(B)/H2O (A), elution gradient 40–100% solvent B for 25 mins followed by isocratic condition at 100%
solvent B for 5 min with a preparative (VP 250/10 NUCLEODUR 100-5 C18 ec, Macherey-Nagel,
Schkeuditz, Germany) 250 × 10 mm, C-18 column as stationary phase and 6mL/min flow rate.
1H-NMR and 1H, 1H COSY of the samples were recorded after wards. Compound 3 and 4 (3 mg
each) were dissolved in deuterated pyridine (6 mL) and transferred into two vials (3mL each).
(R)-(−)-α-Methoxy-α-(trifluoromethyl)phenylacetyl chloride (5 µL) was added to one of the vials
and (S)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (5 µL) was added into the other vial,
and stirred for 3 h. 1NMR and 1H, 1H COSY of the samples were recorded after wards.
3.7. Antimicrobial Assay
Minimum Inhibition Concentrations (MIC) against different test organisms were determined in
serial dilution assay as described previously [17] against Candida tenuis MUCL 29982, Mucor plumbeus
MUCL 49355, Escherichia coli DSM498 and Bacillus subtilis DSM10. The assays were carried out in
96-well microtiter plates in YMG media for filamentous fungi and yeast and MH for bacteria. The stock
solution concentration was 300 µg/mL.
3.8. Cytotoxicity Assay
In vitro cytotoxicity (IC50) of the pure compounds 1–5 was determined against a panel of
mammalian cell lines including mouse fibroblast L929, HeLa (KB-3-1), epidermoid carcinoma cells
A431, breast cancer cells MCF-7, prostate cancer cells PC-3 and adenocarcinomic human alveolar
basal epithelial cells A549. The cell lines were cultured in DMEM (Gibco, ThermoFisher Scientific,
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Hilden, Germany) and MCF-7 in RPMI (Lonza, Cologne, Germany) media, all supplemented with
10% of fetal bovine serum (Gibco) under 10% CO2 at 37 ◦C. The cytotoxicity assay was performed
according to the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) method in
96-well microplates (ThermoFisher Scientific). Briefly 60 µL aliquots of serial dilutions from an
initial stock of 1 mg/mL in MeOH of the test compounds were added to 120 µL aliquots of a cell
suspension (5.0 × 104 cells/mL) in 96-well microplates. After 5 days incubation, a MTT assay was
performed, and the absorbance measured at 590 nm using an ELISA plate reader (Victor, PerkinElmer,
Überlingen, Germany). The concentration at which the growth of cells was inhibited to 50% of the
control (IC50) was obtained from the dose response curves. The negative control was methanol.
3.9. Nematicidal Assay
Compounds 1–5 were assessed for nematicidal activity against Caenorhabditis elegans according
to [18] with slight modifications. Caenorhabditis elegans were inoculated monoxenically on nematode
agar at room temperature for 4–5 days. Thereafter, nematodes were washed down from the plates with
M9 buffer. The final nematodes concentration was adjusted to 500 nematodes/mL of M9 buffer. Assay
was performed in 24-well microtiter plate at four different concentration (100, 50, 25 and 12.5 µ/mL)
of each compound. Ivermectin was used as the positive control and methanol as a negative control.
The plates were incubated at 20 ◦C in the shaker in the dark and nematicidal activity was recorded
after 18 h of incubation and expressed as a LD90.
4. Conclusions
In our continuous search for novel and bioactive compounds from tropical basidiomycetes,
we found five novel steroids from mycelial cultures of Fomitiporia aethiopica. The metabolites are the
first steroids from the genus in the current circumscription, even though triterpenoids and steroids in
particular are of widespread occurrence in Basidiomycota. The new metabolites were tested in various
bioassays, but only moderate to weak cytotoxic activities were observed, and their biological functions
remain obscure. Although closely related pregnane-type steroids have been reported before from
Phellinus igniarius and the marine alga-derived fungus Phaeosphaeria spartinae, such pregnenolone-like
compounds are unprecedented in fungal metabolism [19,20]. Accumulating evidence on triterpenoids
broad spectrum pharmacological activities coupled with a low toxicity profile has sparked discussion
with regard to their application, especially in cancer treatment.
Supplementary Materials: UV, HRMS, 1H- and 13C-NMR, 1H-1H COSY, HSQC, and HMBC and ROESY spectra
of compounds 1–5 and data on the producing organism are available as Supplementary Material.
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ABSTRACT: To explore the chemical diversity of metabo-
lites from new species of Dothideomycetes, the ex-type strain
of Sparticola junci was investigated. Seven highly oxygenated
and functionalized spirodioxynaphthalene natural products
incorporating carboxyalkylidene−cyclopentanoid (1−4), car-
boxyl-functionalized oxabicyclo[3.3.0]octane (5−6), and
annelated 2-cyclopentenone/δ-lactone (7) units, sparticolins
A−G, were isolated from submerged cultures of the fungus.
Their chemical structures including their relative (and
absolute) configurations were established through spectro-
scopic and X-ray crystallographic analyses. Sparticolin B (2)
exhibited inhibitory activity against the Gram-positive bacteria Bacillus subtilis, Micrococcus luteus, and Staphylococcus aureus,
while sparticolin G (7) showed antifungal activities against Schizosaccharomyces pombe and Mucor hiemalis. All other sparticolins
were only weakly active against S. aureus and also showed weak activities against the nematode Caenorhabditis elegans.
Compounds 2 and 7 also showed moderate cytotoxic activities against seven mammalian cell lines.
Fungal metabolites have been shown to be a prolific source ofnovel molecules that can serve as lead candidates for
development of pharmaceutical drugs, agrochemical pesticides,
and other products for the life science industry.1,2 However, the
majority of the fungal species still remain untapped for
secondary metabolite production, and in particular, newly
discovered plant-associated Ascomycota may be a good source
of novel chemistry. During a study of the mycobiota of the plant
genera Clematis and Spartium, several new taxa of Dothideo-
mycetes were discovered, and their cultures were studied for
secondary metabolite production.3 Several of these strains were
subjected to intensive studies, because their extracts showed
interesting biological activities in various bioassays. We have
recently reported a new terpenoid from a Roussoella sp.
associated with Clematis from Thailand that can significantly
inhibit biofilm formation by the human pathogenic bacterium
Staphylococcus aureus.4 In the current study, a type strain of
Sparticola (Sporormiaceae, Pleosporales)3 from the Spanish
broom, Spartium junceum (Fabaceae) found in Italy3 was
explored for its secondary metabolism and associated biological
activity. The present paper reports the isolation, structure
elucidation, and biological characterization of seven unprece-
dented polyketides from the mycelial cultures of Sparticola junci
Phukhamsakda, Camporesi & K.D. Hyde and represent the first
secondary metabolites of the genus Sparticola.
■ RESULTS AND DISCUSSION
The ethyl acetate extract obtained from the Q61/2 medium5
was fractionated by repeated reversed-phase preparative and
semipreparative HPLC to afford compounds 1−7.
The NMR spectroscopic data for sparticolins A−G (1−7)
suggested that they are new members in the spirodioxynaph-
thalene natural products family. The common structural moiety
present in sparticolins 1−7 is a 1,8-dioxynaphthalene linked to
highly functionalized cyclopentanoid, or 5,6-dihydro-2H-pyran-
2-one (in the case of compound 7) substructures, and can be
readily correlated to a spiroketal carbon resonating at
approximately 96−113 ppm in the 13C NMR spectrum.6 The
NMR spectroscopic data of the dioxynaphthalene moieties of all
seven compounds were almost the same (Tables 1 and 2).
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Discussion of the structure elucidation of the 1,8-naphthalene
moiety is provided for sparticolin A (1) to serve as a general
example. Discussion of the structures of sparticolins B−G (2−7)
focused on the remaining portions of each molecule, especially
the relative configurations of derivatives possessing multiple
chiral centers using 2D-ROESY.
Sparticolin A (1) was obtained as an amorphous powder, and
its molecular formula established as C19H14O5 from HR-ESI-
MS, implying 13 degrees of unsaturation.
Detailed analysis of the 1H, 13C, and HSQC-DEPT NMR
spectroscopic data revealed the presence of a carboxylic acid
carbon, a ketal carbon, five nonprotonated aromatic carbons
(two oxygenated and three nonoxygenated), six aromatic
methines, five olefinic methines, and an oxygenated sp3 methine
carbon. In the 1H−1H COSY spectrum of 1, homonuclear
coupling correlations of H-11/H-17 (δH 6.89) with H-12/H-16
(δH 7.40) as well as correlations of H-13/H-15 (δH 7.49) withH-
12/H-16 indicated the presence of two three-proton spin
systems corresponding to the C-11 to C-13 and C-15 to C-17
substructures of 1, which displayed ortho coupling with J-values
of 8.5 and 7.5 Hz. The HMBC correlations of H-11/H-17 with
C-10/C-18 (δC 150.2) and C-19 (δC 115.1) and H-13/H-15
with C-14 (δC 135.9) and C-19 led to the attachment of both
subunits at C-14 and C-19, suggesting the presence of a
naphthalene substructure. In addition, the chemical shifts of C-
10 andC-18 were indicative of a 1,8-dioxynaphthalene fragment.
The remaining part of 1 was constructed through analysis of
COSY and HSQC-DEPT spectroscopic data revealing con-
nectivities (bold line) between H-2 → H-3 → H-4 and H-6 →
H-7 → H-8 (Figure 1a). HMBC correlations of H-2 (δH 5.97)
and H-4 (δH 5.43) with dioxygenated C-1 (δC 108.2) and
olefinic C-5 (δC 149.4) suggested 1-ketal and 5-exo-alkylidene 2-
cyclopenten-4-ol moieties, where the 1,8-dioxynaphthalene
moiety should be connected to ketal C-1 through spiro
annelation. Further HMBC correlations of H-6 (δH 6.75) with
ketal C-1, alcohol C-4 (δC 73.0), and alkylidene C-5 and of H-8
(δH 6.04) with the C-9 (δC 169.9) carboxylic acid carbon
allowed the elucidation of the gross planar structure of 1 (Figure
Chart 1
Table 1. 1H NMR Spectroscopic Data for Sparticolins A−G (1−7)
position 1a 2a 3a 4b 5a 6b 7b
2 5.97, dd (6.2, 1.3) 7.44, d (6.3) 5.83, dd (6.0, 1.6) 4.51, ddd (5.1, 3.4,
0.8)
5.90, ddd (5.8, 1.0,
0.4)
5.91, dd (5.8, 0.9) 6.64, d (10.3)




6.15, dd (6.0, 1.7) 2.30, ddd (13.5, 7.6,
3.5)
6.28, dd (5.8, 1.8) 6.27, dd (5.8, 1.8) 6.29, d (10.3)
3b 2.08, ddd (13.5, 7.1,
5.1)
4 5.43, dd (1.9, 1.7) - 4.59, dt (5.8, 1.7) 5.14, td (7.3, 2.3) 5.10, ddd (7.1, 1.9,
1.0)
5.10, ddd (7.1, 1.8,
1.0)
-
5 - - 2.51 ddd (8.2, 6.9, 5.7) - 3.18, td (9.1, 7.0) 3.19, td (9.1, 7.1) -
6a 6.75, d (11.8) 7.09, d (11.9) 2.87, dddd (15.1, 8.4, 7.1,
1.6)
6.53, dd (11.7, 2.3) 1.83, m 1.82, m 3.38, dt (22.3,
2.3)
6b 2.75, m 3.02, dt (22.3,
2.3)




7.18, dt (15.5, 7.3) 7.89, dd (15.4, 11.7) 4.29, dtd (9.7, 6.5,
5.2)




8 6.04, d (15.5) 6.36, d (15.6) 6.04, dt (15.5, 1.5) 5.87, d (15.4) 2.54, d (6.6) 2.58, d (6.5) 6.41, d (7.3)
11 6.89, d (7.5) 6.99, d (7.6) 6.91, d (7.5) 7.01, d (7.5) 6.86, d (7.5) 6.92, d (7.6) 7.03, d (7.6)
12 7.40, dd (8.3, 7.5) 7.49, dd (8.4,
7.6)
7.41 dd (8.3, 7.5) 7.44 dd (8.5, 7.5) 7.42 dd (8.4, 7.5) 7.43 dd (8.3, 7.6) 7.49 dd (8.4,
7.6)
13 7.49, d (8.5) 7.61, d (8.4) 7.49, d (8.3) 7.52, d (8.5) 7.50, d (8.4) 7.50, d (8.3) 7.61, d (8.4)
14 - - - - - - -
15 7.49, d (8.5) 7.61, d (8.4) 7.49, d (8.3) 7.52, d (8.5) 7.50, d (8.4) 7.50, d (8.3) 7.61, d (8.4)
16 7.40, dd (8.3, 7.5) 7.49, dd (8.4,
7.6)
7.41 dd (8.3, 7.5) 7.44 dd (8.5, 7.5) 7.42 dd (8.4, 7.5) 7.43 dd (8.3, 7.5) 7.49 dd (8.4,
7.6)
17 6.89, d (7.5) 6.99, d (7.6) 6.89 d (7.5) 6.93, d (7.5) 6.92, d (7.5) 6.90, d (7.56 7.00, d (7.6)
9-OMe - - - - 3.66, s -
a500 MHz, MeOH-d4.
b700 MHz, MeOH-d4.
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1a). The geometric orientations of the protons in the Δ5(6) and
Δ7(8) diene moiety were deduced to have trans relationships on
the basis of their vicinal coupling constant (JH‑7, H‑8 = 15.5 Hz)
and ROESY correlation. TheΔ5(6) configuration was established
as E through a ROESY correlation between H-4 and H-7 giving
rise to a 5E,7E geometric configuration in the exo-alkylidiene
carboxylic acid moiety (Figure 1a). The absolute configuration
at C-4 was deduced to be S on the basis of its single crystal X-ray
diffraction data (Figure 2). Thus, the structure of 1 was assigned
as (2Z,4E)-4-((S)-4-hydroxyspiro[cyclopentane-1,2′-naphtho-
[1,8-de][1,3]dioxin]-2-en-5-ylidene)but-2-enoic acid and hith-
erto assigned the trivial name, sparticolin A.
Table 2. 13C NMR Spectroscopic Dataa for Sparticolins A−G (1−7)
position 1b 2b 3b 4c 5b 6c 7c
1 108.2, C 103.7, C 111.1, C 112.6, C 108.2, C 112.6, C 96.3, C
2 130.5, CH 150.8, CH 130.0, CH 73.3, CH 131.6, CH 131.7, CH 138.0, CH
3 141.3, CH 140.6, CH 142.5, CH 41.2, CH2 140.8, CH 140.8, CH 125.4, CH
4 73.0, CH 193.8, C 79.3, CH 69.3, CH 87.2, CH 87.4, CH 163.1, C
5 149.4, C 137.5, C 57.4, CH 150.4, C 52.6, CH 52.6, CH 89.2, C
6 128.6, CH 135.8, CH 31.0, CH2 129.6, CH 34.3, CH2 34.2, CH2 42.3, CH2
7 141.3, CH 138.2, CH 149.4, CH 141.2, CH 80.2, CH 80.1, CH 138.8, CH
8 126.6, CH 133.8, CH 123.8, CH 125.9, CH 41.2, CH2 41.1, CH2 128.8, CH
9 169.9, C 169.2, C 170.1, C 170.0, C 174.8, C 173.2, C 207.0, C
10 150.2, C 149.3, C 150.0, C 149.4, C 150.0, C 150.0, C 147.1, C
11 110.3, CH 110.8, CH 110.1, CH 110.5, CH 110.3, CH 110.3, CH 111.4, CH
12 128.6, CH 128.8, CH 128.6, CH 128.6, CH 128.6, CH 128.6, CH 128.9, CH
13 121.9, CH 122.6, CH 121.7, CH 121.8, CH 121.8, CH 121.8, CH 122.8, CH
14 135.9, C 135.8, C 136.0, C 135.9, C 136.1, C 136.2, C 135.8, C
15 121.9, CH 122.6, CH 121.7, CH 121.8, CH 121.7, CH 121.7, CH 122.8, CH
16 128.6, CH 128.8, CH 128.6, CH 128.5, CH 128.6, CH 128.6, CH 128.9, CH
17 110.2, CH 110.8, CH 109.9, CH 110.0, CH 110.1, CH 110.1, CH 110.9, CH
18 150.2, C 149.3, C 149.8, C 149.4, C 149.8, C 149.8, C 146.6, C
19 115.1, C 114.8, C 115.3, C 115.2, C 115.6, C 115.6, C 114.5, C
9-OMe - - - - - 52.2 -
aCarbon multiplicities were deduced from HSQC−DEPT-135 spectra. b125 MHz, MeOH-d4. c175 MHz, MeOH-d4.
Figure 1. COSY (bold bonds), HMBC (red arrows), and ROESY (blue arrows). Correlations in sparticolins A−G (1−7).
Figure 2. (a) Single crystal X-ray absolute stereostructure of 1, monohydrate. (b) Hydrogen bond networks of 1 with water in the solid state packing.
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Sparticolin B (2) was isolated as a brown syrup. The HR-ESI-
MS of 2 showed a sodiated molecular ion peak at m/z 343.0754
[M + Na]+, corresponding to the molecular formula C19H12O5,
indicating an index of hydrogen deficiency of 14. Detailed
analysis of the NMR spectroscopic data (Tables 1 and 2)
revealed that compound 2 has nearly the same planar structure
as sparticolin A (1), differing only by replacement of the sp3
oxygenated methine at C-4, with a conjugated ketone unit (δC
193.8). This observation was supported by an isolatedH-2→H-
3 spin system deduced from the COSY spectrum, and HMBC
correlations of H-2 (δH 7.44) and H-3 (δH 6.59) with the C-1
dioxygenated carbon (δC 103.7), ketone C-4, and C-5 alkylidene
(δC 137.5) (Figure 1b). The relative configurations of the diene
at C-5 and C-7 were deduced to be E based on coupling constant
analysis and comparison to compound 1. Thus, the structure of
2 was elucidated as shown, and the compound was assigned the
name, sparticolin B.
Sparticolin C (3) was isolated as a light yellow syrup, and its
molecular formula was established as C19H16O5 by HR-ESI-MS
in conjunction with the analysis of its 1H and 13C NMR
spectroscopic data (Tables 1 and 2). Its index of hydrogen
deficiency was determined to be 12. In addition to signals for a
1,8-dioxynaphthalene unit, detailed analysis of the 1H, 13C, and
HSQC-DEPT NMR data (Tables 1 and 2) revealed the
presence of additional signals due to one carboxylic acid, one
doubly oxygenated nonprotonated sp3 carbon, four olefinic
methines, one oxygenated methine, an additional sp3 hybridized
methine, and a methylene carbon. The COSY spectrum showed
the presence of an eight-proton spin system (Figure 1c)
corresponding to the C-2 to C-8 unit in 3. The chemical shifts in
the 1H and 13C spectra along with the COSYNMR data revealed
the loss of the typical alkylidenation at C-5 of the cyclopentenol
moiety present in 1 and 2. The gross structure of 3 was
constructed based on the key HMBC correlations of H-5 and
H2-6 with C-1 and of H-7 and H-8 with carboxyl carbon C-9.
The vicinal coupling constant (3JH‑4,H‑5 = 5.7−5.8 Hz)7 between
H-4 and H-5 revealed a cis configuration at C-4 and C-5 (Figure
1c). Thus, compound 3was identified as shown and assigned the
name, sparticolin C.
Sparticolin D (4) was obtained as a light yellow syrup, and its
molecular formula was established as C19H16O6 based on HR-
ESI-MS data, implying 12 degrees of unsaturation. Examination
of its 1H and 13C NMR spectroscopic data (Tables 1 and 2)
revealed the presence of a carboxylic acid, a ketal, four olefinic
carbons (three of which were protonated), two oxygenated
methines, and a methylene carbon. Analysis of its COSY
spectrum showed correlations for two spin systems, H-2→Η2−
3→Η−4 and the typical three-proton spin-system, H-6→Η−7
→Η−8, which is also present in sparticolins A (1) and B (2) for
the exo-alkylidiene moiety (Figure 1d). Comparison of the 1H
and 13C NMR spectroscopic data (Tables 1 and 2) of 4 with
those of 1−3 along with the COSY andHMBC data revealed the
replacement of olefinic C-2 and C-3 by a carbinol, C-2 (δC 73.3)
connected to a methylene, C-3 (δC 41.2). HMBC correlations of
H-2 with C-1 and C-5 and H-4 with C-5 allowed the elucidation
of a 1-dioxy-2,4-dihydroxycyclopentanoid substructure. The
connection of the carboxylated exo-alkylidiene to the latter
substructure was established by HMBC correlations of H-6 with
C-1 and C-5 (Figure 1d). The relative configuration of
compound 4 was established through analysis of 1H−1H
NMR coupling constants and ROESY data. The 3JH‑2,H‑3a
coupling constant (∼5 Hz) indicated that the 2-OH must
adopt an equatorial orientation, while the 3JH‑3a/H‑3b,H‑4 coupling
constant (∼7 Hz) suggested that the 4-OH is axially oriented.7a
This implies that 4 has a trans relative configuration for
hydroxylated, C-2 and C-4. Strong ROESY correlations were
also observed between H-2 and H-3b and H-3a and H-4. In
addition, a ROESY correlation between H-4 and H-7 was also
noted, pointing to a C-5−C-6 olefin configuration similar to that
of 1 and 2 (Figure 1d). Thus, 4 was established as (2E,4E)-4-
((2S*,4S*)-2,4-dihydroxyspiro[cyclopentane-1,2′-naphtho-
[1,8-de][1,3]dioxin]-5-ylidene)but-2-enoic acid and assigned
the name, sparticolin D.
Sparticolin E (5) was obtained as a reddish-brown syrup. Its
molecular formula was determined to be C19H16O5 by HR-ESI-
MS analysis reflecting 12 degrees of unsaturation, which was also
supported by the 1H and 13C NMR spectroscopic data (Tables 1
and 2). Apart from a set of 13C NMR chemical shifts
characteristic of the 1,8-dioxynaphthalene moiety similar to
those of 1−4, the spectra of 5 showed additional signals for a
carboxylic acid, a ketal, two olefinic methines, three sp3methines
(including two oxygenated functionalities), and two methylene
carbons. The construction of the upper subunit was facilitated
by analysis of 1H−1H COSY and HMBC spectra. Analysis of the
COSY spectroscopic data led to the identification of a nine-
proton spin system (Figure 1) corresponding to the C-2−C-8
unit (Figure 1e). Key HMBC correlations of H-2, H-3, H-4, and
H-5 with dioxygenated carbon C-1 allowed the elucidation of a
C-4/C-5 disubstituted 2-cyclopentene moiety linked to 1,8-
dioxynaphthalene through a spiroketal junction. Annelation of a
tetrahydrofuran moiety at C-4 and C-5 in the cyclopentene
substructure forming a 1-oxabicyclo[3.3.0]octane was estab-
lished on the basis of HMBC correlations of H-4 with C-7 and
those of H-7 with C-4. Finally, HMBC correlations of H-7 and
H-8 with carboxylic acid C-9 completed the planar structure of
sparticolin E (5) (Figure 1e). The cis relationship between H-4
andH-5 was depicted through a∼7Hz vicinal coupling constant
(3JH‑4,H‑5).
8 A ROESY correlation of H-7 with H-4 and H-5
enabled assignment of the relative configurations of the chiral
carbons as 4S*, 5R*, and 7S*. Thus, compound 5 was assigned
the structure as shown.
Compound 6 (sparticolin F) was isolated as a brownish solid.
An HR-ESI-MS analysis gave a molecular ion at m/z 339.1230
[M + H]+, which was consistent with the molecular formula
C20H19O5, indicating 12 degrees of unsaturation. Analysis of the
1D and 2D NMR spectroscopic data of 6 showed structural and
stereochemical similarites with sparticolin E (5) except for the
appearance of an additional oxygenatedmethyl group resonating
at δC 52.2. HMBC correlation of the singlet at δH 3.66 with
carboxyl carbon C-9 indicated that 6 must be the methyl ester
derivative of 5 (Figure 1f). This is supported by a 14 amu
difference in their molecular masses.
Sparticolin G (7) was obtained as an optically active light
yellow oil, and its molecular formula was determined to be
C19H12O5 by HR-ESI-MS analysis. This observation was
consistent with the number of carbon signals (19) observed in
the 13CNMR spectra (Table 2) and was indicative of an index of
hydrogen deficiency of 14. In addition to signals corresponding
to a spiro-annelated 1,8-dioxynaphthalene moiety, detailed
examination of the 1H, 13C, and HSQC-DEPT NMR
spectroscopic data (Tables 1 and 2) revealed additional
resonances corresponding to chemical shifts of an ester carbon,
a ketone, a ketal, four olefinic methines, an oxygenated
nonprotonated sp3 carbon, and an sp3 methylene carbon. The
COSY correlation and chemical shifts observed for H-2 (δH
6.64)/H-3 (δH 6.29) and H2-6 (δH 3.02; δH 3.38)/H-7 (δH
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6.76)/H-8 (δH 6.41) along with HMBC correlations of H-2 and
H-3 with carboxyl ester C-4 and of H-7 and H-8 with ketone C−
9 indicated the presence of α,β-unsaturated carbonyl moieties.
Complete elucidation of the spiro-annelated δ-lactone/2-
cyclopenten-1-one substructure was achieved via HMBC
correlations of H-2 and H-3 with ketal carbon C-1 and
oxygenated tertiary carbon C-5, of H2-6 and H-7 with C-5,
and of H2-6 with C-1 (Figure 1f). The gross structure of 7 was
elucidated by connecting the 1,8-dioxynaphthalene subunit to
dioxygenated C-1, fashioning a second spiro junction. Thus, the
structure of compound 7 was assigned as shown.
While most spirobisnaphthalene derivatives have been
isolated from fungi, several have been detected from plant
sources.9 The first example of a 19 carbon-containing nor
derivative bearing a spiro-nonadiene skeleton, spiromamakone
A, was isolated as an optically inactive compound from an
unidentified nonsporolating endophytic fungus.10 The profound
antimicrobial and cytotoxic activities of spiromamakone A
sparked explorations especially in the fields of complex molecule
synthesis11,12 and medicinal chemistry.13 An additional related
structure, spiropressione A, was reported from the Sporormia-
ceae fungus Preussia sp.14,15 However, it was later found to be
identical to spiromamakone A through synthetic efforts.12 To
our knowledge, sparticolins A−F (1−7) are the first secondary
metabolites reported from the genus Sparticola. The mod-
ification of moieties in the upper rim of each structure is
unprecedented in polyketide metabolites, specifically among the
spirodioxynaphthalene class of natural products.
Sparticolins A−G (1−7) were evaluated for their antimicro-
bial, cytotoxic,16 and nematicidal activities.17 All compounds
showed weak inhibition against Staphylococcus aureus except
sparticolin B (2), which also exhibited inhibitory activity against
other Gram-positive bacteria such as Bacillus subtilis and
Micrococcus luteus and some fungal strains (Table 3).
Sparticolin G (7) showed broad spectrum antifungal activities
with inhibitory activities against Schizosaccharomyces pombe and
Mucor hiemalis with greater or equal potency compared to the
positive control nystatin and showed weaker effects against
Candida albicans, Pichia anomala, and Rhodoturula glutinis as
well as some Gram-positive bacteria (Table 3). Compounds 1−
5 showed very weak nematicidal activity, while compound 6 was
moderately active against C. elegans, and compound 7 was not
tested due to insufficient material.
Interestingly, compounds 2 and 7 also showed moderately
strong cytotoxic activities against seven mammalian cell lines
(Table 4). The presence of electrophilic α,β-unsaturated
carbonyl functionalities such as a 2-cyclopentenone in 2 and a
Table 3. Antibacterial, Antifungal, and Nematicidal Activities of 1−7
MIC [μg/mL]
tested organisms strain no. 1 2 3 4 5 6 7 referencea
fungi
Candida albicans DSM 1665 − − − − − − 33.3 8.3 (N)
Mucor hiemalis DSM 2656 − 16.7 − − − − 2.1 4.2 (N)
Pichia anomala DSM 6766 − − − − − − 66.6 8.3 (N)
Rhodoturula glutinis DSM 10134 − 33.3 − − − − 16.7 1.0 (N)
Schizosaccharomyces pombe DSM 70572 − 33.3 − − − − 8.3 8.3 (N)
bacteria
Bacillus subtilis DSM 10 − 4.2 − − − − 33.3 2.4 (O)
Chromobacterium violaceum DSM 30191 − − − − − − − 4.1 (O)
Escherichia coli DSM 1116 − − − − − − − 33.3 (O)
Micrococcus luteus DSM 1790 − 8.3 − − − − 66.6 4.2 (O)
Mycobacterium smegmatis ATCC 700084 − − − − − − 66.6 4.1 (K)
Pseudomonas aeruginosa DSM PA14 − − − − − − − 1.0 (G)
Staphylococcus aureus DSM 346 66.6 4.2 66.6 66.6 66.6 66.6 16.7 2.1 (O)
nematode LD50 [μg/mL]
Caenorhabditis elegans - 50 50 25 50 50 12.5 nt 1.0 (I)
aPositive drug controls: K = kanamycin, N = nystatin, O = oxytetracyclin hydrochloride, I = ivermectin. Em dash (−): No activity observed at
concentrations of 66 μg/mL. nt: not tested.
Table 4. Cytotoxicity of 1−7 against Mammalian Cell Lines
IC50 [μM]
cell line 1 2 3 4 5 6 7 epothilone B
mouse fibroblast L929 − 0.6 − − 52.4 114.9 0.6 1.4 × 10−3
HeLa cells KB3.1 − 0.8 40.1 − 61.7 70.7 1.2 8.9 × 10−5
human breast adenocarcinoma MCF-7 − 0.4 − − − − 0.4 2.4 × 10−4
human lung carcinoma A549 − 2.2 − − − − 1.6 6.9 × 10−5
human prostate cancer PC-3 − 0.9 − − − − 0.4 1.6 × 10−3
ovarian carcinoma SKOV-3 − 0.6 − − − − 0.3 2.8 × 10−4
squamous cell carcinoma A431 − 0.2 − − − − 0.1 7.9 × 10−5
aThe in vitro cytotoxicity test of sparticolins A−G (1−7) was conducted against seven mammalian cell lines, with epothilone B as a positive
control. The starting concentration for the cytotoxicity assay was 300 μg/mL, and substances were dissolved in MeOH (1 mg/mL). MeOH was
used as the negative control and showed no activity against the tested mammalian cell lines. Results were expressed as IC50: half maximal inhibitory
concentration (μM). Em dash (−): no inhibition.
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2H-pyran-2-one/2-cyclopentenone hybrid in 7 may explain the
observed biological activities.
■ EXPERIMENTAL SECTION
General Experimental Procedures. Specific optical rotations
([α]D) were measured on a PerkinElmer 241 polarimeter in a 100 × 2
mm cell at 22 °C. UV−vis spectra were obtained on a Shimadzu UV-
2450 spectrophotometer with 1 cm quartz cells. Nuclear magnetic
resonance (NMR) spectra were acquired either on a Bruker AV II-500
MHz (1H 500 MHz, 13C 120 MHz) spectrometer or a Bruker Ascend
700MHz spectrometer with a 5 mm TXI cryoprobe (1H 700MHz, 13C
175 MHz). In all cases, spectra were acquired at 25 °C (unless
otherwise specified) in solvents as specified in the text, with referencing
to residual 1H or 13C signals in the deuterated solvents. HR-ESI mass
spectra were measured using an Agilent 1200 series HPLC-UV system
in combination with an ESI-TOF-MS (Maxis, Bruker) [column 2.1 ×
50 mm, 1.7 μm, C18 Acquity UPLC BEH (Waters), solvent A: 95% 5
mM ammonium acetate buffer (pH 5.5, adjusted with 1 M acetic acid)
with 5% acetonitrile, solvent B: 95% acetonitrile with 5% 5 mM
ammonium acetate buffer]. Elution was achieved using a gradient from
10% solvent B increasing to 100% solvent B within 30 min, maintaining
100% B for another 10 min, Rf = 0.3 mLmin−1, UV detection 200−600
nm].
Identity of the Producer Strain. The ascomycete Sparticola junci
Phukhamsakda, Camporesi & K.D. Hyde, which represents the ex-type
strain of the species, was isolated from a dead branch of Spartium junci,
and its characteristics have previously been described in detail by
Phukhamsakda et al.3 The holotype specimen and the ex-type culture
are deposited at the culture collection of Mae Fah Luang University,
Chiang Rai, Thailand, under the designation numbers MFLU 15-1405
and MFLUCC 15-0030, respectively. The GenBank accession number
of the fungal barcode (5.8S gene region, the internal transcribed spacer
ITS1 and ITS2) is provided as NR_154428.
Production, Extraction, Isolation, and Structure Character-
ization of 1−7. A 20 day old Sparticola junci mycelium grown on a
yeast−malt glucose (YMG) agar plate (1% malt extract, 0.4% glucose,
0.4% yeast extract, 2% agar, pH 6.3) was used to prepare a seed culture.
Five plugs of well-grown mycelium were inoculated in 500 mL
Erlenmeyer flasks containing 200 mL of YMG media and incubated on
a rotary shaker at 24 °C and 140 rpm for 30 days. The seed cultures
were homogenized mechanically using an Ultra Turrax. Subsequently,
10 mL of seed culture was transferred to each of the 30 × 500 mL
sterilized Erlenmeyer flasks with 200 mL of Q6 1/2 medium5 (6 L) and
incubated on a rotary shaker (21 days, 24 °C, 140 rpm). Fermentation
was terminated 6 days after glucose depletion (glucose strip test). The
mycelia and supernatant were separated using vacuum filtration, and
the mycelia were homogenized and extracted with acetone under
ultrasonic conditions. The combined acetone extracts were evaporated
in a rotary evaporator (40 °C), and the crude product was suspended in
distilled water (300 mL) and extracted with an equal volume of ethyl
acetate (5×). The aqueous layer was discarded, and the organic phase
was dried over anhydrous Na2SO4 and concentrated under reduced
pressure to yield 2.2 g of crude ethyl acetate extract. The supernatant
was mixed with Amberlite XAD-16 N (30 g per 1 L) and extracted with
an equal volume of ethyl acetate (5×) according to a previously
described procedure. The resulting ethyl acetate extracts were
evaporated to dryness to give 800 mg of crude material. The combined
crude extracts from the mycelia and broth yielded 3 g of a brown syrup.
The extracts were dissolved in methanol and filtered on an RP solid-
phase cartridge (Strata-X 33 mm, polymeric reversed phase;
Phenomenex Aschaffenburg, Germany) to yield 2.7 g of crude material.
For the isolation of the compounds, preparative purifications were
achieved on a preparative HPLC (Gilson, Middleton, WI, USA)
equipped with a GX-271 Liquid Handler, a 172 DAD, and a 305 and
306 pump (with 50SC Piston Pump Head). A VP Nucleodur 100-10
C18 ec column (150 × 40 mm, 7 μm; Macherey-Nagel) was used as
stationary phase. The mobile phase was composed of deionized water
(Milli-Q, Millipore, Schwalbach, Germany) with 0.05% trifluoroacetic
acid (solvent A) and acetonitrile (AcCN, HPLC grade) with 0.05%
trifluoroacetic acid (solvent B). The crude extract (1.8 g) was initially
purified by preparative HPLC using a linear gradient of 15% solvent B
for 5 min, 15−100% solvent B for 40 min, and 100% solvent B for 15
min. The fractions were combined peak-wise, according to UV
absorptions at 210, 254, and 350 nm to afford 18 pooled fractions.
Compound 1 (126 mg) eluted at tR = 25.5−26.2 min from fraction 13.
Fraction 8 (16.6 mg) and fraction 12 (46.9 mg) were further purified
using preparative RP-HPLC on a Gemini 10u C18 110A column (250
× 21.20 mm, 10 μm) with the following gradient: 40% to 100% of
solvent B in 35min, followed by 100% solvent B for 15min. Compound
4 (3.6 mg) eluted at tR = 30−31 min, and compound 3 (4.1 mg) eluted
at tR = 12−13 min. Fraction 15 (39.2 mg) was rechromatographed
using preparative RP-HPLC (solvent system: 40 to 100% of solvent B in
20 min, followed by 100% solvent B for 10 min) to afford compounds 5
(6.1 mg, tR = 16.2−17.2 min) and 6 (1.0 mg, tR = 20.5−21 min).
Fraction 16 (33.6 mg) yielded compound 2 (2.1 mg, tR = 14−15 min),
and fraction 18 (13.3 mg) yielded compound 7 (2.1 mg, tR = 14−15
min) using preparative RP-HPLC employing a gradient of solvent B
from 20 to 50% in 5 min, followed by 50−80% B in 30 min, 80−100% B
in 5 min, and 100% solvent B for 10 additional minutes.
Sparticolin A (1). Sparticolin A (1): Colorless crystals (MeOH−
water); mp 186 °C (dec.); [α]D25 −147 (c 0.001, MeOH); UV (c 0.01,
MeOH) λmax (Δε) 225 (4.71), 258 (4.39), 300 (3.97) nm; 1H and 13C
NMR data, Tables 1 and 2; HR-ESI-MS m/z 345.0723 [M + Na]+
(calcd for C19H14O5Na, 345.0733).
Sparticolin B (2). Sparticolin B (2): Brown syrup; UV (c 0.01,
MeOH) λmax (Δε) 225 (4.67), 299 (4.26) nm; 1H and 13C NMR data,
Tables 1 and 2; HR-ESI-MS m/z 343.0574 [M + Na]+ (calcd for
C19H12O5Na, 343.0582).
Sparticolin C (3). Sparticolin C (3): Light yellow syrup; [α]D
25−201
(c 0.001, MeOH); UV (c 0.01, MeOH) λmax (Δε) 226 (4.63), 300
(3.78), 328 (3.52) nm; 1H and 13CNMR data, Tables 1 and 2; HR-ESI-
MS m/z 347.0881 [M + Na]+ (calcd for C19H16O5Na, 347.0889).
Sparticolin D (4). SparticolinD (4): Light yellow syrup; [α]D
25−287
(c 0.001, MeOH); UV (c 0.01, MeOH) λmax (Δε) 225 (4.64), 260
(4.23) nm; 1H and 13C NMR data, Tables 1 and 2; HR-ESI-MS m/z
363.0834 [M + Na]+ (calcd for C19H16O6Na, 363.0839).
Sparticolin E (5). Sparticolin E (5): Reddish-brown syrup; [α]D
25
−115 (c 0.001,MeOH); UV (c 0.01,MeOH) λmax (Δε) 226 (4.63), 300
(3.78), 328 (3.53) nm; 1H and 13CNMR data, Tables 1 and 2; HR-ESI-
MS m/z 325.1066 [M + H]+ (calcd for C19H17O5, 325.1070).
Sparticolin F (6). Sparticolin F (6): Brownish solid; [α]D
25 −157 (c
0.001, MeOH); UV (c 0.01, MeOH) λmax (Δε) 226 (4.67), 300 (3.83),
328 (3.59) nm; 1H and 13C NMR data, Tables 1 and 2; HR-ESI-MSm/
z 339.1229 [M + H]+ (calcd for C20H19O5, 339.1227).
Sparticolin G (7). Sparticolin G (7): Light yellow oil; [α]D
25 −43 (c
0.001, MeOH); UV (c 0.03, MeOH) λmax (Δε) 224 (4.40), 296 (3.52)
nm; 1H and 13C NMR data, Tables 1 and 2; HR-ESI-MSm/z 321.0762
[M + H]+ (calcd for C19H13O5, 321.0757).
X-ray Crystallographic Analysis of Sparticolin A (1).18
Colorless crystals of 1 were obtained from a MeOH−H2O solution.
The monohydrate of 1 was analyzed with a Bruker D8 Venture
diffractometer with a microfocus tube and Cu Kα radiation (λ =
1.54178 Å). APEX3 was used for data collection, SAINT was used for
cell refinement and data reduction, and SADABS was used for
experimental absorption correction. The structure was solved by
intrinsic phasing using SHELXT, while refinement was done by full-
matrix least-squares on F2 using SHELXL-2018/3.19−21 The hydrogen
atoms were freely refined. The absolute configuration of 1 was solved
using anomalous dispersion from Cu Kα, resulting in a Flack
parameter22 of 0.030(2) using Parsons’ quotient method. Graphics
were drawn using DIAMOND.23 The structural data have been
deposited in the Cambridge Crystallographic Data Center (CCDCNo.
1915632).
Crystal data of 1: C19H14O5·H2O,M= 340.32, orthorhombic system,
space group P2(1)2(1)2(1), a = 5.5027(4) Å, b = 7.9285(5) Å, c =
36.706(2) Å, V = 1601.42(18) Å3, Z = 4, dcalc = 11.412 mg/m
3, crystal
size = 0.630 × 0.120 × 0.057 mm3, F(000) = 712, μ(Mo Kα) = 0.885
mm−1, 6.653 < θ < 80.377°. The 3909 measurements yielded 3318
independent reflections after equivalent data were averaged. The final
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refinement gave R1 = 0.0249 and wR2 = 0.0649 [I > 2σ(I)]. The
absolute structure parameter was 0.03(2).
Cytotoxicity Assay. The cytotoxicity of 1−7 was tested against a
panel of mammalian cell lines. The evaluation of in vitro cytotoxicity
effects (IC50) was performed with mouse fibroblast cell line L929 and
mammalian HeLa KB3.1 cancer cells. Additionally, human ovarian
carcinoma (SKOV-3), human prostate cancer (PC-3), human lung
carcinoma tissue (A549), human skin squamous cell carcinoma
(A431), and human breast adenocarcinoma (MCF-7) were evaluated
for compounds 1−7. The cell lines were cultured in DMEM (Gibco,
ThermoFisher Scientific, Hilden, Germany) and MCF-7 in RPMI
(Lonza, Cologne, Germany) media, all supplemented with 10% fetal
bovine serum (Gibco) under 10%CO2 at 37 °C. The cytotoxicity assays
were performed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide) method in 96-well microplates
(ThermoFisher Scientific). Briefly, 60 μL aliquots of serial dilutions
from an initial stock of 1 mg/mL inMeOH of the test compounds were
added to 120 μL aliquots of a cell suspension (5.0 × 104 cells/mL) in
96-well microplates. After 5 days of incubation, an MTT assay was
performed, and the absorbance was measured at 590 nm using an
ELISA plate reader (Victor, PerkinElmer, Überlingen, Germany). The
concentration at which the growth of cells was inhibited to 50% of the
control (IC50) was obtained from the dose response curves.
Experiments were repeated three times. Epothilone B was used as a
positive control, and the negative control was methanol.16
Antimicrobial Assay. Antimicrobial activities of 1−7 were
evaluated in serial dilution assays against various fungal and bacterial
strains as given in Table 3, using the broth microdilution method
according to our previously described procedures.16 Gentamicin,
kanamycin, and oxytetracyclin were used as positive controls against the
Gram-positive and Gram-negative bacteria, respectively. Nystatin was
used as a positive control against yeasts and filamentous fungi.16
Nematicidal Assay. The nematicidal activity of 1−7 against
Caenorhabditis elegans, monoxenically grown on nematode agar (soy
peptone 2 g, NaCl 1 g, agar 20 g, 1000 mL of deionized water; adding
0.5 mL of cholesterol (1 mg/mL EtOH), 1 mL of 1 M CaCl2, 1 mL of 1
M MgSO4, and 12.5 mL of 40 mM potassium phosphate buffer after
autoclaving; pH adjusted to 6.8) with living E. coli DSM498, at 20 °C
for a week, was assessed according to our previously reported protocol
with slight modifications. The nematodes were then washed from the
plates withM9 buffer, and the buffer was diluted to 500 nematodes/mL.
The assay was performed in 24-well microtiter plates at five different
concentrations (100, 50, 25, 12.5, and 6.25 μg/mL) of each compound.
Ivermectin was used as the positive control, and methanol was used as
the negative control. The plates were incubated at 20 °C in a shaker in
the dark, and nematicidal activity was recorded after 18 h of incubation
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A B S T R A C T
The Basidiomycota constitutes the second largest higher taxonomic group of the Fungi after the Ascomycota and
comprises over 30.000 species. Mycelial cultures of Basidiomycota have already been studied since the 1950s for
production of antibiotics and other beneficial secondary metabolites. Despite the fact that unique and selective
compounds like pleuromutilin were obtained early on, it took several decades more until they were subjected to
a systematic screening for antimicrobial and anticancer activities. These efforts led to the discovery of the
strobilurins and several hundreds of further compounds that mainly constitute terpenoids. In parallel the tra-
ditional medicinal mushrooms of Asia were also studied intensively for metabolite production, aimed at finding
new therapeutic agents for treatment of various diseases including metabolic disorders and the central nervous
system. While the evaluation of this organism group has in general been more tedious as compared to the
Ascomycota, the chances to discover new metabolites and to develop them further to candidates for drugs,
agrochemicals and other products for the Life Science industry have substantially increased over the past decade.
This is owing to the revolutionary developments in –OMICS techniques, bioinformatics, analytical chemistry and
biotechnological process technology, which are steadily being developed further. On the other hand, the new
developments in polythetic fungal taxonomy now also allow a more concise selection of previously untapped
organisms. The current review is dedicated to summarize the state of the art and to give an outlook to further
developments.
1. Introduction
The Basidiomycota (sometimes still referred to by the outdated, in-
valid term “basidiomycetes”, which has characterized a class) is the
second largest division of the Kingdom Fungi after the Ascomycota and
comprise ca. 35.000 species (Kirk et al., 2008). The true number of global
species, however, is probably much higher, since recent studies relying
on methods of molecular ecology (e.g. Tedersoo et al., 2014) have re-
vealed a vast, unexpected diversity in the Basidiomycota as well as in
fungi in general. Many species of Basidiomycota, in particular the class
Agaricomycetes, produce conspicuous fruiting bodies (basidiomes) and
have probably been used as a source of food since early human civili-
zation. Since the edible species are often easily confused with morpho-
logically similar and poisonous mushrooms, the consumption of the
latter species may lead to fatalities. For this reason, the evaluation and
identification of the mushroom toxins, such as muscarine and the ama-
nitins, has been the topic of many of the early chemical studies on fungal
metabolites (e.g. Wieland and Hallermayer, 1941; Wilkinson, 1961).
Curiously, these studies came about at about the same as the discovery of
penicillin, which marked the onset of the “Golden Era of Antibiotics”
(Mohr, 2017), and already in the early 1950s, biotechnologists and
chemists started to study not only soil-derived molds, bacilli and acti-
nobacteria but even Basidiomycota cultures for production of antibiotics.
These efforts have already led to various discoveries of important mo-
lecules, including pleuromutilin (1) (Kavanagh, 1947), from which a
marketed drug and several developmental candidates have been devel-
oped several decades later (see Fig. 1). Further examples of early dis-
covered molecules from cultures of Basidiomycota include pleurotin
(Kavanagh, 1947) and the illudins (McMorris and Anchel, 1963), which
will also be treated in detail further below.
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During the same period of time (from 1950-1975), hundreds- if not
thousands- of researchers have been focusing world-wide on the ex-
ploitations of fungi and bacteria for novel lead compounds in many
indications of the Agro and Pharma sectors. Almost all large pharma-
ceutical and agrochemical companies have been participating in these
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Fig. 1. Chemical structures of compounds used as drug or under development and agrochemicals discovered from Basidiomycota.
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success to the respective discoveries because several blockbuster drugs
have resulted from natural product screening (Bills and Gloer, 2016).
Mostly, these research programs have been following the principle of
random screening of soil isolates and were strongly focused on the
exploitation of fast-growing organisms like actinobacteria, bacilli and
conidial fungi whose fermentation and extraction can easily be stan-
dardized. Basidiomycota have been playing a secondary role in these
scenarios because they can hardly be isolated from soil samples and
their fermentation often requires special protocols (Karwehl and
Stadler, 2017). Only since the mid-1970s, triggered by the exciting
discovery of the strobilurins (see Fig. 1) by a team of German re-
searchers, have these organisms come more strongly into the focus of
natural product based drug discovery. Since then, many new metabo-
lites have been obtained from Basidiomycota, and in the past 15 years,
the majority of new compounds were actually reported by Asian sci-
entists, who studied intensively the “medicinal mushrooms” of their
countries, as demonstrated in the overview of De Silva et al. (2013).
Meanwhile even the biosynthesis of selected molecules produced by
Basidiomycota has been evaluated, and the number of fully sequenced
genomes of these organisms is steadily increasing, owing to the sub-
stantial progress in bioinformatics, genomics and transcriptomics (cf.
Hoffmeister and Stadler, 2015). Moreover, sustainable biotechnological
processes for the production of these molecules have become available,
some of which are even using heterologous hosts. The present review
aims to summarize the state of the art of various aspects relating to the
discovery of new biologically active compounds from Basidiomycota
and their development to market products in a historical context with
emphasis on the literature of the past five years.
2. Brief overview about the taxonomy of the Basidiomycota
The Basidiomycota2 with an estimate of over 30.000 described
species are a phylogenetic sister group of the Ascomycota and presently
comprise of four subphyla (Agaricomycotina, Pucciniomycotina, Usti-
laginomycotina, and Wallemiomycotina (Zhao et al., 2017; Fig. 2). Out
of those, in particular the first mentioned subphylum, which contains
almost all fleshy mushrooms, has been tapped for secondary metabolite
production. Notably, even in the Agaricomycotina, many species have
so far not been made available for studies on the secondary metabolites
in culture or for other biotechnological applications. The reason is that
Basidiomycota form different guilds (= ecological groups) including
ectomycorrhizal fungi, saprotrophs, and pathogens. Some re-
presentative species are depicted in Fig. 3. Within the ectomycorrhizal
group, as represented by many widely recognized genera for fleshy
mushrooms (e.g. Amanita, Boletus, Cantharellus, Cortinarius, Hydnellum,
Lactarius, Sarcodon, and Russula and the respective families like Bole-
taceae, Russulaceae and Cantharellaceae), a mutualistic relationship
between the fungal symbiont and the roots of various plant species
exists. The ectomycorrhizal fungi show the strongest relationship to the
richness of host plant species (i.e. conifers and deciduous trees) and
high soil pH, followed by saprotroph richness than the pathogens
(Tedersoo et al. 2014). Surprisingly, the Agaricomycotina make up
more than 50% of the total mycobiota that were detected in soil, which
should give rise to attempt to make more of their species accessible to
studies of their metabolites in culture. In natural habitats, they effi-
ciently degrade lignocellulose, which makes them indispensable for
maintenance of the global carbon cycles, but they can often not be
taken in artificial axenic culture without the plant symbiont. Therefore,
the available studies on their secondary metabolites are so far largely
restricted to their fruiting bodies. As it would lead too far to include all
fruiting body metabolites in this review, we refer to the respective
papers by Chen and Liu (2017), Schüffler (2018) and De Silva et al.
(2013). Remarkably, even the species of some genera that are con-
sidered to be saprotrophs, such as Pluteus and Lepiota are not easy to
culture, as their spores fail to germinate in the laboratory. The ecolo-
gical preferences of numerous Basidiomycota have so far remained
obscure and can only now be elucidated by using modern methods of
molecular ecology. For instance, some species that were hitherto re-
garded as saprotrophs, such as Hygrocybe virginea, are now suspected to
possess hitherto unknown associations with plants, and conducting in-
depth studies on their ecology might in the future be rewarding (Tello
et al., 2014). However, the endophytic nature of these mushrooms
poses a challenge and partially explains why only a few species of
Hygrocybe have ever been cultivated and studied for secondary meta-
bolites.
While the Wallemiomycotina are a very small taxonomic group and
have so far only been studied scarcely, in particular the biotrophic
pathogens, and almost the entire subdivision Pucciniomycotina (rust
fungi), as well as many members of the Ustilaginomycotina (smut
fungi) are also difficult –if not impossible to culture at large scale. Even
though several complex protocols for cultivation of rusts and smuts as
well as mycorrhizal fungi exist, they often rely on the supplementation
of vitamins or even the use of minimal media that do not support
sustainable mycelial growth. The reasons for this behaviour are often
not clear, but complex, sugar-rich media that easily allow cultivation of
saprotrophic fungi will often turn out not to be suitable for cultivation
of certain Basidiomycota, and there have been relatively few systematic
studies on the nutritional preferences of certain species and genera. As



























Fig. 2. Scheme illustrating the phylogenetic relationships of Basidiomycota as
inferred from recent multi locus genealogies. Modified according to Zhao et al.
(2017). The length of the triangles in the phylogenetic tree does not represent
the species richness of the classes, but merely refers to the phylogenetic dis-
tance.
2 The fungal names used in this review are given as proposed in Mycobank,
the official fungal nomenclature database of the International Mycological
Association (http://www.mycobank.org, last accessed on Dec 27 2018). We do
not provide the authorities of these names and have in some cases pointed out
the synonyms previously used in the literature.
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mycorrhizal fungi were found to harbour numerous genes and gene
clusters that seem to encode for the biosynthesis of secondary meta-
bolites. In the future, it may be possible to isolate and characterise the
respective products, based on strategies for heterologous expression
that are outlined later in the present paper. The DNA can potentially be
extracted from the fruiting bodies, or in case of the less fleshy species,
by letting their mycelia grow for several months.
3. Secondary metabolites from Basidiomycota
3.1. Important drug candidates and agrochemicals from Basidiomycota
Despite the fact that the Basidiomycota have been much less studied
for biologically active metabolites than the Ascomycota, a number of
very important lead compounds have already been obtained from them,
Fig. 3. Morphological diversity of Basidiomycota. (A) Turbinellus sp. (B) Clavulina sp. (C) Agaricus sp. (D) Tremella sp. (E) Amanita rubrovolvata (F) Clavulina sp. (G)
Clathrus sp. (H) Cortinarius sp. (I) Hygrocybe sp. (J) Tylopilus sp. (K) Meripilus giganteus. (L) Lactarius sp.
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which has led to clinical development candidates or even marketed
drugs and agrochemicals. We have briefly summarized the history and
the state of the art on these compounds in the following paragraphs.
3.1.1. Pleuromutilins are the newest class of antibacterial antibiotics
launched on the market
Pleuromutilin (1) is a naturally occurring antibiotic from the culture
of the mushroom Clitopilus passeckerianus (formerly named Pleurotus
passeckerianus) and was already discovered several decades ago
(Kavanagh, 1947; Kavanagh et al., 1951). This tricyclic diterpenoid was
also reported from “Drosophila subatrata” (currently valid name: Para-
sola conopilus), Clitopilus scyphoides, and some other Clitopilus species
(Hartley et al., 2009; Kavanagh et al., 1952). Even though the potent
activity of pleuromutilin against most Gram-positive and some Gram-
negative pathogens was quite promising, at that time resistance to β-
lactams antibiotics was not regarded as a critical issue, therefore the
interest in antibiotic research including pleuromutilins was limited
(Paukner and Riedl, 2018). Questions regarding the metabolic stability,
gastrointestinal side effects, cardiac safety and intravenous tolerability
to this class of compounds further limited their application in humans
(Novak, 2011). However, the semisynthetic pleuromutilin derivatives,
tiamulin (2) and valnemulin (3), were introduced to veterinary medi-
cine in 1979 and 1999, respectively, for the treatment of swine dys-
entery and enzootic pneumonia (Poulsen et al., 2001). Despite the use
of pleuromutilins for treatment in veterinary medicine for many years,
resistance development has been uncommon. This could be attributed
to the unique and highly specific mode of action of this class of com-
pounds, which inhibit protein synthesis in bacteria by binding to the
peptidyl transferase component of the 50S subunit of their ribosomes.
The wide spread emergence of antimicrobial resistance has renewed the
research on the pleuromutilins. Synthetic derivatization of this com-
pound has also resulted in the development of retapamulin (4), a
semisynthetic analogue approved for treatment of skin infections in
humans, which is the first approved antibiotic drug from the Basidio-
mycota. The recent advances in lead optimization by combining potent
antibacterial activity with favorable pharmaceutical properties have led
to the synthesis of three further new semisynthetic pleuromutilin de-
rivatives, BC-3205 (5), BC-7013 (6) and BC-3781 (7) that are currently
in clinical trials. BC-3781 is currently at phase II and phase III trial
against acute bacterial skin structure infections and community ac-
quired bacterial pneumonia respectively (Paukner and Riedl, 2018;
Prince et al., 2013).
3.1.2. Strobilurins are one of the most successful classes of agrochemical
fungicides
The strobilurins (Fig. 1) are another important class of compounds
from Basidiomycota that have served as lead compounds for the de-
velopment of the agricultural β-methoxyacrylate fungicides (Sauter
et al., 1999). These compounds are known from the mycelial cultures of
various Basidiomycota including Favolaschia, Mycena, Oudemansiella,
Strobilurus and Xerula (Hoffmeister and Stadler, 2015). After 50 years of
intensive research on this class of compounds it is quite interesting that
new derivatives like the 9-oxo strobilurin derivatives reported from
Favolaschia calocera originating from Kenya (Chepkirui et al., 2016) can
still be discovered. Strobilurins prevent mycelial growth and germina-
tion of spores by binding to the ubiquinol-oxididation center in the
mitochondrial cytochromes, which is responsible for the generation of
the proton gradient used for ATP synthesis and the transfer electrons to
nitrogenase, consequently blocking electron transfer (Sauter et al.,
1999). The fact that some strobilurins exhibit strong antifungal activity
coupled with their low cytotoxicity towards mammals and plants, and
the relatively easy access by total synthesis made them promising lead
compounds for synthesis of agricultural fungicides (Anke, 1995). Al-
though strobilurin analogs were very successful in the market since the
late 1990s, resistance to these fungicides developed in populations of
plant pathogenic fungi only two years after their introduction to the
market. This was attributed to them being “single-target” compounds,
and it is easy for the pathogens to acquire resistance through single
point mutation in the target proteins (Ishii et al., 2001; Vaghefi and
Hay, 2016; Zhang et al., 2009). Nevertheless, azoxystrobin (9) and
kresoxim-methyl are still being applied at large scale in combination
with other antifungal agents such as azoles. The fact that even re-
sistances against azoles are now becoming more frequent among both,
human and plant pathogens is really frightening because they are
presently the only class of environmentally friendly fungicides and also
constitute the optimal therapeutic drugs against certain fungal human
pathogens. Unfortunately, the pipeline for the development of novel
fungicides and antimycotics of the large companies seems to be even
more empty than in case of the antibacterial antibiotics. This can in part
be attributed to the negligence of natural product-based antifungal
agents over the past decades.
3.1.3. The genus Omphalotus is a source of potential anticancer drugs and
agrochemical pesticides
Species of the genera Omphalotus and Lampteromyces consistently
produce acylfulvene (or illudane) type sesquiterpenes, featuring an
unusual cyclopropane ring (Schobert et al., 2011; Tanasova and Sturla,
2012). Illudins M and S (10-11) were the first members of this terpe-
noid family to be discovered in the 1950s (Kavanagh, 1947). Even
though Illudins were studied extensively for their cytotoxicity in var-
ious tumor cell types and tumor xenografts, the frequent animal deaths,
associated with the high toxicity of illudins, initially restricted their
potential use as anticancer agents. However, this stimulated a pursuit
for analogues that combine high potency with better therapeutic
characteristics (Schobert et al., 2008, 2011; Tanasova and Sturla,
2012). Irofulven, also known as 6-hydroxymethylacylfulvene or HMAF
(12), a semisynthetic analogue of illudin S, is currently under devel-
opment as anticancer drug (Tanasova and Sturla, 2012). More recently,
several "new generation" illudin analogs with improved tumor specifi-
city have been synthesized by Schobert and co-workers. The semisyn-
thetic chlorambucil analogs (13-14) were reported to show promising
improved specificity toward tumor cells over normal fibroblasts, while
M−ferrocene conjugates (15) were found to be more active against
melanoma cells as compared to leukemia cell lines or nonmalignant
fibroblasts (Knauer et al., 2009; Schobert et al., 2008).
Recently, eight illudanes have also been found in the wood-de-
caying fungus Granulobasidium vellereum, out of which the cytotoxic
illuladienes A (16) and B (17) constitute novel natural products (Nord
et al., 2015). Two other new illuladane sesquiterpenoids named gran-
ulolactone (18) and granulodione (19) were reported later on from the
same species (Kokubun et al., 2016). Only granulodione (19) exhibited
acaricidal activity against Tetranychus urticae, with 83% mortality after
2 h of exposure in a contact activity test.
Curiously, in addition to the illudins, all species hitherto studied of
the genus Omphalotus also produce cyclopeptides of the omphalotin
type with pronounced activities against root knot nematodes like
Meloidogyne incognita (Mayer et al. 1999).Sterner et al. (1997) first re-
ported omphalotin A (20) from Omphalotus olearius. Later, several other
derivatives of this compound were isolated from the same fungus
(Büchel et al., 1998; Liermann et al., 2009). These compounds co-occur
in the cultures with illudins, while the latter compounds are located in
both the basidiomes and the mycelia of the fungi.
3.2. Novel biologically active compounds from Basidiomycota
The mushroom-forming fungi have been used for many centuries as
remedies of various diseases especially in Asia. Some of these “medic-
inal mushrooms” in particular are known to be prolific producers of
bioactive metabolites and they have been widely exploited (De Silva
et al., 2013). The therapeutic benefits of these mushrooms go back in
many cases to complex high molecular weight compounds such as
polysaccharides, proteins and lipids as active principles, which are not
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Ganoleucoin A (23), R1=-CH2OH, R2=O, R3=H, R4=OH, R5=H, R6=COOH, R7=CH3
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Fig. 4. Chemical structures of compounds isolated from Ganoderma species.
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being treated here in detail. We instead concentrate on those species
that are known to produce compounds with low-molecular weight, such
as terpenoids, polyketides, and alkaloids.
3.2.1. Metabolites from Ganoderma species
Aside from Ophiocordyceps sinensis, which belongs to the
Ascomycota and is thus not being treated in detail here, Ganoderma
lingzhi (previously often falsely reported in the literature as “G. lucidum”
sensu lato) is surely the most important (group of) medicinal mushroom
(s). The taxonomy and nomenclature of the Chinese medicinal
Ganoderma spp. has been heavily disputed among mycologists
(Hawksworth, 2005; Richter et al., 2015). Recently, a paper co-au-
thored by several eminent specialists in the taxonomy of the Basidio-
mycota has been published that will hopefully settle this matter and
allow the name G. lingzhi to take preference over competing names once
and for all (Dai et al., 2017).
In Chinese traditional folk medicine the fruit bodies of Ganoderma
(aside from the Lingzhi, also other species like G. sinense have been
used) are regarded as a panacea for all types of diseases due to its de-
monstrated efficacy as a popular remedy to treat hepatopathy, chronic
hepatitis, nephritis, hypertension, hyperlipemia among others diseases
(Jong and Birmingham, 1992). Several secondary metabolites have
been isolated from different species belonging to this genus (a selection
thereof is depicted in Fig. 4). The majority of known secondary meta-
bolites from Ganoderma species are largely triterpenoids belong to the
class of lanostane-type or ergostane-type and pentacyclic triterpenes
(Richter et al., 2015). These include the cytotoxic triterpenoids such as
ganoderic acids, lucidimols, ganodermanondiols, ganoderiols, lucidenic
acids and ganodermanontriols. The biological activities of these com-
pounds have been discussed at length by De Silva et al. (2013). Gano-
deric acid T (21) and a closely related triterpenoid named ganoderic
acid DM (22) produced by “Ganoderma lucidum” are some of the com-
pounds that have been studied in detail with regard to their application
in cancer treatment. Tang et al. (2006) reported that ganoderic acid T
induces apoptosis of metastatic lung tumor cells through an intrinsic
pathway related to mitochondrial dysfunction. Ganoderic acid DM (22),
on the other hand, was shown to inhibit cell proliferation and colony
formation in MCF-7 human breast cancer cells and also induced cell
cycle (G1) arrest and apoptosis in MCF7 cells (Liu et al., 2012; Wu et al.,
2012).
In the past years, several other lanostane triterpenes have been
discovered from Ganoderma species. From basidiomes of Ganoderma
leucocontextum, several lanostane triterpenes named ganoleucoins A−P
were isolated. Ganoleucoins A-C (23-25), F (26), K-N (27-30) and ga-
noleucoin O (structure not shown) exhibited inhibitory effects on both
HMG-CoA reductase and α-glucosidase in the μM range (Kai et al.,
2015). Peng et al. (2014) also reported several triterpenoids from G.
cochlear. These include cochlates A (31) and B (32) featuring a 3,4-seco-
9,10-seco-9,19-cyclo skeleton, as well as fornicatins D–F (33-35) and
ganodercochlearins A–C (36-38). Fornicatins D (33) and F (35) were
reported to lower both, the alanine aminotransferase (ALT) and as-
partate aminotransferase (AST) levels in HepG2 cells treated with H2O2,
indicating that they could display in vivo hepatoprotective activities.
From “Ganoderma sp. KM01”, the ganodermalactones A-G (39-45) were
obtained, but when these compounds were tested against Plasmodium
falciparum, only ganodermalactone F showed significant antimalarial
activity (Lakornwong et al., 2014). Furthermore, cochlearines A (46)
and B (47) along with cochlearoids A–E (48-52) (Fig. 5) were isolated
from cultures of G. cochlear. Compounds 46, 48 and 50 significantly
inhibited the calcium channel Cav3.1 TTCC (Zhou et al., 2015). Mer-
oterpenoids named chizhines A (53), B (54) and C (55)–F were reported
from “G. lucidum“ by Luo et al. (2015b). These compounds significantly
inhibited the monocyte chemotactic protein 1 (MCP-1) and fibronectin
production with chizhine F (56) being the most potent derivative. The
nortriterpenes, ganoboninketals A–C (57-59), which feature a rear-
ranged 3,4-seco-27-norlanostane skeleton, were reported to occur in
Ganoderma boninense and showed antiplasmodial activity against Plas-
modium falciparum and weak cytotoxicity against A549 cells (Ma et al.,
2014). A dimeric meroterpenoid applanatumin A (60) with a new
hexacyclic skeleton was isolated from “G. applanatum” (actually this
fungus was probably misidentified because this European species has
never been safely recorded from China). In any case, compound (60)
exhibited potent antifibrotic activity in TGF-β1-induced human renal
proximal tubular cells (Luo et al., 2015a). In summary, the genus Ga-
noderma appears to be an almost inexhaustable source of novel chem-
istry, but it is very unfortunate that many of the reports on new com-
pounds do not deal with material that has been identified by specialists
and often not even voucher specimens are deposited in the public do-
main for later verification of the taxonomy.
3.2.2. Metabolites from the Inonotus linteus complex
Inonotus and Phellinus are two genera in the Hymenochaetaceae that
have been traditionally distinguished by the morphology of their basi-
diomes and are very difficult to separate; hence, the boundaries be-
tween these genera always remained unclear. This is the reason why
one of the most important groups of medicinal mushrooms was his-
torically referred to alternatively as the Inonotus linteus or the Phellinus
linteus complex. A recent phylogenetic study has resulted in the re-
solution of this species complex and a rearrangement of those taxa that
were formerly placed in Inonotus or Phellinus, which are now being
accommodated in the new genera Sanghuangporus and Tropicoporus
(Zhou et al., 2016a).
The respective fungi have been widely used in Asia for the treatment
of gastrointestinal cancer, cardiovascular disease, tuberculosis, liver or
heart diseases, as well as diabetes as a traditional medicine (de Silva
et al., 2013; Solomon and Alexander, 1999). Their characteristic me-
tabolites include unique complex styrylpyrone derivatives like phelli-
gridins and the closely related inoscavins and inonoblins that exhibit
antioxidant and cytotoxic effects (De Silva et al., 2013). In the past five
years, two additional phelligridin derivatives have been reported. One
of them is phelligridin L (61) (Fig. 5) from the cultures of San-
ghuangporus sp. This compound demonstrated moderate antibacterial
activity as well as nematicidal activity against Caenorhabditis elegans
(Chepkirui et al., 2018a). From another medicinal fungus that was
previously referred to as Phellinus ribis (current name Phylloporia ribis) a
new spiroindene pigment phelliribsin A (62) with cytotoxic activity
against PC12 cells at a concentration of 30 μM was isolated. This
compound was reported together with the known compounds phelli-
gridin F and inoscavin B (Kubo et al., 2014).
Another predominant class of metabolites that occurs in these fungi
are the sesquiterpenoids, as evidenced by recent literature. Yin et al.
(2014) isolated two tremulanes, i.e., 6β,11,12-trihydroxy-tremul-1(10)-
ene (63) and 10β,12-dihydroxy-tremulene (64) from P. igniarius. These
sesquiterpenes exhibited different levels of vascular-relaxing activities
against KCl-induced vasoconstriction. Exploitation of the well-known
medicinal mushroom “Phellinus linteus” (currently valid name: Tropi-
coporus linteus (Zhou et al., 2016a) over the years has resulted in the
isolation of several bioactive metabolites. These include some anti-
microbial sesquiterpenes, which are part of the oral composition of an
antibacterial agent used in the treatment or prevention of periodontal
disease and related diseases; they are also used in the form of tooth-
paste, mouthwash and lozenge (Kobayashi et al., 2010). Huang et al.
(2013) reported phellilins A-C (65-67) with weak inhibitory activity on
superoxide anion generation and elastase release from this fungus. The
inonoalliacanes A–I (68-72), which have an alliacane carbon skeleton,
were isolated from the culture broth of another Inonotus sp. BCC 22670.
Inonoalliacane B showed antiviral activity against Herpes Simplex Virus
type 1 (Isaka et al., 2017). The same group also reported the isolation of
romadendrane sesquiterpenoids named inonotins (including the in-
onotins A-G; 73-79) from Inonotus sp. strain BCC 23706, but failed to
detect any bioactivities (Isaka et al., 2015). The related species, Inonotus
obliquus (commonly known as Chaga mushroom) is used in Chinese






































Fig. 5. Chemical structures of compounds isolated from various medicinal mushrooms.
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Fig. 6. Chemical structures of compounds isolated from various medicinal mushrooms.
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traditional medicine to treat diabetes and was studied for its secondary
metabolite production by Ying et al. (2014). The authors reported la-
nostane-type triterpenoids bearing α,β-dimethyl, α,β-unsaturated d-
lactone side chains named inotolactones A (80) and B (81). Interest-
ingly, the latter compounds exhibited more potent alpha-glucosidase
inhibitory activities than the positive control, i.e., the marketed drug
Acarbose (Ying et al., 2014). Furthermore, some closely related terpe-
noids named inonotusanes A–C (82-84) along with 3β-hydroxy-
25,26,27-trinorlanosta-8,22E-dien-24-oic acid (85) from the same
fungus were reported to exhibit strong cytotoxicity against A549 tumor
cell lines and moderate activities against several other cell lines in-
cluding HT29, Hela and L1210 (Zhao et al., 2015). Hispindic acids A
(86) and B (87) (Fig. 6), which are also lanostane-type triterpenoids,
were isolated from Inonotus hispidus. They showed stronger activation
abilities of melanogenesis and tyrosinase in B16 melanoma cells (Qing
et al., 2017). The new isopimarane diterpenoid lactones, inonotolides
A-C (88-90) are yet another class of compounds that have been re-
ported from Inonotus sinensis. The compounds were evaluated for their
cytotoxicity against various cancer cell lines, but they were devoid of
activity (Ding et al., 2018).
3.2.3. Hericium species and their neurotrophic and other biologically active
metabolites
The medicinal mushrooms of the genus Hericium and in particular
Hericium erinaceus have been used in traditional Chinese medicine for a
long time as food supplements and alternative medicine (Thongbai
et al., 2015). Metabolites with various biological activities including
antimicrobial, cytotoxic and neuritogenic effects were isolated from
both the fruiting bodies and cultures of these fungi (Kawagishi et al.,
1994; Thongbai et al., 2015; Wittstein et al., 2016). Both, the erinacines
and hericenones/corallocins were reported to induce nerve growth
factor (NGF) and brain-derived neutrophic factor (BDNF). This illus-
trates their therapeutic potential for the treatment of Alzheimer’s dis-
ease and other neurodegenerative disorders by compounds produced by
H. erinaceus and other species of the genus. Interestingly, the erinacines,
which are cyathane diterpenoids, are produced exclusively in the cul-
tures whereas the hericenones and other isoindolinones are prevailing
in the basidiomes.
In the past years, several further cyathane diterpenoids from the
genus Hericium have been reported. Erinacine S (91) (Fig. 6) was iso-
lated from the mycelial ethanol extract of H. erinaceus. The amyloid
pathology potentials of this compound and erinacine A were studied in
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Fig. 7. Chemical structures of compounds isolated from different Hericium species.
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compounds were found to significantly increase the level of insulin-
degrading enzyme (IDE) in cerebral cortex thus reducing the AB10-
stained plaque burden (Chen et al., 2016). Other cyathane diterpenoids
named hericinoids A–C (92-94) and the unnamed compound 95 were
isolated from the same fungus. The hericinoids did not enhance neurite
outgrowth in PC-12 cells, maybe owing to their moderate cytotoxicity,
which was tested against HL-60 cell lines (Chen et al., 2018). Notably,
metabolites that have cytotoxic properties will often not show activities
in these NGF-induction assays. Compound 95 exhibited moderate an-
tibacterial activities and cytotoxic effects against the human cancer cell
lines K562, LANCAP and HEP2 (Zhang et al., 2015). Two additional
erinacine derivatives (96-97) along with several known erinacines were
isolated from the cultures of this fungus or of the related species H.
flagellum (Rupcic et al., 2018). The erinacine derivative (96) and sev-
eral known congeners were found to enhance neurotrophin production
in astrocytic cells significantly by acting on Brain-Derived Neurotrophic
Factor (BDNF), as well on NGF (Rupcic et al., 2018). These results were
confirmed by quantitative PCR, corroborating the morphological stu-
dies on the cells, where differentiation was actually observed. However,
the biochemical mechanisms leading to these neurotrophic effects re-
main to be elucidated. Interestingly, Premnath et al. (2018) recently
reported the mutacin synthesis inhibitory effects of erinacine C in
Streptococcus mutans.
Erinacerines are alkaloids that are commonly isolated from both the
cultures and fruiting bodies of H. erinaceus. The first erinacerines (i.e
erinacerines A and B) were isolated by Yaoita et al. (2005) from the
basidiomes, and Wang et al. (2015a) later reported the isolation of
erinacerines C–L (98-107) from the cultures of the fungus. Erinacerines
D-L (99-107) showed inhibitory activities against α-glucosidase.
Structure–activity analysis indicated that the erinacerines side chain
and the phenolic hydroxy groups contributed greatly to the α-glucosi-
dase inhibitory activity. Furthermore, erinacerines M-T were also re-
ported to occur in solid cultures of the same fungus. Erinacerines Q-T
showed inhibitory activities against both protein tyrosine phosphatase-
1B (PTP1B) and α-glucosidase while erinacerines M-P (108-111)
showed moderate cytotoxicity against K562 cells and doxorubicin-re-
sistant K562 cells (Wang et al., 2015b). The closely related crinaceo-
lactams A-E (e.g. erinaceolactam D; 112) from H. erinaceus were found
inactive against the carcinoma cell lines SMMC-7221 and MHCC-97H
(Wang et al., 2016). Erinacerine derivatives are apparently genus spe-
cific marker metabolites of Hericium species. From the medicinal and
edible mushroom Hericium coralloides, the corallocins A–C (corallocin C
(113), Fig. 7) were found to induce NGF and BDNF expression in human
1321N1 astrocytes (Wittstein et al., 2016). Further, isoindolinone-
containing meroterpene dimers, named caputmedusins A- B along with
their analogues caputmedusins C–K were reported from Hericium caput-
medusae cultures. The caputmedusins A (114), B (115) and C showed
moderate inhibitory activity against α-glucosidase (Chen et al., 2017a).
There are also a few reports of other constituents of H. erinaceus that
represent different types of molecules. For example, the erinarols G–J
are ergostane-type sterols, isolated from a methanol extract of the dried
fruiting bodies of H. erinaceus. Erinarols H (117) and J (118) exhibited
inhibitory activity against TNF-a secretion (Li et al., 2015). Moreover,
an ergosterol conjunction-type alkaloid, hericirine (119), was isolated
from the dried fruiting bodies of the Lion’s Mane mushroom and re-
ported to significantly inhibit protein expression of iNOS and COX-2
and to reduce NO, PGE2, TNF-α, IL-6 and IL-1β production in
RAW264.7 cells exposed to LPS (Li et al., 2014). Li et al. (2017) also
isolated a closely related sterol, cerevisterol 6-cinnamate (120) from
the same fungus. Finally, the cerebroside (116) was reported to at-
tenuate cisplatin-induced nephrotoxicity in LLC-PK1 cells and inhibits
the effect on angiogenesis in HUVECs at concentration 25 μM (Lee
et al., 2015).
Several other fungi that have been used in Asian traditional medi-
cine and presently under evaluation and this work is steadily yielding
new molecules. A good way to expand such activities in the future
would be to study the relatives of the Asian species in other parts of the
world for comparison. There is, after all, no reason to assume that, e.g.
the Ganoderma and Hericium species of Latin America and Africa would
be less creative with regard to the production of secondary metabolites
just because they are less popular in the folk medicine of these geo-
graphic areas.
3.3. New metabolites that have been obtained from random screening
approaches
Historically, most known fungal metabolites have been discovered
during the course of screening programs aimed at novel antibiotics
discovery. In this approach, suspensions of pathogenic organisms are
tested in cell-based assays like serial dilution assays for susceptibility of
growth towards fungal and microbial extracts. Other types of biological
assays are not well-suited for testing of crude extracts because those
contain ubiquitous compounds, such as linoleic acid which are fre-
quently present in large amounts in the crude samples and cause false
positive hits or cytotoxic effects that disguise interesting activities in
assays based on mammalian cell lines. Therefore, pre-fractionation of
the crude extracts prior to screening may constitute a valid alternative,
but it is extremely time and work consuming and can hardly be carried
out at high throughput without automation. A pragmatic approach can
be to perform a thorough dereplication of the crude samples by HPLC-
DAD/MS and look for new chemistry in parallel, and then isolate po-
tentially new compounds that are detected in the crude extracts and
make them available for testing in a pure compound library. It is also
worth mentioning that the major advances that have been made in
fungal taxonomy over the years can also play an important role in the
discovery of new bioactive fungal metabolites. For many years, it has
been known that secondary metabolite production and taxonomy may
be closely aligned within narrow phylogenetic lineages in many or-
ganism groups (Karwehl and Stadler, 2017). A striking example are the
recent studies on Basidiomycota from Thailand, where very high per-
centages of novel species were encountered, and concurrent investiga-
tions of the secondary metabolites of these species have already re-
sulted in a very high hit rate of new metabolites from new species
(Hyde et al., 2018). The advantage of combining classical and modern
expertise on taxonomy to establish correlations between biological and
chemical diversity within the fungal kingdom is the elimination of re-
dundancies like duplicates and well-studied taxa and known producers
of toxins while giving priority to putatively new species and other hi-
therto untapped taxa (Karwehl and Stadler, 2017). In our laboratory,
the thorough taxonomic characterization of the strains prior to the
screening has led to a substantial increase of the rate of new compound
discovery. Several new compounds have been recently reported by
employing a classical screening approach, following preselection by
molecular phylogeny and chemotaxonomy. Some examples are given
below.
3.3.1. Triterpenoids and cyathane diterpenoids
Terpenoids are fairly common among mushroom metabolites with
sesquiterpenoids, diterpenoids and triterpenoids being the most com-
monly isolated metabolites from Basidiomycota. These fungi even
produce numerous terpenoid carbon skeletons that have so far been
found in neither plants nor Ascomycota and specifically occur in certain
genera or families (Schüffler, 2018). One example are the cyathanes,
which are the characteristic diterpenoids of the Bird’s nest fungi (Ni-
dulariaceae) and in particular the genus Cyathus (Anke and
Oberwinkler, 1977; Ayer and Taube, 1972; Ayer et al., 1978).
We will focus here on recently discovered metabolites that have
been published over the past five years. Substituted cyathane diterpe-
noids named pyristriatin A (121) and B (122) (Fig. 8) from a Cyathus
species, for which the name C. pyristriatus was later proposed (Hyde
et al., 2016) were recently reported by Richter et al. (2016). These
pyristriatins, which exhibited moderate antimicrobial and weak
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cytotoxic activity, are the first terpenoids featuring a pyridine ring.
Furthermore, highly oxygenated polycyclic cyathane-xylosides, named
striatoids A–F (123-128), were isolated from cultures of a closely re-
lated species, Cyathus striatus. These striatoids showed dose-depen-
dently enhanced nerve growth factor (NGF)-mediated neurite out-
growth in rat pheochromocytoma (PC-12) cells (Bai et al., 2015). To
illustrate the frequent occurrence of this class of compounds in the
genus Cyathus, structurally related diterpenes were also isolated from
Cyathus gansuensis. These compounds, which were named cyathins J–P
(129-135), exhibited moderate inhibitory activity against nitric oxide
(NO) production in lipopolysaccharide-activated macrophages (Wang
et al., 2014). A similar compound, cyathin Q (136) was isolated from
another Cyathus species, Cyathus africanus. This compound was re-
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Fig. 8. Chemical structures of compounds isolated from random screening of different Basidiomycota.
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including caspase activation, cytochrome c release, poly (ADP-ribose)
polymerase (PARP) cleavage, and depolarization of the mitochondrial
inner transmembrane potential (He et al., 2016). Other cyathanes
named laxitextines A (137) and B (138) with activity against Gram
positive bacteria including methicillin resistant Staphylococcus aureus
(MRSA) were reported to occur in cultures of Laxitextum incrustatum
(Mudalungu et al., 2016). Interestingly, the genus Laxitextum belongs to
the Hericiaceae and is very closely related to the medicinal mushrooms
of the genus Hericium, which also predominantly produce cyathanes in
their cultures (see Fig. 4 and section 3.2.4).
Triterpenes are a predominant class of secondary metabolites, above
all in the wood-inhabiting polypore species, where they often are pre-
sent in the basidiomes in large quantities. Therefore, many re-
presentatives of this class of molecules have already been reported in
the last century (Liu, 2014; Ríos et al., 2012; Weete et al., 2010).
However, as will be demonstrated here, the Basidiomycota are by far
not exhausted with respect to the discovery of novel derivatives. For
instance, the lanostane-type triterpenoids laetiporins A (139) and B
(140) were isolated from a Laetiporus sp. originating from Kenya along
with some known congeners, which showed cytotoxic activity against
various human cancer cell lines. Laetiporin A (139) in particular, which
features an unusual methylation at C-16, showed significant cytotoxic
activity against L929, HeLa (KB-3-1), A431, MCF-7, PC-3 and A549 cell
lines (Chepkirui et al., 2017). The spiro-lanostanes, antrolactones A
(141) and B (142) from the ethanol extracts of the polypore Antrodia
heteromorpha showed inhibitory effects on receptor activator of nuclear
factor-kappaB ligand-induced osteoclastogenesis (Kwon et al., 2016).
Fomitopsins D–F (143-145, Fig. 9) from Fomitopsis feei exhibited ac-
tivity against Bacillus cereus. Fomitopsin D also showed activity against
herpes simplex virus type 1 (HSV-1) (Masahiko et al., 2017). From a
methanol extract of the fruiting bodies of a basidiomycete named
“Fomes officinalis” (currently valid name: Laricifomes officinalis), eight
24-methyl-lanostane triterpenes named officimalonic acids A-H (146-
153) were isolated. Officimalonic acids D, E, G and H are antioxidants,
showing inhibitory effects on nitric oxide production in lipopoly-
saccharide-induced RAW264.7 cells in the range of 5.1–8.9 μM. More-
over, officimalonic acids E, G and H exhibited moderate cytotoxicity
against H460, HepG2 and BGC-823 human cell lines (Han et al., 2016).
Unusual pregnenolone type triterpenes named aethiopinolones A-E
(154-158) were found in rather large quantities (total production rates
ca. 50 mg/litre) in solid state fermentations of Fomitiporia aethiopica
originating from Kenya (Chepkirui et al., 2018b). This type of tri-
terpenes is almost unprecedented in fungi. Even though these com-
pounds exhibited only weak cytotoxic activities against various human
cancer cell lines (being otherwise inactive in biological systems), their
biotechnological production may provide an alternative access to
therapeutic drugs such as contraceptives and hydrocortisone that have
a similar carbon skeleton
3.3.2. Sesquiterpenoids
Basidiomycota are also intricate producers of sesquiterpenoids. In
fact, sesquiterpene synthases appear to be the most abundant class of
natural products scaffold generating enzymes in Basidiomycota
(Schmidt-Dannert, 2015, 2016). Therefore, it comes as no surprise that
a manifold sesquiterpenoids have been isolated in recent years
(Abraham, 2001).
A number of antioxidant spirobenzofuran-derived sesquiterpenoids
(159-161; Fig. 10) have been isolated from the culture broth of “Co-
prinus echinosporus” (currently valid name Coprinopsis echinospora), a
fungus commonly found on dung. Compounds 51 and 53 showed only
weak antioxidant activity in the ABTS assay, with IC50 values in the 50
μM range (Ki et al., 2015). Another Asian species known for its anti-
oxidant properties, the Enoki mushroom, (previously referred to in the
literature under the European name, Flammulina velutipes, but recently
recognised to represent an own species named F. filiformis, by Wang
et al., 2018a) also cherished for its culinary value, has long been known
to produce the enokipodines (Ishikawa et al., 2001). However, a recent
investigation of a wild specimen of this mushroom led to the identifi-
cation of two new seco-cuparane sesquiterpenes, named flammufur-
anone A (162) and B (163); as well as 13 new sesquiterpenes (164-
176), among which are the flammuspirones A–J (164-173), and flam-
velutpenoid F (176) with nor-eudesmane, spiroaxane, cadinane, and
cuparane skeletons. Only a few of these metabolites (163, 164 and 166)
exhibited moderate inhibition of DPP-4 (Dipeptidylpeptidase-4) and
HMG-CoA reductase and none of the derivatives showed any signs of
cytotoxicity (Tao et al., 2016a). A recent investigation of solid cultures
of the edible abalone mushroom, Pleurotus cystidiosus, has found nine
novel clitocybulol derivatives (Fig. 10 clitocybulols G (177) and L (178)
depicted) with moderate inhibitory activity against protein tyrosine
phosphatase-1B (PTP1B), an important regulator related to obesity (Tao
et al., 2016b). Yet another edible mushroom, the gray shag, Coprinopsis
cinerea, has been studied for its secondary metabolite profile (Otaka
et al., 2017), due to its role as a model basidiomycete for the study of
fruiting body development and mating types (Muraguchi et al., 2015).
The study found two novel norsesquiterpenoids, Hitoyol A (179), with a
unique exo-tricyclo[5.2.1.02,6]decane skeleton, and B (180), with a
novel 4-cyclopentene-1,3-dione skeleton. Hitoyol B (180) displayed
weak anti-malarial activity against Plasmodium falciparum with an IC50
value of 59 μM (Otaka et al., 2017). On a more recent occasion, C.
cinerea was found to produce three further cuparene-like sesquiterpe-
noids, hitoyopodin A (181), featuring a benzoxabicyclo[3.2.1]octane
core, and its unnamed hydroxy derivatives (182-183). The metabolites
showed moderate cytotoxic activity against HL-60 cells with IC50 values
in the 3 to 16 μM range and 181 exhibited antiplasmodial activity
against P. falciparum, IC50 of 6.7 μM (Otaka et al., 2018). A chemical
investigation of a Deconica species from Thailand led to the discovery of
five cuparene-type sesquiterpenoids, deconins A-E (184-188; Fig. 11),
of which four show a the common scaffold to be extended by mevalonic
acid. Mevalonic acid is known to be the precursor of all terpenes syn-
thesized in the HMG-CoA reductase pathway. It has, however, never
been observed as a substituent of another terpene skeleton (Surup et al.,
2015). The crust-like polypore Perenniporia maackiae is one of the
causes of white-rot in deciduous trees (Jang et al., 2014) and was
therefore extensively studied for its production of secondary metabo-
lites. In a 2018 study, seven novel drimane sesquiterpenoids (189-195)
were isolated from solid-state cultures of the same species. Compounds
189, 190, and 194 displayed cytotoxic activities against six carcinoma
cells (ACHN, HCT-15, MDA-MB-231, NCI-H23, NUGC-3, and PC-3
cells), with IC50 values ranging from 1.2 to 6.0 μM (Kwon et al., 2018).
The genus Stereum, which is fairly widespread among the lignicolous
mushrooms has been the origin of many bioactive sesquiterpenoids,
such as the sterostreins, known for their antimalarial activity (Isaka
et al., 2011). Recently, three novel sterostreins, sterostrein R (196), S
(197), and sterostrein T (198) have been extracted from submerged
cultures of Stereum sp. YMF1.1686 isolated in China, Yunnan Province
(Tian et al., 2016).
3.3.3. Mixed terpenoids
The same research group also studied another Stereum species,
Stereum insigne CGMCC5.57, and isolated a novel dihydrobenzofuran
(199; Fig. 12), as well as six known metabolites, which constitute the
first secondary metabolites from this species (Tian et al., 2017). The
false turkey-tail mushroom, Stereum ostrea, previously mentioned for its
sterostreins, also produces ostalactones A–C (200-202), novel β- and ε-
lactones. The scaffold of 200 and 201 is characterized by a β-lactone
containing a fused bicyclic core structure, while ostalactone C (202)
possesses a 2-oxepinone ring system, making it a potential biosynthetic
precursor of 200 and 201. Ostalactones A (200) and B (201) also ex-
hibited moderate activity against human pancreatic lipase with IC50
values of 9.0 and 3.2 μM, respectively (Kang and Kim, 2016). This
comes as no surprise, as β-lactones have been known to inhibit the
human pancreatic lipase by blocking the hydrolysis of triglycerides via
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covalent modification of the serine residues in the active site
(Borgström, 1988; Hadváry et al., 1988; Kang and Kim, 2016). Another
known pancreatic lipase inhibitor is the β-lactone, vibralactone A
(203), isolated from Borostereum vibrans (Liu et al., 2006). Since then, a
number of vibralactones have been isolated. In the meantime, vi-
bralactone R (204), which features a γ-lactone, and vibralactone S
(205), with an 2(7H)-oxepinone, which includes an unusual 3,6-sub-
stituted oxepin-2(7H)-one ring system, unknown in the vibralactone/
fomannoxin family, have been isolated from a stereaceous mushroom
“BY1” together with methyl seco-fomannoxinate (206), which displays
a 2-methylprop-1-enyl ether moiety (Schwenk et al., 2016). Additional
vibralactones U–W (207-209) have been isolated again from Bor-
ostereum vibrans, but they did, however, not display any cytotoxicity,
and their further bioactivities remain to be evaluated (Duan et al.,
2018). A different wood degrader is the polypore Cryptoporus volvatus,
which typically infects rotting conifers after an attack by the pine bark
beetle (Davis et al., 2012). Investigating this fungal species for its cy-
totoxic constituents in the past, the group of Asakawa isolated several
cytotoxic cryptoporic acids (Hashimoto and Asakawa, 1998). More re-
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Fig. 9. Chemical structures of compounds isolated from random screening of different Basidiomycota.
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derivatives, ICA-B trimethyl ester (210), ICA-E (211), ICA-E penta-
methyl ester (212), and ICA-G (213). Only 213 exhibited stronger cy-
totoxic activities with IC50 values in the range of cis-platin (Zhou et al.,
2016b). A polypore infecting the mangrove plant Ceriops tagal as en-
dophyte was isolated and identified as Coriolopsis sp. The investigation
of its secondary metabolites production on solid rice medium led to the
discovery of six novel unnamed furan derivatives (214-219); as well as
two novel furan-carboxylic acids (220-221) (Chen et al., 2017b). Ho-
henbuehelia grisea, the producing organism of the earlier mentioned
antibiotic pleurotin (222), was recently found to also produce the an-
tiviral (HCV) metabolite 4-hydroxypleurogrisein (223), as well as nine
other novel pleurotin derivatives (224-232). The new heterocycle
pleurothiazole (231) and most of the other compounds exhibited
moderate to weak antimicrobial activity (Sandargo et al., 2018a, b).
3.3.4. Polyketides and other metabolite classes
Polyketides are a fairly diverse group of natural products, their
common denominator, however, is their biosynthetic machinery (Cox
and Simpson, 2009). In recent years, a number of secondary metabo-
lites of (partial) polyketide origin have been isolated from Basidiomy-
cota. The exobasidiomycete Acaromyces ingoldii, isolated from the
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metabolites, the naphtha-[2,3-b]pyrandione analogue, acaromycin A
(233; Fig. 13) and its thiazole analogue, acaromyester A (234). Acar-
omycin A (233) showed moderate cytotoxic activities against the breast
cancer cell line MCF-7 with an IC50 value of 6.7 μM (Gao et al., 2016).
The polyporaceous mushroom Lentinus strigellus was found to produce
four novel lentinoids A-D (235–238). These lentinoids belong to a
group of compounds, which are characterized by an isoprenyl residue
attached to an oxygenated cyclohexenyl ring and may be of mixed
biosynthetic origin (Vásquez et al., 2018). Earlier the very same fungus
was found to produce three novel benzopyran derivatives (239-241) as
well as an isopanepoxydone derivative (242), with anti-parasitic ac-
tivity (Julca-Canto et al., 2016). The saprotrophic species Phlebiopsis
gigantea is commonly used as a biocontrol agent to prevent root rot
caused by Heterobasidion. This has drawn attention to the fungus’s
secondary metabolome, and a recent study investigated the production
of secondary metabolites by P. gigantea. Five cyclopentanoid com-
pounds, of which three were novel diarylcyclopentenones, phlebiopsins
A-C (243-245), and a new p-terphenyl (246), were isolated from cul-
tures of P. gigantea. For methyl-terfestatin A (246) this was the first
report as a naturally occurring compound. The compounds did not
show any significant antifungal activities against Heterobasidion species,
hence their natural function in the biocontrol interactions between P.
gigantea and Heterobasidion species remains obscure (Kälvö et al., 2018).
The ectomycorrhizal mushroom Hygrophorus abieticola, associated
with Abies alba, was found to contain 4-oxo fatty acids named pseu-
dohygrophorones A12 (247) and B12 (248) in its fruiting bodies. These
are the first naturally occurring alkyl cyclohexenones of a fatty acid-
polyketide metabolic origin. (Otto et al., 2016). The fruiting bodies also
contained the alkyl cyclopentenone hygrophorone B12 (249), of which















Fig. 11. Chemical structures of sesquiterpenoids isolated from random screening of different Basidiomycota.
B. Sandargo, et al. Biotechnology Advances 37 (2019) 107344
16
Both, pseudohygrophorones A12 (247) and B12 (248), and hygro-
phorone B12 (249) showed moderate activities against the phyto-
pathogens Phytophthora infestans, Botrytis cinerea, and Septoria tritici
(Otto et al., 2016).
3.3.5. Alkaloids
In recent years, a number of alkaloids have been discovered in
Basidiomycota. Most recently, Lohmann et al. (2018a) published two
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Fig. 12. Chemical structures of mixed terpenoids isolated from random screening of different Basidiomycota.
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Fig. 14), isolated from the fruiting bodies of the mushroom Mycena
rosella. Root exposure of rosellin A (250) to Lepidium sativum led to a
bleaching of its leaves (Lohmann et al., 2018a),. Mycena is a genus of
small sapotrophic mushrooms and known for a range of toxic species.
The fruiting bodies of Mycena cyanorhiza, for example, contain the
widely known hallucinogen psilocybin (252) and Mycena pura the toxic
muscarine (253) (Allen et al., 1991) Another unusual Mycena species,
the bleeding fairy helmet (M. haematopus), was reported to produce the
pyrroloquinoline alkaloid, haematopodin (254) (Baumann et al., 1993).
This compound was later shown to be a direct degradation product of
haematopodin B (255) (Peters et al., 2008). The same species was re-
cently found to produce four additional pyrroloquinoline alkaloids, i.e.,
the yellow mycenaflavins A (256), B (257), and C (258), and the purple
mycenaflavin D (259) in its fruiting bodies. Structurally, they are highly
related to haematopodin and the mycenarubins (Peters et al., 2008;
Peters and Spiteller, 2007) Mycenaflavin D (259) is the first known
dimeric pyrroloquinoline alkaloid with a C−C bridge between the two
pyrroloquinoline units, possibly responsible for its purple color
(Lohmann et al., 2018b). Yet another Mycena species, the blackedge
bonnet (M. pelianthina), joins the group of pyrroloquinoline alkaloid
producing Mycenae. Its pelianthinarubins A (260) and B (261) are red
pyrroloquinoline alkaloids featuring an S-hercynine moiety, so far un-
known to pyrroloquinoline alkaloids, whether from marine organisms
or otherMycena species (Pulte et al., 2016).Mycena, however, is not the
only genus within the Basidiomycota producing alkaloids. Recently,
three novel pyrrole alkaloids, the phlebopines A–C (262–264), were
isolated from the fruiting bodies of Phlebopus portentosus (Sun et al.,
2018). Two rather unusual alkaloids, schizines A (265) and B (266), are
the first naturally occurring iminolactones to be mentioned and have
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Fig. 13. Chemical structures of various polyketides isolated from random screening of different Basidiomycota.
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showing cytotoxic activity against different cancer cell lines (Liu et al.,
2015). While some of the alkaloids showed cytotoxic or antimicrobial
activities, for many the bioactivity remains to be revealed. Never-
theless, a role in the fungal defense system cannot be excluded
(Spiteller, 2008).
4. Recent discoveries in chemical ecology of Basidiomycota
4.1. Chemical defense
Just as plants, fungi are very creative in their defense against other
organisms. (Spiteller, 2015) While for many of the earlier mentioned
novel secondary metabolites (chapter 3) the biological role remains
unknown, most can also be attributed to one of the three currently
known chemical defense strategies, the constitutive chemical defense. A
constitutive chemical defense relies on permanently, readily available
metabolites, as either toxins, such as the amatoxins (Fig. 15) anti-
microbials, like the antifungal strobilurins (chapter 3.1.2) or the re-
cently isolated anti-staphylococcal calopins (267-269) from fruiting
bodies of the bitter rooting bolete Caloboletus radicans (Tareq et al.,
2018), or like nematicides, such as the laccanthrilic acids A-C (270-
272) produced by different Laccaria spp. (Schrey et al., 2019), or bitter
tasting agents, like many alkaloids (chapter 3.3.5; see Spiteller, 2015).
The second strategy of chemical defence includes the generation of
bioactive compounds from inactive precursors that can be induced, e.g.
by injury of the basidiomes. Instead of permanently keeping bioactive
metabolites at hand, some Basidiomycota store precursor forms of their
warfare, and within seconds upon being attacked, convert these pre-
cursor metabolites into active chemicals (Spiteller, 2008). Only recently
Caspar and Spiteller (2015) discovered in fruiting bodies of Marasmius
oreades that upon injury cyanohydrin (273) decomposes to HCN and
glyoxylic acid (274), as means of a wound-activated defense. Through
feeding experiments, they established glycine (275) to be the biosyn-
thetic precursor of the cyanohydrin (273) of glyoxylic acid (274)
prompting a radically different way of cyanogenesis in fungi, compared
to plants. (Caspar and Spiteller, 2015). Unlike constitutive or wound-
activated defense, an induced chemical defense (the third strategy of
chemical defence employed by fungi) is a slower process, which starts
with the expression or upregulation of the biosynthetic genes for de-
fensive secondary metabolites. (Spiteller, 2008) As of yet, this defense
strategy is only known in mycelia of Basidiomycota in co-cultivation
with other fungi. (Kettering et al., 2004) A recent example for this is the
stereous mushroom BY1. Brandt et al. (2017) identified a double-bond
shifting polyketide synthase (PPS1) belonging to a previously unknown
clade of polyketide synthases, which is upregulated upon mycelial in-
jury and catalyzes the entire de novo synthesis of the antilarval polyenes
18-methyl-19-oxoicosaoctaenoic acid (276) and 20-methyl-21-ox-
odocosanonaenoic acid (277). (Brandt et al., 2017)
4.2. Chemical communication in the ectomycorrhiza
Besides warfare, fungi are known to produce secondary metabolites
in order to establish symbioses with various organisms. For
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establishment of ectomycorrhiza (Spiteller, 2015). However, only few
Basidiomycota, such as Laccaria bicolor, were shown to produce phy-
tohormones, like the auxin indole-3-acetic acid (IAA; 278), in order to
modify the root morphology of their host plants. (Vayssières et al.,
2015) The pine tree associated fungus Tricholoma vaccinum has been
assumed to live in a mutual symbiosis with its host tree, Picea abies.
Wagner et al. (2016) now discovered that the secondary metabolite,
D’orenone (279), is produced by a third-party, belonging to the soil-
borne Zygomycota. This compound can promote hyphal branching and
















Fig. 15. Chemical structures of various metabolites isolated from different Basidiomycota.
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phytohormone responsible for cell differentiation and growth in plants,
by T. vaccinum. Likewise, D’orenone (279) also had stimulating effects
on the lateral root length and hypertrophy of root cortex cells of spruce
seedlings of the host tree. (Wagner et al., 2016) These findings only give
a glimpse on the complexity of such chemical interactions.
Growth and fruiting body formation of the ectomycorrhizal mush-
room also largely depends on the fungi’s microbiome, however, little is
also known about microbial interactions on its fruiting bodies. It was
only recently shown in a study for Tricholoma matsutake, how different
bacteria can promote or slow down growth of this pine mushroom and
its fruiting bodies. In addition, the bacteria also indirectly influenced
the fungus by suppressing moulds, which would otherwise have in-
fected the fruiting bodies (Oh et al., 2018). In co-cultivation of asso-
ciated bacteria with Tricholoma, growth promotion could be related to
soluble chemicals transmitted via the media. Growth inhibition by
other bacteria, was demonstrated not only to be due to soluble che-
micals but also volatile metabolites (Oh and Lim, 2018; Oh et al., 2018)
Even though individual compounds have not been identified yet, such
dual antagonism culture studies, also between two competing fungi,
and the analysis of their VOC or DOC profiles are just coming up, and
much can be expected in the near future (Hiscox et al., 2018).
5. Genomics and molecular biology of secondary metabolite
biosynthesis in Basidiomycota
The first completed whole genome sequence of Saccharomyces cer-
evisiae strain S288C was a milestone in fungal genomics and biology
(Goffeau et al., 1996). Thereafter, the genome of the fission yeast
Schizosaccharomyces pombe (Wood et al., 2002) was sequenced, fol-
lowed by the pathogen Cryptococcus neoformans (Loftus et al., 2005),
and the wood-degrading saprotroph, Phanerochaete chrysosporium
(Martinez et al., 2004), which were the first species of the Basidiomy-
cota of which a genome sequence became available. Concurrently with
Ascomycota that have become model organisms in fungal biology like
Magnaporthe grisea (Dean et al., 2005) and Aspergillus nidulans (Galagan
et al., 2005), the genome of the plant pathogenic rust fungus, Ustilago
maydis (Kämper et al., 2006) was also completed early on in the history
of fungal genomics. However, in the following years, the Ascomycota
were very much favored by the mycological community because they
turned out to be easier to handle, owing to their less complicated ge-
netics. For instance, with the purpose of understanding evolutionary
history, a comparative genomic and transcriptomic approach has first
been used for the fission yeasts of the genus Schizosaccharomyces by
Rhind et al. (2011).
5.1. Fungal genome databases and identification of secondary metabolites
genes
By realizing the importance of fungal genomics, in 2000 the
Whitehead Institute/MIT center for genome research—now the Broad
Institute, set up the Fungal Genome Initiative (FGI, https://www.
broadinstitute.org/fungal-genome-initiative) with the purpose to se-
quence the genomes of fungi throughout the kingdom, ensuing a series
of databases which have been launched by mycologists to accelerate the
pace of fungal genomics (Table 1); access of these fungal genome data
and functions are listed. The selection of organisms followed various
criteria, but a major goal was to achieve a broad phylogenetic diversity
and to include strains and specimens from various lineages of the fungal
kingdom. The increasing availability of genome sequences has recently
led to the discovery of various secondary metabolite biosynthetic genes
from various fungi by genome mining strategies, using the computa-
tional tools listed in Table 2. The presumptive function of genes can be
predicted by performing an “hmmsearch” from Hidden Markov Model
(HMMER, http://hmmer.org/) (Eddy, 1998) of target protein sequences
using the Pfam (Finn et al., 2016) database as query sequences. In order
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could be heterologously expressed in hosts, such as Aspergillus niger
(Boecker et al., 2018).
5.2. Fungal gene clusters and identification strategies
Fungi tend to cluster genes encoding biosynthetic pathways within
their genome, and in particular, terpene synthases are frequently part of
biosynthetic clusters that include additional genes such as cytochrome
P450 monoxygenases for modification of the terpene backbone. Most of
the earlier studies have been conducted with Ascomycota: For instance,
the trichothecene biosynthesis cluster has been studied in great detail
by engineering Saccharomyces cerevisiae for de novo production using
cDNAs derived from the original producer, Fusarium graminearum Tri5
and Tri4 (Tokai et al., 2007). Another well-studied example is the bo-
trydial biosynthesis cluster from Botrytis cinerea, which comprises five
genes named BcBOT1 - BcBOT5 (Pinedo et al., 2008). For Basidiomy-
cota, Agger et al. (2009) were the first to describe the functional
characterization of six sesquiterpene synthases (Cop1 - Cop6) and two
terpene oxidizing cytochrome P450 monooxygenases (Cox1 - Cox2)
from “Coprinus cinereus” (current correct name Coprinopsis cinerea). The
genes were cloned and, except for Cop5, functionally expressed in Es-
cherichia coli and/or Saccharomyces cerevisiae.
An exception from this rule was found during studies on the se-
quiterpenoids of the melleolide type (see Fig. 15), whose biosynthesis is
catalyzed by the protoilludene synthase in the first committed step. This
synthase was among the first ones to be identified from Basidiomycota
and a sequence comparison of the isolated 6-protoilludene synthase
revealed a rather distant relationship to other known fungal terpene
synthases (derived from Ascomycota), the protoilludene synthase was
partially purified from Armillaria gallica and corresponding cDNAs were
expressed in E.coli (Engels et al., 2011). The characterization of the
ArmA adenylation domain, which is also related to melleolide bio-
synthesis in Armillaria mellea implied that the genus Armillaria has a
highly diverse secondary metabolism (Misiek et al., 2011). Following
this, two years later a heterologously produced Armillaria polyketide
synthase ArmB was found to produce orsellinic acid (OA) in vitro and
also performs a cross-coupling activity, which forms OA esters with the
various protoilludane sesquiterpenoid alcohols, leading to the different
melleolides produced by Armillaria spp. (Lackner et al., 2013). A variety
of melleolides, such as melleolide D (280), consist of a chlorinated
orsellinic acid moiety, which was shown to be synthesized by five
parallelized flavin-dependent A. mellea halogenases (ArmH1 to
ArmH5), which were heterologously produced in Escherichia coli. All
five enzymes are responsible for the transfer of a single chlorine atom
onto the melleolide backbone (Wick et al., 2016).
The seven-gene diterpene pleuromutilin biosynthesis cluster from
Clitopilus pseudopinsitus and C. passeckerianus was identified and later on
reconstructed in Aspergillus oryzae, giving a significant increase (over
2000%) in production of pleuromutilin (1) (Alberti et al., 2017; Bailey
et al., 2016; Yamane et al., 2017). This great technology may in the
future significantly facilitate the production of this highly important
precursor of marketed antibiotics. The biosynthesis cluster of erinacines
has been characterized containing three cytochrome P450s (EriA, EriC
and Eril), one GGPPS (EriE), two prenyltransferases (EriF and EriG) and
a UDP-glycosyltransferase (EriJ) (Yang et al., 2017).
Genomic and transcriptomic data implied that the triterpene cy-
clases of Basidiomycota is being coregulated during tissue-developing
stages, rather than to cluster with genes encoding downstream tailoring
enzymes. For instance, cytochrome P450 genes in the medicinal
mushroom “Ganoderma lucidum” (taxonomy probably not correct as the
study was carried out in China where this European species was never
cultured) shown to be co-expressed with the lanosterol synthase gene
and upregulated in the transition from mycelia to primordia (Chen
et al., 2012). CYP5150L8 has been characterized as the first cytochrome
P450 monooxygenases from Ganoderma, which is responsible for the
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vivo and in vitro assay in Saccharomyces cerevisiae (Wang et al., 2018b).
Aside from terpenoids, other classes of metabolites have also been
targeted and the biosynthesis was elucidated. One such example is the
recent discovery of psilocybin biosynthesis. The alkaloid psilocybin
(252) serves as a prodrug of its dephosphorylated psychotropic analog,
psilocin (281, Fig. 15). Decarboxylation of tryptophan is performed by
the enzyme PsiD which represents a new class of fungal l-tryptophan
decarboxylases. A P450 monooxygenase, PsiH, introduces the hydroxy
function, followed by a phosphotransferase (PsiK), and a SAM-de-
pendant methyltransferase (PsiM), which catalyzes the N-methyl
transfer in a final biosynthetic step (Fricke et al., 2017).
Strobilurins and the related oudemansins are produced by a number
of different species of Basidiomycota and have long served as lead
compounds for the development of the agricultural β-methoxyacrylate
fungicides (see chapter 3.1.2), however until recently, the biosynthesis
remained obscure. In a 2018 study, the strobilurin biosynthetic gene
cluster (BGC) was identified inStrobilurus tenacellus and S. lutea (for-
merly known as Bolinea lutea, Ascomycota). The BGC was shown to
encode for a highly reducing polyketide synthase with very unusual C-
terminal hydrolase and methyltransferase domains. The expression in
Aspergillus oryzae lead to the isolation of prestrobilurin A (282). The
oxidative rearrangement, which leads to the β-methoxyacrylate tox-
ophore, is achieved either by a flavin-dependent oxidase, encoded by
the gene str9. In the last steps, two SAM-dependent methyltransferases,
encoded by str2 and str3, complete the synthesis (Nofiani et al., 2018).
For the cyclopeptide omphalotin A (20), which displays strong and
selective activity against plant-pathogenic nematodes (see above 3.1.3),
two biosynthesis genes OphMA and OphP were identified by mining the
genome of Omphalotus olearius in two independent studies by Ramm
et al. (2017) and Van der Velden et al. (2017). The authors postulated a
hitherto unprecedented biosynthesis mechanism for a ribosomally
synthesized and posttranslationally modified peptide (RiPP) in which
the modifying enzyme delivers its own precursor peptide. This me-
chanism is much different from NRPS biosynthesis of other fungal cy-
clopeptides and is so far unparalleled in fungi.
The highly toxic amatoxins, produced by different Amanita and
Galerina species, have been shown in the past to be ribosomally syn-
thesized as proproteins and not by NRPS (Walton et al., 2012). The
genes for α-amanitin (Ama1) and phallacidin (Pha1) belong to a large
family of related genes, consisting of highly conserved nucleotide se-
quences flanked by a hypervariable “toxin” region, which is again
flanked by invariant proline residues. In the case of phalloidin (284),
the cleavage of the proprotein was conducted by a serine protease in the
prolyl oligopeptidase (POP) subfamily, discharging the linear hepta-/
octapeptide (Walton et al., 2012) For α-amanitin (Fig. 15) post-
translational processing, it was shown that a specific POP, Gmpop5, was
responsible for catalyzing the hydrolysis at an internal Pro to deliver
the C-terminal 25-mer from the 35-mer propeptide and transpeptida-
tion at the second Pro to generate the cyclic octamer (Luo et al., 2014).
An example of an unprecedented class (type VI) of fungal side-
rophore synthetases, is the nonribosomal peptide synthetase CsNPS2.
Identified in Ceriporiopsis subvermispora, and expressed in A. nidulans,
this seven –domain NRPS catalyzes in vitro the formation of the first
trimeric hydroxamate siderophore basidioferrin (285) Orthologous
genes can be found across various Basidiomycota and appear to be
widespread (Brandenburger et al., 2017). Other siderophore biosyn-
thetic genes were characterised from, e.g., Ustilago (Yuan et al., 2001;
Winterberg et al., 2010) and Omphalotus (Welzel et al., 2005).
The ectomycorrhizal fungus Paxillus involutus was found to secret an
Fe3+ reducing pigment, named involutin (286), in order to facilitate
the oxidative decomposition of lignocellulose, assisting its host plant in
nutrient acquisition (Shah et al., 2015). Through early feeding experi-
ments, it was known for involutin to be tyrosine-derived (Gill and
Steglich, 1987). In a recent study, Braesel et al. (2015) could constitute
a biosynthesis scheme, identifying atromentin (287) as a precursor,
synthesized by highly similar tridomain synthetases: InvA1, InvA2, and
InvA5. Also, an additional atromentin synthetase, InvA3, was found to
gain activity after a domain swap replacing its native thioesterase do-
main with that of InvA5. (Braesel et al., 2015). The atromentin syn-
thetase and the corresponding gene cluster had actually already been
characterized in a previous study by Schneider et al. (2008) on the
related species, Tapinella panuoides. These pulvinic acids have recently
been proven by Tauber et al. (2016, 2017) to be directly involved in
chemical defence reactions during the course of dual culturing studies
involving Paxillus involutus, Serpula lacrymans and bacteria. They are
being elicited in response to the presence of bacteria and inhibit bac-
terial motility.
Taking advantages of gene clustering in fungi, several computa-
tional modes have been developed to identify metabolic gene clusters
(Table 2). However, it is not clear whether they work well in all Basi-
diomycota because there are still too few examples of elucidated
pathways for known products. Gene clusters can also be identified by
manually walking genome sequence±20 kb of predicted secondary
metabolites genes with expected borders that clusters are predicted by
existence of big gaps between genes or existence of several successive
genes that are not related to natural product biosynthesis (Wawrzyn
et al., 2012a). The study of Quin et al. (2014) revealed that antiSMASH
2.0 identified four of the eleven manually identified putative terpene
synthases in the genome of Omphalotus olearius (Wawrzyn et al.,
2012b). Similarly, five out of eighteen manually predicted terpene
synthase sequences were identified in Stereum hirsutum (Quin et al.,
2013). By comparing the results from algorithms platform and manu-
ally screening, we conclude that maybe because of the intricacy and
variability of fungal gene clusters, these tools undervalued size of gene
clusters. However, numerous secondary metabolites biosynthesis
pathways have been characterized from Basidiomycota, which calls for
algorithms to be trained more accurately. Currently, when considering
to study secondary metabolite gene clusters in Basidiomycota, using a
combination of algorithms platform and manual annotation is re-
commended.
In summary, the tools for exploitation of the secondary metabolite
biosynthesis are readily available, and it is even possible to produce
some of the metabolites using heterologous hosts, but the vast majority
of the unique compounds treated in this review still remain to be tar-
geted. An interesting strategy that could arise from these prerequisites
in the future could be to express the numerous genes and gene clusters
that are steadily being detected in the genomes of slow-growing species
or even mycorrhizal fungi, for which no means of cultivation has so far
been established, using heterologous expression. Almost concurrently
with the present paper, a review by Lin et al. (2019) has been pub-
lished, which gives further details on the state of the art and includes
additional examples. We highly recommend this paper for further
reading.
6. Biotechnology of products from Basidiomycota
6.1. Current products of industrial importance from Basidiomycota
6.1.1. Products for pharmaceutical applications
As was mentioned in previous sections, the strobilurins inspired
synthetic agrochemical fungicides and the illudins led to the prodrug
irofulven currently under phase II clinical trials by Oncology Venture
but the only example of a currently marketed product of pharmaceu-
tical importance derived from a basidiomycete (Pleurotus passeck-
erianus) is pleuromutilin (see chapter 1 and Kavanagh et al., 1951). The
first semisynthetic pleuromutilin analog retapamulin, was developed by
GSK under the tradename Altargo. More recently, potent RNA poly-
merase II inhibitors produced by several Amanita species have been
investigated as anti-body drug conjugates, like the amanitins with very
promising results in pre-clinical studies (Flygare et al., 2013; Pahl et al.,
2018). The material for such studies is either isolated from collected
fruiting bodies of the mycorrhizal species, Amanita phalloides, which is
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to our knowledge not cultivable, or from cultures of Galerina species
(Muraoka et al., 1999). Curiously, there is one single paper on a species
named Amanita exitialis (Zhang et al., 2005) which has been reported to
grow in axenic culture on agar and used to produce amatoxins. The
authors reported 728.3±43.8 μg/g (dry matter) of α-amanitin and
60.0±20.7 μg/g (dry matter) of β -amanitin, which represents about
10% of the total dry weight in the fruiting bodies. Unfortunately, this
report has so far apparently not resulted in any follow-up studies, and
the results presented also appear quite questionable because no other
species in the sect. Phalloideae of Amanita that is known to contain
amanitins has ever been established in axenic culture. On the other
hand, species of the saprotrophic genus Galerina are often readily able
to grow in culture and should be regarded as the better option to obtain
amanitins in sufficient amounts to support a sustainable biotechnolo-
gical production process.
6.1.2. Complex products from mycelia and fruiting bodies
Currently the bulk of commercial products derived from
Basidiomycota are complex preparations from fruiting bodies or the
fruiting bodies itself and or mycelia as well as fractions and prepara-
tions of submerged or solid state fermentations. Beside their use as
edible mushrooms, different preparations from medicinal mushrooms
are used due to the beneficial effects attributed to them. Due to the
growing demand, the industrial production of different mushrooms gets
more and more important. Fig. 16 shows the production increase from
1960 to 2002 (Cheung, 2008) with a market value of over U.S.$40
billion in 2001 and a reported market value of U.S.$45 billion (Chang,
2006a) for mushroom products overall and U.S.$18 billion for dietary
supplements derived from medicinal mushrooms in 2012 (Chang,
2006a; Cheung, 2008; Wasser, 2014). For some of these numbers the
original source is not stated (Wasser, 2014). The paper by Chang
(2006b) seems to be the most reliable and most cited source for such
numbers. In 1997 Asia contributed 74.4% to the total production,
Europe 16.3%, North America 7% and Africa and Latin America to-
gether less than 1% but numbers from non-Asian countries are in-
creasing (Cheung, 2008). Beside the usage as nutrient and valuable
protein and vitamin source, a large portion is used for the production of
medicinal mushroom products, which are to 80-85% derived from ei-
ther, cultivated or wild grown and collected fruiting bodies. Only
around 15% of these medicinal products are derived from mycelia and
the smallest portion of these products stems from culture filtrates
(Cheung, 2008).
Medicinal mushrooms are thought to have beneficial effects in












Fig. 16. Illustration of increase in mushroom production from 1960 to 2012.
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about 130 medicinal indications (Wasser, 2014), but notably, most of
them have not been standardised and proven for efficacy following the
rules of the Federal Drug Administration (FDA) or other agencies that
are responsible for registration of classical, “ethical” prescription drugs.
Many of them are sold over the counter, e.g. as nutraceuticals or
“herbal” medicines. Table 3 is a list of the most important indications in
combination with a list of the most important medicinal mushrooms
and their products derived from them (Cheung, 2008; Lindequist et al.,
2005; Turło, 2014; Wasser, 2014). The majority of these mushroom-
derived products are extracts containing complex polysaccharide frac-
tions of different composition. Trade names of these products are
Lentinan, a polysaccharide fraction isolated from Lentinula edodes,
Schizophyllan (SPG, Sonfilan or Sizofilan), a polysaccharide fraction
isolated from Schizophyllum commune, Grifolan, a polysaccharide frac-
tion isolated from Grifola frondosa, Krestin, a protein-polysaccharide
complex isolated from Trametes versicolor, and Ganopoly, a poly-
saccharide extract from Ganoderma lucidum (Lindequist et al., 2005;
Turło, 2014; Wasser, 2014).The activity of these and other fungal ex-
tracts seems to be mostly related to the immunomodulatory activities of
the glucans and glycans derived from these, clinical trials and animal
studies have been undertaken. For example, Krestin is a prescription
drug in Japan for the treatment of cancer. Research on the mode of
action of these partially complex mixtures is ongoing, a complete eva-
luation of available literature regarding Krestin (Trametes versicolor)
concluded that the product may have positive effects upon disease and
survival outcomes based on clinical trials with non-small cell lung
cancer (Lindequist et al., 2005; Turło, 2014; Wasser, 2014). These
products are being sold all over Asia as “mycopharmaceuticals” and can
meanwhile even be obtained via the Internet as nutraceuticals in the
Western World. However, despite the fact that some products even
showed efficacy in clinical trials, most of them will hardly be approved
by the European and American agencies as ethical drugs because they
fail to meet the criteria, in particular with respect to standardisation.
Notably, there are also some glycolipids that are being used in areas
other than pharmaceuticals, such as the glycolipids from Ustilago maydis
that are being under investigation as biosurfactants (Spoeckner et al.,
1999). Their biosynthesis has recently been elucidated (Hewald et al.
2006), and they are now being produced by submerged fermentation in
kg scale (Günther et al., 2017). A new class of glycolipids has also been
obtained from cultures of the tropical species Dacryopinax spathularia
(Dacrymycetales) and can be produced in gram per liter scale in bior-
eactors (Stadler et al., 2014). These compounds are highly effective
natural preservatives and have recently been licensed by the German
company Lanxess, who started their production at industrial scale.
6.2. Methods used for production of biologically active metabolites from
Basidiomycota
6.2.1. Traditional mushroom cultivation
Traditionally, fungi have been cultured on solid substrates suitable
for farming without sophisticated equipment according to their biolo-
gical and nutritional requirements for fruiting body formation. These
procedures have been improved and intensified due to the rising de-
mands for nutritional and pharmaceutical purposes. A good overview
on common cultivation techniques and further reading can be found in
the book by Cheung (2008). For example, Agaricus bitorquis and A.
bisporus are cultivated using composted material available locally. This
material is then pasteurized to remove unwanted bacteria and treated
in a special manner to be used further on in indoor cultivations. The
quality of this compost enhances the number of harvests possible.
Cultivation of Lentinula edodes in commercial scale is usually done in
sterilized plastic bags filled with hardwood sawdust and other supple-
ments, which are inoculated with the mycelium and put for fruiting
body formation after colonization of the sawdust mixture at 16-18°C.
The cultivation of Pleurotus sajor-caju can be done on solid substrate
consisting mainly of cotton seed hull, water hyacinth and/or rice or
cereal straw. The fruiting body formation is triggered by white light.
Volvariella is cultured indoor for industrial purposes on cotton wastes.
Agaricus subrufescens is cultured on rice straw or bagasse enriched with
air-dried cattle dung and poultry manure and some fertilizers to en-
hance growth. The exact composition varies depending on the local
availability of raw material. Methods for the cultivation of “Ganoderma
lucidum“ and other species of Ganoderma have been developed in China.
The fungus is grown on saw-dust bags or wood logs. Sterilized wood
logs deliver the best quality of fruiting bodies. More detailed explana-
tions are provided by Cheung (2008), Savoie and Mata (2016) and
Smith et al. (2002). The products achieved with this method are the
fruiting bodies of the respective fungus, the quality and composition of
these varies depending on the source of substrate, the number of har-
vests the way the mushrooms are cultivated and many other factors.
The same is true for the mushrooms collected in the nature. Therefore,
more reproducible and controllable production processes, especially for
pharmaceutical purposes are required (Lindequist et al., 2005; Smith
et al., 2002; Turło, 2014; Wasser, 2002).
6.2.2. Solid phase cultivation in bioreactors
The traditional production of mushrooms described above usually
takes several months and the quality of the material obtained is prone
to variations. To reduce the required time for biomass production two
different technologies have been developed which allow, aside from
media composition, the control of several physical process parameters
like temperature, aeration and pH for optimized growth of the organism
of choice. One possibility is the growth of the organism in a submerged
liquid culture, which does not resemble the environment of the fungus
in nature at all. Another possibility is the cultivation on sterilized solid
substrates inside of static or mixed chambers with reduced amount of
water, compared to submerged liquid cultivations, which allows for a
nature like growth of the mycelium on the substrate (Berovic and
Podgornik, 2016). The advantage using a solid substrate fermentation is
the absence of free water in the cultivation chamber, which reduces the
required volume for the distribution of nutrients. The control of para-
meters like aeration, CO2 stripping, pH and temperature in certain
ranges enhances and promotes the fast growth of the mycelium. Tra-
ditionally complex substrates have been used for fungal cultivations in
solid substrate fermentations, which resemble those from chapter 6.1.
The advantage of these systems is the fast growth of the fungal mycelia
due to ideal biochemical conditions that can be achieved using ground
and more or less homogeneous substrates according to the requirements
of the fungus. Additionally, mixing of the substrate is possible in certain
reactor types, which leads to new germination points inside the sub-
strate bed and thereby increases colonization speed of the solid sub-
strate. To optimize these processes and to address issues with upscaling,
heat removal, mixing etc. several different types of reactors have been
constructed, a good overview is given in Arora et al. (2018), Durand
(2003) and Musoni et al. (2015). Tray reactors contain for example
shelf like installations, which contain the substrate and are inoculated
with the organism. These shelves inside the reactor are in some cases
perforated and a nutrient containing liquid is dropping from top to the
bottom. Other reactor types contain a packed static bed, which is for-
cefully aerated. The disadvantage of these reactors is the in-
homogeneous growth of the organism (Musoni et al., 2015) and the
resulting problems in aeration, pH and nutrient gradients and removal
of heat. Rotating drum reactors of various types mix the substrate
during the course of the cultivation and create thereby a more homo-
geneous environment. Problems arising with this design can be the
constant mechanical disruption of the mycelium and upscaling issues
when removing heat and supplying sufficient oxygen (Arora et al.,
2018; Durand, 2003). There have been special developments for or-
ganism specific purposes in each of the above-mentioned reactor types
but only tray reactors seem to be further developed for industrial pro-
duction for pharmaceuticals. One example is the “PlaFractorTM” a pa-
tented technology based on equipment which has originally been used
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for soy sauce fermentation (“koji” fermentation), (Suryanarayan,
2003). This is, to best of our knowledge, the only example of a solid-
phase cultivation process, which has been cited as source of a FDA
approved natural product: lovastatin (Barrios-González and Miranda,
2010) but this approval could not be confirmed by investigating the
original publication by Suryanarayan (2003) or the company homepage
of Biocon India (https://www.biocon.com/). There are several reports
where solid-substrate fermentation is used for the production of small
molecules like antibiotics, alkaloids and toxins with promising out-
comes regarding product titers (Robinson et al., 2001; Subramaniyam &
Vimala, 2012). The general conclusion nevertheless is that the derived
products, due to problems associated with reproducibility of in-
homogeneous cultivations and complicated downstream processing of
the solids, are not fulfilling the high standards required for pharma-
ceutical use of the derived products in humans and further development
for process standardization and understanding is necessary (Arora et al.,
2018; Durand, 2003; Musoni et al., 2015; Robinson et al., 2001). For
the majority of the organisms listed in Table 3 methods for mycelia
generation in solid-substrate fermenters have been developed. For an
overview about processes and literature we recommend Berovic &
Podgornik (2016).
6.2.3. Submerged liquid cultivation in bioreactors
Submerged liquid cultivation of Basidiomycota for pharmaceutical
purposes will be the method of choice when dealing with medicinal
mushrooms since the necessary process reproducibility and the there-
fore required process monitoring and control is only achievable with
this reactor type. There is consent in literature that the necessary pro-
duct quality and reproducibility of different charges of the same pro-
duct can be only achieved with bioreactors suitable for this cultiuvation
method (Cheung, 2008; Lindequist et al., 2005; Turło, 2014; Wasser,
2014). The task of the bioreactor is the measurement, control and
maintenance of all important physical parameters, which have been
identified and optimized experimentally. The base of the experiment is
the culture media, which delivers nutrients and oxygen to the fungus
according to its requirements. Due to the tight control, reproducible
cultivations can be achieved which allows for a high batch to batch
comparability even over years. Material obtained from such cultiva-
tions is suitable for the investigation of beneficial effects from medic-
inal mushroom products in clinical studies.
The reason for the preferred use of submerged liquid cultivation
over solid substrate fermentations is that despite promising results re-
garding product yields, which can be achieved with solid substrate
fermentations in bioreactors, the use of submerged liquid cultivations
allows a much higher level of implementation of process analytical
tools as well as process control strategies resulting from on-line data
acquisition, which cannot be achieved with solid-state fermenters due
to lacking online analytics. This high standard of control and process
understanding is due to the decades of studies and developments, which
have been undertaken to characterize and model bioprocesses in sub-
merged liquid bioreactors. An overview about available online and at-
line analytical technology as well as critical parameters and future di-
rections in process modelling and knowledge based control is found
(Formenti et al., 2014; Rodríguez-Duran et al., 2016; Schügerl, 2001).
This enhanced process understanding is important due to the in 2004
released PAT-Guidance3, which is the collaborative work of several FDA
departments (CDER = Center for Drug Evaluation and Research, CVM
= Center for Veterinary Medicine, ORA = Office of Regulatory Affairs)
with the purpose to continuously improve the patient safety when using
pharmaceutical products derived from complex and difficult to under-
stand bioprocesses using complex substrates and whole cell catalysts.
The PAT-initiative is supported by the European Medicines Agency
(EMA), the Japanese Ministry for Health, Labor and Welfare (MHLW)
and by the guidelines of the International Conference on Harmonization
(ICH). For further reading we recommend Food and Drug
Administration-FDA (2004) and Rathore et al. (2010).
The first reports known to us of submerged cultivations of
Basidiomycota date to 1966 (Gregory et al., 1966) where several hun-
dred species of Basidiomycota have been cultured in shake flask to
evaluate their biological activity. The majority of the reports dealing
with novel secondary metabolites from Basidiomycota state submerged
liquid cultivation as method for production of these compounds as well
as media for cultivation of all major medicinal mushrooms have been
developed (Cheung, 2008; Elisashvili, 2012; Turło, 2014) which will
facilitate and ease future work and further investigations of these in-
teresting organisms. One thing which has to be kept in mind and which
adds additional complexity to these fungal cultivations is the fact that
under most circumstances the Basidiomycota grow as mycelium clumps
in the liquid phase and secrete polysaccharides into the surrounding
media. This growth pattern is leading to nutrient gradients from the
surface of these pellets to the core, which can strongly influence the
regulation and the productivity of the respective organism. Additionally
the secretion of polysaccharides, which is regularly observed in sub-
merged liquid cultivations, can change the rheology of the culture li-
quid completely and reduces thereby the mixing efficiency and the
oxygen and nutrient supply to the core-cells. There have been intense
investigations with Ascomycota to understand and address these issues
and to model the underlying principles (Antecka et al., 2016; Hille
et al., 2009; Krull et al., 2013) but the general outcome is that these
effects rely totally on the organism and the applied physical and bio-
chemical culture conditions and a general strategy to predict possible
outcomes regarding productivity and culture rheology is currently not
available. Promising onsets with ascomycete cultures, which are prob-
ably transferable to Basidiomycota, are the addition of particles into the
liquid phase which enhance desired growth-patterns of the organism on
those. In addition, variations in the osmolality seem to influence such
cultivations beneficially and are transferable into bioreactor scale.
Nevertheless the common consensus is, that more work has to be done
and especially methodologies for faster possibly automated measure-
ment and analysis of such effects on the morphology of the investigated
organism has to be developed in order to speed up understanding of
these phenomena (Antecka et al., 2016; Krull et al., 2013;
Wucherpfennig et al., 2010; Wucherpfennig et al., 2013; Žnidaršič and
Pavko, 2001).
6.3. Biotechnological processes to produce pharmaceutically relevant
compounds
6.3.1. Overview about statistical methods to improve productivity of fungal
cultivations
Once a biologically active product is promising enough for further
development usually, the production from natural sources is hampered
by low titers. To increase the produced amounts of compound one can
optimize either the producer itself or the physical and biochemical
conditions. Reports on genetic work with Basidiomycota are rather
limited although a few examples exist (Xiao and Zhong, 2016). Due to
the act that strain optimization will mostly rely on random mutagenesis
therefore we will focus here only on a short general overview about
process- rather than strain optimization since the applied methodology
does not differ from development of processes involving bacteria or
Ascomycota. Application of such methodologies is also in accordance
with the PAT-initiative since it increases process understanding and
reduces thereby the risk of unexpected outcomes. We briefly report on
the few examples of existing work on process development with Basi-
diomycota for single molecule production using statistical and com-
putational methods.
Starting point of process development is usually the development of
a suitable medium (carbon-, nitrogen-, phosphate source), inoculation
3 PAT=Process Analytical Technology) of the FDA, see (https://www.fda.
gov/downloads/drugs/guidances/ucm070305.pdf)
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density and other factors, which can be accessed using shake flask ex-
periments (Singh et al., 2017). Classically these factors have been in-
vestigated changing one parameter or factor at the time (OFAT) which
is time consuming and will not unravel interactions between factors.
These experiments are done by removing, replacing or exchanging
media components and process parameters. When no prior knowledge
about the strain requirement exists, e.g. from literature or preliminary
screenings, such experiments can be yet quite helpful to develop an
experimental knowledge base for statistical methods for media opti-
mization (Singh et al., 2017).
The investigation of all factors of interest on all levels of interest
using a so called “full factorial” experimental design unravels the in-
teractions of lower order (factor influenced by other factor) and also
higher order interactions (factor influenced by interaction and inter-
action influenced by interaction). Such designs deliver the best results
in terms of resolution of interactions but are laborious. It requires in
case of four factors on two levels 24 = 16 experiments. This number
increases fast when the number of factors or the number of levels in-
creases e.g. 5 factors on two levels require 25 = 32 experiments, 26 =
64 experiments…., 210 = 1024 and so on. To reduce the amount of
experiments so called “fractional factorial” experimental designs can be
used. These designs allow, under the assumption that in most cases only
direct interactions are of importance and higher order interactions can
be neglected, a reduction of the number of the experiments. Therefore
specifically designed experimental plans are used, which omit those
experiments that unravel higher order interactions between factors, at
the cost of resolution. This means the lower the amount of experiments
the higher the chance to confound first order interactions with higher
order ones(Montgomery, 2013; Singh et al., 2017). These plans and the
evaluation of the results have to be carefully adapted on the purpose,
the required accuracy and also the expected outcome of the experi-
ments. Using specific carefully designed experimental plans, the sta-
tistically designed experiments allow for reduction of the number of
these experiments and the discovery of interactions of such parameters
(Montgomery, 2013; Singh et al., 2017).
A detailed explanation of the underlying statistical principles and
possible methodologies is beyond the scope of this review and we refer
to Montgomery (2013) for further reading. Usually a predefined ex-
perimental design is adapted to the purposes required by adjusting
concentration boundaries, central points according to the evaluation
method (Mandenius and Brundin, 2008; Montgomery, 2013; Singh
et al., 2017). This adjustment is crucial to the outcome of the experi-
ment and requires expert knowledge about the process to be optimized.
Usually these experiments are carried out in a certain experimental
space and evaluated using statistical software, which allows then for
graphical and numerical illustration of results (Mandenius and Brundin,
2008; Montgomery, 2013; Singh et al., 2017). Further optimization
from there can be achieved using response surface methods (RSM) and
more recent literature also describes and compares the application of
artificial neural networks (ANN) and genetic algorithms (GA) to such
optimization problems (Mandenius and Brundin, 2008; Montgomery,
2013; Singh et al., 2017; Weuster-Botz, 2000). Since such experiments
carried out in shake flasks usually do not consider factors like pH, pO2
composition of the gas phase effects of stirring and different tempera-
tures they do not necessarily match results obtained in bioreactors
(Singh et al., 2017). Therefore, an early transfer into a system which
closely resembles that later used for production purposes can be useful
although experiments in bioreactors usually reduce the number of
throughput tremendously due to the complexity of the setup. Essential
for a successful and meaningful experimental outcome when using
Basidiomycota is from our experience to standardize all steps as much
as possible and try to achieve the highest possible reduction of variance
in the single experiments since small variations can have big effects on
the experimental output.
There are only a few examples dealing with Basidiomycota and
advanced bioprocess engineering. To the best of our knowledge, no data
have been published from Glaxo Smith Kline describing the production
process of the retapamulin precursor pleuromutilin with Clitopilus pas-
seckerianus CP2. There are a number of reports dealing with the opti-
mization of pleuromutilin with “Pleurotus mutilus” (currently valid
name: Clitopilus scyphoides). Khaouane et al. (2012) used a central
composite design and neural network as well as particle swarm opti-
mization to find optimal pleuromutilin production conditions. Their
estimated optimal process parameters were stirrer speed 258 vs. 242
rpm, 26.78°C vs. 26.88°C and pH 5.98 vs pH 6.06. The obtained product
titers with these changes were 7900 μg/g biomass and 10149 μg/g
biomass, respectively, which differed only slightly from the estimated
ones. They further modeled the bioprocess using feed forward neural
networks
(Khaouane et al., 2013). Lu et al. (2011) used response surface
methodology and artificial neural networks to optimize triterpene
production (without stating which triterpenes). Malinowska et al.
(2009) used a central composite rotational design and response surface
methodology to optimize polysaccharide and biomass production.
7. Conclusion and outlook
The current review demonstrates that the Basidiomycota have by far
not been exhaustively exploited for novel biologically active molecules.
The recent progress in analytical techniques, as well as in genomics,
transcriptomics and biotechnological process development now sub-
stantially facilitates the evaluation of these fascinating organisms,
which show a very high biodiversity and a very interesting ecology. In
fact, only very few genera and species have so far been explored sys-
tematically for secondary metabolite production and even fewer species
were subjected to straightforward biotechnological process develop-
ment. Many new compounds were recently obtained in the course of
collaborations of chemists and biotechnologists with taxonomists who
also still dispose of skills in classical microbiology that are often ne-
cessary to obtain cultures of the rather slow-growing species that re-
main totally untapped. Furthermore, there is a great chance to find new
molecules in the endemic species from the tropics, which remain widely
unstudied in particular in those countries where capacities for my-
cology yet remain to be built. Interdisciplinary and international col-
laborations on this topic should therefore be strengthened further in the
future.
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